line number	data source	Drug ID	Gene Name#AA Mutation	Drug Name（raw）	Drug Name 中文名	商用药物机理	Gene Name	AA Mutation	临床疗效	Reference	Association text	Association text中文	中国是否上市	FDA批准适应症	FDA批准药物局限性	III 期在研适应症	研究所在疾病	Evidence level	Drug Name	Drug status
L01694	Cancer Genome Interpreter	.	AR:over	4OHtestosterone	4OHtestosterone		AR	AR overexpression	敏感性增加	ASCO 2015 (abstr 1003)	.		.	.		.	Breast invasive carcinoma	Early trials	4OHtestosterone	Clinical Trials
L01474	Cancer Genome Interpreter	.	ERBB2:norm,ESR1:over	Abemaciclib	Abemaciclib		ERBB2	ERBB2 expression + ESR1 overexpression	敏感性增加	PMID: 26658964	.		.	.		.	Breast invasive carcinoma	Early trials	Abemaciclib	.
L01773	Cancer Genome Interpreter	.	ERBB2:norm,ESR1:over	Abemaciclib	Abemaciclib		ESR1	ERBB2 expression + ESR1 overexpression	敏感性增加	PMID: 26658964	.		.	.		.	Breast invasive carcinoma	Early trials	Abemaciclib	.
L01549	Cancer Genome Interpreter	.	KRAS:.	Abemaciclib	Abemaciclib		KRAS	KRAS oncogenic mutation	敏感性增加	PMID: 27217383	.		.	.		.	Lung cancer	Early trials	Abemaciclib	.
L01670	Cancer Genome Interpreter	.	TP53:.	Abemaciclib	Abemaciclib		TP53	TP53 oncogenic mutation	耐药性增加	PMID: 27217383	.		.	.		.	Breast invasive carcinoma	Early trials	Abemaciclib	.
L00261	Cancer Genome Interpreter	D02STN	AR#p.L702H	Abiraterone	Abiraterone (阿比特龙)		AR	p.L702H	耐药性增加	PMID: 26537258	.		是	前列腺癌		.	Prostate Cancer	Early trials	Abiraterone	Approved
L00262	Cancer Genome Interpreter	D02STN	AR#p.T878A	Abiraterone	Abiraterone (阿比特龙)		AR	p.T878A	耐药性增加	PMID: 26537258	.		是	前列腺癌		.	Prostate Cancer	Early trials	Abiraterone	Approved
L01695	Cancer Genome Interpreter	D02STN	AR:amp	Abiraterone	Abiraterone (阿比特龙)		AR	AR amplification	耐药性增加	PMID: 26537258	.		是	前列腺癌		.	Prostate adenocarcinoma	Early trials	Abiraterone	Approved
L01759	Cancer Genome Interpreter	D02STN	CYP17A1:norm	Abiraterone	Abiraterone (阿比特龙)		CYP17A1	CYP17A1 expression	敏感性增加	PMID: 22184395	.		是	前列腺癌		.	Prostate adenocarcinoma	Early trials	Abiraterone	Approved
L02080	hotspot3D	D05UFG	EGFR#p.D807H	Afatinib	Afatinib	kinase inhibitor	EGFR	p.D807H	耐药性增加	.			是	肺癌		NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	cancer	prediction	Afatinib	
L00248	Cancer Genome Interpreter	D05UFG	ERBB3#p.G284R	Afatinib	Afatinib	kinase inhibitor	ERBB3	p.G284R	敏感性增加	PMID: 27044931	.		是	肺癌		NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Bladder Carcinoma	Case report	Afatinib	Approved
L00249	Cancer Genome Interpreter	D05UFG	ERBB3#p.G284R	Afatinib	Afatinib	kinase inhibitor	ERBB3	p.G284R	敏感性增加	ASCO 2015 (abstr e15516)	.		是	肺癌		NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Bladder Carcinoma	Case report	Afatinib	Approved
L00417	Cancer Genome Interpreter	D05UFG	EGFR#p.G719A	Afatinib	Afatinib	kinase inhibitor	EGFR	p.G719A	敏感性增加	FDA	.		是	肺癌		NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	NCCN guidelines	Afatinib	Approved
L00418	Cancer Genome Interpreter	D05UFG	EGFR#p.G719C	Afatinib	Afatinib	kinase inhibitor	EGFR	p.G719C	敏感性增加	FDA	.		是	肺癌		NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	NCCN guidelines	Afatinib	Approved
L00419	Cancer Genome Interpreter	D05UFG	EGFR#p.G719D	Afatinib	Afatinib	kinase inhibitor	EGFR	p.G719D	敏感性增加	FDA	.		是	肺癌		NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	NCCN guidelines	Afatinib	Approved
L00420	Cancer Genome Interpreter	D05UFG	EGFR#p.G719S	Afatinib	Afatinib	kinase inhibitor	EGFR	p.G719S	敏感性增加	FDA	.		是	肺癌		NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	NCCN guidelines	Afatinib	Approved
L00421	Cancer Genome Interpreter	D05UFG	EGFR#p.L747S	Afatinib	Afatinib	kinase inhibitor	EGFR	p.L747S	敏感性增加	FDA	.		是	肺癌		NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	NCCN guidelines	Afatinib	Approved
L00401	Cancer Genome Interpreter	D05UFG	EGFR#p.L858R	Afatinib	Afatinib	kinase inhibitor	EGFR	p.L858R	敏感性增加	FDA	.		是	肺癌		NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	FDA guidelines	Afatinib	Approved
L00422	Cancer Genome Interpreter	D05UFG	EGFR#p.L861P	Afatinib	Afatinib	kinase inhibitor	EGFR	p.L861P	敏感性增加	FDA	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	NCCN guidelines	Afatinib	Approved
L00423	Cancer Genome Interpreter	D05UFG	EGFR#p.L861Q	Afatinib	Afatinib	kinase inhibitor	EGFR	p.L861Q	敏感性增加	FDA	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	NCCN guidelines	Afatinib	Approved
L00424	Cancer Genome Interpreter	D05UFG	EGFR#p.L861R	Afatinib	Afatinib	kinase inhibitor	EGFR	p.L861R	敏感性增加	FDA	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	NCCN guidelines	Afatinib	Approved
L00250	Cancer Genome Interpreter	D05UFG	ERBB3#p.R103G	Afatinib	Afatinib	kinase inhibitor	ERBB3	p.R103G	敏感性增加	PMID: 27044931	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Bladder Carcinoma	Case report	Afatinib	Approved
L00251	Cancer Genome Interpreter	D05UFG	ERBB3#p.R103G	Afatinib	Afatinib	kinase inhibitor	ERBB3	p.R103G	敏感性增加	ASCO 2015 (abstr e15516)	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Bladder Carcinoma	Case report	Afatinib	Approved
L00425	Cancer Genome Interpreter	D05UFG	EGFR#p.S768I	Afatinib	Afatinib	kinase inhibitor	EGFR	p.S768I	敏感性增加	FDA	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell  Lung Cancer	NCCN guidelines	Afatinib	Approved
L02081	hotspot3D	D05UFG	EGFR#p.S811C	Afatinib	Afatinib	kinase inhibitor	EGFR	p.S811C	耐药性增加	.			是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	cancer	prediction	Afatinib	
L00469	Cancer Genome Interpreter	D05UFG	EGFR#p.T790M	Afatinib	Afatinib	kinase inhibitor	EGFR	p.T790M	耐药性增加	NCCN	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Lung Cancer	NCCN/CAP guidelines	Afatinib	Approved
L00588	COSMIC	D05UFG	EGFR#p.T790M	Afatinib	Afatinib	kinase inhibitor	EGFR	p.T790M	.	PMID: 27553514	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small Cell Lung Cancer	.	Afatinib	Approved
L00252	Cancer Genome Interpreter	D05UFG	ERBB3#p.V104M	Afatinib	Afatinib	kinase inhibitor	ERBB3	p.V104M	敏感性增加	PMID: 27044931	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Bladder Carcinoma	Case report	Afatinib	Approved
L01447	Cancer Genome Interpreter	D05UFG	EGFR::consequence::inframe_deletion:729-761	Afatinib	Afatinib	kinase inhibitor	EGFR	EGFR exon 19 deletions	敏感性增加	FDA	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Non-small cell lung cancer	FDA guidelines	Afatinib	Approved
L01445	Cancer Genome Interpreter	D05UFG	EGFR::consequence::inframe_insertion:729-761	Afatinib	Afatinib	kinase inhibitor	EGFR	EGFR exon 19 insertions	敏感性增加	PMID: 22753918, 25589191	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Lung cancer	Late trials	Afatinib	Approved
L01446	Cancer Genome Interpreter	D05UFG	EGFR::consequence::inframe_insertion:729-761	Afatinib	Afatinib	kinase inhibitor	EGFR	EGFR exon 19 insertions	敏感性增加	ESMO 2012 (abstr 1289)	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Lung cancer	Early trials	Afatinib	Approved
L01501	Cancer Genome Interpreter	D05UFG	ERBB2:amp	Afatinib	Afatinib	kinase inhibitor	ERBB2	ERBB2 amplification	敏感性增加	AACR 2014 (abstr CT228)	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Stomach cancer	Case report	Afatinib	Approved
L01502	Cancer Genome Interpreter	D05UFG	ERBB2:amp	Afatinib	Afatinib	kinase inhibitor	ERBB2	ERBB2 amplification	敏感性增加	PMID: 20142587, 22418700, 23632474	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Breast invasive carcinoma	Late trials	Afatinib	Approved
L01503	Cancer Genome Interpreter	D05UFG	ERBB2:amp	Afatinib	Afatinib	kinase inhibitor	ERBB2	ERBB2 amplification	敏感性增加	PMID: 27044931	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Bladder Urothelial Carcinoma	Case report	Afatinib	Approved
L01504	Cancer Genome Interpreter	D05UFG	ERBB2::consequence::inframe_insertion:775-881	Afatinib	Afatinib	kinase inhibitor	ERBB2	ERBB2 proximal exon 20	敏感性增加	PMID: 26598547	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Lung adenocarcinoma	Early trials	Afatinib	Approved
L01505	Cancer Genome Interpreter	D05UFG	ERBB2::consequence::inframe_insertion:775-881	Afatinib	Afatinib	kinase inhibitor	ERBB2	ERBB2 proximal exon 20	敏感性增加	PMID: 26598547,ASCO 2017 (abstr 9071)	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Lung adenocarcinoma	Early trials	Afatinib	Approved
L01762	Cancer Genome Interpreter	D05UFG	ERBB4__.	Afatinib	Afatinib	kinase inhibitor	ERBB4	ERBB4 fusion	敏感性增加	PMID: 24727320	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Lung adenocarcinoma	Pre-clinical	Afatinib	Approved
L01889	Cancer Genome Interpreter	D05UFG	NRG1__.	Afatinib	Afatinib	kinase inhibitor	NRG1	NRG1 fusion	敏感性增加	AACR 2016 (abstr 2631)	.		是	肺癌	注意胚胎毒性	NCT01345669: 头颈癌, NCT01345682: 头颈癌, NCT01427478: 头颈癌, NCT01856478: 头颈癌, NCT02131155: 头颈癌	Lung adenocarcinoma	Case report	Afatinib	Approved
L00265	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.G719A	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.G719A	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00266	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.G719C	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.G719C	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00267	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.G719D	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.G719D	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00268	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.G719S	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.G719S	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00269	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.L747S	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.L747S	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00270	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.L858R	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.L858R	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00271	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.L861P	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.L861P	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00272	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.L861Q	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.L861Q	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00273	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.L861R	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.L861R	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00274	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.S768I	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.S768I	敏感性增加	ESMO 2012 (abstr 1289)	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00275	Cancer Genome Interpreter	D05UFG-D0N5OV	EGFR#p.T790M	Afatinib + Cetuximab	Afatinib + Cetuximab		EGFR	p.T790M	敏感性增加	PMID: 25074459	.		.	.		.	Lung Cancer	Early trials	Afatinib + Cetuximab	.
L00264	Cancer Genome Interpreter	D05UFG-D0FJ1W	EGFR#p.T790M	Afatinib + Nimotuzumab	Afatinib + Nimotuzumab		EGFR	p.T790M	敏感性增加	PMID: 26667485	.		.	.		.	Lung Cancer	Early trials	Afatinib + Nimotuzumab	.
L01818	Cancer Genome Interpreter	D0R3OP	IDH1:.	AG-120	AG-120		IDH1	IDH1 oncogenic mutation	敏感性增加	NCT02073994, 23558169	.		.	.		.	Glioma	Early trials	AG-120	Clinical Trials
L00279	Cancer Genome Interpreter	D0K7FT	IDH2#p.R140K	AG-221	AG-221		IDH2	p.R140K	敏感性增加	AACR 2014 (abstr CT103)	.		.	.		.	Hematologic Malignancies	Early trials	AG-221	.
L00280	Cancer Genome Interpreter	D0K7FT	IDH2#p.R172K	AG-221	AG-221		IDH2	p.R172K	敏感性增加	AACR 2014 (abstr CT103)	.		.	.		.	Hematologic Malignancies	Early trials	AG-221	.
L00172	Cancer Genome Interpreter	.	PIK3CB#p.D1067Y	AKT inhibitors	AKT 抑制剂		PIK3CB	p.D1067Y	敏感性增加	PMID: 26759240	.		.	.		.	Breast Cancer	Pre-clinical	AKT inhibitors	.
L00134	Cancer Genome Interpreter	.	AKT1#p.E17K	AKT inhibitors	AKT 抑制剂		AKT1	p.E17K	敏感性增加	PMID: 21464312, 17611497, 23134728, ENA 2015 (abstr B109)	.		.	.		.	Cancer	Pre-clinical	AKT inhibitors	.
L00037	Cancer Genome Interpreter	.	AKT1#p.E17K	allosteric AKT inhibitors	AKT 抑制剂		AKT1	p.E17K	敏感性增加	PMID: 21464312, 17611497	.		.	.		.	Breast Cancer	Pre-clinical	allosteric AKT inhibitors	.
L00607	COSMIC	D0U3SY	ALK#p.G1202R	Alectinib	Alectinib (艾乐替尼)	kinase inhibitor	ALK	p.G1202R	敏感性增加	PMID: 27130468	.		否	肺癌	注意重症肌痛和胚胎毒性		Non-small Cell Lung Cancer	.	Alectinib	Phase 3
L00608	COSMIC	D0U3SY	ALK#p.I1171N	Alectinib	Alectinib (艾乐替尼)	kinase inhibitor	ALK	p.I1171N	.	PMID: 25393798	.		否	肺癌	注意重症肌痛和胚胎毒性		Non-small Cell Lung Cancer	.	Alectinib	Phase 3
L00609	COSMIC	D0U3SY	ALK#p.I1171S	Alectinib	Alectinib (艾乐替尼)	kinase inhibitor	ALK	p.I1171S	.	PMID: 25393796	.		否	肺癌	注意重症肌痛和胚胎毒性		Non-small Cell Lung Cancer	.	Alectinib	Phase 3
L00610	COSMIC	D0U3SY	ALK#p.I1171S	Alectinib	Alectinib (艾乐替尼)	kinase inhibitor	ALK	p.I1171S	.	PMID: 26464158	.		否	肺癌	注意重症肌痛和胚胎毒性		Non-small Cell Lung Cancer	.	Alectinib	Phase 3
L00223	Cancer Genome Interpreter	D0U3SY	ALK#p.I1171T	Alectinib	Alectinib (艾乐替尼)	kinase inhibitor	ALK	p.I1171T	耐药性增加	PMID: 25228534	.		否	肺癌	注意重症肌痛和胚胎毒性		Lung Adenocarcinoma	Case report	Alectinib	Phase 3
L01423	Cancer Genome Interpreter	D0U3SY	ALK__.	Alectinib	Alectinib (艾乐替尼)	kinase inhibitor	ALK	ALK fusion	敏感性增加	FDA	.		否	肺癌	注意重症肌痛和胚胎毒性		Non-small cell lung cancer	FDA guidelines	Alectinib	Clinical_Trials
L01424	Cancer Genome Interpreter	D0U3SY	ALK__.	Alectinib	Alectinib (艾乐替尼)	kinase inhibitor	ALK	ALK fusion	敏感性增加	FDA	.		否	肺癌	注意重症肌痛和胚胎毒性		Lung adenocarcinoma	FDA guidelines	Alectinib	Clinical_Trials
L01314	search pubmed	D0I0RJ	SLC9A1#p.F167L	Amiloride	Amiloride		SLC9A1	p.F167L	耐药性增加	PMID: 8389452	.		.	.		.	Chronic acidosis	.	Amiloride	Approved
L00472	Cancer Genome Interpreter	D0I0RJ	KCNJ5#p.L168R	Amiloride	Amiloride		KCNJ5	p.L168R	敏感性增加	PMID: 24506072	.		.	.		.	Adrenal Adenoma	Pre-clinical	Amiloride	Approved
L01537	Cancer Genome Interpreter	D0W0BF	ERBB2:norm,ESR1:over	Anastrozole	Anastrozole		ERBB2	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		.	乳腺癌		.	Breast invasive carcinoma	FDA guidelines	Anastrozole	Approved
L01782	Cancer Genome Interpreter	D0W0BF	ERBB2:norm,ESR1:over	Anastrozole	Anastrozole		ESR1	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		.	乳腺癌		.	Breast invasive carcinoma	FDA guidelines	Anastrozole	Approved
L01315	search pubmed	D00GHZ	AR#p.F876L	Antiandrogens	Antiandrogens		AR	p.F876L	耐药性增加	PMID: 26137992	.		.	.		.	Prostate Cancer	.	Antiandrogens	Phase 2
L01857	Cancer Genome Interpreter	.	NF2:del	AR42	AR42		NF2	NF2 deletion	敏感性增加	PMID: 21778190	.		.	.		.	Schwannoma	Pre-clinical	AR42	.
L01858	Cancer Genome Interpreter	.	NF2:del	AR42	AR42		NF2	NF2 deletion	敏感性增加	ASCO 2016 (abstr 2558)	.		.	.		.	Meningioma	Early trials	AR42	.
L01859	Cancer Genome Interpreter	.	NF2:.	AR42	AR42		NF2	NF2 oncogenic mutation	敏感性增加	PMID: 21778190	.		.	.		.	Schwannoma	Pre-clinical	AR42	.
L01860	Cancer Genome Interpreter	.	NF2:.	AR42	AR42		NF2	NF2 oncogenic mutation	敏感性增加	ASCO 2016 (abstr 2558)	.		.	.		.	Meningioma	Early trials	AR42	.
L00205	Cancer Genome Interpreter	D0S7LG	AR#p.F877L	Arn-509	Arn-509		AR	p.F877L	耐药性增加	PMID: 23779130	.		.	.		.	Prostate Cancer	Case report	Arn-509	Phase 3
L00049	Cancer Genome Interpreter	D0S7LG	AR#p.T878A	Arn-509	Arn-509		AR	p.T878A	敏感性增加	PMID: 23779130	.		.	.		.	Prostate Cancer	Case report	Arn-509	Phase 3
L01741	Cancer Genome Interpreter	.	CD274:over	Atezolizumab	Atezolizumab (阿特珠单抗)	programmed death-ligand 1 (PD-L1) blocking antibody	CD274	CD274 overexpression	敏感性增加	NCT01375842,doi: 10.1093/annonc/mdu337.2	.		否	膀胱癌, 肺癌	TECENTRIQ会引起胚胎毒性	NCT02839707: 卵巢癌, NCT02891824: 卵巢癌, NCT02908672: 黑色素瘤, NCT02912559: 结肠癌, NCT02928406: 尿路上皮癌, NCT02997228: 结直肠癌, NCT03016312: 前列腺癌, NCT03024996: 肾细胞癌, NCT03038100: 卵巢癌, NCT03125902: 乳腺癌, NCT03197935: 乳腺癌, NCT03273153: 黑色素瘤, NCT03281954: 乳腺癌, NCT03371017: 乳腺癌, NCT03434379: 肝癌	Cancer, Cutaneous carcinoma, Renal cancer	Early trials	Atezolizumab	Clinical Trials
L00477	Cancer Genome Interpreter	D01ZRI	ABL1#p.T315I	Axitinib	Axitinib (阿昔替尼)		ABL1	p.T315I	敏感性增加	PMID: 25686603	.		是	肾癌		NCT01744249: 神经内分泌癌	Cancer	Pre-clinical	Axitinib	.
L01958	Cancer Genome Interpreter	D01ZRI	VHL:.	Axitinib	Axitinib (阿昔替尼)		VHL	VHL oncogenic mutation	敏感性增加	PMID: 18635227	.		是	肾癌		NCT01744249: 神经内分泌癌	Renal cancer	Pre-clinical	Axitinib	Approved
L01691	Cancer Genome Interpreter	D01ZAQ	AKT3__.	AZD5363	AZD5363		AKT3	AKT3 fusion	敏感性增加	PMID: 22722202	.		.	.		.	Breast invasive carcinoma	Pre-clinical	AZD5363	Clinical Trials,Clinical Trials
L01376	search pubmed	D0T5DP	MAP2K1#p.C121S	AZD6244	AZD6244		MAP2K1	p.C121S	耐药性增加	PMID: 19915144, PMID: 21383288, PMID: 23444215	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01380	search pubmed	D0T5DP	MAP2K1#p.D67N	AZD6244	AZD6244		MAP2K1	p.D67N	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01381	search pubmed	D0T5DP	MAP2K1#p.E120D	AZD6244	AZD6244		MAP2K1	p.E120D	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01382	search pubmed	D0T5DP	MAP2K1#p.F129L	AZD6244	AZD6244		MAP2K1	p.F129L	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01383	search pubmed	D0T5DP	MAP2K1#p.F133L	AZD6244	AZD6244		MAP2K1	p.F133L	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01384	search pubmed	D0T5DP	MAP2K1#p.G128D	AZD6244	AZD6244		MAP2K1	p.G128D	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01385	search pubmed	D0T5DP	MAP2K1#p.H119P	AZD6244	AZD6244		MAP2K1	p.H119P	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01386	search pubmed	D0T5DP	MAP2K1#p.I103N	AZD6244	AZD6244		MAP2K1	p.I103N	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01387	search pubmed	D0T5DP	MAP2K1#p.I111N	AZD6244	AZD6244		MAP2K1	p.I111N	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01389	search pubmed	D0T5DP	MAP2K1#p.I99T	AZD6244	AZD6244		MAP2K1	p.I99T	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01390	search pubmed	D0T5DP	MAP2K1#p.K104N	AZD6244	AZD6244		MAP2K1	p.K104N	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01391	search pubmed	D0T5DP	MAP2K1#p.K57N	AZD6244	AZD6244		MAP2K1	p.K57N	耐药性增加	PMID: 19915144, PMID: 21383288, PMID: 23444215	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01392	search pubmed	D0T5DP	MAP2K1#p.L215P	AZD6244	AZD6244		MAP2K1	p.L215P	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01396	search pubmed	D0T5DP	MAP2K1#p.P124L	AZD6244	AZD6244		MAP2K1	p.P124L	耐药性增加	PMID: 19915144, PMID: 21383288, PMID: 23444215	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01397	search pubmed	D0T5DP	MAP2K1#p.P124S	AZD6244	AZD6244		MAP2K1	p.P124S	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01398	search pubmed	D0T5DP	MAP2K1#p.Q56P	AZD6244	AZD6244		MAP2K1	p.Q56P	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01401	search pubmed	D0T5DP	MAP2K1#p.V211D	AZD6244	AZD6244		MAP2K1	p.V211D	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	.	AZD6244	Phase 2
L01680	Cancer Genome Interpreter	D0H9DA	TP53:del	AZD6738	AZD6738		TP53	TP53 deletion	敏感性增加	NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html	.		.	.		.	B Cell lymphoma	Early trials	AZD6738	Clinical Trials
L01706	Cancer Genome Interpreter	D0H9DA	ATM:.	AZD6738	AZD6738		ATM	ATM biallelic inactivation	敏感性增加	NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html	.		.	.		.	B Cell lymphoma	Early trials	AZD6738	Clinical Trials
L01675	Cancer Genome Interpreter	D0H9DA	TP53:.	AZD6738	AZD6738		TP53	TP53 oncogenic mutation	敏感性增加	NCT01955668,https: //ash.confex.com/ash/2014/webprogram/Paper71027.html	.		.	.		.	B Cell lymphoma	Early trials	AZD6738	Clinical Trials
L00604	COSMIC	D0RT2C	EGFR#p.C797S	AZD9291	AZD9291		EGFR	p.C797S	.	PMID: 25939061	.		.	.		.	Non-small Cell Lung Cancer	.	AZD9291	Phase 3
L00605	COSMIC	D0RT2C	EGFR#p.T790M	AZD9291	AZD9291		EGFR	p.T790M	.	PMID: 25939061	.		.	.		.	Non-small Cell Lung Cancer	.	AZD9291	Phase 3
L00606	COSMIC	D0RT2C	EGFR#p.T790M	AZD9291	AZD9291		EGFR	p.T790M	.	PMID: 26473643	.		.	.		.	Non-small Cell Lung Cancer	.	AZD9291	Phase 3
L01550	Cancer Genome Interpreter	.	KRAS:.	BCL2 inhibitor	BCL2 抑制剂		KRAS	KRAS oncogenic mutation	敏感性增加	PMID: 25968887	.		.	.		.	Ovarian cancer	Pre-clinical	BCL2 inhibitor	.
L01852	Cancer Genome Interpreter	.	MLL__.	Belinostat	Belinostat	histone deacetylase inhibitor	MLL	MLL fusion	敏感性增加	NCT00351975,NCT00357032, 22015773	.		否	淋巴瘤	可能引起胚胎毒性，建议药物治疗期间避免怀孕		Acute Myeloid Leukemia	Early trials	Belinostat	Approved
L01744	Cancer Genome Interpreter	.	CD69:under	Bendamustine	Bendamustine (苯达莫司汀)		CD69	CD69 undexpression	敏感性增加	PMID: 26701728	.		否	慢性淋巴细胞白血病，非霍奇金淋巴瘤		.	Chronic lymphocytic leukemia	Pre-clinical	Bendamustine	Approved
L01601	Cancer Genome Interpreter	D04KBL	NF1:del	Bevacizumab	Bevacizumab (贝伐珠单抗)	vascular endothelial growth factor-specific angiogenesis inhibitor	NF1	NF1 deletion	敏感性增加	PMID: 24232489, 2485933	.		是	肺癌, 腹膜癌, 宫颈癌, 胶质母细胞瘤, 结直肠癌, 卵巢癌, 肾癌, 输卵管癌	可能发生胃肠道穿孔和出血	NCT00028990: 乳腺癌, NCT00088894: 胰腺癌, NCT00109239: 乳腺癌, NCT00110214: 前列腺癌, NCT00262067: 乳腺癌, NCT00281697: 乳腺癌,NCT00324987: 胃肠道间质瘤, NCT00333775: 乳腺癌, NCT00373256: 乳腺癌, NCT00391092: 乳腺癌, NCT00448591: 乳腺癌, NCT00450203: 胃癌, NCT00486759: 淋巴瘤, NCT00520975: 乳腺癌, NCT00528567: 乳腺癌, NCT00545077: 乳腺癌, NCT00548548: 胃癌, NCT00567554: 乳腺癌, NCT00600340: 乳腺癌, NCT00625898: 乳腺癌, NCT00868634: 乳腺癌, NCT00887822: 胃癌, NCT00929240: 乳腺癌,  NCT01093235: 乳腺癌, NCT01200212: 乳腺癌, NCT01214720: 胰腺癌, NCT01236560: 脑癌，星形细胞瘤, NCT01250379: 乳腺癌, NCT01303679: 乳腺癌, NCT03434379: 肝癌	Glioma	Case report	Bevacizumab	Approved
L01602	Cancer Genome Interpreter	D04KBL	NF1:del	Bevacizumab	Bevacizumab (贝伐珠单抗)	vascular endothelial growth factor-specific angiogenesis inhibitor	NF1	NF1 deletion	敏感性降低	ASCO 2016 (abstr 11053)	.		是	肺癌, 腹膜癌, 宫颈癌, 胶质母细胞瘤, 结直肠癌, 卵巢癌, 肾癌, 输卵管癌	可能发生胃肠道穿孔和出血	NCT00028990: 乳腺癌, NCT00088894: 胰腺癌, NCT00109239: 乳腺癌, NCT00110214: 前列腺癌, NCT00262067: 乳腺癌, NCT00281697: 乳腺癌,NCT00324987: 胃肠道间质瘤, NCT00333775: 乳腺癌, NCT00373256: 乳腺癌, NCT00391092: 乳腺癌, NCT00448591: 乳腺癌, NCT00450203: 胃癌, NCT00486759: 淋巴瘤, NCT00520975: 乳腺癌, NCT00528567: 乳腺癌, NCT00545077: 乳腺癌, NCT00548548: 胃癌, NCT00567554: 乳腺癌, NCT00600340: 乳腺癌, NCT00625898: 乳腺癌, NCT00868634: 乳腺癌, NCT00887822: 胃癌, NCT00929240: 乳腺癌,  NCT01093235: 乳腺癌, NCT01200212: 乳腺癌, NCT01214720: 胰腺癌, NCT01236560: 脑癌，星形细胞瘤, NCT01250379: 乳腺癌, NCT01303679: 乳腺癌, NCT03434379: 肝癌	Malignant peripheral nerve sheat tumor	Early trials	Bevacizumab	Approved
L01865	Cancer Genome Interpreter	D04KBL	NF2:del	Bevacizumab	Bevacizumab (贝伐珠单抗)	vascular endothelial growth factor-specific angiogenesis inhibitor	NF2	NF2 deletion	敏感性增加	PMID: 19587327, 22805104, 26022982	.		是	肺癌, 腹膜癌, 宫颈癌, 胶质母细胞瘤, 结直肠癌, 卵巢癌, 肾癌, 输卵管癌	可能发生胃肠道穿孔和出血	NCT00028990: 乳腺癌, NCT00088894: 胰腺癌, NCT00109239: 乳腺癌, NCT00110214: 前列腺癌, NCT00262067: 乳腺癌, NCT00281697: 乳腺癌,NCT00324987: 胃肠道间质瘤, NCT00333775: 乳腺癌, NCT00373256: 乳腺癌, NCT00391092: 乳腺癌, NCT00448591: 乳腺癌, NCT00450203: 胃癌, NCT00486759: 淋巴瘤, NCT00520975: 乳腺癌, NCT00528567: 乳腺癌, NCT00545077: 乳腺癌, NCT00548548: 胃癌, NCT00567554: 乳腺癌, NCT00600340: 乳腺癌, NCT00625898: 乳腺癌, NCT00868634: 乳腺癌, NCT00887822: 胃癌, NCT00929240: 乳腺癌,  NCT01093235: 乳腺癌, NCT01200212: 乳腺癌, NCT01214720: 胰腺癌, NCT01236560: 脑癌，星形细胞瘤, NCT01250379: 乳腺癌, NCT01303679: 乳腺癌, NCT03434379: 肝癌	Schwannoma	Early trials	Bevacizumab	Approved
L01603	Cancer Genome Interpreter	D04KBL	NF1:.	Bevacizumab	Bevacizumab (贝伐珠单抗)	vascular endothelial growth factor-specific angiogenesis inhibitor	NF1	NF1 oncogenic mutation	敏感性增加	PMID: 24232489, 2485933	.		是	肺癌, 腹膜癌, 宫颈癌, 胶质母细胞瘤, 结直肠癌, 卵巢癌, 肾癌, 输卵管癌	可能发生胃肠道穿孔和出血	NCT00028990: 乳腺癌, NCT00088894: 胰腺癌, NCT00109239: 乳腺癌, NCT00110214: 前列腺癌, NCT00262067: 乳腺癌, NCT00281697: 乳腺癌,NCT00324987: 胃肠道间质瘤, NCT00333775: 乳腺癌, NCT00373256: 乳腺癌, NCT00391092: 乳腺癌, NCT00448591: 乳腺癌, NCT00450203: 胃癌, NCT00486759: 淋巴瘤, NCT00520975: 乳腺癌, NCT00528567: 乳腺癌, NCT00545077: 乳腺癌, NCT00548548: 胃癌, NCT00567554: 乳腺癌, NCT00600340: 乳腺癌, NCT00625898: 乳腺癌, NCT00868634: 乳腺癌, NCT00887822: 胃癌, NCT00929240: 乳腺癌,  NCT01093235: 乳腺癌, NCT01200212: 乳腺癌, NCT01214720: 胰腺癌, NCT01236560: 脑癌，星形细胞瘤, NCT01250379: 乳腺癌, NCT01303679: 乳腺癌, NCT03434379: 肝癌	Glioma	Case report	Bevacizumab	Approved
L01604	Cancer Genome Interpreter	D04KBL	NF1:.	Bevacizumab	Bevacizumab (贝伐珠单抗)	vascular endothelial growth factor-specific angiogenesis inhibitor	NF1	NF1 oncogenic mutation	敏感性降低	ASCO 2016 (abstr 11053)	.		是	肺癌, 腹膜癌, 宫颈癌, 胶质母细胞瘤, 结直肠癌, 卵巢癌, 肾癌, 输卵管癌	可能发生胃肠道穿孔和出血	NCT00028990: 乳腺癌, NCT00088894: 胰腺癌, NCT00109239: 乳腺癌, NCT00110214: 前列腺癌, NCT00262067: 乳腺癌, NCT00281697: 乳腺癌,NCT00324987: 胃肠道间质瘤, NCT00333775: 乳腺癌, NCT00373256: 乳腺癌, NCT00391092: 乳腺癌, NCT00448591: 乳腺癌, NCT00450203: 胃癌, NCT00486759: 淋巴瘤, NCT00520975: 乳腺癌, NCT00528567: 乳腺癌, NCT00545077: 乳腺癌, NCT00548548: 胃癌, NCT00567554: 乳腺癌, NCT00600340: 乳腺癌, NCT00625898: 乳腺癌, NCT00868634: 乳腺癌, NCT00887822: 胃癌, NCT00929240: 乳腺癌,  NCT01093235: 乳腺癌, NCT01200212: 乳腺癌, NCT01214720: 胰腺癌, NCT01236560: 脑癌，星形细胞瘤, NCT01250379: 乳腺癌, NCT01303679: 乳腺癌, NCT03434379: 肝癌	Malignant peripheral nerve sheat tumor	Early trials	Bevacizumab	Approved
L01866	Cancer Genome Interpreter	D04KBL	NF2:.	Bevacizumab	Bevacizumab (贝伐珠单抗)	vascular endothelial growth factor-specific angiogenesis inhibitor	NF2	NF2 oncogenic mutation	敏感性增加	PMID: 19587327, 22805104, 26022982	.		是	肺癌, 腹膜癌, 宫颈癌, 胶质母细胞瘤, 结直肠癌, 卵巢癌, 肾癌, 输卵管癌	可能发生胃肠道穿孔和出血	NCT00028990: 乳腺癌, NCT00088894: 胰腺癌, NCT00109239: 乳腺癌, NCT00110214: 前列腺癌, NCT00262067: 乳腺癌, NCT00281697: 乳腺癌,NCT00324987: 胃肠道间质瘤, NCT00333775: 乳腺癌, NCT00373256: 乳腺癌, NCT00391092: 乳腺癌, NCT00448591: 乳腺癌, NCT00450203: 胃癌, NCT00486759: 淋巴瘤, NCT00520975: 乳腺癌, NCT00528567: 乳腺癌, NCT00545077: 乳腺癌, NCT00548548: 胃癌, NCT00567554: 乳腺癌, NCT00600340: 乳腺癌, NCT00625898: 乳腺癌, NCT00868634: 乳腺癌, NCT00887822: 胃癌, NCT00929240: 乳腺癌,  NCT01093235: 乳腺癌, NCT01200212: 乳腺癌, NCT01214720: 胰腺癌, NCT01236560: 脑癌，星形细胞瘤, NCT01250379: 乳腺癌, NCT01303679: 乳腺癌, NCT03434379: 肝癌	Schwannoma	Early trials	Bevacizumab	Approved
L01959	Cancer Genome Interpreter	D04KBL	VHL:.	Bevacizumab	Bevacizumab (贝伐珠单抗)	vascular endothelial growth factor-specific angiogenesis inhibitor	VHL	VHL oncogenic mutation	敏感性增加	PMID: 18635227	.		是	肺癌, 腹膜癌, 宫颈癌, 胶质母细胞瘤, 结直肠癌, 卵巢癌, 肾癌, 输卵管癌	可能发生胃肠道穿孔和出血	NCT00028990: 乳腺癌, NCT00088894: 胰腺癌, NCT00109239: 乳腺癌, NCT00110214: 前列腺癌, NCT00262067: 乳腺癌, NCT00281697: 乳腺癌,NCT00324987: 胃肠道间质瘤, NCT00333775: 乳腺癌, NCT00373256: 乳腺癌, NCT00391092: 乳腺癌, NCT00448591: 乳腺癌, NCT00450203: 胃癌, NCT00486759: 淋巴瘤, NCT00520975: 乳腺癌, NCT00528567: 乳腺癌, NCT00545077: 乳腺癌, NCT00548548: 胃癌, NCT00567554: 乳腺癌, NCT00600340: 乳腺癌, NCT00625898: 乳腺癌, NCT00868634: 乳腺癌, NCT00887822: 胃癌, NCT00929240: 乳腺癌,  NCT01093235: 乳腺癌, NCT01200212: 乳腺癌, NCT01214720: 胰腺癌, NCT01236560: 脑癌，星形细胞瘤, NCT01250379: 乳腺癌, NCT01303679: 乳腺癌, NCT03434379: 肝癌	Renal cancer	Pre-clinical	Bevacizumab	Approved
L01319	search pubmed	D0V9BD	AR#p.W741C	Bicalutamide	Bicalutamide (比卡鲁胺)		AR	p.W741C	耐药性增加	PMID: 25852559	.		是	前列腺癌		.	Prostate Cancer	.	Bicalutamide	Approved
L01320	search pubmed	D0V9BD	AR#p.W741L	Bicalutamide	Bicalutamide (比卡鲁胺)		AR	p.W741L	耐药性增加	PMID: 25852559	.		是	前列腺癌		.	Prostate Cancer	.	Bicalutamide	Approved
L01699	Cancer Genome Interpreter	D0V9BD	AR:over	Bicalutamide	Bicalutamide (比卡鲁胺)		AR	AR overexpression	敏感性增加	ASCO 2015 (abstr 1003)	.		是	前列腺癌		.	Breast invasive carcinoma	Early trials	Bicalutamide	Clinical Trials
L01745	Cancer Genome Interpreter	D0V9BD	CDH1:.	Bicalutamide	Bicalutamide (比卡鲁胺)		CDH1	CDH1 oncogenic mutation	敏感性增加	PMID: 27397505	.		是	前列腺癌		.	Breast invasive carcinoma	Pre-clinical	Bicalutamide	Clinical Trials
L01855	Cancer Genome Interpreter	D0V9BD	MLL2:.	Bicalutamide	Bicalutamide (比卡鲁胺)		MLL2	MLL2 oncogenic mutation	敏感性增加	PMID: 27397505	.		是	前列腺癌		.	Lung squamous cell carcinoma	Pre-clinical	Bicalutamide	Clinical Trials
L02050	search pubmed	.	HER2 amplification	BKM120	BKM120		HER2	HER2 amplification	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		.	.		.	Breast Cancer	In vitro	BKM120	
L02044	search pubmed	.	PI3KCA oncogenic mutation	BKM120	BKM120		PIK3CA	PI3KCA oncogenic mutation	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		.	.		.	Breast Cancer	In vitro	BKM120	
L01323	search pubmed	D0SH3I	PSMB5#p.A49T	Bortezomib	Bortezomib (硼替佐米)	proteasome inhibitor	PSMB5	p.A49T	耐药性增加	PMID: 19426847	.		是	多发性骨髓瘤, 淋巴瘤	有常规的多器官毒性，还具有胚胎毒性风险	NCT01788020: 华氏巨球蛋白血症, NCT03345303: 肝癌	T lymphoblastic lymphoma/leukemia	.	Bortezomib	Approved
L01324	search pubmed	D0SH3I	PSMB5#p.A49V	Bortezomib	Bortezomib (硼替佐米)		PSMB5	p.A49V	耐药性增加	PMID: 19426847	.		是	多发性骨髓瘤, 淋巴瘤	有常规的多器官毒性，还具有胚胎毒性风险	NCT01788020: 华氏巨球蛋白血症, NCT03345303: 肝癌	T lymphoblastic lymphoma/leukemia	.	Bortezomib	Approved
L01325	search pubmed	D0SH3I	PSMB5#p.A50V	Bortezomib	Bortezomib (硼替佐米)		PSMB5	p.A50V	耐药性增加	PMID: 19426847	.		是	多发性骨髓瘤, 淋巴瘤	有常规的多器官毒性，还具有胚胎毒性风险	NCT01788020: 华氏巨球蛋白血症, NCT03345303: 肝癌	T lymphoblastic lymphoma/leukemia	.	Bortezomib	Approved
L00569	Cancer Genome Interpreter	D0SH3I	FGFR3#p.Y373C	Bortezomib	Bortezomib (硼替佐米)		FGFR3	p.Y373C	耐药性增加	PMID: 19331127, 21273588	.		是	多发性骨髓瘤, 淋巴瘤	有常规的多器官毒性，还具有胚胎毒性风险	NCT01788020: 华氏巨球蛋白血症, NCT03345303: 肝癌	Myeloma	Pre-clinical	Bortezomib	Approved
L01711	Cancer Genome Interpreter	D0SH3I	BCL2:over	Bortezomib	Bortezomib (硼替佐米)		BCL2	BCL2 overexpression	敏感性增加	ASH 2015 (Blood 2015 126: 2975)	.		是	多发性骨髓瘤, 淋巴瘤	有常规的多器官毒性，还具有胚胎毒性风险	NCT01788020: 华氏巨球蛋白血症, NCT03345303: 肝癌	Multiple myeloma	Early trials	Bortezomib	Approved
L01793	Cancer Genome Interpreter	D0SH3I	FGFR3:K650.	Bortezomib	Bortezomib (硼替佐米)		FGFR3	FGFR3 (K650)	敏感性增加	PMID: 19331127, 21273588	.		是	多发性骨髓瘤, 淋巴瘤	有常规的多器官毒性，还具有胚胎毒性风险	NCT01788020: 华氏巨球蛋白血症, NCT03345303: 肝癌	Myeloma	Pre-clinical	Bortezomib	Approved
L02141	hotspot3D	D0OB0F	ABL1#p.D400Y	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.D400Y	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L02124	hotspot3D	D0OB0F	CAMK2A#p.D90N	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	CAMK2A	p.D90N	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L02125	hotspot3D	D0OB0F	CAMK2A#p.E17K	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	CAMK2A	p.E17K	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L00453	Cancer Genome Interpreter	D0OB0F	ABL1#p.E255K	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.E255K	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L00454	Cancer Genome Interpreter	D0OB0F	ABL1#p.E255V	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.E255V	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L02166	hotspot3D	D0OB0F	SRC#p.E348K	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	SRC	p.E348K	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L00455	Cancer Genome Interpreter	D0OB0F	ABL1#p.F317C	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F317C	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L00456	Cancer Genome Interpreter	D0OB0F	ABL1#p.F317I	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F317I	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L00457	Cancer Genome Interpreter	D0OB0F	ABL1#p.F317L	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F317L	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L00458	Cancer Genome Interpreter	D0OB0F	ABL1#p.F317V	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F317V	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L00459	Cancer Genome Interpreter	D0OB0F	ABL1#p.F359C	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F359C	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L00460	Cancer Genome Interpreter	D0OB0F	ABL1#p.F359I	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F359I	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L01189	COSMIC	D0OB0F	ABL1#p.F359I	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F359I	.	PMID: 23044928	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Blast Phase Chronic Myeloid Leukaemia	.	Bosutinib	Phase 1/2
L00461	Cancer Genome Interpreter	D0OB0F	ABL1#p.F359V	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F359V	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L01186	COSMIC	D0OB0F	ABL1#p.F359V	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 21357704	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	.	Bosutinib	Phase 1/2
L02055	hotspot3D	D0OB0F	ABL1#p.F401L	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.F401L	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L02118	hotspot3D	D0OB0F	ERBB3#p.G1221D	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ERBB3	p.G1221D	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L02162	hotspot3D	D0OB0F	SRC#p.G353E	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	SRC	p.G353E	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L02145	hotspot3D	D0OB0F	ABL1#p.K106N	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.K106N	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L01190	COSMIC	D0OB0F	ABL1#p.L248R	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.L248R	.	PMID: 23044928	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Blast Phase Chronic Myeloid Leukaemia	.	Bosutinib	Phase 1/2
L02119	hotspot3D	D0OB0F	ERBB3#p.L792V	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ERBB3	p.L792V	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L01187	COSMIC	D0OB0F	ABL1#p.M351T	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 21357704	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	.	Bosutinib	Phase 1/2
L02149	hotspot3D	D0OB0F	ABL1#p.R783G	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.R783G	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L02126	hotspot3D	D0OB0F	CAMK2A#p.S25L	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	CAMK2A	p.S25L	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L00462	Cancer Genome Interpreter	D0OB0F	ABL1#p.T315A	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.T315A	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L00391	Cancer Genome Interpreter	D0OB0F	ABL1#p.T315I	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.T315I	耐药性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Bosutinib	Phase 1/2
L01966	search pubmed	D0OB0F	SRC#p.V140M	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	SRC	p.V140M		.	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性			.	Bosutinib	
L01188	COSMIC	D0OB0F	ABL1#p.V299L	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.V299L	.	PMID: 23086624	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	.	Bosutinib	Phase 1/2
L02159	hotspot3D	D0OB0F	SRC#p.V346I	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	SRC	p.V346I	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L02153	hotspot3D	D0OB0F	ABL1#p.V390L	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.V390L	耐药性增加	.			否	白血病	注意监测胃肠、肝、肾、胚胎毒性		cancer	prediction	Bosutinib	
L00463	Cancer Genome Interpreter	D0OB0F	ABL1#p.Y253H	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	p.Y253H	敏感性增加	PMID: 21562040	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic Myeloid Leukaemia	NCCN guidelines	Bosutinib	Phase 1/2
L01688	Cancer Genome Interpreter	D0OB0F	ABL1__BCR	Bosutinib	Bosutinib (博舒替尼)	kinase inhibitor	ABL1	ABL1-BCR fusion	敏感性增加	FDA	.		否	白血病	注意监测胃肠、肝、肾、胚胎毒性		Chronic myeloid leukemia	FDA guidelines	Bosutinib	Approved
L00164	Cancer Genome Interpreter	.	MAP2K2#p.C125S	BRAF inhibitors	BRAF 抑制剂		MAP2K2	p.C125S	耐药性增加	PMID: 24265153	.		.	.		.	Cutaneous Melanoma	Pre-clinical	BRAF inhibitors	.
L00083	Cancer Genome Interpreter	.	AKT1#p.E17K	BRAF inhibitors	BRAF 抑制剂		AKT1	p.E17K	耐药性增加	PMID: 24265152	.		.	.		.	Cutaneous Melanoma	Case report	BRAF inhibitors	.
L00094	Cancer Genome Interpreter	.	PIK3CA#p.E545*	BRAF inhibitors	BRAF 抑制剂		PIK3CA	p.E545*	耐药性增加	PMC3936420	.		.	.		.	Cutaneous Melanoma	Case report	BRAF inhibitors	.
L00166	Cancer Genome Interpreter	.	MAP2K2#p.L46F	BRAF inhibitors	BRAF 抑制剂		MAP2K2	p.L46F	耐药性增加	PMID: 24265153	.		.	.		.	Cutaneous Melanoma	Pre-clinical	BRAF inhibitors	.
L00085	Cancer Genome Interpreter	.	BRAF#p.L597R	BRAF inhibitors	BRAF 抑制剂		BRAF	p.L597R	敏感性增加	PMID: 23715574	.		.	.		.	Cutaneous Melanoma	Case report	BRAF inhibitors	.
L00168	Cancer Genome Interpreter	.	MAP2K2#p.N126D	BRAF inhibitors	BRAF 抑制剂		MAP2K2	p.N126D	耐药性增加	PMID: 24265153	.		.	.		.	Cutaneous Melanoma	Pre-clinical	BRAF inhibitors	.
L00033	Cancer Genome Interpreter	.	MAP2K1#p.P124S	BRAF inhibitors	BRAF 抑制剂		MAP2K1	p.P124S	耐药性增加	PMID: 19915144, 21383288	.		.	.		.	Cutaneous Melanoma	Case report	BRAF inhibitors	.
L00032	Cancer Genome Interpreter	.	MAP2K1#p.Q56P	BRAF inhibitors	BRAF 抑制剂		MAP2K1	p.Q56P	耐药性增加	PMID: 19915144, 21383288	.		.	.		.	Cutaneous Melanoma	Case report	BRAF inhibitors	.
L00089	Cancer Genome Interpreter	.	MAP2K2#p.Q60P	BRAF inhibitors	BRAF 抑制剂		MAP2K2	p.Q60P	耐药性增加	PMID: 24265154	.		.	.		.	Cutaneous Melanoma	Case report	BRAF inhibitors	.
L00084	Cancer Genome Interpreter	.	AKT1#p.Q79K	BRAF inhibitors	BRAF 抑制剂		AKT1	p.Q79K	耐药性增加	PMID: 24265152	.		.	.		.	Cutaneous Melanoma	Case report	BRAF inhibitors	.
L00170	Cancer Genome Interpreter	.	MAP2K2#p.V35M	BRAF inhibitors	BRAF 抑制剂		MAP2K2	p.V35M	耐药性增加	PMID: 24265153	.		.	.		.	Cutaneous Melanoma	Pre-clinical	BRAF inhibitors	.
L00080	Cancer Genome Interpreter	.	BRAF#p.V600E	BRAF inhibitors	BRAF 抑制剂		BRAF	p.V600E	敏感性增加	PMID: 22608338	.		.	.		.	Ovary Cancer	Case report	BRAF inhibitors	.
L00131	Cancer Genome Interpreter	.	BRAF#p.V600E	BRAF inhibitors	BRAF 抑制剂		BRAF	p.V600E	敏感性增加	PMID: 22038996, 22586120	.		.	.		.	Glioma	Pre-clinical	BRAF inhibitors	.
L00128	Cancer Genome Interpreter	.	BRAF#p.V600E	BRAF inhibitor + CDK2/4 inhibitors	BRAF 抑制剂 + CDK2/4 抑制剂		BRAF	p.V600E	敏感性增加	PMID: 22997239	.		.	.		.	Cutaneous Melanoma	Pre-clinical	BRAF inhibitor + CDK2/4 inhibitors	.
L00126	Cancer Genome Interpreter	.	BRAF#p.V600E	BRAF inhibitor + HSP90 inhibitors	BRAF 抑制剂 + HSP90 抑制剂		BRAF	p.V600E	敏感性增加	PMID: 22351686	.		.	.		.	Cutaneous Melanoma	Pre-clinical	BRAF inhibitor + HSP90 inhibitors	.
L00098	Cancer Genome Interpreter	.	BRAF#p.V600E	BRAF inhibitor + MEK inhibitors	BRAF 抑制剂 + MEK 抑制剂		BRAF	p.V600E	敏感性增加	ASCO 2013 (abstr 9029)	.		.	.		.	Thyroid Cancer	Early trials	BRAF inhibitor + MEK inhibitors	.
L00127	Cancer Genome Interpreter	.	BRAF#p.V600E	BRAF inhibitor + PI3K pathway inhibitors	BRAF 抑制剂 + PI3K pathway 抑制剂		BRAF	p.V600E	敏感性增加	PMID: 22389471, 21156289	.		.	.		.	Cutaneous Melanoma	Pre-clinical	BRAF inhibitor + PI3K pathway inhibitors	.
L01422	Cancer Genome Interpreter	D08PIE	ALK:amp	Brigatinib	Brigatinib (布加替尼)		ALK	ALK amplification	敏感性增加	ASCO 2017 (abstr 9065)	.		否	肺癌			Lung adenocarcinoma	Case report	Brigatinib	Approved
L01421	Cancer Genome Interpreter	D08PIE	ALK__.	Brigatinib	Brigatinib (布加替尼)		ALK	ALK fusion	敏感性增加	FDA	.		否	肺癌			Non-small cell lung cancer	FDA guidelines	Brigatinib	Approved
L01724	Cancer Genome Interpreter	D0W7HE	BRAF:V600.	BYL719	BYL719		BRAF	BRAF (V600)	敏感性增加	ENA 2014 (abstr 11LBA)	.		.	.		.	Colorectal adenocarcinoma	Early trials	BYL719	Approved, Approved,Clinical Trials
L01912	Cancer Genome Interpreter	D0W7HE	PTEN:.	BYL719	BYL719		PTEN	PTEN biallelic inactivation	耐药性增加	PMID: 25409150	.		.	.		.	Breast invasive carcinoma	Case report	BYL719	Clinical Trials
L00565	Cancer Genome Interpreter	D0IQ6P	RET#p.C634W	Cabozantinib	Cabozantinib (卡博替尼)	kinase inhibitor	RET	p.C634W	敏感性增加	PMID: 21470995	.		否	甲状腺癌, 肾癌	cometriqy引起1-3%患者发生胃穿孔或瘘，少数出现严重出血现象	NCT01522443: 前列腺癌, NCT01605227: 前列腺癌	Thyroid Cancer	Pre-clinical	Cabozantinib	.
L00515	Cancer Genome Interpreter	D0IQ6P	ROS1#p.G2032R	Cabozantinib	Cabozantinib (卡博替尼)	kinase inhibitor	ROS1	p.G2032R	敏感性增加	PMID: 25351743	.		否	甲状腺癌, 肾癌	cometriqy引起1-3%患者发生胃穿孔或瘘，少数出现严重出血现象	NCT01522443: 前列腺癌, NCT01605227: 前列腺癌	Lung Adenocarcinoma	Pre-clinical	Cabozantinib	.
L00566	Cancer Genome Interpreter	D0IQ6P	RET#p.M918T	Cabozantinib	Cabozantinib (卡博替尼)	kinase inhibitor	RET	p.M918T	敏感性增加	PMID: 21470995	.		否	甲状腺癌, 肾癌	cometriqy引起1-3%患者发生胃穿孔或瘘，少数出现严重出血现象	NCT01522443: 前列腺癌, NCT01605227: 前列腺癌	Thyroid Cancer	Pre-clinical	Cabozantinib	.
L00503	Cancer Genome Interpreter	D0IQ6P	ABL1#p.V299L	Cabozantinib	Cabozantinib (卡博替尼)	kinase inhibitor	ABL1	p.V299L	敏感性增加	PMID: 26924578	.		否	甲状腺癌, 肾癌	cometriqy引起1-3%患者发生胃穿孔或瘘，少数出现严重出血现象	NCT01522443: 前列腺癌, NCT01605227: 前列腺癌	Cancer	Pre-clinical	Cabozantinib	.
L01813	Cancer Genome Interpreter	D0IQ6P	HGF:over	Cabozantinib	Cabozantinib (卡博替尼)	kinase inhibitor	HGF	HGF overexpression	敏感性增加	PMID: 25534569	.		否	甲状腺癌, 肾癌	cometriqy引起1-3%患者发生胃穿孔或瘘，少数出现严重出血现象	NCT01522443: 前列腺癌, NCT01605227: 前列腺癌	Urinary tract carcinoma	Pre-clinical	Cabozantinib	Approved
L01584	Cancer Genome Interpreter	D0IQ6P	MET:amp	Cabozantinib	Cabozantinib (卡博替尼)	kinase inhibitor	MET	MET amplification	敏感性增加	ENA 2015 (abstr A52)	.		否	甲状腺癌, 肾癌	cometriqy引起1-3%患者发生胃穿孔或瘘，少数出现严重出血现象	NCT01522443: 前列腺癌, NCT01605227: 前列腺癌	Colorectal adenocarcinoma	Case report	Cabozantinib	Clinical Trials
L01925	Cancer Genome Interpreter	D0IQ6P	RET__.	Cabozantinib	Cabozantinib (卡博替尼)	kinase inhibitor	RET	RET fusion	敏感性增加	PMID: 28447912	.		否	甲状腺癌, 肾癌	cometriqy引起1-3%患者发生胃穿孔或瘘，少数出现严重出血现象	NCT01522443: 前列腺癌, NCT01605227: 前列腺癌	Lung adenocarcinoma	Early trials	Cabozantinib	Clinical Trials
L01924	Cancer Genome Interpreter	D0IQ6P	RET__TPCN1	Cabozantinib	Cabozantinib (卡博替尼)	kinase inhibitor	RET	RET-TPCN1 fusion	敏感性增加	PMID: 21470995	.		否	甲状腺癌, 肾癌	cometriqy引起1-3%患者发生胃穿孔或瘘，少数出现严重出血现象	NCT01522443: 前列腺癌, NCT01605227: 前列腺癌	Thyroid carcinoma	Pre-clinical	Cabozantinib	Clinical Trials
L01932	Cancer Genome Interpreter	D0IQ6P	ROS1__.	Cabozantinib	Cabozantinib (卡博替尼)	kinase inhibitor	ROS1	ROS1 fusion	敏感性增加	PMID: 27370605	.		否	甲状腺癌, 肾癌	cometriqy引起1-3%患者发生胃穿孔或瘘，少数出现严重出血现象	NCT01522443: 前列腺癌, NCT01605227: 前列腺癌	Lung adenocarcinoma	Case report	Cabozantinib	Clinical Trials
L01620	Cancer Genome Interpreter	D09VMI	NF1:del	Cediranib	Cediranib		NF1	NF1 deletion	敏感性降低	NCT00326872	.		.	.		.	Plexiform neurofibroma	Early trials	Cediranib	Phase 3
L01621	Cancer Genome Interpreter	D09VMI	NF1:.	Cediranib	Cediranib		NF1	NF1 oncogenic mutation	敏感性降低	NCT00326872	.		.	.		.	Plexiform neurofibroma	Early trials	Cediranib	Phase 3
L00006	COSMIC	D04LVK	ALK#p.F1174C	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.F1174C	.	PMID: 24675041	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Non-small Cell Lung Cancer	.	Ceritinib	Approved
L00007	COSMIC	D04LVK	ALK#p.F1174V	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.F1174V	.	PMID: 24675041	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Non-small Cell Lung Cancer	.	Ceritinib	Approved
L00001	Cancer Genome Interpreter	D04LVK	ALK#p.G1123S	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.G1123S	耐药性增加	PMID: 26134233	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Lung Adenocarcinoma	Case report	Ceritinib	Approved
L00008	COSMIC	D04LVK	ALK#p.G1202R	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.G1202R	敏感性增加	PMID: 24675041	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Non-small Cell Lung Cancer	.	Ceritinib	Approved
L00002	Cancer Genome Interpreter	D04LVK	ALK#p.G1269A	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.G1269A	敏感性增加	PMID: 24670165, 24327273	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Lung Adenocarcinoma	FDA guidelines	Ceritinib	Approved
L00009	COSMIC	D04LVK	ALK#p.G1269A	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.G1269A	敏感性增加	PMID: 24675041	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Non-small Cell Lung Cancer	.	Ceritinib	Approved
L00003	Cancer Genome Interpreter	D04LVK	ALK#p.I1171T	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.I1171T	敏感性增加	PMID: 24670165, 24327273	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Lung Adenocarcinoma	FDA guidelines	Ceritinib	Approved
L00004	Cancer Genome Interpreter	D04LVK	ALK#p.L1196M	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.L1196M	敏感性增加	PMID: 24670165, 24327273	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Lung Adenocarcinoma	FDA guidelines	Ceritinib	Approved
L00010	COSMIC	D04LVK	ALK#p.L1196M	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.L1196M	敏感性增加	PMID: 24675041	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Non-small Cell Lung Cancer	.	Ceritinib	Approved
L00005	Cancer Genome Interpreter	D04LVK	ALK#p.S1206Y	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	p.S1206Y	敏感性增加	PMID: 24670165, 24327273	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Lung Adenocarcinoma	FDA guidelines	Ceritinib	Approved
L01420	Cancer Genome Interpreter	D04LVK	ALK::consequence::inframe_insertion:.1151T.	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	ALK inframe insertion (1151T)	敏感性增加	PMID: 24670165	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Lung adenocarcinoma	FDA guidelines	Ceritinib	Clinical Trials
L01417	Cancer Genome Interpreter	D04LVK	ALK__.	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	ALK fusion	敏感性增加	NCT02186821	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Hematologic malignancy	Early trials	Ceritinib	Clinical Trials
L01418	Cancer Genome Interpreter	D04LVK	ALK__.	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	ALK fusion	敏感性增加	PMID: 26633560, 26933125, 27742657	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Colorectal adenocarcinoma, Inflammatory myofibroblastic cancer	Case report	Ceritinib	Clinical Trials
L01419	Cancer Genome Interpreter	D04LVK	ALK__.	Ceritinib	Ceritinib (赛立替尼)	kinase inhibitor	ALK	ALK fusion	敏感性增加	FDA	.		否	肺癌	批准用于ALK阳性的NSCLC，药物治疗具有较严重的胃肠道毒性和一定的胚胎毒性		Lung adenocarcinoma, Non-small cell lung cancer	FDA guidelines	Ceritinib	Approved
L00412	Cancer Genome Interpreter	D0N5OV	KRAS#p.G13D	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	KRAS	p.G13D	敏感性降低	PMID: 27114605	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Adenocarcinoma	Late trials	Cetuximab	Approved
L01326	search pubmed	D0N5OV	KRAS#p.G13D	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	KRAS	p.G13D	耐药性增加	PMID: 27114605	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal cancer	.	Cetuximab	Approved
L00199	Cancer Genome Interpreter	D0N5OV	EGFR#p.G465R	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	p.G465R	耐药性增加	PMID: 22270724, 26059438, 25623215, 22270724, 26888827	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Adenocarcinoma	Case report	Cetuximab	Approved
L00504	Cancer Genome Interpreter	D0N5OV	EGFR#p.G465R	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	p.G465R	耐药性增加	PMID: 25623215	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Adenocarcinoma	Pre-clinical	Cetuximab	Approved
L00505	Cancer Genome Interpreter	D0N5OV	EGFR#p.I491M	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	p.I491M	耐药性增加	PMID: 25623215	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Adenocarcinoma	Pre-clinical	Cetuximab	Approved
L00200	Cancer Genome Interpreter	D0N5OV	EGFR#p.K467T	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	p.K467T	耐药性增加	PMID: 22270724, 26059438, 25623215, 22270724, 26888827	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Adenocarcinoma	Case report	Cetuximab	Approved
L00246	Cancer Genome Interpreter	D0N5OV	EGFR#p.P546S	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	p.P546S	敏感性增加	PMID: 23578570	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Head And Neck Cancer	Case report	Cetuximab	Approved
L02013	search pubmed	D0N5OV	PTEN#p.R159S	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	PTEN	p.R159S	敏感性降低	PMID: 21163703	PTEN loss is associated with lack of benefit from the anti-EGFR antibody, cetuximab		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Cancer	Case report	Cetuximab	
L01965	search pubmed	D0N5OV	PTEN#p.R233*	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	PTEN	p.R233*	敏感性降低	PMID: 21163703	PTEN loss is associated with lack of benefit from the anti-EGFR antibody, cetuximab		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Cancer	Case report	Cetuximab	
L00201	Cancer Genome Interpreter	D0N5OV	EGFR#p.R451C	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	p.R451C	耐药性增加	PMID: 22270724, 26059438, 25623215, 22270724, 26888827	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Adenocarcinoma	Case report	Cetuximab	Approved
L00506	Cancer Genome Interpreter	D0N5OV	EGFR#p.S464L	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	p.S464L	耐药性增加	PMID: 25623215	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Adenocarcinoma	Pre-clinical	Cetuximab	Approved
L00202	Cancer Genome Interpreter	D0N5OV	EGFR#p.S492R	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	p.S492R	耐药性增加	PMID: 22270724, 26059438, 25623215, 22270724, 26888827	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Adenocarcinoma	Case report	Cetuximab	Approved
L00411	Cancer Genome Interpreter	D0N5OV	BRAF#p.V600E	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	BRAF	p.V600E	耐药性增加	PMID: 20619739, 21163703, 23325582	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal Adenocarcinoma	Late trials	Cetuximab	Approved
L01466	Cancer Genome Interpreter	D0N5OV	EGFR::consequence::inframe_insertion:729-761	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	EGFR exon 19 insertions	敏感性增加	ESMO 2012 (abstr 1289)	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Lung cancer	Early trials	Cetuximab	Approved
L01463	Cancer Genome Interpreter	D0N5OV	NF2:del,EGFR:.	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	NF2 deletion + EGFR oncogenic mutation	耐药性增加	PMID: 24813888	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Lung cancer	Case report	Cetuximab	Approved
L01879	Cancer Genome Interpreter	D0N5OV	NF2:del,EGFR:.	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	NF2	NF2 deletion + EGFR oncogenic mutation	耐药性增加	PMID: 24813888	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Lung cancer	Case report	Cetuximab	Approved
L01719	Cancer Genome Interpreter	D0N5OV	BRAF:V600.	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	BRAF	BRAF (V600)	敏感性增加	PMID: 27729313	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal adenocarcinoma	Early trials	Cetuximab	Approved
L01465	Cancer Genome Interpreter	D0N5OV	EGFR:over	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	EGFR overexpression	敏感性增加	FDA	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal adenocarcinoma	FDA guidelines	Cetuximab	Approved
L01561	Cancer Genome Interpreter	D0N5OV	KRAS:.	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	KRAS	KRAS oncogenic mutation	耐药性增加	FDA guidelines	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal adenocarcinoma	FDA guidelines	Cetuximab	Approved
L01464	Cancer Genome Interpreter	D0N5OV	NF2:.,EGFR:.	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	EGFR	NF2 oncogenic mutation + EGFR oncogenic mutation	耐药性增加	PMID: 24813888	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Lung cancer	Case report	Cetuximab	Approved
L01880	Cancer Genome Interpreter	D0N5OV	NF2:.,EGFR:.	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	NF2	NF2 oncogenic mutation + EGFR oncogenic mutation	耐药性增加	PMID: 24813888	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Lung cancer	Case report	Cetuximab	Approved
L01886	Cancer Genome Interpreter	D0N5OV	NRAS:.	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	NRAS	NRAS oncogenic mutation	耐药性增加	PMID: 24024839, 20619739, 23325582	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal adenocarcinoma	NCCN guidelines	Cetuximab	Approved
L02272	Cancer Genome Interpreter	D0N5OV	NRAS:wild-type	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	NRAS	NRAS oncogenic mutation	耐药性增加	FDA	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal adenocarcinoma	NCCN guidelines	Cetuximab	Approved
L01896	Cancer Genome Interpreter	D0N5OV	PIK3CA:.	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	PIK3CA	PIK3CA oncogenic mutation	耐药性增加	PMID: 19223544, 20619739	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal adenocarcinoma	Late trials	Cetuximab	Approved
L01911	Cancer Genome Interpreter	D0N5OV	PTEN:.	Cetuximab	Cetuximab (西妥昔单抗)	epidermal growth factor receptor (EGFR) antagonist	PTEN	PTEN biallelic inactivation	耐药性增加	Caris molecular intelligence	.		是	结直肠癌, 头颈癌	较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	NCT00075686: 胰腺癌, NCT00095199: 非小细胞肺癌, NCT00112294: 非小细胞肺癌, NCT00148798: 非小细胞肺癌, NCT00509561: 食管癌, NCT00820755: 非小细胞肺癌, NCT02438722: 非小细胞肺癌	Colorectal adenocarcinoma	Case report	Cetuximab	Approved
L00196	Cancer Genome Interpreter	D0N5OV-D03LJR	EGFR#p.P753S	Cetuximab + Sirolimus	Cetuximab + Sirolimus		EGFR	p.P753S	敏感性增加	PMID: 24934779	.		.	.		.	Head And Neck Cancer	Case report	Cetuximab + Sirolimus	.
L01703	Cancer Genome Interpreter	.	RAD50:L1237F,ATM:del	CHK1/2 inhibitor	CHK1/2 抑制剂		ATM	RAD50 (L1237F) + ATM deletion	敏感性增加	PMID: 24934408	.		.	.		.	Cancer	Case report	CHK1/2 inhibitor	.
L01913	Cancer Genome Interpreter	.	RAD50:L1237F,ATM:del	CHK1/2 inhibitor	CHK1/2 抑制剂		RAD50	RAD50 (L1237F) + ATM deletion	敏感性增加	PMID: 24934408	.		.	.		.	Cancer	Case report	CHK1/2 inhibitor	.
L01708	Cancer Genome Interpreter	D0U5HU	ATM:del	Cisplatin	Cisplatin		ATM	ATM deletion	敏感性增加	PMID: 26238431	.		.	.		.	Bladder Urothelial Carcinoma	Early trials	Cisplatin	Approved
L01765	Cancer Genome Interpreter	D0U5HU	ERCC1:del	Cisplatin	Cisplatin		ERCC1	ERCC1 deletion	敏感性增加	PMID: 23275151, 23934192	.		.	.		.	Lung cancer	Pre-clinical	Cisplatin	Approved
L01785	Cancer Genome Interpreter	D0U5HU	FANCC:del	Cisplatin	Cisplatin		FANCC	FANCC deletion	敏感性增加	PMID: 26238431	.		.	.		.	Bladder Urothelial Carcinoma	Early trials	Cisplatin	Approved
L01919	Cancer Genome Interpreter	D0U5HU	RB1:del	Cisplatin	Cisplatin		RB1	RB1 deletion	敏感性增加	PMID: 26238431	.		.	.		.	Bladder Urothelial Carcinoma	Early trials	Cisplatin	Approved
L01709	Cancer Genome Interpreter	D0U5HU	ATM:.	Cisplatin	Cisplatin		ATM	ATM oncogenic mutation	敏感性增加	PMID: 26238431	.		.	.		.	Bladder Urothelial Carcinoma	Early trials	Cisplatin	Approved
L01737	Cancer Genome Interpreter	D0U5HU	BRCA1:.	Cisplatin	Cisplatin		BRCA1	BRCA1 oncogenic mutation	敏感性增加	PMID: 26801247	.		.	.		.	Breast invasive carcinoma	Early trials	Cisplatin	Approved
L01435	Cancer Genome Interpreter	D0U5HU	BRCA2:.	Cisplatin	Cisplatin		BRCA2	BRCA2 oncogenic mutation	敏感性增加	PMID: 26801247	.		.	.		.	Breast invasive carcinoma	Early trials	Cisplatin	Approved
L01766	Cancer Genome Interpreter	D0U5HU	ERCC1:.	Cisplatin	Cisplatin		ERCC1	ERCC1 oncogenic mutation	敏感性增加	PMID: 23275151, 23934192	.		.	.		.	Lung cancer	Pre-clinical	Cisplatin	Approved
L01764	Cancer Genome Interpreter	D0U5HU	ERCC1:over	Cisplatin	Cisplatin		ERCC1	ERCC1 overexpression	耐药性增加	PMID: 20846399, 21177407	.		.	.		.	Bladder Urothelial Carcinoma	Pre-clinical	Cisplatin	Approved
L01767	Cancer Genome Interpreter	D0U5HU	ERCC2:.	Cisplatin	Cisplatin		ERCC2	ERCC2 oncogenic mutation	敏感性增加	PMID: 25096233	.		.	.		.	Bladder Urothelial Carcinoma	Early trials	Cisplatin	Approved
L01768	Cancer Genome Interpreter	D0U5HU	ERCC4:.	Cisplatin	Cisplatin		ERCC4	ERCC4 oncogenic mutation	敏感性增加	PMID: 25634215	.		.	.		.	Ovarian cancer	Pre-clinical	Cisplatin	Approved
L01769	Cancer Genome Interpreter	D0U5HU	ERCC6:.	Cisplatin	Cisplatin		ERCC6	ERCC6 oncogenic mutation	敏感性增加	PMID: 25634215	.		.	.		.	Ovarian cancer	Pre-clinical	Cisplatin	Approved
L01786	Cancer Genome Interpreter	D0U5HU	FANCC:.	Cisplatin	Cisplatin		FANCC	FANCC oncogenic mutation	敏感性增加	PMID: 26238431	.		.	.		.	Bladder Urothelial Carcinoma	Early trials	Cisplatin	Approved
L01850	Cancer Genome Interpreter	D0U5HU	MDM2:amp	Cisplatin	Cisplatin		MDM2	MDM2 amplification	耐药性增加	PMID: 27646943	.		.	.		.	Male germ cell tumor	Early trials	Cisplatin	Approved
L01920	Cancer Genome Interpreter	D0U5HU	RB1:.	Cisplatin	Cisplatin		RB1	RB1 oncogenic mutation	敏感性增加	PMID: 26238431	.		.	.		.	Bladder Urothelial Carcinoma	Early trials	Cisplatin	Approved
L01677	Cancer Genome Interpreter	D0U5HU	TP53:.	Cisplatin	Cisplatin		TP53	TP53 oncogenic mutation	耐药性增加	PMID: 27646943	.		.	.		.	Female germ cell tumor, Male germ cell tumor	Early trials	Cisplatin	Approved
L01945	Cancer Genome Interpreter	D0U5HU	TPMT:.	Cisplatin	Cisplatin		TPMT	TPMT biallelic inactivation	毒性增加 (Ototoxicity)	FDA	.		.	.		.	Cancer	FDA guidelines	Cisplatin	Approved
L01944	Cancer Genome Interpreter	D0U5HU	TPMT::consequence::splice_acceptor_variant:.	Cisplatin	Cisplatin		TPMT	TPMT splice acceptor variant	毒性增加 (Ototoxicity)	FDA	.		.	.		.	Cancer	FDA guidelines	Cisplatin	Approved
L01980	search pubmed	.	BRAF#p.V600E	Cobimetinib	Cobimetinib (卡比替尼)	部分患者具有严重的光敏感，建议避免长时间阳光照射；具有胎儿毒性，建议具有生殖能力的女性进行有效保护。	BRAF	p.V600E	敏感性增加	FDA	.		否	黑色素瘤			Melanoma	FDA guidelines	Cobimetinib	Approved
L01987	search pubmed	.	BRAF#p.V600K	Cobimetinib	Cobimetinib (卡比替尼)	部分患者具有严重的光敏感，建议避免长时间阳光照射；具有胎儿毒性，建议具有生殖能力的女性进行有效保护。	BRAF	p.V600K	敏感性增加	FDA	.		否	黑色素瘤			Melanoma	FDA guidelines	Cobimetinib	Approved
L00286	Cancer Genome Interpreter	D02AYJ	PDGFRA#p.D842V	Crenolanib	Crenolanib		PDGFRA	p.D842V	敏感性增加	ASCO 2016 (abstr 11010)	.		.	.		.	Gastrointestinal Stromal Tumour	Early trials	Crenolanib	.
L00517	Cancer Genome Interpreter	D02AYJ	PDGFRA#p.G853D	Crenolanib	Crenolanib		PDGFRA	p.G853D	敏感性增加	PMID: 24132921	.		.	.		.	Cutaneous Melanoma	Pre-clinical	Crenolanib	.
L00518	Cancer Genome Interpreter	D02AYJ	PDGFRA#p.H845Y	Crenolanib	Crenolanib		PDGFRA	p.H845Y	敏感性增加	PMID: 24132921	.		.	.		.	Cutaneous Melanoma	Pre-clinical	Crenolanib	.
L00521	Cancer Genome Interpreter	D02AYJ	PDGFRA#p.P577S	Crenolanib	Crenolanib		PDGFRA	p.P577S	敏感性增加	PMID: 24132921	.		.	.		.	Cutaneous Melanoma	Pre-clinical	Crenolanib	.
L00519	Cancer Genome Interpreter	D02AYJ	PDGFRA#p.R841K	Crenolanib	Crenolanib		PDGFRA	p.R841K	敏感性增加	PMID: 24132921	.		.	.		.	Cutaneous Melanoma	Pre-clinical	Crenolanib	.
L00520	Cancer Genome Interpreter	D02AYJ	PDGFRA#p.V658A	Crenolanib	Crenolanib		PDGFRA	p.V658A	敏感性增加	PMID: 24132921	.		.	.		.	Cutaneous Melanoma	Pre-clinical	Crenolanib	.
L01799	Cancer Genome Interpreter	D02AYJ	FLT3:N676.	Crenolanib	Crenolanib		FLT3	FLT3 (N676)	敏感性增加	PMID: 24619500	.		.	.		.	Acute Myeloid Leukemia	Pre-clinical	Crenolanib	.
L00570	Cancer Genome Interpreter	D03ZBT	ALK#p.A348D	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.A348D	敏感性增加	PMID: 26032424	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Acute Myeloid Leukaemia	Pre-clinical	Crizotinib	Approved
L00206	Cancer Genome Interpreter	D03ZBT	ALK#p.C1156Y	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.C1156Y	耐药性增加	PMID: 22277784, 25228534	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00225	Cancer Genome Interpreter	D03ZBT	ALK#p.C1156Y	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.C1156Y	耐药性增加	PMID: 20979473	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small Cell  Lung Cancer	Case report	Crizotinib	Approved
L00582	COSMIC	D03ZBT	ALK#p.C1156Y	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.C1156Y	.	PMID: 23434628	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small Cell Lung Cancer	.	Crizotinib	Approved
L00207	Cancer Genome Interpreter	D03ZBT	ALK#p.F1174L	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.F1174L	耐药性增加	PMID: 22277784, 25228534	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00555	Cancer Genome Interpreter	D03ZBT	ALK#p.F1174L	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.F1174L	耐药性增加	PMID: 22072639	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Glioma	Pre-clinical	Crizotinib	Approved
L00556	Cancer Genome Interpreter	D03ZBT	ALK#p.F1245C	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.F1245C	敏感性增加	PMID: 22072639	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Glioma	Pre-clinical	Crizotinib	Approved
L00571	Cancer Genome Interpreter	D03ZBT	ALK#p.F856S	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.F856S	敏感性增加	PMID: 26032424	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Acute Myeloid Leukaemia	Pre-clinical	Crizotinib	Approved
L00557	Cancer Genome Interpreter	D03ZBT	ALK#p.G1128A	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.G1128A	敏感性增加	PMID: 22072639	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Glioma	Pre-clinical	Crizotinib	Approved
L00208	Cancer Genome Interpreter	D03ZBT	ALK#p.G1202R	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.G1202R	耐药性增加	PMID: 22277784, 25228534	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00209	Cancer Genome Interpreter	D03ZBT	ALK#p.G1269A	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.G1269A	耐药性增加	PMID: 22277784, 25228534	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00583	COSMIC	D03ZBT	ALK#p.G1269A	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.G1269A	.	PMID: 23344087	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small Cell Lung Cancer	.	Crizotinib	Approved
L00584	COSMIC	D03ZBT	ALK#p.G1269A	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.G1269A	.	PMID: 23434628	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small Cell Lung Cancer	.	Crizotinib	Approved
L00585	COSMIC	D03ZBT	ALK#p.G1269A	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.G1269A	.	PMID: 24675041	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small Cell Lung Cancer	.	Crizotinib	Approved
L00215	Cancer Genome Interpreter	D03ZBT	ROS1#p.G2032R	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ROS1	p.G2032R	耐药性增加	PMID: 23724914, 25688157	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00077	Cancer Genome Interpreter	D03ZBT	MET#p.H1112L	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	p.H1112L	敏感性增加	AACR 2012 (abstr 1786)	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Cancer	Pre-clinical	Crizotinib	Approved
L00479	Cancer Genome Interpreter	D03ZBT	MET#p.H1112R	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	p.H1112R	敏感性增加	PMID: 17483355	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Cancer	Pre-clinical	Crizotinib	Approved
L00558	Cancer Genome Interpreter	D03ZBT	ALK#p.I1171N	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.I1171N	敏感性增加	PMID: 22072639	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Glioma	Pre-clinical	Crizotinib	Approved
L00210	Cancer Genome Interpreter	D03ZBT	ALK#p.I1171T	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.I1171T	耐药性增加	PMID: 22277784, 25228534	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00211	Cancer Genome Interpreter	D03ZBT	ALK#p.L1152R	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.L1152R	耐药性增加	PMID: 22277784, 25228534	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00212	Cancer Genome Interpreter	D03ZBT	ALK#p.L1196M	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.L1196M	耐药性增加	PMID: 22277784, 25228534	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00226	Cancer Genome Interpreter	D03ZBT	ALK#p.L1196M	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.L1196M	耐药性增加	PMID: 20979473	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small Cell  Lung Cancer	Case report	Crizotinib	Approved
L00586	COSMIC	D03ZBT	ALK#p.L1196M	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.L1196M	.	PMID: 23434628	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small Cell Lung Cancer	.	Crizotinib	Approved
L00213	Cancer Genome Interpreter	D03ZBT	ALK#p.L1198F	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.L1198F	敏感性增加	PMID: 26698910	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00480	Cancer Genome Interpreter	D03ZBT	MET#p.M1268T	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	p.M1268T	敏感性增加	PMID: 17483355	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Cancer	Pre-clinical	Crizotinib	Approved
L00559	Cancer Genome Interpreter	D03ZBT	ALK#p.R1192P	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.R1192P	敏感性增加	PMID: 22072639	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Glioma	Pre-clinical	Crizotinib	Approved
L00560	Cancer Genome Interpreter	D03ZBT	ALK#p.R1275Q	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.R1275Q	敏感性增加	PMID: 22072639	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Glioma	Pre-clinical	Crizotinib	Approved
L00481	Cancer Genome Interpreter	D03ZBT	MET#p.R988C	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	p.R988C	敏感性增加	PMID: 17483355	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Cancer	Pre-clinical	Crizotinib	Approved
L00214	Cancer Genome Interpreter	D03ZBT	ALK#p.S1206Y	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.S1206Y	耐药性增加	PMID: 22277784, 25228534	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung Adenocarcinoma	Case report	Crizotinib	Approved
L00587	COSMIC	D03ZBT	ALK#p.S1206Y	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	p.S1206Y	.	PMID: 24675041	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small Cell Lung Cancer	.	Crizotinib	Approved
L00482	Cancer Genome Interpreter	D03ZBT	MET#p.T1010I	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	p.T1010I	敏感性增加	PMID: 17483355	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Cancer	Pre-clinical	Crizotinib	Approved
L00483	Cancer Genome Interpreter	D03ZBT	MET#p.V1110I	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	p.V1110I	敏感性增加	PMID: 17483355	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Cancer	Pre-clinical	Crizotinib	Approved
L00478	Cancer Genome Interpreter	D03ZBT	ABL1#p.V299L	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ABL1	p.V299L	敏感性增加	PMID: 26924578	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Cancer	Pre-clinical	Crizotinib	Approved
L01415	Cancer Genome Interpreter	D03ZBT	ALK::consequence::inframe_insertion:.1151T.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	ALK inframe insertion (1151T)	耐药性增加	PMID: 22277784	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung adenocarcinoma	Case report	Crizotinib	Clinical trials
L01413	Cancer Genome Interpreter	D03ZBT	ALK:amp	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	ALK amplification	耐药性增加	PMID: 22277784	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung adenocarcinoma	Case report	Crizotinib	Clinical trials
L01414	Cancer Genome Interpreter	D03ZBT	ALK:amp	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	ALK amplification	耐药性增加	PMID: 22235099	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small cell lung cancer	Clinical trials	Crizotinib	Approved
L01410	Cancer Genome Interpreter	D03ZBT	ALK__.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	ALK fusion	敏感性增加	PMID: 24491302,NCT02270034	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Glioblastoma, Liposarcoma	Early trials	Crizotinib	Clinical trials
L01411	Cancer Genome Interpreter	D03ZBT	ALK__.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	ALK fusion	敏感性增加	PMID: 20979472, 24687827	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Inflammatory myofibroblastic cancer, Thyroid carcinoma	Case report	Crizotinib	Clinical trials
L01412	Cancer Genome Interpreter	D03ZBT	ALK__.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	ALK fusion	敏感性增加	FDA	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung adenocarcinoma, Non-small cell lung cancer	FDA guidelines	Crizotinib	Approved
L01416	Cancer Genome Interpreter	D03ZBT	ALK:.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ALK	ALK oncogenic mutation	耐药性增加	PMID: 22235099	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small cell lung cancer	Clinical trials	Crizotinib	Approved
L01570	Cancer Genome Interpreter	D03ZBT	MET:Y1230C,Y1235D	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	MET (Y1230C,Y1235D)	耐药性增加	PMID: 17483355	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Cancer	Pre-clinical	Crizotinib	Clinical trials
L01573	Cancer Genome Interpreter	D03ZBT	MET:amp	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	MET amplification	敏感性增加	NCT02499614,ASCO 2015 (abstr 2595)	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small cell lung cancer	Early trials	Crizotinib	Clinical Trials
L01574	Cancer Genome Interpreter	D03ZBT	MET:amp	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	MET amplification	敏感性增加	ASCO 2014 (abstr 8001),ASCO 2015 (abstr 2595),ASCO GI 2015 (abstr 1)	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung adenocarcinoma, Stomach cancer	Early trials	Crizotinib	Clinical trials
L01575	Cancer Genome Interpreter	D03ZBT	MET:amp	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	MET amplification	敏感性增加	PMID: 22162573	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Glioma	Case report	Crizotinib	Clinical trials
L01572	Cancer Genome Interpreter	D03ZBT	MET:amp,BRAF:V600E	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	MET amplification + BRAF (V600E)	敏感性增加	PMID: 27325282	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Colorectal adenocarcinoma	Case report	Crizotinib	Clinical trials
L01713	Cancer Genome Interpreter	D03ZBT	MET:amp,BRAF:V600E	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	BRAF	MET amplification + BRAF (V600E)	敏感性增加	PMID: 27325282	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Colorectal adenocarcinoma	Case report	Crizotinib	Clinical trials
L01477	Cancer Genome Interpreter	D03ZBT	MET:amp,ERBB2:amp	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ERBB2	MET amplification + ERBB2 amplification	敏感性增加	PMID: 26432108	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Stomach cancer	Case report	Crizotinib	Clinical trials
L01571	Cancer Genome Interpreter	D03ZBT	MET:amp,ERBB2:amp	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	MET amplification + ERBB2 amplification	敏感性增加	PMID: 26432108	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Stomach cancer	Case report	Crizotinib	Clinical trials
L01569	Cancer Genome Interpreter	D03ZBT	MET__.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	MET fusion	敏感性增加	PMID: 27748748	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Glioma	Case report	Crizotinib	Clinical trials
L01576	Cancer Genome Interpreter	D03ZBT	MET:1132-1330	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	MET	MET mutation in exon 16-19	敏感性增加	AACR 2016 (abstr CT2006)	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Renal cancer	Early trials	Crizotinib	Clinical trials
L01891	Cancer Genome Interpreter	D03ZBT	NTRK1__.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	NTRK1	NTRK1 fusion	敏感性增加	ASCO 2013 (abstr 8023)	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung adenocarcinoma	Case report	Crizotinib	Clinical trials
L01929	Cancer Genome Interpreter	D03ZBT	ROS1__.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ROS1	ROS1 fusion	敏感性增加	FDA	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Non-small cell lung cancer	FDA guidelines	Crizotinib	Clinical trials
L01930	Cancer Genome Interpreter	D03ZBT	ROS1__.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ROS1	ROS1 fusion	敏感性增加	PMID: 24875859	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Inflammatory myofibroblastic cancer	Case report	Crizotinib	Clinical trials
L01931	Cancer Genome Interpreter	D03ZBT	ROS1__.	Crizotinib	Crizotinib (克唑替尼)	kinase inhibitor	ROS1	ROS1 fusion	敏感性增加	PMID: 25264305	.		是	肺癌	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者		Lung adenocarcinoma	Early trials	Crizotinib	Clinical trials
L01327	search pubmed	D05ROI	MAP2K2#p.C125S	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	MAP2K2	p.C125S	耐药性增加	PMID: 24265153, PMID: 25452114	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01328	search pubmed	D05ROI	AKT1#p.E17K	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	AKT1	p.E17K	耐药性增加	PMID: 24265152	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01329	search pubmed	D05ROI	MAP2K2#p.E207K	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	MAP2K2	p.E207K	耐药性增加	PMID: 25452114	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01330	search pubmed	D05ROI	PIK3CA#p.E545*	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	PIK3CA	p.E545*	耐药性增加	PMID: 24265155	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01331	search pubmed	D05ROI	MAP2K1#p.G128D	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	MAP2K1	p.G128D	耐药性增加	PMID: 25452114	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01332	search pubmed	D05ROI	NRAS#p.G12D	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	NRAS	p.G12D	耐药性增加	PMID: 25452114	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01333	search pubmed	D05ROI	MAP2K1#p.K57E	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	MAP2K1	p.K57E	耐药性增加	PMID: 24463458	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01334	search pubmed	D05ROI	MAP2K2#p.L46F	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	MAP2K2	p.L46F	耐药性增加	PMID: 24265153	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01335	search pubmed	D05ROI	MAP2K2#p.N126D	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	MAP2K2	p.N126D	耐药性增加	PMID: 24265153	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01336	search pubmed	D05ROI	MAP2K1#p.P124S	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	MAP2K1	p.P124S	耐药性增加	PMID: 24265153	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01337	search pubmed	D05ROI	MAP2K2#p.Q60P	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	MAP2K2	p.Q60P	耐药性增加	PMID: 24265154, PMID: 25705882	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01338	search pubmed	D05ROI	NRAS#p.Q61K	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	NRAS	p.Q61K	耐药性增加	PMID: 24265153	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L01339	search pubmed	D05ROI	AKT1#p.Q79K	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	AKT1	p.Q79K	耐药性增加	PMID: 24265152	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L00400	Cancer Genome Interpreter	D05ROI	G6PD#p.S218F	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	G6PD	p.S218F	毒性增加 (Haemolytic Anemia)	FDA	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Cancer	FDA guidelines	Dabrafenib	Approved
L01340	search pubmed	D05ROI	MAP2K2#p.V35M	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	MAP2K2	p.V35M	耐药性增加	PMID: 24265153	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Melanoma	.	Dabrafenib	Approved
L00194	Cancer Genome Interpreter	D05ROI	BRAF#p.V600E	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	BRAF	p.V600E	敏感性增加	PMID: 23470635, 22608338	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者		Gastrointestinal Stromal Tumour	Case report	Dabrafenib	Approved
L00195	Cancer Genome Interpreter	D05ROI	BRAF#p.V600E	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	BRAF	p.V600E	敏感性增加	PMID: 23470635, 22608338	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免		Non-small cell lung cancer	Case report	Dabrafenib	Approved
L00257	Cancer Genome Interpreter	D05ROI	BRAF#p.V600E	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	BRAF	p.V600E	敏感性增加	PMID: 23524406, 22608338,ASCO 2013 (abstr 8009),ESMO 2014 (abstr LBA38_PR), 20818844, 23489023, 27080216	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免		Thyroid Cancer	Early trials	Dabrafenib	Approved
L00394	Cancer Genome Interpreter	D05ROI	BRAF#p.V600E	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	BRAF	p.V600E	敏感性增加	FDA	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免		Cutaneous Melanoma	FDA guidelines	Dabrafenib	Approved
L00415	Cancer Genome Interpreter	D05ROI	BRAF#p.V600E	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	BRAF	p.V600E	敏感性增加	NCCN	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免		Non-small Cell  Lung Cancer	NCCN guidelines	Dabrafenib	Approved
L00276	Cancer Genome Interpreter	D05ROI	BRAF#p.V600R	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	BRAF	p.V600R	敏感性增加	PMID: 23237741	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免		Cutaneous Melanoma	Early trials	Dabrafenib	Approved
L01715	Cancer Genome Interpreter	D05ROI	BRAF:V600.	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	BRAF	BRAF (V600)	敏感性增加	ENA 2014 (abstr 11LBA)	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免		Colorectal adenocarcinoma	Early trials	Dabrafenib	Approved, Approved,Clinical Trials
L01808	Cancer Genome Interpreter	D05ROI	G6PD:V98M,G6PD:N156D	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	G6PD	G6PD (V98M) + G6PD (N156D)	毒性增加 (Haemolytic Anemia)	FDA	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免		Cancer	FDA guidelines	Dabrafenib	Approved
L01809	Cancer Genome Interpreter	D05ROI	G6PD:.	Dabrafenib	Dabrafenib (达拉非尼)	kinase inhibitor	G6PD	G6PD biallelic inactivation	毒性增加 (Haemolytic Anemia)	FDA	.		否	黑色素瘤	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免		Cancer	FDA guidelines	Dabrafenib	Approved
L00192	Cancer Genome Interpreter	D05ROI-D04XVN	BRAF#p.V600E	Dabrafenib + Trametinib	Dabrafenib + Trametinib		BRAF	p.V600E	敏感性增加	PMID: 27048246	.		.	.		.	Neuroendocrine Tumors	Case report	Dabrafenib + Trametinib	.
L00255	Cancer Genome Interpreter	D05ROI-D04XVN	BRAF#p.V600E	Dabrafenib + Trametinib	Dabrafenib + Trametinib		BRAF	p.V600E	敏感性增加	PMID: 26392102,ASCO 2015 (abstr 8006)	.		.	.		.	Colorectal Adenocarcinoma	Early trials	Dabrafenib + Trametinib	.
L00392	Cancer Genome Interpreter	D05ROI-D04XVN	BRAF#p.V600E	Dabrafenib + Trametinib	Dabrafenib + Trametinib		BRAF	p.V600E	敏感性增加	PMID: 27283860	.		.	.		.	Lung Adenocarcinoma	FDA guidelines	Dabrafenib + Trametinib	.
L00397	Cancer Genome Interpreter	D05ROI-D04XVN	BRAF#p.V600E	Dabrafenib + Trametinib	Dabrafenib + Trametinib		BRAF	p.V600E	敏感性增加	FDA			.	.		.	Cutaneous Melanoma	FDA guidelines	Dabrafenib + Trametinib	.
L00407	Cancer Genome Interpreter	D05ROI-D04XVN	BRAF#p.V600K	Dabrafenib + Trametinib	Dabrafenib + Trametinib		BRAF	p.V600K	敏感性增加	FDA	.		.	.		.	Cutaneous Melanoma	FDA guidelines	Dabrafenib + Trametinib	.
L01506	Cancer Genome Interpreter	D06XXH	ERBB2:.	Dacomitinib	Dacomitinib		ERBB2	ERBB2 oncogenic mutation	敏感性增加	PMID: 25899785	.		.	.		.	Non-small cell lung cancer	Early trials	Dacomitinib	Phase 3
L00578	Cancer Genome Interpreter	D0E6XR	CBL#p.C384R	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	CBL	p.C384R	敏感性增加	PMID: 23696637	.		是	白血病		NCT00744497: 前列腺癌	Myelodysplastic Syndromes	Pre-clinical	Dasatinib	Approved
L02142	hotspot3D	D0E6XR	ABL1#p.D400Y	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.D400Y	耐药性增加	.			是	白血病		NCT00744497: 前列腺癌	cancer	prediction	Dasatinib	
L01341	search pubmed	D0E6XR	ABL1#p.D444Y	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.D444Y	耐药性增加	PMID: 20673586	.		是	白血病		NCT00744497: 前列腺癌	Leukemia	.	Dasatinib	Approved
L00499	Cancer Genome Interpreter	D0E6XR	KIT#p.D816F	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	KIT	p.D816F	敏感性增加	PMID: 16397263	.		是	白血病		NCT00744497: 前列腺癌	Cancer	Pre-clinical	Dasatinib	Approved
L00247	Cancer Genome Interpreter	D0E6XR	KIT#p.D816V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	KIT	p.D816V	敏感性增加	PMID: 18986703	.		是	白血病		NCT00744497: 前列腺癌	Acute Myeloid Leukaemia	Case report	Dasatinib	Approved
L00285	Cancer Genome Interpreter	D0E6XR	KIT#p.D816V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	KIT	p.D816V	敏感性增加	PMID: 18559612	.		是	白血病		NCT00744497: 前列腺癌	Systemic Mastocytosis	Early trials	Dasatinib	Approved
L00500	Cancer Genome Interpreter	D0E6XR	KIT#p.D816V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	KIT	p.D816V	敏感性增加	PMID: 16397263	.		是	白血病		NCT00744497: 前列腺癌	Cancer	Pre-clinical	Dasatinib	Approved
L00501	Cancer Genome Interpreter	D0E6XR	KIT#p.D816Y	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	KIT	p.D816Y	敏感性增加	PMID: 16397263	.		是	白血病		NCT00744497: 前列腺癌	Cancer	Pre-clinical	Dasatinib	Approved
L00573	Cancer Genome Interpreter	D0E6XR	PDGFRA#p.D842V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	PDGFRA	p.D842V	敏感性增加	PMID: 18794084	.		是	白血病		NCT00744497: 前列腺癌	Gastrointestinal Stromal Tumour	Pre-clinical	Dasatinib	Approved
L00446	Cancer Genome Interpreter	D0E6XR	ABL1#p.E255K	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.E255K	敏感性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	NCCN guidelines	Dasatinib	Approved
L00628	COSMIC	D0E6XR	ABL1#p.E255K	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 21931113	.		是	白血病		NCT00744497: 前列腺癌	Acute Lymphoblastic Leukaemia	.	Dasatinib	Approved
L01162	COSMIC	D0E6XR	ABL1#p.E255K	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 21156844	.		是	白血病		NCT00744497: 前列腺癌	Blast Phase Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L00447	Cancer Genome Interpreter	D0E6XR	ABL1#p.E255V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.E255V	敏感性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	NCCN guidelines	Dasatinib	Approved
L01342	search pubmed	D0E6XR	ABL1#p.E355G	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.E355G	耐药性增加	PMID: 19260121, PMID: 20673586	.		是	白血病		NCT00744497: 前列腺癌	Leukemia	.	Dasatinib	Approved
L00385	Cancer Genome Interpreter	D0E6XR	ABL1#p.F317C	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317C	耐药性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Dasatinib	Approved
L00386	Cancer Genome Interpreter	D0E6XR	ABL1#p.F317I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317I	耐药性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Dasatinib	Approved
L00387	Cancer Genome Interpreter	D0E6XR	ABL1#p.F317L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317L	耐药性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Dasatinib	Approved
L01154	COSMIC	D0E6XR	ABL1#p.F317L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 19156415	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01155	COSMIC	D0E6XR	ABL1#p.F317L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 21357704	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01156	COSMIC	D0E6XR	ABL1#p.F317L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 22873741	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01163	COSMIC	D0E6XR	ABL1#p.F317L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 21156844	.		是	白血病		NCT00744497: 前列腺癌	Blast Phase Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01164	COSMIC	D0E6XR	ABL1#p.F317L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 21264552	.		是	白血病		NCT00744497: 前列腺癌	Blast Phase Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L00629	COSMIC	D0E6XR	ABL1#p.F317R	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317R	.	PMID: 23044928	.		是	白血病		NCT00744497: 前列腺癌	Acute Lymphoblastic Leukaemia	.	Dasatinib	Approved
L00388	Cancer Genome Interpreter	D0E6XR	ABL1#p.F317V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F317V	耐药性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Dasatinib	Approved
L00448	Cancer Genome Interpreter	D0E6XR	ABL1#p.F359C	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F359C	敏感性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	NCCN guidelines	Dasatinib	Approved
L00449	Cancer Genome Interpreter	D0E6XR	ABL1#p.F359I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F359I	敏感性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	NCCN guidelines	Dasatinib	Approved
L01343	search pubmed	D0E6XR	ABL1#p.F359I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F359I	耐药性增加	PMID: 19260121	.		是	白血病		NCT00744497: 前列腺癌	Leukemia	.	Dasatinib	Approved
L00450	Cancer Genome Interpreter	D0E6XR	ABL1#p.F359V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F359V	敏感性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	NCCN guidelines	Dasatinib	Approved
L00630	COSMIC	D0E6XR	ABL1#p.F359V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 26308885	.		是	白血病		NCT00744497: 前列腺癌	Acute Lymphoblastic Leukaemia	.	Dasatinib	Approved
L02056	hotspot3D	D0E6XR	ABL1#p.F401L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.F401L	耐药性增加	.			是	白血病		NCT00744497: 前列腺癌	cancer	prediction	Dasatinib	
L02157	hotspot3D	D0E6XR	BTK#p.FG540LC	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	BTK	p.FG540LC	耐药性增加	.			是	白血病		NCT00744497: 前列腺癌	cancer	prediction	Dasatinib	
L01165	COSMIC	D0E6XR	ABL1#p.G250E	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 21264552	.		是	白血病		NCT00744497: 前列腺癌	Blast Phase Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L00508	Cancer Genome Interpreter	D0E6XR	DDR2#p.G253C	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	DDR2	p.G253C	敏感性增加	PMID: 22328973	.		是	白血病		NCT00744497: 前列腺癌	Lung Squamous Cell Carcinoma	Pre-clinical	Dasatinib	Approved
L00514	Cancer Genome Interpreter	D0E6XR	EPHA2#p.G391R	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	EPHA2	p.G391R	敏感性增加	PMID: 20360610	.		是	白血病		NCT00744497: 前列腺癌	Lung Squamous Cell Carcinoma	Pre-clinical	Dasatinib	Approved
L02059	hotspot3D	D0E6XR	BMX#p.G424E	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	BMX	p.G424E	耐药性增加	.			是	白血病		NCT00744497: 前列腺癌	cancer	prediction	Dasatinib	
L00507	Cancer Genome Interpreter	D0E6XR	BRAF#p.G466V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	BRAF	p.G466V	敏感性增加	PMID: 22649091	.		是	白血病		NCT00744497: 前列腺癌	Lung Adenocarcinoma	Pre-clinical	Dasatinib	Approved
L00509	Cancer Genome Interpreter	D0E6XR	DDR2#p.G505S	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	DDR2	p.G505S	敏感性增加	PMID: 22328973	.		是	白血病		NCT00744497: 前列腺癌	Lung Squamous Cell Carcinoma	Pre-clinical	Dasatinib	Approved
L00510	Cancer Genome Interpreter	D0E6XR	DDR2#p.G774V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	DDR2	p.G774V	敏感性增加	PMID: 22328973	.		是	白血病		NCT00744497: 前列腺癌	Lung Squamous Cell Carcinoma	Pre-clinical	Dasatinib	Approved
L00511	Cancer Genome Interpreter	D0E6XR	DDR2#p.I638F	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	DDR2	p.I638F	敏感性增加	PMID: 22328973	.		是	白血病		NCT00744497: 前列腺癌	Lung Squamous Cell Carcinoma	Pre-clinical	Dasatinib	Approved
L02146	hotspot3D	D0E6XR	ABL1#p.K106N	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.K106N	耐药性增加	.			是	白血病		NCT00744497: 前列腺癌	cancer	prediction	Dasatinib	
L02139	hotspot3D	D0E6XR	BTK#p.K60E	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	BTK	p.K60E	耐药性增加	.			是	白血病		NCT00744497: 前列腺癌	cancer	prediction	Dasatinib	
L00512	Cancer Genome Interpreter	D0E6XR	DDR2#p.L239R	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	DDR2	p.L239R	敏感性增加	PMID: 22328973	.		是	白血病		NCT00744497: 前列腺癌	Lung Squamous Cell Carcinoma	Pre-clinical	Dasatinib	Approved
L01344	search pubmed	D0E6XR	ABL1#p.L273M	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.L273M	耐药性增加	PMID: 20673586	.		是	白血病		NCT00744497: 前列腺癌	Leukemia	.	Dasatinib	Approved
L02071	hotspot3D	D0E6XR	BTK#p.L528F	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	BTK	p.L528F	耐药性增加	.			是	白血病		NCT00744497: 前列腺癌	cancer	prediction	Dasatinib	
L02011	search pubmed	D0E6XR	KIT#p.L576P	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	KIT	p.L576P	敏感性增加	PMID: 17372901, 18448188	A KIT-mutated case of thymic carcinoma reported in the literature harbored an L576P mutation in exon 11. No follow-up of the patient was reported regarding therapeutics with specific inhibitors. However, this mutation has also previously been described in GIST and melanoma. It has been biologically characterized as being sensitive to imatinib but even more sensitive to sunitinib and dasatinib.		是	白血病		NCT00744497: 前列腺癌	Thymic Carcinoma	Case report	Dasatinib	
L00513	Cancer Genome Interpreter	D0E6XR	DDR2#p.L63V	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	DDR2	p.L63V	敏感性增加	PMID: 22328973	.		是	白血病		NCT00744497: 前列腺癌	Lung Squamous Cell Carcinoma	Pre-clinical	Dasatinib	Approved
L00572	Cancer Genome Interpreter	D0E6XR	KIT#p.N822K	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	KIT	p.N822K	敏感性增加	PMID: 23149070	.		是	白血病		NCT00744497: 前列腺癌	Acute Myeloid Leukaemia	Pre-clinical	Dasatinib	Approved
L02150	hotspot3D	D0E6XR	ABL1#p.R783G	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.R783G	耐药性增加	.			是	白血病		NCT00744497: 前列腺癌	cancer	prediction	Dasatinib	
L00222	Cancer Genome Interpreter	D0E6XR	DDR2#p.S768R	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	DDR2	p.S768R	敏感性增加	PMID: 22328973	.		是	白血病		NCT00744497: 前列腺癌	Lung Squamous Cell Carcinoma	Case report	Dasatinib	Approved
L00389	Cancer Genome Interpreter	D0E6XR	ABL1#p.T315A	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.T315A	耐药性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Dasatinib	Approved
L01157	COSMIC	D0E6XR	ABL1#p.T315A	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.T315A	.	PMID: 23044928	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L00074	Cancer Genome Interpreter	D0E6XR	ABL1#p.T315I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.T315I	耐药性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Dasatinib	Approved
L00631	COSMIC	D0E6XR	ABL1#p.T315I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 21931113	.		是	白血病		NCT00744497: 前列腺癌	Acute Lymphoblastic Leukaemia	.	Dasatinib	Approved
L00632	COSMIC	D0E6XR	ABL1#p.T315I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 26308885	.		是	白血病		NCT00744497: 前列腺癌	Acute Lymphoblastic Leukaemia	.	Dasatinib	Approved
L01158	COSMIC	D0E6XR	ABL1#p.T315I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 21357704	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01159	COSMIC	D0E6XR	ABL1#p.T315I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 22873741	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01166	COSMIC	D0E6XR	ABL1#p.T315I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 21264552	.		是	白血病		NCT00744497: 前列腺癌	Blast Phase Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01345	search pubmed	D0E6XR	ABL1#p.T495R	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.T495R	耐药性增加	PMID: 19260121	.		是	白血病		NCT00744497: 前列腺癌	Leukemia	.	Dasatinib	Approved
L00046	Cancer Genome Interpreter	D0E6XR	CSF3R#p.T615A	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	CSF3R	p.T615A	敏感性增加	PMID: 23656643	.		是	白血病		NCT00744497: 前列腺癌	Atypical Chronic Myeloid Leukemia	Pre-clinical	Dasatinib	Approved
L00047	Cancer Genome Interpreter	D0E6XR	CSF3R#p.T618I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	CSF3R	p.T618I	敏感性增加	PMID: 23656643	.		是	白血病		NCT00744497: 前列腺癌	Atypical Chronic Myeloid Leukemia	Pre-clinical	Dasatinib	Approved
L02170	search pubmed	.	DDR2#p.T654I	dasatinib	dasatinib (达沙替尼)	kinase inhibitor	DDR2	p.T654I	耐药性增加	PMID: 24296828	DDR2 T654I is a gatekeeper mutation site which confers dasatinib resistance in a manner analogous to EGFR T790M (50). We have shown previously that expression of DDR2 T654I mutants in HCC-366 and NCI-H2286 confers dasatinib resistance, with an increase in GI50 of 209- and 35-fold respectively for dasatinib in HCC-366 and NCI-H2286 		.	.		.	Lung cancer	In vitro	dasatinib	
L01963	search pubmed	D0E6XR	SRC#p.V140M	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	SRC	p.V140M		.	.		是	白血病		NCT00744497: 前列腺癌		.	Dasatinib	
L00390	Cancer Genome Interpreter	D0E6XR	ABL1#p.V299L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.V299L	耐药性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Dasatinib	Approved
L00633	COSMIC	D0E6XR	ABL1#p.V299L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.V299L	.	PMID: 26308885	.		是	白血病		NCT00744497: 前列腺癌	Acute Lymphoblastic Leukaemia	.	Dasatinib	Approved
L01160	COSMIC	D0E6XR	ABL1#p.V299L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.V299L	.	PMID: 23086624	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01346	search pubmed	D0E6XR	ABL1#p.V379I	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.V379I	耐药性增加	PMID: 20673586	.		是	白血病		NCT00744497: 前列腺癌	Leukemia	.	Dasatinib	Approved
L02154	hotspot3D	D0E6XR	ABL1#p.V390L	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.V390L	耐药性增加	.			是	白血病		NCT00744497: 前列腺癌	cancer	prediction	Dasatinib	
L01347	search pubmed	D0E6XR	ABL1#p.Y253F	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.Y253F	耐药性增加	PMID: 20673586	.		是	白血病		NCT00744497: 前列腺癌	Leukemia	.	Dasatinib	Approved
L00451	Cancer Genome Interpreter	D0E6XR	ABL1#p.Y253H	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.Y253H	敏感性增加	PMID: 21562040	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	NCCN guidelines	Dasatinib	Approved
L01161	COSMIC	D0E6XR	ABL1#p.Y253H	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21357704	.		是	白血病		NCT00744497: 前列腺癌	Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01167	COSMIC	D0E6XR	ABL1#p.Y253H	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21264552	.		是	白血病		NCT00744497: 前列腺癌	Blast Phase Chronic Myeloid Leukaemia	.	Dasatinib	Approved
L01348	search pubmed	D0E6XR	ABL1#p.Y353H	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	p.Y353H	耐药性增加	PMID: 20673586	.		是	白血病		NCT00744497: 前列腺癌	Leukemia	.	Dasatinib	Approved
L00579	Cancer Genome Interpreter	D0E6XR	CBL#p.Y371H	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	CBL	p.Y371H	敏感性增加	PMID: 23696637	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Myelodysplastic Syndromes	Pre-clinical	Dasatinib	Approved
L00221	Cancer Genome Interpreter	D0E6XR	BRAF#p.Y472C	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	BRAF	p.Y472C	敏感性增加	PMID: 22649091	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Lung Adenocarcinoma	Case report	Dasatinib	Approved
L01624	Cancer Genome Interpreter	D0E6XR	NF1:del	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	NF1	NF1 deletion	耐药性增加	PMID: 24296828	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Lung cancer	Pre-clinical	Dasatinib	Clinical Trials
L01685	Cancer Genome Interpreter	D0E6XR	ABL1__BCR	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	ABL1-BCR fusion	敏感性增加	PMID: 27582059	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Acute Lymphoblastic Leukemia	Pre-clinical	Dasatinib	Clinical Trials
L01686	Cancer Genome Interpreter	D0E6XR	ABL1__BCR	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	ABL1	ABL1-BCR fusion	敏感性增加	FDA	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Acute Lymphoblastic Leukemia, Chronic myeloid leukemia	FDA guidelines	Dasatinib	Approved
L01757	Cancer Genome Interpreter	D0E6XR	CSF3R#p.S783fs	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	CSF3R	CSF3R frameshift variant (D771),frameshift variant (S783)	敏感性增加	PMID: 23656643	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Atypical Chronic Myeloid Leukemia	Pre-clinical	Dasatinib	Clinical Trials
L01758	Cancer Genome Interpreter	D0E6XR	CSF3R#p.D771fs	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	CSF3R	CSF3R frameshift variant (D771),frameshift variant (S783)	敏感性增加	PMID: 23656643	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Atypical Chronic Myeloid Leukemia	Pre-clinical	Dasatinib	Clinical Trials
L01761	Cancer Genome Interpreter	D0E6XR	EPHA2:amp	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	EPHA2	EPHA2 amplification	敏感性增加	PMID: 18047674, 19010823, 19861960	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Cancer	Pre-clinical	Dasatinib	Clinical Trials
L01817	Cancer Genome Interpreter	D0E6XR	IDH1:.	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	IDH1	IDH1 oncogenic mutation	敏感性增加	NCT02428855	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Cholangiocarcinoma	Early trials	Dasatinib	Clinical Trials
L01816	Cancer Genome Interpreter	D0E6XR	IDH1:R132.	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	IDH1	IDH1 R132*	敏感性增加	PMID: 27231123	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Billiary tract cancer	Pre-clinical	Dasatinib	Clinical Trials
L01543	Cancer Genome Interpreter	D0E6XR	IDH2:.	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	IDH2	IDH2 oncogenic mutation	敏感性增加	NCT02428855	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Cholangiocarcinoma	Early trials	Dasatinib	Clinical Trials
L01835	Cancer Genome Interpreter	D0E6XR	KIT:550-592,627-664	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	KIT	KIT mutation in exon 9,11,13,14 or 17	敏感性增加	PMID: 19671763	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Cutaneous carcinoma	Case report	Dasatinib	Clinical Trials
L01836	Cancer Genome Interpreter	D0E6XR	KIT::wildtype:.	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	KIT	KIT wildtype	敏感性增加	PMID: 16397263	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Gastrointestinal Stromal Tumor	Pre-clinical	Dasatinib	Clinical Trials
L02171	search pubmed	.	NF1 loss	dasatinib	dasatinib (达沙替尼)	kinase inhibitor	NF1	NF1 loss	耐药性增加	PMID: 24296828	NF1 loss has been nominated as a mechanism of acquired resistance to both BRAF and EGFR-directed therapy (35). Activation of other signaling molecules in the RAS/RAF/MEK/ERK pathway has been described in the setting of acquired resistance to BRAF inhibitors (34). Given that NF1 loss appeared to drive acquired resistance in the setting of NCI-H2286-DR, we also probed two additional dasatinib-sensitive lung cancer cell lines to examine if NF1 loss may be a general mechanism of resistance to dasatinib in the lung cancer context.		.	.	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	.	Lung cancer	In vitro	dasatinib	
L01625	Cancer Genome Interpreter	D0E6XR	NF1:.	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	NF1	NF1 oncogenic mutation	耐药性增加	PMID: 24296828	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Lung cancer	Pre-clinical	Dasatinib	Clinical Trials
L01662	Cancer Genome Interpreter	D0E6XR	PDGFRA::wildtype:.	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	PDGFRA	PDGFRA wildtype	敏感性增加	PMID: 16397263	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Gastrointestinal Stromal Tumor	Pre-clinical	Dasatinib	Clinical Trials
L01542	Cancer Genome Interpreter	D0E6XR	IDH2:R172.	Dasatinib	Dasatinib (达沙替尼)	kinase inhibitor	IDH2	R172*	敏感性增加	PMID: 27231123	.		是	白血病	可能引起胚胎毒性、肝肾功影响以及心脏QT延长等副作用	NCT00744497: 前列腺癌	Billiary tract cancer	Pre-clinical	Dasatinib	Clinical Trials
L01439	Cancer Genome Interpreter	D01XWG	DNMT3A:.	Daunorubicin	Daunorubicin		DNMT3A	DNMT3A oncogenic mutation	敏感性增加	PMID: 22417203	.		.	.		.	Acute Myeloid Leukemia	FDA guidelines	Daunorubicin	Approved
L01853	Cancer Genome Interpreter	D01XWG	MLL__.	Daunorubicin	Daunorubicin		MLL	MLL fusion	敏感性增加	PMID: 22417203	.		.	.		.	Acute Myeloid Leukemia	FDA guidelines	Daunorubicin	Approved
L01883	Cancer Genome Interpreter	D01XWG	NPM1:.	Daunorubicin	Daunorubicin		NPM1	NPM1 oncogenic mutation	敏感性增加	PMID: 22417203	.		.	.		.	Acute Myeloid Leukemia	FDA guidelines	Daunorubicin	Approved
L01567	Cancer Genome Interpreter	D0X5XU	KRAS:.	Decitabine	Decitabine		KRAS	KRAS oncogenic mutation	敏感性增加	PMID: 25968887	.		.	.		.	Ovarian cancer	Pre-clinical	Decitabine	Approved
L01678	Cancer Genome Interpreter	D0X5XU	TP53:.	Decitabine	Decitabine		TP53	TP53 oncogenic mutation	敏感性增加	PMID: 27959731	.		.	.		.	Acute Myeloid Leukemia, Myelodisplasic proliferative syndrome	Early trials	Decitabine	Approved
L01962	search pubmed	D08WSY	NOTCH2#p.G2223termination	Denosumab	Denosumab (狄诺塞麦)	RANK ligand (RANKL) inhibitor	NOTCH2	p.G2223X	敏感性增加	PMID: 27592446	The 6667C>T mutation in exon 34 of NOTCH2 leads to the creation of a Stop codon and a predicted truncated protein product of 2222 amino acids.		否	骨巨细胞瘤??		NCT00838201: 前列腺癌, NCT01824342: 前列腺癌, NCT03324932: 乳腺癌	Hajdu Cheney Syndrome	Case report	Denosumab	Approved
L01562	Cancer Genome Interpreter	D0O5WP	STK11:del,KRAS:.	Docetaxel	Docetaxel		KRAS	STK11 deletion + KRAS oncogenic mutation	耐药性增加	PMID: 22425996	.		.	.		.	Lung adenocarcinoma	Pre-clinical	Docetaxel	Approved
L01938	Cancer Genome Interpreter	D0O5WP	STK11:del,KRAS:.	Docetaxel	Docetaxel		STK11	STK11 deletion + KRAS oncogenic mutation	耐药性增加	PMID: 22425996	.		.	.		.	Lung adenocarcinoma	Pre-clinical	Docetaxel	Approved
L01563	Cancer Genome Interpreter	D0O5WP	STK11:.,KRAS:.	Docetaxel	Docetaxel		KRAS	STK11 oncogenic mutation + KRAS oncogenic mutation	耐药性增加	PMID: 22425996	.		.	.		.	Lung adenocarcinoma	Pre-clinical	Docetaxel	Approved
L01939	Cancer Genome Interpreter	D0O5WP	STK11:.,KRAS:.	Docetaxel	Docetaxel		STK11	STK11 oncogenic mutation + KRAS oncogenic mutation	耐药性增加	PMID: 22425996	.		.	.		.	Lung adenocarcinoma	Pre-clinical	Docetaxel	Approved
L00058	Cancer Genome Interpreter	D0K3OY	FGFR2#p.E566G	Dovitinib	Dovitinib		FGFR2	p.E566G	耐药性增加	PMID: 23908597	.		.	.		.	Endometrium Cancer	Pre-clinical	Dovitinib	Phase 2
L00056	Cancer Genome Interpreter	D0K3OY	FGFR2#p.I548V	Dovitinib	Dovitinib		FGFR2	p.I548V	耐药性增加	PMID: 23908597	.		.	.		.	Endometrium Cancer	Pre-clinical	Dovitinib	Phase 2
L00059	Cancer Genome Interpreter	D0K3OY	FGFR2#p.K660E	Dovitinib	Dovitinib		FGFR2	p.K660E	耐药性增加	PMID: 23908597	.		.	.		.	Endometrium Cancer	Pre-clinical	Dovitinib	Phase 2
L00060	Cancer Genome Interpreter	D0K3OY	FGFR2#p.L618M	Dovitinib	Dovitinib		FGFR2	p.L618M	耐药性增加	PMID: 23908597	.		.	.		.	Endometrium Cancer	Pre-clinical	Dovitinib	Phase 2
L00061	Cancer Genome Interpreter	D0K3OY	FGFR2#p.M536I	Dovitinib	Dovitinib		FGFR2	p.M536I	耐药性增加	PMID: 23908597	.		.	.		.	Endometrium Cancer	Pre-clinical	Dovitinib	Phase 2
L00057	Cancer Genome Interpreter	D0K3OY	FGFR2#p.M538I	Dovitinib	Dovitinib		FGFR2	p.M538I	耐药性增加	PMID: 23908597	.		.	.		.	Endometrium Cancer	Pre-clinical	Dovitinib	Phase 2
L00062	Cancer Genome Interpreter	D0K3OY	FGFR2#p.V565I	Dovitinib	Dovitinib		FGFR2	p.V565I	耐药性增加	PMID: 23908597	.		.	.		.	Endometrium Cancer	Pre-clinical	Dovitinib	Phase 2
L01789	Cancer Genome Interpreter	D0K3OY	FGF3:amp	Dovitinib	Dovitinib		FGF3	FGF3 amplification	敏感性增加	PMID: 23658459	.		.	.		.	Breast invasive carcinoma	Early trials	Dovitinib	Phase 2
L01791	Cancer Genome Interpreter	D0K3OY	FGF4:amp	Dovitinib	Dovitinib		FGF4	FGF4 amplification	敏感性增加	PMID: 23658459	.		.	.		.	Breast invasive carcinoma	Early trials	Dovitinib	Phase 2
L01673	Cancer Genome Interpreter	D07VLY	TP53:.	Doxorubicin	Doxorubicin		TP53	TP53 oncogenic mutation	敏感性增加	PMID: 27397505	.		.	.		.	Bladder Urothelial Carcinoma	Pre-clinical	Doxorubicin	Approved
L00072	Cancer Genome Interpreter	.	EGFR#p.C797S	EGFR inhibitor 3rd gens	EGFR 抑制剂		EGFR	p.C797S	耐药性增加	PMID: 25939061	.		.	.		.	Lung Cancer	Early trials	EGFR inhibitor 3rd gens	.
L00082	Cancer Genome Interpreter	.	EGFR#p.D761Y	EGFR inhibitor 1st gens	EGFR 抑制剂		EGFR	p.D761Y	耐药性增加	PMID: 19680293	.		.	.		.	Non-small Cell  Lung Cancer	Case report	EGFR inhibitor 1st gens	.
L02030	search pubmed	.	PIK3CA#p.E542K	EGFR TKIs	EGFR 抑制剂		PIK3CA	p.E542K	耐药性增加	PMID: 16906227	.		.	.		.	Non-Small Cell Lung Cancer	Case report	EGFR TKIs	
L02031	search pubmed	.	PIK4CA#p.E545K	EGFR TKIs	EGFR 抑制剂		PIK4CA	p.E545K	耐药性增加	PMID: 16906227	.		.	.		.	Non-Small Cell Lung Cancer	Case report	EGFR TKIs	
L02032	search pubmed	.	PIK5CA#p.E545Q	EGFR TKIs	EGFR 抑制剂		PIK5CA	p.E545Q	耐药性增加	PMID: 16906227	.		.	.		.	Non-Small Cell Lung Cancer	Case report	EGFR TKIs	
L00081	Cancer Genome Interpreter	.	BRAF#p.G469A	EGFR TK inhibitors	EGFR 抑制剂		BRAF	p.G469A	耐药性增加	PMID: 22773810	.		.	.		.	Lung Adenocarcinoma	Case report	EGFR TK inhibitors	.
L00114	Cancer Genome Interpreter	.	EGFR#p.G719A	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.G719A	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L00115	Cancer Genome Interpreter	.	EGFR#p.G719C	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.G719C	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L00116	Cancer Genome Interpreter	.	EGFR#p.G719D	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.G719D	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L00117	Cancer Genome Interpreter	.	EGFR#p.G719S	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.G719S	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L02033	search pubmed	.	PIK6CA#p.H1047L	EGFR TKIs	EGFR 抑制剂		PIK6CA	p.H1047L	耐药性增加	PMID: 16906227	.		.	.		.	Non-Small Cell Lung Cancer	Case report	EGFR TKIs	
L02034	search pubmed	.	PIK7CA#p.H1047R	EGFR TKIs	EGFR 抑制剂		PIK7CA	p.H1047R	耐药性增加	PMID: 16906227	.		.	.		.	Non-Small Cell Lung Cancer	Case report	EGFR TKIs	
L00118	Cancer Genome Interpreter	.	EGFR#p.L747S	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.L747S	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L00119	Cancer Genome Interpreter	.	EGFR#p.L858R	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.L858R	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L00120	Cancer Genome Interpreter	.	EGFR#p.L861P	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.L861P	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L00121	Cancer Genome Interpreter	.	EGFR#p.L861Q	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.L861Q	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L00122	Cancer Genome Interpreter	.	EGFR#p.L861R	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.L861R	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L00123	Cancer Genome Interpreter	.	EGFR#p.S768I	EGFR TK inhibitors	EGFR 抑制剂		EGFR	p.S768I	敏感性增加	PMID: 22753918	.		.	.		.	Lung Cancer	Late trials	EGFR TK inhibitors	.
L00124	Cancer Genome Interpreter	.	EGFR#p.T790M	EGFR inhibitor 1st gens	EGFR 抑制剂		EGFR	p.T790M	耐药性增加	PMID: 19680293	.		.	.		.	Non-small Cell  Lung Cancer	Late trials	EGFR inhibitor 1st gens	.
L00125	Cancer Genome Interpreter	.	EGFR#p.T790M	EGFR inhibitor 2nd gens	EGFR 抑制剂		EGFR	p.T790M	耐药性增加	PMID: 22452896	.		.	.		.	Non-small Cell  Lung Cancer	Late trials	EGFR inhibitor 2nd gens	.
L00111	Cancer Genome Interpreter	.	EGFR#p.T790M	EGFR inhibitor 3rd gens	EGFR 抑制剂		EGFR	p.T790M	敏感性增加	ASCO 2014 (abstr 8009),ENA 2014 (abstr 10LBA),ENA 2014 (abstr 9LBA),ASCO 2015 (abstr 8001)	.		.	.		.	Lung Cancer	Early trials	EGFR inhibitor 3rd gens	.
L00079	Cancer Genome Interpreter	.	BRAF#p.V600E	EGFR TK inhibitors	EGFR 抑制剂		BRAF	p.V600E	耐药性增加	PMID: 22773810	.		.	.		.	Lung Adenocarcinoma	Case report	EGFR TK inhibitors	.
L00066	Cancer Genome Interpreter	D0N2NI	NTRK1#p.G595R	Entrectinib	Entrectinib		NTRK1	p.G595R	耐药性增加	PMID: 26546295	.		.	.		.	Colorectal Adenocarcinoma	Case report	Entrectinib	Phase 1
L01349	search pubmed	D0N2NI	NTRK3#p.G623R	Entrectinib	Entrectinib		NTRK3	p.G623R	耐药性增加	PMID: 26884591	.		.	.		.	Mammary analogue secretory carcinoma	.	Entrectinib	Phase 1
L00067	Cancer Genome Interpreter	D0N2NI	NTRK1#p.G667C	Entrectinib	Entrectinib		NTRK1	p.G667C	耐药性增加	PMID: 26546295	.		.	.		.	Colorectal Adenocarcinoma	Case report	Entrectinib	Phase 1
L01892	Cancer Genome Interpreter	D0N2NI	NTRK1__.	Entrectinib	Entrectinib		NTRK1	NTRK1 fusion	敏感性增加	PMID: 26546295	.		.	.		.	Colorectal adenocarcinoma	Case report	Entrectinib	Phase 1
L01408	Cancer Genome Interpreter	.	ALK__.	Entrictinib	Entrictinib		ALK	ALK fusion	敏感性增加	PMID: 26633560, 26933125	.		.	.		.	Colorectal adenocarcinoma	Case report	Entrictinib	.
L01350	search pubmed	D0QK5X	AR#p.F876L	Enzalutamide	Enzalutamide (恩杂鲁胺)		AR	p.F876L	耐药性增加	PMID: 23842682	.		否	前列腺癌		.	Prostate Cancer	.	Enzalutamide	Approved
L00204	Cancer Genome Interpreter	D0QK5X	AR#p.F877L	Enzalutamide	Enzalutamide (恩杂鲁胺)		AR	p.F877L	耐药性增加	PMID: 23779130	.		否	前列腺癌		.	Prostate Cancer	Case report	Enzalutamide	Approved
L00048	Cancer Genome Interpreter	D0QK5X	AR#p.T878A	Enzalutamide	Enzalutamide (恩杂鲁胺)		AR	p.T878A	敏感性增加	PMID: 23779130	.		否	前列腺癌		.	Prostate Cancer	Case report	Enzalutamide	Approved
L01698	Cancer Genome Interpreter	D0QK5X	AR:F877L,AR:T878A	Enzalutamide	Enzalutamide (恩杂鲁胺)		AR	AR (F877L) + AR (T878A)	敏感性增加	PMID: 27196756	.		否	前列腺癌		.	Prostate adenocarcinoma	Pre-clinical	Enzalutamide	Clinical Trials
L01696	Cancer Genome Interpreter	D0QK5X	AR:over	Enzalutamide	Enzalutamide (恩杂鲁胺)		AR	AR overexpression	敏感性增加	ASCO 2015 (abstr 1003)	.		否	前列腺癌		.	Breast invasive carcinoma	Early trials	Enzalutamide	Clinical Trials
L01697	Cancer Genome Interpreter	D0QK5X	AR:over	Enzalutamide	Enzalutamide (恩杂鲁胺)		AR	AR overexpression	敏感性增加	PMID: 24882673	.		否	前列腺癌		.	Prostate adenocarcinoma	Early trials	Enzalutamide	Approved
L01760	Cancer Genome Interpreter	D0QK5X	CYP17A1:norm	Enzalutamide	Enzalutamide (恩杂鲁胺)		CYP17A1	CYP17A1 expression	敏感性增加	PMID: 24882673	.		否	前列腺癌		.	Prostate adenocarcinoma	Early trials	Enzalutamide	Approved
L01428	Cancer Genome Interpreter	D0I6VU	BCOR:.	Enzastaurin	Enzastaurin		BCOR	BCOR oncogenic mutation	敏感性增加	PMID: 27397505	.		.	.		.	Stomach cancer	Pre-clinical	Enzastaurin	Phase 3
L01539	Cancer Genome Interpreter	D02BBA	EZH2:Y641.,A677.	EPZ-005687	EPZ-005687		EZH2	EZH2 (Y641,A677)	敏感性增加	PMID: 23023262, 24563539	.		.	.		.	Liposarcoma	Pre-clinical	EPZ-005687	Pre-clinical
L01854	Cancer Genome Interpreter	D0C6GK	MLL__.	EPZ-5676	EPZ-5676		MLL	MLL fusion	敏感性增加	NCT02141828,NCT01684150, 21741596	.		.	.		.	Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodisplasic syndrome	Early trials	EPZ-5676	Clinical Trials
L01538	Cancer Genome Interpreter	D00EQL	EZH2:Y641.,A677.	EPZ-6438	EPZ-6438		EZH2	EZH2 (Y641,A677)	敏感性增加	PMID: 23023262, 24563539	.		.	.		.	Liposarcoma	Pre-clinical	EPZ-6438	Pre-clinical
L00135	Cancer Genome Interpreter	.	ERBB3#p.G284R	ERBB3 mAb inhibitors	ERBB3 mAb 抑制剂		ERBB3	p.G284R	敏感性增加	PMID: 23680147	.		.	.		.	Cancer	Pre-clinical	ERBB3 mAb inhibitors	.
L00143	Cancer Genome Interpreter	.	ERBB3#p.P262H	ERBB3 mAb inhibitors	ERBB3 mAb 抑制剂		ERBB3	p.P262H	敏感性增加	PMID: 23680147	.		.	.		.	Cancer	Pre-clinical	ERBB3 mAb inhibitors	.
L01669	Cancer Genome Interpreter	D0KK2E	TERT::consequence::promoters_core:.	Eribulin	Eribulin (艾瑞布林)		TERT	TERT promoters core	敏感性增加	PMID: 25375122,https: //academic.oup.com/neuro-oncology/article-abstract/18/suppl_4/iv50/2222864/P08-41-Development-of-a-novel-TERT-targeting?cited-by=yes&legid=neuonc,18/suppl_4/iv50-b	.		否	乳腺癌		.	Glioblastoma multiforme	Pre-clinical	Eribulin	Approved
L00043	Cancer Genome Interpreter	.	MAP2K1#p.F129L	ERK inhibitors	ERK 抑制剂		MAP2K1	p.F129L	敏感性增加	PMID: 23614898	.		.	.		.	Cancer	Pre-clinical	ERK inhibitors	.
L00140	Cancer Genome Interpreter	.	NRAS#p.G12C	ERK inhibitors	ERK 抑制剂		NRAS	p.G12C	敏感性增加	PMID: 23614898	.		.	.		.	Cancer	Pre-clinical	ERK inhibitors	.
L00044	Cancer Genome Interpreter	.	MAP2K1#p.I103N	ERK inhibitors	ERK 抑制剂		MAP2K1	p.I103N	敏感性增加	PMID: 23614898	.		.	.		.	Cancer	Pre-clinical	ERK inhibitors	.
L00045	Cancer Genome Interpreter	.	MAP2K1#p.L215P	ERK inhibitors	ERK 抑制剂		MAP2K1	p.L215P	敏感性增加	PMID: 23614898	.		.	.		.	Cancer	Pre-clinical	ERK inhibitors	.
L00129	Cancer Genome Interpreter	.	BRAF#p.V600E	ERK inhibitors	ERK 抑制剂		BRAF	p.V600E	敏感性增加	PMID: 23614898, 22997239	.		.	.		.	Cutaneous Melanoma	Pre-clinical	ERK inhibitors	.
L00561	Cancer Genome Interpreter	D07POC	EGFR#p.A289V	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.A289V	敏感性增加	PMID: 17177598	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Glioma	Pre-clinical	Erlotinib	Approved
L01351	search pubmed	D07POC	EGFR#p.D761Y	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.D761Y	耐药性增加	PMID: 19680293	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung Cancer	.	Erlotinib	Approved
L00217	Cancer Genome Interpreter	D07POC	EGFR#p.E746G	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.E746G	敏感性增加	PMID: 26773740	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung Cancer	Case report	Erlotinib	Approved
L00562	Cancer Genome Interpreter	D07POC	EGFR#p.G598V	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.G598V	敏感性增加	PMID: 17177598	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Glioma	Pre-clinical	Erlotinib	Approved
L02082	hotspot3D	D07POC	EGFR#p.G719A	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.G719A	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L02085	hotspot3D	D07POC	EGFR#p.G719D	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.G719D	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L02088	hotspot3D	D07POC	EGFR#p.G721V	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.G721V	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L02091	hotspot3D	D07POC	EGFR#p.I789M	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.I789M	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L02094	hotspot3D	D07POC	EGFR#p.K716R	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.K716R	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L00218	Cancer Genome Interpreter	D07POC	EGFR#p.K757R	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.K757R	敏感性增加	PMID: 26773740	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung Cancer	Case report	Erlotinib	Approved
L00016	Cancer Genome Interpreter	D07POC	EGFR#p.L858R	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.L858R	敏感性增加	NCCN	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Erlotinib	Approved
L00402	Cancer Genome Interpreter	D07POC	EGFR#p.L858R	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.L858R	敏感性增加	FDA	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Non-small Cell  Lung Cancer	FDA guidelines	Erlotinib	Approved
L02097	hotspot3D	D07POC	EGFR#p.L858R	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.L858R	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L02100	hotspot3D	D07POC	EGFR#p.N842H	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.N842H	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L00563	Cancer Genome Interpreter	D07POC	EGFR#p.R108K	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.R108K	敏感性增加	PMID: 17177598	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Glioma	Pre-clinical	Erlotinib	Approved
L02103	hotspot3D	D07POC	EGFR#p.S720C	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.S720C	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L00017	Cancer Genome Interpreter	D07POC	EGFR#p.S768I	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.S768I	敏感性增加	NCCN	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Erlotinib	Approved
L00219	Cancer Genome Interpreter	D07POC	DDR2#p.S768R	Erlotinib	Erlotinib (厄洛替尼)		DDR2	p.S768R	敏感性增加	PMID: 22328973	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung Squamous Cell Carcinoma	Case report	Erlotinib	Approved
L00564	Cancer Genome Interpreter	D07POC	EGFR#p.T263P	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.T263P	敏感性增加	PMID: 17177598	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Glioma	Pre-clinical	Erlotinib	Approved
L00470	Cancer Genome Interpreter	D07POC	EGFR#p.T790M	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.T790M	耐药性增加	NCCN	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung Cancer	NCCN/CAP guidelines	Erlotinib	Approved
L00589	COSMIC	D07POC	EGFR#p.T790M	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.T790M	.	PMID: 21430269	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Non-small Cell Lung Cancer	.	Erlotinib	Approved
L00590	COSMIC	D07POC	EGFR#p.T790M	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.T790M	.	PMID: 24781527	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Non-small Cell Lung Cancer	.	Erlotinib	Approved
L02106	hotspot3D	D07POC	EGFR#p.T790M	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.T790M	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L02109	hotspot3D	D07POC	EGFR#p.V742I	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.V742I	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L02112	hotspot3D	D07POC	EGFR#p.V769L	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.V769L	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L02115	hotspot3D	D07POC	EGFR#p.V774M	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.V774M	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L01457	Cancer Genome Interpreter	D07POC	EGFR::consequence::inframe_deletion:729-761	Erlotinib	Erlotinib (厄洛替尼)		EGFR	EGFR exon 19 deletions	敏感性增加	FDA	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Non-small cell lung cancer	FDA guidelines	Erlotinib	Approved
L01456	Cancer Genome Interpreter	D07POC	EGFR::consequence::inframe_insertion:729-761	Erlotinib	Erlotinib (厄洛替尼)		EGFR	EGFR exon 19 insertions	敏感性增加	PMID: 22190593	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Early trials	Erlotinib	Approved
L01455	Cancer Genome Interpreter	D07POC	EGFR::consequence::inframe_insertion:769-770	Erlotinib	Erlotinib (厄洛替尼)		EGFR	EGFR inframe insertion (769-770)	敏感性增加	PMID: 26773740, 23328547	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Case report	Erlotinib	Approved
L01613	Cancer Genome Interpreter	D07POC	NF1:del	Erlotinib	Erlotinib (厄洛替尼)		NF1	NF1 deletion	耐药性增加	PMID: 24535670	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Pre-clinical	Erlotinib	Approved
L01614	Cancer Genome Interpreter	D07POC	NF1:del	Erlotinib	Erlotinib (厄洛替尼)		NF1	NF1 deletion	敏感性降低	PMID: 24634382	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Glioma	Case report	Erlotinib	Approved
L01615	Cancer Genome Interpreter	D07POC	NF1:del	Erlotinib	Erlotinib (厄洛替尼)		NF1	NF1 deletion	敏感性增加	PMID: 22434731	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Glioma	Case report	Erlotinib	Approved
L01868	Cancer Genome Interpreter	D07POC	NF2:del	Erlotinib	Erlotinib (厄洛替尼)		NF2	NF2 deletion	敏感性降低	PMID: 20736812	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Schwannoma	Early trials	Erlotinib	Approved
L01448	Cancer Genome Interpreter	D07POC	NF2:del,EGFR:.	Erlotinib	Erlotinib (厄洛替尼)		EGFR	NF2 deletion + EGFR oncogenic mutation	耐药性增加	PMID: 24813888	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Case report	Erlotinib	Approved
L01867	Cancer Genome Interpreter	D07POC	NF2:del,EGFR:.	Erlotinib	Erlotinib (厄洛替尼)		NF2	NF2 deletion + EGFR oncogenic mutation	耐药性增加	PMID: 24813888	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Case report	Erlotinib	Approved
L02167	hotspot3D	D07POC	EGFR#p.771in_frame_insSVD	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.771in_frame_insSVD	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L02163	hotspot3D	D07POC	EGFR#p.ELREA746in_frame_del	Erlotinib	Erlotinib (厄洛替尼)		EGFR	p.ELREA746in_frame_ del	耐药性增加	.			是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	cancer	prediction	Erlotinib	
L01453	Cancer Genome Interpreter	D07POC	EGFR:L858R,L861.,G719.,S768I	Erlotinib	Erlotinib (厄洛替尼)		EGFR	EGFR (L858R,L861,G719,S768I)	敏感性增加	NCCN	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Non-small cell lung cancer	NCCN guidelines	Erlotinib	Approved
L01452	Cancer Genome Interpreter	D07POC	EGFR:S720.	Erlotinib	Erlotinib (厄洛替尼)		EGFR	EGFR (S720)	敏感性降低	PMID: 26773740	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Case report	Erlotinib	Approved
L01454	Cancer Genome Interpreter	D07POC	EGFR:amp	Erlotinib	Erlotinib (厄洛替尼)		EGFR	EGFR amplification	敏感性降低	ASCO2015(abstre19028)	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Early trials	Erlotinib	Approved
L01450	Cancer Genome Interpreter	D07POC	EGFR__RAD51	Erlotinib	Erlotinib (厄洛替尼)		EGFR	EGFR-RAD51 fusion	敏感性增加	PMID: 27102076	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Non-small cell lung cancer	Case report	Erlotinib	Approved
L01451	Cancer Genome Interpreter	D07POC	EGFR__RAD51	Erlotinib	Erlotinib (厄洛替尼)		EGFR	EGFR-RAD51 fusion	敏感性增加	PMID: 27102076	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Case report	Erlotinib	Approved
L01819	Cancer Genome Interpreter	D07POC	IGF1R:amp	Erlotinib	Erlotinib (厄洛替尼)		IGF1R	IGF1R amplification	耐药性增加	PMID: 24458568	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung adenocarcinoma	Pre-clinical	Erlotinib	Approved
L01616	Cancer Genome Interpreter	D07POC	NF1:.	Erlotinib	Erlotinib (厄洛替尼)		NF1	NF1 oncogenic mutation	耐药性增加	PMID: 24535670	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Pre-clinical	Erlotinib	Approved
L01617	Cancer Genome Interpreter	D07POC	NF1:.	Erlotinib	Erlotinib (厄洛替尼)		NF1	NF1 oncogenic mutation	敏感性降低	PMID: 24634382	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Glioma	Case report	Erlotinib	Approved
L01618	Cancer Genome Interpreter	D07POC	NF1:.	Erlotinib	Erlotinib (厄洛替尼)		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 22434731	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Glioma	Case report	Erlotinib	Approved
L01870	Cancer Genome Interpreter	D07POC	NF2:.	Erlotinib	Erlotinib (厄洛替尼)		NF2	NF2 oncogenic mutation	敏感性降低	PMID: 20736812	.		是	肺癌, 胰腺癌		NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Schwannoma	Early trials	Erlotinib	Approved
L01449	Cancer Genome Interpreter	D07POC	NF2:.,EGFR:.	Erlotinib	Erlotinib (厄洛替尼)	kinase inhibitor	EGFR	NF2 oncogenic mutation + EGFR oncogenic mutation	耐药性增加	PMID: 24813888	.		是	肺癌, 胰腺癌	不推荐与铂类化疗药物使用	NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Case report	Erlotinib	Approved
L01869	Cancer Genome Interpreter	D07POC	NF2:.,EGFR:.	Erlotinib	Erlotinib (厄洛替尼)	kinase inhibitor	NF2	NF2 oncogenic mutation + EGFR oncogenic mutation	耐药性增加	PMID: 24813888	.		是	肺癌, 胰腺癌	不推荐与铂类化疗药物使用	NCT00263822: 卵巢癌, NCT00265824: 结直肠癌, NCT00412217: 头颈癌, NCT00442455: 头颈癌, NCT00448240: 头颈癌, NCT01149122: 胆管癌, NCT01752205: 食管癌	Lung cancer	Case report	Erlotinib	Approved
L02048	search pubmed	D0K3QS	HER2 amplification	Everolimus	Everolimus	kinase inhibitor	HER2	HER2 amplification	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast Cancer	In vitro	Everolimus	
L02036	search pubmed	D0K3QS	PI3KCA oncogenic mutation	Everolimus	Everolimus	kinase inhibitor	PI3KCA	PI3KCA oncogenic mutation	敏感性增加	PMID: 22932669, 23714559	Both PIK3CA and PTEN mutations were associated with increased MK-2206 sensitivity		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast Cancer	In vitro	Everolimus	
L02042	search pubmed	D0K3QS	PI3KCA oncogenic mutation	Everolimus	Everolimus	kinase inhibitor	PIK3CA	PI3KCA oncogenic mutation	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast Cancer	In vitro	Everolimus	
L02039	search pubmed	D0K3QS	PTEN loss (Loss of PTEN activity)	Everolimus	Everolimus	kinase inhibitor	PTEN	PTEN loss (Loss of PTEN activity)	敏感性增加	PMID: 22932669, 23714559	Both PIK3CA and PTEN mutations were associated with increased MK-2206 sensitivity		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast Cancer	In vitro	Everolimus	
L01964	search pubmed	D0K3QS	TSC1#p.E636fs	Everolimus	Everolimus (依维莫司)	kinase inhibitor	TSC1	p.E636fs	敏感性增加	PMID: 22923433	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Bladder Cancer	Case report	Everolimus	
L02172	search pubmed	D0K3QS	FGFR4#p.G388R	Everolimus	Everolimus (依维莫司)	kinase inhibitor	FGFR4	p.G388R	敏感性降低	PMID:  22986737	FGFR4-R388 promotes tumor progression by increasing intraperitoneal spread and metastatic growth within the liver. Unlike FGFR4-G388, FGFR4-R388 BON1 tumors exhibited diminished responsiveness to everolimus. Concordantly, there was a statistically significant reduction in response to everolimus in patients with FGFR4-R388		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Pancreatic neuroendocrine tumor	In vivo	Everolimus	
L01794	Cancer Genome Interpreter	D0K3QS	FLCN:del	Everolimus	Everolimus (依维莫司)	kinase inhibitor	FLCN	FLCN deletion	敏感性增加	PMID: 25295501	FLCN, a tumor-suppressor gene that encodes folliculin. Inactivation of FLCN has been shown to result in increased mTOR activity,14 raising the possibility that this mutation, along with the TSC2 mutation, may contribute to sensitivity to everolimus.	FLCN是一种肿瘤抑制基因，编码卵泡素。FLCN的失活已被证明会增加mTOR活性，增加TSC2突变的可能性，可能有助于对Everolimus的敏感性。	是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Thyroid carcinoma	Case report	Everolimus	Approved
L01626	Cancer Genome Interpreter	D0K3QS	NF1:del	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 deletion	敏感性降低	NCT01365468	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Malignant peripheral nerve sheat tumor	Early trials	Everolimus	Approved
L01627	Cancer Genome Interpreter	D0K3QS	NF1:del	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 deletion	敏感性增加	PMID: 26859683,ASCO 2016 (abstr e17557)	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Head and neck cancer, Salivary glands cancer	Case report	Everolimus	Approved
L01628	Cancer Genome Interpreter	D0K3QS	NF1:del	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 deletion	敏感性降低	ASCO 2016 (abstr 11053)	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Malignant peripheral nerve sheat tumor	Early trials	Everolimus	Approved
L01629	Cancer Genome Interpreter	D0K3QS	NF1:del	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 deletion	敏感性降低	PMID: 24634382	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Glioma	Case report	Everolimus	Approved
L01875	Cancer Genome Interpreter	D0K3QS	NF2:del	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF2	NF2 deletion	敏感性增加	PMID: 24311643,2556735	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Schwannoma	Early trials	Everolimus	Approved
L01876	Cancer Genome Interpreter	D0K3QS	NF2:del	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF2	NF2 deletion	敏感性增加	PMID: 26015296	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Meningioma	Pre-clinical	Everolimus	Approved
L01655	Cancer Genome Interpreter	D0K3QS	PBRM1:under	Everolimus	Everolimus (依维莫司)	kinase inhibitor	PBRM1	PBRM1 undexpression	敏感性增加	PMID: 25997916	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Renal cancer	Pre-clinical	Everolimus	Approved
L01908	Cancer Genome Interpreter	D0K3QS	PTEN:del	Everolimus	Everolimus (依维莫司)	kinase inhibitor	PTEN	PTEN deletion	敏感性增加	PMID: 23582881	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Prostate adenocarcinoma	Early trials	Everolimus	Approved
L01528	Cancer Genome Interpreter	D0K3QS	ERBB2:amp	Everolimus	Everolimus (依维莫司)	kinase inhibitor	ERBB2	ERBB2 amplification	敏感性增加	PMID: 21107682, 20975068	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast invasive carcinoma	Early trials	Everolimus	Approved
L01527	Cancer Genome Interpreter	D0K3QS	ERBB2:norm,ESR1:over	Everolimus	Everolimus (依维莫司)	kinase inhibitor	ERBB2	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast invasive carcinoma	FDA guidelines	Everolimus	Approved
L01781	Cancer Genome Interpreter	D0K3QS	ERBB2:norm,ESR1:over	Everolimus	Everolimus (依维莫司)	kinase inhibitor	ESR1	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast invasive carcinoma	FDA guidelines	Everolimus	Approved
L01795	Cancer Genome Interpreter	D0K3QS	FLCN:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	FLCN	FLCN oncogenic mutation	敏感性增加	PMID: 23995526	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Renal cancer	Case report	Everolimus	Approved
L01630	Cancer Genome Interpreter	D0K3QS	NF1:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 oncogenic mutation	敏感性增加	NCT01365468	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Neurofibroma	Late trials	Everolimus	Approved
L01631	Cancer Genome Interpreter	D0K3QS	NF1:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 oncogenic mutation	敏感性降低	NCT01365468	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Malignant peripheral nerve sheat tumor	Early trials	Everolimus	Approved
L01632	Cancer Genome Interpreter	D0K3QS	NF1:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 oncogenic mutation	敏感性增加	PMID: 26859683,ASCO 2016 (abstr e17557)	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Head and neck cancer, Salivary glands cancer	Case report	Everolimus	Approved
L01633	Cancer Genome Interpreter	D0K3QS	NF1:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 oncogenic mutation	敏感性降低	ASCO 2016 (abstr 11053)	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Malignant peripheral nerve sheat tumor	Early trials	Everolimus	Approved
L01634	Cancer Genome Interpreter	D0K3QS	NF1:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 oncogenic mutation	敏感性降低	PMID: 24634382	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Glioma	Case report	Everolimus	Approved
L01635	Cancer Genome Interpreter	D0K3QS	NF1:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF1	NF1 oncogenic mutation	敏感性增加	PMID: 24931142	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Hepatic carcinoma	Case report	Everolimus	Approved
L01877	Cancer Genome Interpreter	D0K3QS	NF2:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF2	NF2 oncogenic mutation	敏感性增加	PMID: 24311643,2556735	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Schwannoma	Early trials	Everolimus	Approved
L01878	Cancer Genome Interpreter	D0K3QS	NF2:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	NF2	NF2 oncogenic mutation	敏感性增加	PMID: 26015296	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Meningioma	Pre-clinical	Everolimus	Approved
L01526	Cancer Genome Interpreter	D0K3QS	PIK3CA:.,ERBB2:amp	Everolimus	Everolimus (依维莫司)	kinase inhibitor	ERBB2	PIK3CA oncogenic mutation + ERBB2 amplification	敏感性增加	PMID: 27091708	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast invasive carcinoma	Late trials	Everolimus	Approved
L01895	Cancer Genome Interpreter	D0K3QS	PIK3CA:.,ERBB2:amp	Everolimus	Everolimus (依维莫司)	kinase inhibitor	PIK3CA	PIK3CA oncogenic mutation + ERBB2 amplification	敏感性增加	PMID: 27091708	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast invasive carcinoma	Late trials	Everolimus	Approved
L02054	search pubmed	D0K3QS	PIK3CG oncogenic mutation	Everolimus	Everolimus (依维莫司)	kinase inhibitor	PIK3CG	PIK3CG oncogenic mutation	敏感性增加	PMID: 29285035	The results showed that patients with mTOR, NF1, PIK3CA, TSC1, TSC2, and PIK3CG mutations could benefit from the mTOR inhibitor everolimus.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast Cancer	.	Everolimus	
L01910	Cancer Genome Interpreter	D0K3QS	PTEN:.	Everolimus	Everolimus (依维莫司)	kinase inhibitor	PTEN	PTEN oncogenic mutation	敏感性增加	PMID: 23582881	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Prostate adenocarcinoma	Early trials	Everolimus	Approved
L01525	Cancer Genome Interpreter	D0K3QS	PTEN:.,ERBB2:amp	Everolimus	Everolimus (依维莫司)	kinase inhibitor	ERBB2	PTEN oncogenic mutation + ERBB2 amplification	敏感性增加	PMID: 27091708	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast invasive carcinoma	Late trials	Everolimus	Approved
L01909	Cancer Genome Interpreter	D0K3QS	PTEN:.,ERBB2:amp	Everolimus	Everolimus (依维莫司)	kinase inhibitor	PTEN	PTEN oncogenic mutation + ERBB2 amplification	敏感性增加	PMID: 27091708	.		是	乳腺癌, 肾癌, 胰腺癌,胃肠道神经内分泌瘤	.	NCT00799188: 皮肤癌, NCT00879333: 胃癌	Breast invasive carcinoma	Late trials	Everolimus	Approved
L01946	Cancer Genome Interpreter	D0K3QS	TSC1:del	Everolimus or Temsirolimus	Everolimus or Temsirolimus		TSC1	TSC1 deletion	敏感性增加	PMID: 24622468,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)	.		.	.		.	Renal cancer	Case report	Everolimus or Temsirolimus	Approved
L01947	Cancer Genome Interpreter	D0K3QS	TSC1:.	Everolimus or Temsirolimus	Everolimus or Temsirolimus		TSC1	TSC1 oncogenic mutation	敏感性增加	PMID: 22923433	.		.	.		.	Bladder Urothelial Carcinoma	Early trials	Everolimus or Temsirolimus	Approved
L01948	Cancer Genome Interpreter	D0K3QS	TSC1:.	Everolimus or Temsirolimus	Everolimus or Temsirolimus		TSC1	TSC1 oncogenic mutation	敏感性增加	FDA	.		.	.		.	Giant cell astrocytoma	FDA guidelines	Everolimus or Temsirolimus	Approved
L01949	Cancer Genome Interpreter	D0K3QS	TSC1:.	Everolimus or Temsirolimus	Everolimus or Temsirolimus		TSC1	TSC1 oncogenic mutation	敏感性增加	PMID: 26859683	.		.	.		.	Sarcoma, Stomach cancer	Case report	Everolimus or Temsirolimus	Approved
L01950	Cancer Genome Interpreter	D0K3QS	TSC1:.	Everolimus or Temsirolimus	Everolimus or Temsirolimus		TSC1	TSC1 oncogenic mutation	敏感性增加	FDA	.		.	.		.	Rheumatoid Arthritis	FDA guidelines	Everolimus or Temsirolimus	Approved
L01951	Cancer Genome Interpreter	D0K3QS	TSC1:.	Everolimus or Temsirolimus	Everolimus or Temsirolimus		TSC1	TSC1 oncogenic mutation	敏感性增加	PMID: 24622468, 26859683,ASCO 2015 (abstr 11010),ASCO 2015 (abstr 4519)	.		.	.		.	Renal cancer	Case report	Everolimus or Temsirolimus	Approved
L01952	Cancer Genome Interpreter	D0K3QS	TSC2:.	Everolimus or Temsirolimus	Everolimus or Temsirolimus		TSC2	TSC2 oncogenic mutation	敏感性增加	PMID: 22923433	.		.	.		.	Bladder Urothelial Carcinoma	Early trials	Everolimus or Temsirolimus	Approved
L01953	Cancer Genome Interpreter	D0K3QS	TSC2:.	Everolimus or Temsirolimus	Everolimus or Temsirolimus		TSC2	TSC2 oncogenic mutation	敏感性增加	FDA	.		.	.		.	Renal angiomyolipoma,Giant cell astrocytoma	FDA guidelines	Everolimus or Temsirolimus	Approved
L01523	Cancer Genome Interpreter	D0D2VS	ERBB2:norm,ESR1:over	Exemestane	Exemestane (依西美坦)		ERBB2	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		是	乳腺癌		.	Breast invasive carcinoma	FDA guidelines	Exemestane	Approved
L01779	Cancer Genome Interpreter	D0D2VS	ERBB2:norm,ESR1:over	Exemestane	Exemestane (依西美坦)		ESR1	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		是	乳腺癌		.	Breast invasive carcinoma	FDA guidelines	Exemestane	Approved
L01778	Cancer Genome Interpreter	D0D2VS	ESR1:.	Exemestane	Exemestane (依西美坦)		ESR1	ESR1 oncogenic mutation	耐药性增加	PMID: 27269946	.		是	乳腺癌		.	Breast invasive carcinoma	Late trials	Exemestane	Approved
L00146	Cancer Genome Interpreter	D0V3JS	FGFR2#p.K660N	FGFR inhibitors	FGFR 抑制剂		FGFR2	p.K660N	敏感性增加	PMID: 23786770, 25035393	.		.	.		.	Lung Squamous Cell Carcinoma	Pre-clinical	FGFR inhibitors	.
L00175	Cancer Genome Interpreter	D0V3JS	FGFR2#p.N550K	FGFR inhibitors	FGFR 抑制剂		FGFR2	p.N550K	敏感性增加	PMID: 18552176, 22238366, 23002168	.		.	.		.	Endometrium Cancer	Pre-clinical	FGFR inhibitors	.
L00174	Cancer Genome Interpreter	D0V3JS	FGFR2#p.S252W	FGFR inhibitors	FGFR 抑制剂		FGFR2	p.S252W	敏感性增加	PMID: 18552176, 22238366, 23002168	.		.	.		.	Endometrium Cancer	Pre-clinical	FGFR inhibitors	.
L00147	Cancer Genome Interpreter	D0V3JS	FGFR2#p.S320C	FGFR inhibitors	FGFR 抑制剂		FGFR2	p.S320C	敏感性增加	PMID: 23786770, 25035393	.		.	.		.	Lung Squamous Cell Carcinoma	Pre-clinical	FGFR inhibitors	.
L00183	Cancer Genome Interpreter	D0V3JS	FGFR3#p.V555M	FGFR inhibitors	FGFR 抑制剂		FGFR3	p.V555M	耐药性增加	PMID: 22869148	.		.	.		.	Myeloma	Pre-clinical	FGFR inhibitors	.
L00176	Cancer Genome Interpreter	D0V3JS	FGFR2#p.V565I	FGFR inhibitors	FGFR 抑制剂		FGFR2	p.V565I	敏感性增加	ENA 2014 (abstr 381)	.		.	.		.	Endometrium Cancer	Pre-clinical	FGFR inhibitors	.
L00145	Cancer Genome Interpreter	D0V3JS	FGFR2#p.W290C	FGFR inhibitors	FGFR 抑制剂		FGFR2	p.W290C	敏感性增加	PMID: 23786770, 25035393	.		.	.		.	Lung Squamous Cell Carcinoma	Pre-clinical	FGFR inhibitors	.
L00019	Cancer Genome Interpreter	D0V3JS	FGFR3#p.Y373C	FGFR inhibitors	FGFR 抑制剂		FGFR3	p.Y373C	敏感性增加	PMID: 16091734, 20439987, 22869148	.		.	.		.	Myeloma	Pre-clinical	FGFR inhibitors	.
L01443	Cancer Genome Interpreter	D0O0UU	DPYD:.	Flourouracil	Flourouracil		DPYD	DPYD biallelic inactivation	毒性增加	FDA	.		.	.		.	Cancer	FDA guidelines	Flourouracil	Approved
L01442	Cancer Genome Interpreter	D0O0UU	DPYD::consequence::splice_donor_variant:.	Flourouracil	Flourouracil		DPYD	DPYD splice donor variant	毒性增加	FDA	.		.	.		.	Cancer	FDA guidelines	Flourouracil	Approved
L01770	Cancer Genome Interpreter	.	ESR1:.	Fluvestrant	Fluvestrant		ESR1	ESR1 oncogenic mutation	敏感性增加	PMID: 27269946	.		.	.		.	Breast invasive carcinoma	Late trials	Fluvestrant	.
L00078	Cancer Genome Interpreter	D0D1GF	ABL1#p.V299L	Foretinib	Foretinib		ABL1	p.V299L	敏感性增加	PMID: 26924578	.		.	.		.	Cancer	Pre-clinical	Foretinib	.
L01903	Cancer Genome Interpreter	D0D1GF	PTCH1:.	Foretinib	Foretinib		PTCH1	PTCH1 oncogenic mutation	敏感性增加	PMID: 25391241	.		.	.		.	Medulloblastoma	Pre-clinical	Foretinib	Phase 2
L01524	Cancer Genome Interpreter	D0JO7Y	ERBB2:norm,ESR1:over	Fulvestrant	Fulvestrant (氟维司群)		ERBB2	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		是	乳腺癌		.	Breast invasive carcinoma	FDA guidelines	Fulvestrant	Approved
L01780	Cancer Genome Interpreter	D0JO7Y	ERBB2:norm,ESR1:over	Fulvestrant	Fulvestrant (氟维司群)		ESR1	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		是	乳腺癌		.	Breast invasive carcinoma	FDA guidelines	Fulvestrant	Approved
L00611	COSMIC	D0LB7J	SMO#p.D473H	GDC-0449	GDC-0449		SMO	p.D473H	.	PMID: 19726788	.		.	.		.	Primitive Neuroectodermal Tumour Medulloblastoma	.	GDC-0449	Phase 2
L00012	Cancer Genome Interpreter	D02ICJ	ESR1#p.E380Q	GDC-0810	GDC-0810		ESR1	p.E380Q	敏感性增加	AACR 2015 (abstr CT231)	.		.	.		.	Breast Cancer	Case report	GDC-0810	.
L00013	Cancer Genome Interpreter	D02ICJ	ESR1#p.P535H	GDC-0810	GDC-0810		ESR1	p.P535H	敏感性增加	AACR 2015 (abstr CT231)	.		.	.		.	Breast Cancer	Case report	GDC-0810	.
L01774	Cancer Genome Interpreter	D02ICJ	ESR1:E380Q,.537.,.538.,L536.,P535H	GDC-0810	GDC-0810		ESR1	ESR1 (E380Q,537,538,L536,P535H)	敏感性增加	AACR 2015 (abstr CT231)	.		.	.		.	Breast invasive carcinoma	Case report	GDC-0810	.
L01378	search pubmed	D0T1ZO	PIK3CB#p.D1067Y	GDC-0941	GDC-0941		PIK3CB	p.D1067Y	耐药性增加	PMID: 26759240	.		.	.		.	Breast Cancer	.	GDC-0941	Phase 2
L02051	search pubmed	D0T1ZO	HER2 amplification	GDC-0941	GDC-0941		HER2	HER2 amplification	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		.	.		.	Breast Cancer	In vitro	GDC-0941	
L02053	search pubmed	D0T1ZO	HER2 amplification + PI3KCA oncogenic mutation	GDC-0941	GDC-0941		PIK3CA,HER2	HER2 amplification + PI3KCA oncogenic mutation	敏感性增加	PMID: 20453058, 23714559	Combined presence of HER2 gene amplifıcation along with PIK3CA mutation was found to be highly predictive of sensitivity to GDC-0941.		.	.		.	Breast Cancer	.	GDC-0941	
L02045	search pubmed	D0T1ZO	PI3KCA oncogenic mutation	GDC-0941	GDC-0941		PIK3CA	PI3KCA oncogenic mutation	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		.	.		.	Breast Cancer	In vitro	GDC-0941	
L00426	Cancer Genome Interpreter	D09XZB	EGFR#p.G719A	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.G719A	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Gefitinib	Approved
L02083	hotspot3D	D09XZB	EGFR#p.G719A	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.G719A	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L00427	Cancer Genome Interpreter	D09XZB	EGFR#p.G719C	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.G719C	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Gefitinib	Approved
L00428	Cancer Genome Interpreter	D09XZB	EGFR#p.G719D	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.G719D	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Gefitinib	Approved
L02086	hotspot3D	D09XZB	EGFR#p.G719D	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.G719D	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L00429	Cancer Genome Interpreter	D09XZB	EGFR#p.G719S	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.G719S	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Gefitinib	Approved
L02089	hotspot3D	D09XZB	EGFR#p.G721V	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.G721V	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L02092	hotspot3D	D09XZB	EGFR#p.I789M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.I789M	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L02095	hotspot3D	D09XZB	EGFR#p.K716R	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.K716R	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L00430	Cancer Genome Interpreter	D09XZB	EGFR#p.L747S	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.L747S	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Gefitinib	Approved
L00403	Cancer Genome Interpreter	D09XZB	EGFR#p.L858R	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.L858R	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	FDA guidelines	Gefitinib	Approved
L02098	hotspot3D	D09XZB	EGFR#p.L858R	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.L858R	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L00431	Cancer Genome Interpreter	D09XZB	EGFR#p.L861P	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.L861P	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Gefitinib	Approved
L00432	Cancer Genome Interpreter	D09XZB	EGFR#p.L861Q	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.L861Q	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Gefitinib	Approved
L00433	Cancer Genome Interpreter	D09XZB	EGFR#p.L861R	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.L861R	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Gefitinib	Approved
L02101	hotspot3D	D09XZB	EGFR#p.N842H	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.N842H	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L02104	hotspot3D	D09XZB	EGFR#p.S720C	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.S720C	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L00434	Cancer Genome Interpreter	D09XZB	EGFR#p.S768I	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.S768I	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell  Lung Cancer	NCCN guidelines	Gefitinib	Approved
L00591	COSMIC	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	.	PMID: 18509184	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell Lung Cancer	.	Gefitinib	Approved
L00592	COSMIC	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	.	PMID: 20686428	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell Lung Cancer	.	Gefitinib	Approved
L00593	COSMIC	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	.	PMID: 20871262	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell Lung Cancer	.	Gefitinib	Approved
L00594	COSMIC	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	.	PMID: 21030498	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell Lung Cancer	.	Gefitinib	Approved
L00595	COSMIC	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	.	PMID: 22215752	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell Lung Cancer	.	Gefitinib	Approved
L00596	COSMIC	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	.	PMID: 22815900	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell Lung Cancer	.	Gefitinib	Approved
L00597	COSMIC	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	.	PMID: 23180674	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell Lung Cancer	.	Gefitinib	Approved
L00598	COSMIC	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	.	PMID: 23407566	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell Lung Cancer	.	Gefitinib	Approved
L00599	COSMIC	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	.	PMID: 23886554	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small Cell Lung Cancer	.	Gefitinib	Approved
L02107	hotspot3D	D09XZB	EGFR#p.T790M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.T790M	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L02110	hotspot3D	D09XZB	EGFR#p.V742I	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.V742I	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L02113	hotspot3D	D09XZB	EGFR#p.V769L	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.V769L	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L02116	hotspot3D	D09XZB	EGFR#p.V774M	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.V774M	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L00245	Cancer Genome Interpreter	D09XZB	EGFR#p.V843I	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.V843I	敏感性降低	PMID: 21274259	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Head And Neck Cancer	Case report	Gefitinib	Approved
L01461	Cancer Genome Interpreter	D09XZB	EGFR::consequence::inframe_deletion:729-761	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	EGFR exon 19 deletions	敏感性增加	FDA	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Non-small cell lung cancer	FDA guidelines	Gefitinib	Approved
L01460	Cancer Genome Interpreter	D09XZB	EGFR::consequence::inframe_deletion:L747.,::inframe_insertion:P753PS	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	EGFR inframe deletion (L747),inframe insertion (P753PS)	敏感性降低	PMID: 21274259	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Head and neck cancer	Case report	Gefitinib	Approved
L02168	hotspot3D	D09XZB	EGFR#p.771in_frame_insSVD	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.771in_frame_insSVD	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L02164	hotspot3D	D09XZB	EGFR#p.ELREA746in_frame_del	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	p.ELREA746in_frame_ del	耐药性增加	.			是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	cancer	prediction	Gefitinib	
L01458	Cancer Genome Interpreter	D09XZB	EGFR:amp	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	EGFR amplification	敏感性降低	PMID: 21274259, 22261807	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Head and neck cancer	Early trials	Gefitinib	Approved
L01459	Cancer Genome Interpreter	D09XZB	EGFR:amp	Gefitinib	Gefitinib (吉非替尼)	tyrosine kinase inhibitor	EGFR	EGFR amplification	敏感性增加	PMID: 24950987	.		是	肺癌	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	NCT00352079: 膀胱癌, NCT01243398: 胃癌，食管癌	Endometrial cancer	Late trials	Gefitinib	Approved
L01553	Cancer Genome Interpreter	D03UVS	KRAS:.	Gemcitabine	Gemcitabine		KRAS	KRAS oncogenic mutation	敏感性增加	PMID: 23583440	.		.	.		.	Pancreatic cancer	Early trials	Gemcitabine	Approved
L01933	Cancer Genome Interpreter	D03UVS	SLC29A1:.	Gemcitabine	Gemcitabine		SLC29A1	SLC29A1 oncogenic mutation	耐药性增加	PMID: 21166756	.		.	.		.	Bladder Urothelial Carcinoma	Pre-clinical	Gemcitabine	Approved
L01672	Cancer Genome Interpreter	D03UVS	TP53:.	Gemcitabine	Gemcitabine		TP53	TP53 oncogenic mutation	敏感性增加	PMID: 27397505	.		.	.		.	Bladder Urothelial Carcinoma	Pre-clinical	Gemcitabine	Approved
L01316	search pubmed	D05TNY	NR3C1#p.L672P	Generalized glucocorticoid	Generalized glucocorticoid		NR3C1	p.L672P	耐药性增加	PMID: 27120390	.		.	.		.	Adrenal incidentalomas	.	Generalized glucocorticoid	Investigative
L01317	search pubmed	D05TNY	NR3C1#p.R477S	Generalized glucocorticoid	Generalized glucocorticoid		NR3C1	p.R477S	耐药性增加	PMID: 27120390	.		.	.		.	Adrenal incidentalomas	.	Generalized glucocorticoid	Investigative
L01322	search pubmed	D05TNY	NR3C1#p.Y478C	Generalized glucocorticoid	Generalized glucocorticoid		NR3C1	p.Y478C	耐药性增加	PMID: 27120390	.		.	.		.	Adrenal incidentalomas	.	Generalized glucocorticoid	Investigative
L01690	Cancer Genome Interpreter	D01NEC	AKT3__.	GSK2141795	GSK2141795		AKT3	AKT3 fusion	敏感性增加	PMID: 22722202	.		.	.		.	Breast invasive carcinoma	Pre-clinical	GSK2141795	Clinical Trials,Clinical Trials
L00075	Cancer Genome Interpreter	D05NUH	EGFR#p.T790M	HM61713	HM61713		EGFR	p.T790M	敏感性增加	NCT02322281	.		.	.		.	Non-small Cell  Lung Cancer	Late trials	HM61713	Approved
L00188	Cancer Genome Interpreter	.	PDGFRA#p.D842V	HSP90 inhibitors	HSP90 抑制剂		PDGFRA	p.D842V	敏感性增加	PMID: 18794084	.		.	.		.	Gastrointestinal Stromal Tumour	Pre-clinical	HSP90 inhibitors	.
L00101	Cancer Genome Interpreter	.	EGFR#p.G719A	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.G719A	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00102	Cancer Genome Interpreter	.	EGFR#p.G719C	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.G719C	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00103	Cancer Genome Interpreter	.	EGFR#p.G719D	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.G719D	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00104	Cancer Genome Interpreter	.	EGFR#p.G719S	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.G719S	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00105	Cancer Genome Interpreter	.	EGFR#p.L747S	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.L747S	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00106	Cancer Genome Interpreter	.	EGFR#p.L858R	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.L858R	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00107	Cancer Genome Interpreter	.	EGFR#p.L861P	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.L861P	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00108	Cancer Genome Interpreter	.	EGFR#p.L861Q	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.L861Q	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00109	Cancer Genome Interpreter	.	EGFR#p.L861R	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.L861R	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00141	Cancer Genome Interpreter	.	TP53#p.R175H	HSP90 inhibitors	HSP90 抑制剂		TP53	p.R175H	敏感性增加	PMID: 26009011	.		.	.		.	Cancer	Pre-clinical	HSP90 inhibitors	.
L00142	Cancer Genome Interpreter	.	TP53#p.R248Q	HSP90 inhibitors	HSP90 抑制剂		TP53	p.R248Q	敏感性增加	PMID: 26009011	.		.	.		.	Cancer	Pre-clinical	HSP90 inhibitors	.
L00110	Cancer Genome Interpreter	.	EGFR#p.S768I	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.S768I	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L00112	Cancer Genome Interpreter	.	EGFR#p.T790M	HSP90 inhibitors	HSP90 抑制剂		EGFR	p.T790M	敏感性增加	ESMO 2012 (abstr 4380)	.		.	.		.	Lung Cancer	Early trials	HSP90 inhibitors	.
L01475	Cancer Genome Interpreter	.	ERBB2:amp	HSP90 inhibitor	HSP90 抑制剂		ERBB2	ERBB2 amplification	敏感性增加	PMID: 21558407	.		.	.		.	Breast invasive carcinoma	Early trials	HSP90 inhibitor	.
L01352	search pubmed	D09KTS	CCND1#p.C47S	Ibrutinib	Ibrutinib (依鲁替尼)	kinase inhibitor	CCND1	p.C47S	耐药性增加	PMID: 27713153	.		否	白血病, 淋巴瘤	药物有胎儿毒性，使用时避免孕妇接触，同时建议药物使用期间避免抚养孩子		Refractory hematologic malignancy	.	Ibrutinib	Approved
L00281	Cancer Genome Interpreter	D09KTS	BTK#p.C481S	Ibrutinib	Ibrutinib (依鲁替尼)	kinase inhibitor	BTK	p.C481S	耐药性增加	PMID: 24869598, 27199251	.		否	白血病, 淋巴瘤	药物有胎儿毒性，使用时避免孕妇接触，同时建议药物使用期间避免抚养孩子		Chronic Lymphocytic Leukaemia	Early trials	Ibrutinib	Approved
L00011	Cancer Genome Interpreter	D09KTS	MYD88#P.L265P	Ibrutinib	Ibrutinib (依鲁替尼)	kinase inhibitor	MYD88	p.L265P	敏感性增加	PMID: 25853747	.		否	白血病, 淋巴瘤	药物有胎儿毒性，使用时避免孕妇接触，同时建议药物使用期间避免抚养孩子		Waldenstr'm macroglobulinemia	FDA guidelines	Ibrutinib	Approved
L01353	search pubmed	D09KTS	MYD88#p.L265P	Ibrutinib	Ibrutinib (依鲁替尼)	kinase inhibitor	MYD88	p.L265P	耐药性增加	PMID: 25858358	.		否	白血病, 淋巴瘤	药物有胎儿毒性，使用时避免孕妇接触，同时建议药物使用期间避免抚养孩子		Refractory hematologic malignancy	.	Ibrutinib	Approved
L00282	Cancer Genome Interpreter	D09KTS	PLCG2#p.L845F	Ibrutinib	Ibrutinib (依鲁替尼)	kinase inhibitor	PLCG2	p.L845F	耐药性增加	PMID: 24869598	.		否	白血病, 淋巴瘤	药物有胎儿毒性，使用时避免孕妇接触，同时建议药物使用期间避免抚养孩子		Chronic Lymphocytic Leukaemia	Early trials	Ibrutinib	Approved
L00283	Cancer Genome Interpreter	D09KTS	PLCG2#p.R665W	Ibrutinib	Ibrutinib (依鲁替尼)	kinase inhibitor	PLCG2	p.R665W	耐药性增加	PMID: 24869598	.		否	白血病, 淋巴瘤	药物有胎儿毒性，使用时避免孕妇接触，同时建议药物使用期间避免抚养孩子		Chronic Lymphocytic Leukaemia	Early trials	Ibrutinib	Approved
L01354	search pubmed	D09KTS	CCND1#p.T286A	Ibrutinib	Ibrutinib (依鲁替尼)	kinase inhibitor	CCND1	p.T286A	耐药性增加	PMID: 27713153	.		否	白血病, 淋巴瘤	药物有胎儿毒性，使用时避免孕妇接触，同时建议药物使用期间避免抚养孩子		Refractory hematologic malignancy	.	Ibrutinib	Approved
L01355	search pubmed	D09KTS	CCND1#p.Y44D	Ibrutinib	Ibrutinib (依鲁替尼)	kinase inhibitor	CCND1	p.Y44D	耐药性增加	PMID: 27713153	.		否	白血病, 淋巴瘤	药物有胎儿毒性，使用时避免孕妇接触，同时建议药物使用期间避免抚养孩子		Refractory hematologic malignancy	.	Ibrutinib	Approved
L01738	Cancer Genome Interpreter	D09KTS	BTK:C481.	Ibrutinib	Ibrutinib (依鲁替尼)	kinase inhibitor	BTK	BTK (C481)	耐药性增加	PMID: 25082755	.		否	白血病, 淋巴瘤	药物有胎儿毒性，使用时避免孕妇接触，同时建议药物使用期间避免抚养孩子		Mantle cell lymphoma	Case report	Ibrutinib	Approved
L01437	Cancer Genome Interpreter	.	CDKN2A:del	Ilorasertib	Ilorasertib		CDKN2A	CDKN2A deletion	敏感性增加	NCT02478320	.		.	.		.	Cancer	Early trials	Ilorasertib	Clinical Trials
L01438	Cancer Genome Interpreter	.	CDKN2A:.	Ilorasertib	Ilorasertib		CDKN2A	CDKN2A oncogenic mutation	敏感性增加	NCT02478320	.		.	.		.	Cancer	Early trials	Ilorasertib	Clinical Trials
L01027	COSMIC	D0AZ3C	ABL1#p.?	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.?	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01310	COSMIC	D0AZ3C	KIT#p.?fs	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.?fs	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00293	Cancer Genome Interpreter	D0AZ3C	ABL1#p.A344V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A344V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00294	Cancer Genome Interpreter	D0AZ3C	ABL1#p.A350V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A350V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00295	Cancer Genome Interpreter	D0AZ3C	ABL1#p.A365V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A365V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00296	Cancer Genome Interpreter	D0AZ3C	ABL1#p.A366G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A366G	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00297	Cancer Genome Interpreter	D0AZ3C	ABL1#p.A380T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A380T	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00298	Cancer Genome Interpreter	D0AZ3C	ABL1#p.A397P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A397P	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00660	COSMIC	D0AZ3C	ABL1#p.A397P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A397P	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00661	COSMIC	D0AZ3C	ABL1#p.A397P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A397P	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00662	COSMIC	D0AZ3C	ABL1#p.A397P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A397P	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00663	COSMIC	D0AZ3C	ABL1#p.A399T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A399T	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00299	Cancer Genome Interpreter	D0AZ3C	ABL1#p.A433T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A433T	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00664	COSMIC	D0AZ3C	ABL1#p.A433T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A433T	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00665	COSMIC	D0AZ3C	ABL1#p.A433T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.A433T	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00038	Cancer Genome Interpreter	D0AZ3C	KIT#p.A829P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.A829P	耐药性增加	PMID: 23582185, 21689725, 17259998	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumour	Pre-clinical	Imatinib	Approved
L01206	COSMIC	D0AZ3C	KIT#p.A829P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.A829P	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01207	COSMIC	D0AZ3C	KIT#p.A829P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.A829P	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01208	COSMIC	D0AZ3C	KIT#p.A829P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.A829P	.	PMID: 23456621	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01209	COSMIC	D0AZ3C	KIT#p.A829P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.A829P	.	PMID: 26779618	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01210	COSMIC	D0AZ3C	KIT#p.C809G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.C809G	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01211	COSMIC	D0AZ3C	KIT#p.C809G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.C809G	.	PMID: 17875769	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01212	COSMIC	D0AZ3C	KIT#p.C809G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.C809G	.	PMID: 18452195	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01213	COSMIC	D0AZ3C	KIT#p.C809G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.C809G	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00666	COSMIC	D0AZ3C	ABL1#p.D276A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D276A	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00300	Cancer Genome Interpreter	D0AZ3C	ABL1#p.D276G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D276G	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00612	COSMIC	D0AZ3C	ABL1#p.D276G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D276G	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00667	COSMIC	D0AZ3C	ABL1#p.D276G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D276G	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00668	COSMIC	D0AZ3C	ABL1#p.D276G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D276G	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00669	COSMIC	D0AZ3C	ABL1#p.D276G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D276G	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00670	COSMIC	D0AZ3C	ABL1#p.D276G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D276G	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00671	COSMIC	D0AZ3C	ABL1#p.D276N	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D276N	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00301	Cancer Genome Interpreter	D0AZ3C	ABL1#p.D363Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D363Y	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L02143	hotspot3D	D0AZ3C	ABL1#p.D400Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D400Y	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L00672	COSMIC	D0AZ3C	ABL1#p.D482V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.D482V	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01215	COSMIC	D0AZ3C	KIT#p.D716N	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D716N	.	PMID: 15685537	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01216	COSMIC	D0AZ3C	KIT#p.D816A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D816A	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01217	COSMIC	D0AZ3C	KIT#p.D816E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D816E	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01218	COSMIC	D0AZ3C	KIT#p.D816E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D816E	.	PMID: 18452195	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01219	COSMIC	D0AZ3C	KIT#p.D816G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D816G	.	PMID: 15685537	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01220	COSMIC	D0AZ3C	KIT#p.D816H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D816H	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01221	COSMIC	D0AZ3C	KIT#p.D816H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D816H	.	PMID: 17875769	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01222	COSMIC	D0AZ3C	KIT#p.D816H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D816H	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01223	COSMIC	D0AZ3C	KIT#p.D816H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D816H	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01224	COSMIC	D0AZ3C	KIT#p.D816H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D816H	.	PMID: 20032375	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01225	COSMIC	D0AZ3C	KIT#p.D820A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820A	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01226	COSMIC	D0AZ3C	KIT#p.D820A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820A	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01227	COSMIC	D0AZ3C	KIT#p.D820E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820E	.	PMID: 15685537	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01228	COSMIC	D0AZ3C	KIT#p.D820E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820E	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01229	COSMIC	D0AZ3C	KIT#p.D820E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820E	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01230	COSMIC	D0AZ3C	KIT#p.D820E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820E	.	PMID: 18452195	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01231	COSMIC	D0AZ3C	KIT#p.D820E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820E	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01232	COSMIC	D0AZ3C	KIT#p.D820G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820G	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01233	COSMIC	D0AZ3C	KIT#p.D820G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820G	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01234	COSMIC	D0AZ3C	KIT#p.D820G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820G	.	PMID: 18452195	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01235	COSMIC	D0AZ3C	KIT#p.D820G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820G	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01236	COSMIC	D0AZ3C	KIT#p.D820G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820G	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01237	COSMIC	D0AZ3C	KIT#p.D820G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820G	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00231	Cancer Genome Interpreter	D0AZ3C	KIT#p.D820Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820Y	敏感性增加	PMID: 23775962	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Cutaneous Melanoma	Case report	Imatinib	Approved
L01238	COSMIC	D0AZ3C	KIT#p.D820Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820Y	.	PMID: 15685537	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01239	COSMIC	D0AZ3C	KIT#p.D820Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820Y	.	PMID: 15930355	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01240	COSMIC	D0AZ3C	KIT#p.D820Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820Y	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01241	COSMIC	D0AZ3C	KIT#p.D820Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820Y	.	PMID: 18452195	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01242	COSMIC	D0AZ3C	KIT#p.D820Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820Y	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01243	COSMIC	D0AZ3C	KIT#p.D820Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820Y	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01244	COSMIC	D0AZ3C	KIT#p.D820Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820Y	.	PMID: 23456621	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01245	COSMIC	D0AZ3C	KIT#p.D820Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D820Y	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00413	Cancer Genome Interpreter	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	耐药性增加	PMID: 22718859, 16638875	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumour	Late trials,Pre-clinical	Imatinib	Approved
L01246	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 12949711	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01247	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 14645423	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01248	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 15685537	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01249	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 15930355	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01250	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01251	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01252	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 20043176	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01253	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 20568982	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01254	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 22718859	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01255	COSMIC	D0AZ3C	PDGFRA#p.D842V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.D842V	.	PMID: 26130666	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L02024	search pubmed	D0AZ3C	KIT#p.D861H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D861H	耐药性增加	PMID: 18955458	In patients with KIT-mutated gastrointestinal stromal tumor (GIST), D861H mutations have been detected in patients who develop acquired resistance to imatinib therapy.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Melanoma	Case report	Imatinib	
L00302	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00613	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 11853795	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00614	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 11964322	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00615	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00646	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00673	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 11964322	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00674	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00675	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00676	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00677	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00678	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00679	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00680	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00681	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00682	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 20512393	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00683	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00684	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00685	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 21357704	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00686	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00687	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00688	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00689	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 23355941	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00690	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00691	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00692	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00693	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 25807654	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01028	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 11853795	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01029	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01030	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01031	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01032	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01033	COSMIC	D0AZ3C	ABL1#p.E255K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00303	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00616	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 11853795	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00647	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00694	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00695	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00696	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00697	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00698	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00699	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 21357704	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00700	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00701	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00702	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01034	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01035	COSMIC	D0AZ3C	ABL1#p.E255V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00304	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E258D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E258D	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00305	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E275K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E275K	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00703	COSMIC	D0AZ3C	ABL1#p.E275K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E275K	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00306	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E275Q	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E275Q	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L01036	COSMIC	D0AZ3C	ABL1#p.E279A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E279A	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00307	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E279K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E279K	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00704	COSMIC	D0AZ3C	ABL1#p.E279K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E279K	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00705	COSMIC	D0AZ3C	ABL1#p.E279Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E279Y	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00706	COSMIC	D0AZ3C	ABL1#p.E279Z	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E279Z	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00707	COSMIC	D0AZ3C	ABL1#p.E282G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E282G	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00308	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E292Q	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E292Q	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00309	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E292V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E292V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00708	COSMIC	D0AZ3C	ABL1#p.E292V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E292V	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00709	COSMIC	D0AZ3C	ABL1#p.E292V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E292V	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00710	COSMIC	D0AZ3C	ABL1#p.E352D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E352D	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00711	COSMIC	D0AZ3C	ABL1#p.E352G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E352G	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00712	COSMIC	D0AZ3C	ABL1#p.E355?	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355?	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00310	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E355A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355A	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00713	COSMIC	D0AZ3C	ABL1#p.E355A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355A	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00714	COSMIC	D0AZ3C	ABL1#p.E355A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355A	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00311	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E355D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355D	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00312	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00648	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00715	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00716	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00717	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00718	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00719	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00720	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00721	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00722	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00723	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00724	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00725	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00726	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00727	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00728	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00729	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 25740611	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01037	COSMIC	D0AZ3C	ABL1#p.E355G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E355G	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00313	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E373K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E373K	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00730	COSMIC	D0AZ3C	ABL1#p.E450?	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450?	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00314	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E450A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450A	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00731	COSMIC	D0AZ3C	ABL1#p.E450A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450A	.	PMID: 20512393	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01038	COSMIC	D0AZ3C	ABL1#p.E450A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450A	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00315	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E450G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450G	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00732	COSMIC	D0AZ3C	ABL1#p.E450G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450G	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00733	COSMIC	D0AZ3C	ABL1#p.E450G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450G	.	PMID: 20512393	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00734	COSMIC	D0AZ3C	ABL1#p.E450G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450G	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00316	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E450K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450K	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00735	COSMIC	D0AZ3C	ABL1#p.E450K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450K	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00317	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E450V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E450V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00318	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E453A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453A	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00736	COSMIC	D0AZ3C	ABL1#p.E453A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453A	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00737	COSMIC	D0AZ3C	ABL1#p.E453D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453D	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00319	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E453G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453G	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00738	COSMIC	D0AZ3C	ABL1#p.E453G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453G	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00320	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E453K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453K	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00739	COSMIC	D0AZ3C	ABL1#p.E453K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453K	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00740	COSMIC	D0AZ3C	ABL1#p.E453K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453K	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01039	COSMIC	D0AZ3C	ABL1#p.E453L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453L	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00321	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E453V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E453V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00322	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E459A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459A	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00323	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E459G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459G	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00741	COSMIC	D0AZ3C	ABL1#p.E459G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459G	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00742	COSMIC	D0AZ3C	ABL1#p.E459G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459G	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00743	COSMIC	D0AZ3C	ABL1#p.E459G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459G	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00324	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00744	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00745	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00746	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00747	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 20512393	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00748	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00749	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00750	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00751	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 21357704	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00752	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00753	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01040	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01041	COSMIC	D0AZ3C	ABL1#p.E459K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459K	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00754	COSMIC	D0AZ3C	ABL1#p.E459Q	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459Q	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00325	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E459V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E459V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L02026	search pubmed	D0AZ5C	KIT#p.E490K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.E490K	敏感性增加	PMID: 21325067	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Thymic Carcinoma	Case report	Imatinib	
L00755	COSMIC	D0AZ3C	ABL1#p.E494G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E494G	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00326	Cancer Genome Interpreter	D0AZ3C	ABL1#p.E507G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.E507G	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L02079	hotspot3D	D0AZ3C	DDR1#p.E618Q	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	DDR1	p.E618Q	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L00327	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F311I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F311I	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00756	COSMIC	D0AZ3C	ABL1#p.F311I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F311I	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00757	COSMIC	D0AZ3C	ABL1#p.F311I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F311I	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00758	COSMIC	D0AZ3C	ABL1#p.F311I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F311I	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00759	COSMIC	D0AZ3C	ABL1#p.F311I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F311I	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01042	COSMIC	D0AZ3C	ABL1#p.F311I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F311I	.	PMID: 21264552	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00328	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F311L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F311L	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00760	COSMIC	D0AZ3C	ABL1#p.F311L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F311L	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00761	COSMIC	D0AZ3C	ABL1#p.F311L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F311L	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00329	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F317C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317C	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00330	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F317I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317I	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00331	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00649	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00762	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 11964322	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00763	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00764	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00765	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00766	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00767	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00768	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00769	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 20512393	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00770	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00771	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00772	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00773	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 21357704	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00774	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00775	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00776	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00777	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01043	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01044	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01045	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 21264552	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01046	COSMIC	D0AZ3C	ABL1#p.F317L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00332	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F317V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00778	COSMIC	D0AZ3C	ABL1#p.F317V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F317V	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01356	search pubmed	D0AZ3C	ABL1#p.F359*	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359*	耐药性增加	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Leukemia	.	Imatinib	Approved
L00779	COSMIC	D0AZ3C	ABL1#p.F359?	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359?	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00780	COSMIC	D0AZ3C	ABL1#p.F359?	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359?	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00781	COSMIC	D0AZ3C	ABL1#p.F359A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359A	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00333	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F359C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359C	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00650	COSMIC	D0AZ3C	ABL1#p.F359C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00782	COSMIC	D0AZ3C	ABL1#p.F359C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00783	COSMIC	D0AZ3C	ABL1#p.F359C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00784	COSMIC	D0AZ3C	ABL1#p.F359C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00785	COSMIC	D0AZ3C	ABL1#p.F359C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00786	COSMIC	D0AZ3C	ABL1#p.F359C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00787	COSMIC	D0AZ3C	ABL1#p.F359C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00788	COSMIC	D0AZ3C	ABL1#p.F359C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00334	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F359I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359I	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00789	COSMIC	D0AZ3C	ABL1#p.F359I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359I	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00790	COSMIC	D0AZ3C	ABL1#p.F359I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359I	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00791	COSMIC	D0AZ3C	ABL1#p.F359I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359I	.	PMID: 23044928	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00792	COSMIC	D0AZ3C	ABL1#p.F359I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359I	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01047	COSMIC	D0AZ3C	ABL1#p.F359I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359I	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00335	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F359L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359L	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00336	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00617	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00651	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00793	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00794	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00795	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00796	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00797	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00798	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00799	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00800	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00801	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00802	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00803	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00804	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 21357704	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00805	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00806	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00807	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00808	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00809	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01048	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01049	COSMIC	D0AZ3C	ABL1#p.F359V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00337	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F382L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F382L	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00810	COSMIC	D0AZ3C	ABL1#p.F382L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F382L	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01050	COSMIC	D0AZ3C	ABL1#p.F382L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F382L	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L02057	hotspot3D	D0AZ3C	ABL1#p.F401L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F401L	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L00338	Cancer Genome Interpreter	D0AZ3C	ABL1#p.F486S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F486S	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00811	COSMIC	D0AZ3C	ABL1#p.F486S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F486S	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00812	COSMIC	D0AZ3C	ABL1#p.F486S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F486S	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00813	COSMIC	D0AZ3C	ABL1#p.F486S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F486S	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00814	COSMIC	D0AZ3C	ABL1#p.F486S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F486S	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00815	COSMIC	D0AZ3C	ABL1#p.F486S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F486S	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00816	COSMIC	D0AZ3C	ABL1#p.F486S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F486S	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00817	COSMIC	D0AZ3C	ABL1#p.F486S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.F486S	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00339	Cancer Genome Interpreter	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00618	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00818	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00819	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00820	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00821	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00822	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00823	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00824	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00825	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 20512393	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00826	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 20682399	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00827	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00828	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00829	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 21357704	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00830	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00831	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00832	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00833	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00834	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00835	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00836	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00837	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 25807654	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00838	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 26413254	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01051	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 11964322	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01052	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01053	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01054	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01055	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 21264552	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01056	COSMIC	D0AZ3C	ABL1#p.G250E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00340	Cancer Genome Interpreter	D0AZ3C	ABL1#p.G250R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G250R	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00839	COSMIC	D0AZ3C	ABL1#p.G251D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G251D	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00840	COSMIC	D0AZ3C	ABL1#p.G251E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G251E	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00841	COSMIC	D0AZ3C	ABL1#p.G398R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.G398R	.	PMID: 25740611	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L02161	hotspot3D	D0AZ3C	DDR1#p.G731R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	DDR1	p.G731R	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L02127	hotspot3D	D0AZ3C	KIT#p.G812V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.G812V	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L00527	Cancer Genome Interpreter	D0AZ3C	PDGFRA#p.G853D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.G853D	敏感性增加	PMID: 24132921	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Cutaneous Melanoma	Pre-clinical	Imatinib	Approved
L00341	Cancer Genome Interpreter	D0AZ3C	ABL1#p.H396A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396A	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00342	Cancer Genome Interpreter	D0AZ3C	ABL1#p.H396P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396P	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00619	COSMIC	D0AZ3C	ABL1#p.H396P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396P	.	PMID: 11853795	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00620	COSMIC	D0AZ3C	ABL1#p.H396P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396P	.	PMID: 22299775	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00652	COSMIC	D0AZ3C	ABL1#p.H396P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396P	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00842	COSMIC	D0AZ3C	ABL1#p.H396P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396P	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00343	Cancer Genome Interpreter	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00843	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00844	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00845	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00846	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00847	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00848	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00849	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00850	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00851	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00852	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00853	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00854	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00855	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00856	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00857	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01057	COSMIC	D0AZ3C	ABL1#p.H396R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00039	Cancer Genome Interpreter	D0AZ3C	KIT#p.H697Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.H697Y	耐药性增加	PMID: 23582185, 21689725, 17259998	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumour	Pre-clinical	Imatinib	Approved
L00528	Cancer Genome Interpreter	D0AZ3C	PDGFRA#p.H845Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.H845Y	敏感性增加	PMID: 24132921	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Cutaneous Melanoma	Pre-clinical	Imatinib	Approved
L00344	Cancer Genome Interpreter	D0AZ3C	ABL1#p.I242T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.I242T	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00345	Cancer Genome Interpreter	D0AZ3C	ABL1#p.I293V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.I293V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00346	Cancer Genome Interpreter	D0AZ3C	ABL1#p.I418S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.I418S	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00347	Cancer Genome Interpreter	D0AZ3C	ABL1#p.I418V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.I418V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00858	COSMIC	D0AZ3C	ABL1#p.I418V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.I418V	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01058	COSMIC	D0AZ3C	ABL1#p.I418V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.I418V	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L02129	hotspot3D	D0AZ3C	KIT#p.I571K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.I571K	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L02147	hotspot3D	D0AZ3C	ABL1#p.K106N	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.K106N	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L00348	Cancer Genome Interpreter	D0AZ3C	ABL1#p.K247R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.K247R	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L01059	COSMIC	D0AZ3C	ABL1#p.K294>RGG	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.K294>RGG	.	PMID: 21264552	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01357	search pubmed	D0AZ3C	ABL1#p.K294RGG	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.K294RGG	耐药性增加	PMID: 21264552	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Leukemia	.	Imatinib	Approved
L00859	COSMIC	D0AZ3C	ABL1#p.K378R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.K378R	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00860	COSMIC	D0AZ3C	ABL1#p.K419E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.K419E	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01256	COSMIC	D0AZ3C	KIT#p.K642E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.K642E	.	PMID: 20043176	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01257	COSMIC	D0AZ3C	KIT#p.K642E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.K642E	.	PMID: 20043176	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01258	COSMIC	D0AZ3C	KIT#p.K642E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.K642E	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L02005	search pubmed	D0AZ3C	KIT#p.K642E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.K642E	敏感性增加	PMID: 18066592	the KIT W557R mutation was sensitive to imatinib in preclinical studies		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Melanoma	Case report	Imatinib	
L01204	COSMIC	D0AZ3C	KIT#p.K818_D820>N	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.K818_D820>N	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00349	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00861	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00862	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 17008892	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00863	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00864	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00865	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00866	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00867	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00868	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00869	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00870	COSMIC	D0AZ3C	ABL1#p.L248V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L248V	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00350	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L273M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L273M	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00871	COSMIC	D0AZ3C	ABL1#p.L273M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L273M	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00872	COSMIC	D0AZ3C	ABL1#p.L273M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L273M	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00351	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L298V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L298V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00873	COSMIC	D0AZ3C	ABL1#p.L298V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L298V	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00874	COSMIC	D0AZ3C	ABL1#p.L298V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L298V	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00875	COSMIC	D0AZ3C	ABL1#p.L298V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L298V	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00876	COSMIC	D0AZ3C	ABL1#p.L298V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L298V	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00352	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L324Q	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L324Q	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00653	COSMIC	D0AZ3C	ABL1#p.L324Q	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L324Q	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00877	COSMIC	D0AZ3C	ABL1#p.L340L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L340L	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00353	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L364I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L364I	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00878	COSMIC	D0AZ3C	ABL1#p.L364I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L364I	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00879	COSMIC	D0AZ3C	ABL1#p.L364I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L364I	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00880	COSMIC	D0AZ3C	ABL1#p.L364I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L364I	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00881	COSMIC	D0AZ3C	ABL1#p.L364I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L364I	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00354	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L370P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L370P	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00355	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L384M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L384M	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00882	COSMIC	D0AZ3C	ABL1#p.L384M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L384M	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00883	COSMIC	D0AZ3C	ABL1#p.L384M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L384M	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00884	COSMIC	D0AZ3C	ABL1#p.L384M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L384M	.	PMID: 26413254	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00356	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L387F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387F	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00885	COSMIC	D0AZ3C	ABL1#p.L387F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387F	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00357	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L387M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387M	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00886	COSMIC	D0AZ3C	ABL1#p.L387M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387M	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00887	COSMIC	D0AZ3C	ABL1#p.L387M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387M	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00888	COSMIC	D0AZ3C	ABL1#p.L387M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387M	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00889	COSMIC	D0AZ3C	ABL1#p.L387M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387M	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00890	COSMIC	D0AZ3C	ABL1#p.L387M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387M	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00891	COSMIC	D0AZ3C	ABL1#p.L387M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387M	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00892	COSMIC	D0AZ3C	ABL1#p.L387M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387M	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00358	Cancer Genome Interpreter	D0AZ3C	ABL1#p.L387V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.L387V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L02001	search pubmed	D0AZ3C	KIT#p.L576P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.L576P	敏感性增加	PMID: 18066592	the KIT W557R mutation was sensitive to imatinib in preclinical studies		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Melanoma	Case report	Imatinib	
L02029	search pubmed	D0AZ8C	KIT#p.L576P	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.L576P	敏感性增加	PMID: 17372901, 18448188	A KIT-mutated case of thymic carcinoma reported in the literature harbored an L576P mutation in exon 11. No follow-up of the patient was reported regarding therapeutics with specific inhibitors. However, this mutation has also previously been described in GIST and melanoma. It has been biologically characterized as being sensitive to imatinib but even more sensitive to sunitinib and dasatinib.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Thymic Carcinoma	Case report	Imatinib	
L00359	Cancer Genome Interpreter	D0AZ3C	ABL1#p.M237V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M237V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00360	Cancer Genome Interpreter	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00621	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 22299775	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00654	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00893	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00894	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00895	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00896	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 19156415	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00897	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00898	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00899	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00900	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00901	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00902	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00903	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00904	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00905	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00906	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00907	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00908	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00909	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00910	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00911	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01060	COSMIC	D0AZ3C	ABL1#p.M244V	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00361	Cancer Genome Interpreter	D0AZ3C	ABL1#p.M343T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M343T	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L01061	COSMIC	D0AZ3C	ABL1#p.M343T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M343T	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00912	COSMIC	D0AZ3C	ABL1#p.M351K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351K	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00362	Cancer Genome Interpreter	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00913	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 11964322	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00914	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00915	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00916	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00917	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00918	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 15381060	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00919	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00920	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00921	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00922	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00923	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00924	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 21357704	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00925	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00926	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00927	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00928	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 23355941	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00929	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00930	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00931	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00932	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01062	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01063	COSMIC	D0AZ3C	ABL1#p.M351T	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00363	Cancer Genome Interpreter	D0AZ3C	ABL1#p.M388L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M388L	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00933	COSMIC	D0AZ3C	ABL1#p.M388L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M388L	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00934	COSMIC	D0AZ3C	ABL1#p.M388L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M388L	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00364	Cancer Genome Interpreter	D0AZ3C	ABL1#p.M472I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.M472I	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00935	COSMIC	D0AZ3C	ABL1#p.N368S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.N368S	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00936	COSMIC	D0AZ3C	ABL1#p.N374Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.N374Y	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01259	COSMIC	D0AZ3C	KIT#p.N680K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N680K	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01260	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 15685537	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01261	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 15930355	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01262	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01263	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01264	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 17875769	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01265	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01266	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01267	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01268	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 23456621	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01269	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01270	COSMIC	D0AZ3C	KIT#p.N822K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822K	.	PMID: 26316776	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01271	COSMIC	D0AZ3C	KIT#p.N822Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822Y	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01272	COSMIC	D0AZ3C	KIT#p.N822Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822Y	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01273	COSMIC	D0AZ3C	KIT#p.N822Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.N822Y	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00645	COSMIC	D0AZ3C	ABL1#p.P310S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.P310S	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00384	Cancer Genome Interpreter	D0AZ3C	ABL1#p.P480L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.P480L	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00659	COSMIC	D0AZ3C	ABL1#p.P480L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.P480L	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00530	Cancer Genome Interpreter	D0AZ3C	PDGFRA#p.P577S	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.P577S	敏感性增加	PMID: 24132921	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Cutaneous Melanoma	Pre-clinical	Imatinib	Approved
L00937	COSMIC	D0AZ3C	ABL1#p.Q252E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252E	.	PMID: 15381060	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00365	Cancer Genome Interpreter	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00938	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00939	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00940	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00941	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00942	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00943	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00944	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00945	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00946	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00947	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 22489663	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00948	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00949	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01064	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01065	COSMIC	D0AZ3C	ABL1#p.Q252H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00950	COSMIC	D0AZ3C	ABL1#p.Q252K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252K	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00655	COSMIC	D0AZ3C	ABL1#p.Q252M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252M	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00366	Cancer Genome Interpreter	D0AZ3C	ABL1#p.Q252R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252R	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L01066	COSMIC	D0AZ3C	ABL1#p.Q252R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Q252R	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00951	COSMIC	D0AZ3C	ABL1#p.R328M	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.R328M	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00018	Cancer Genome Interpreter	D0AZ3C	PDGFRA#p.R748G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.R748G	敏感性增加	NCCN guidelines	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumour	NCCN guidelines	Imatinib	Approved
L02151	hotspot3D	D0AZ3C	ABL1#p.R783G	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.R783G	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L00529	Cancer Genome Interpreter	D0AZ3C	PDGFRA#p.R841K	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.R841K	敏感性增加	PMID: 24132921	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Cutaneous Melanoma	Pre-clinical	Imatinib	Approved
L00367	Cancer Genome Interpreter	D0AZ3C	ABL1#p.S417F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.S417F	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00368	Cancer Genome Interpreter	D0AZ3C	ABL1#p.S417Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.S417Y	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00952	COSMIC	D0AZ3C	ABL1#p.S417Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.S417Y	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00953	COSMIC	D0AZ3C	ABL1#p.S417Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.S417Y	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00954	COSMIC	D0AZ3C	ABL1#p.S417Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.S417Y	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00955	COSMIC	D0AZ3C	ABL1#p.S417Y	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.S417Y	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00369	Cancer Genome Interpreter	D0AZ3C	ABL1#p.S438C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.S438C	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00956	COSMIC	D0AZ3C	ABL1#p.S438C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.S438C	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00957	COSMIC	D0AZ3C	ABL1#p.S438C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.S438C	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01274	COSMIC	D0AZ3C	KIT#p.S709F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.S709F	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01275	COSMIC	D0AZ3C	KIT#p.S821F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.S821F	.	PMID: 25735500	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00370	Cancer Genome Interpreter	D0AZ3C	ABL1#p.T277A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T277A	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00958	COSMIC	D0AZ3C	ABL1#p.T277A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T277A	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01067	COSMIC	D0AZ3C	ABL1#p.T277A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T277A	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01358	search pubmed	D0AZ3C	ABL1#p.T315A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315A	耐药性增加	PMID: 23223358	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Leukemia	.	Imatinib	Approved
L00371	Cancer Genome Interpreter	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00622	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 11853795	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00623	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00656	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00959	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 11964322	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00960	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00961	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00962	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00963	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00964	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00965	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00966	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00967	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00968	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00969	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 20512393	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00970	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00971	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00972	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00973	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 21357704	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00974	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00975	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 22489663	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00976	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00977	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00978	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 23355941	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00979	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00980	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00981	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01068	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 11964322	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01069	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01070	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01071	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01072	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01073	COSMIC	D0AZ3C	ABL1#p.T315I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00982	COSMIC	D0AZ3C	ABL1#p.T315N	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.T315N	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01276	COSMIC	D0AZ3C	KIT#p.T670E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670E	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01277	COSMIC	D0AZ3C	KIT#p.T670E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670E	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00253	Cancer Genome Interpreter	D0AZ3C	KIT#p.T670I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670I	耐药性增加	PMID: 24687822	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumour	Case report	Imatinib	Approved
L01278	COSMIC	D0AZ3C	KIT#p.T670I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670I	.	PMID: 15685537	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01279	COSMIC	D0AZ3C	KIT#p.T670I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670I	.	PMID: 15930355	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01280	COSMIC	D0AZ3C	KIT#p.T670I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670I	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01281	COSMIC	D0AZ3C	KIT#p.T670I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670I	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01282	COSMIC	D0AZ3C	KIT#p.T670I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670I	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01283	COSMIC	D0AZ3C	KIT#p.T670I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670I	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01284	COSMIC	D0AZ3C	KIT#p.T670I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670I	.	PMID: 20028860	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01285	COSMIC	D0AZ3C	KIT#p.T670I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.T670I	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00254	Cancer Genome Interpreter	D0AZ3C	PDGFRA#p.T674I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	p.T674I	耐药性增加	PMID: 12660384	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Hyper Eosinophilic Syndrome	Case report	Imatinib	Approved
L00983	COSMIC	D0AZ3C	ABL1#p.V256L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V256L	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00372	Cancer Genome Interpreter	D0AZ3C	ABL1#p.V280A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V280A	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00373	Cancer Genome Interpreter	D0AZ3C	ABL1#p.V289A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V289A	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00984	COSMIC	D0AZ3C	ABL1#p.V289F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V289F	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00985	COSMIC	D0AZ3C	ABL1#p.V289F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V289F	.	PMID: 23355941	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00986	COSMIC	D0AZ3C	ABL1#p.V289F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V289F	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00374	Cancer Genome Interpreter	D0AZ3C	ABL1#p.V289I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V289I	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00375	Cancer Genome Interpreter	D0AZ3C	ABL1#p.V299L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V299L	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00987	COSMIC	D0AZ3C	ABL1#p.V299L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V299L	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00988	COSMIC	D0AZ3C	ABL1#p.V299L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V299L	.	PMID: 23086624	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00376	Cancer Genome Interpreter	D0AZ3C	ABL1#p.V371A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V371A	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00377	Cancer Genome Interpreter	D0AZ3C	ABL1#p.V379I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V379I	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00989	COSMIC	D0AZ3C	ABL1#p.V379I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V379I	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00990	COSMIC	D0AZ3C	ABL1#p.V379I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V379I	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00991	COSMIC	D0AZ3C	ABL1#p.V379I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V379I	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00992	COSMIC	D0AZ3C	ABL1#p.V379I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V379I	.	PMID: 26413254	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L02155	hotspot3D	D0AZ3C	ABL1#p.V390L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.V390L	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L01993	search pubmed	D0AZ3C	KIT#p.V559A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V559A	敏感性增加	PMID: 18066592	the KIT W557R mutation was sensitive to imatinib in preclinical studies		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Melanoma	Case report	Imatinib	
L02028	search pubmed	D0AZ7C	KIT#p.V559A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V559A	敏感性增加	PMID: 20736294	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Thymic Carcinoma	Case report	Imatinib	
L01997	search pubmed	D0AZ3C	KIT#p.V559D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V559D	敏感性增加	PMID: 18066592	the KIT W557R mutation was sensitive to imatinib in preclinical studies		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Melanoma	Case report	Imatinib	
L00040	Cancer Genome Interpreter	D0AZ3C	KIT#p.V559I	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V559I	耐药性增加	PMID: 23582185, 21689725, 17259998	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumour	Pre-clinical	Imatinib	Approved
L00580	COSMIC	D0AZ3C	BRAF#p.V600E	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	BRAF	p.V600E	耐药性增加	PMID: 25182956	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L02131	hotspot3D	D0AZ3C	KIT#p.V603D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V603D	耐药性增加	.			是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	cancer	prediction	Imatinib	
L00041	Cancer Genome Interpreter	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	耐药性增加	PMID: 23582185, 21689725, 17259998	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumour	Pre-clinical	Imatinib	Approved
L01286	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 15685537	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01287	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 15930355	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01288	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01289	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01290	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 17875769	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01291	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 18488000	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01292	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01293	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 18830121	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01294	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01295	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 23348204	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01296	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 23456621	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01297	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 25182956	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01298	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01299	COSMIC	D0AZ3C	KIT#p.V654A	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V654A	.	PMID: 26779618	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00378	Cancer Genome Interpreter	D0AZ3C	ABL1#p.W261L	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.W261L	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L01989	search pubmed	D0AZ3C	KIT#p.W557R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.W557R	敏感性增加	PMID: 18066592	the KIT W557R mutation was sensitive to imatinib in preclinical studies		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Melanoma	Case report	Imatinib	
L02027	search pubmed	D0AZ6C	KIT#p.W557R	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.W557R	敏感性增加	PMID: 12960119	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Thymic Carcinoma	Case report	Imatinib	
L00379	Cancer Genome Interpreter	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00657	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00993	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00994	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 12623848	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00995	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00996	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00997	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00998	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00999	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01000	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01001	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01074	COSMIC	D0AZ3C	ABL1#p.Y253F	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253F	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00380	Cancer Genome Interpreter	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00624	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 11853795	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00625	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 11964322	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00626	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00627	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukaemia	.	Imatinib	Approved
L00658	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 25281405	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01002	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 12399961	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01003	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01004	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 15381060	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01005	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 19567878	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01006	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 19625707	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01007	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 19768693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01008	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 19925053	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01009	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 20055659	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01010	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 20367437	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01011	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 20512393	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01012	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 20697894	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01013	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01014	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01015	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21239056	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01016	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21357704	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01017	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 22873741	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01018	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01019	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 23355941	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01020	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 23433665	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01021	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 23676790	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01022	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 23799845	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01023	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 24456693	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01024	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 26413254	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01075	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 12204532	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01076	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 14745431	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01077	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21156844	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01078	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21221851	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L01079	COSMIC	D0AZ3C	ABL1#p.Y253H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 21264552	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Blast Phase Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00381	Cancer Genome Interpreter	D0AZ3C	ABL1#p.Y320C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y320C	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L01025	COSMIC	D0AZ3C	ABL1#p.Y320C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y320C	.	PMID: 23053188	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00382	Cancer Genome Interpreter	D0AZ3C	ABL1#p.Y342H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y342H	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L01026	COSMIC	D0AZ3C	ABL1#p.Y353H	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y353H	.	PMID: 21663510	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	.	Imatinib	Approved
L00383	Cancer Genome Interpreter	D0AZ3C	ABL1#p.Y393C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	p.Y393C	耐药性增加	PMID: 21562040	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Imatinib	Approved
L00227	Cancer Genome Interpreter	D0AZ3C	KIT#p.Y553N	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y553N	敏感性增加	PMID: 21969494	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Thymic Carcinoma	Case report	Imatinib	Approved
L02025	search pubmed	D0AZ4C	KIT#p.Y553N	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y553N	敏感性增加	PMID: 21969494	This mutation was described in a patient with a refractory metastatic thymic carcinoma tumor, exhibiting response to imatinib		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Thymic Carcinoma	Case report	Imatinib	
L00577	Cancer Genome Interpreter	D0AZ3C	CSF1R#p.Y571D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	CSF1R	p.Y571D	敏感性增加	PMID: 18971950	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Myelodysplastic Syndromes	Pre-clinical	Imatinib	Approved
L01300	COSMIC	D0AZ3C	KIT#p.Y578C	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y578C	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L00042	Cancer Genome Interpreter	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	耐药性增加	PMID: 23582185, 21689725, 17259998	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumour	Pre-clinical	Imatinib	Approved
L01301	COSMIC	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	.	PMID: 15930355	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01302	COSMIC	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	.	PMID: 16551858	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01303	COSMIC	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	.	PMID: 16954519	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01304	COSMIC	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	.	PMID: 17875769	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01305	COSMIC	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	.	PMID: 18623623	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01306	COSMIC	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	.	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01307	COSMIC	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	.	PMID: 20043176	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01308	COSMIC	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	.	PMID: 23456621	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01309	COSMIC	D0AZ3C	KIT#p.Y823D	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.Y823D	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01834	Cancer Genome Interpreter	D0AZ3C	KIT::consequence::inframe_deletion:416-422,::inframe_insertion:416-422	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT inframe deletion (416-422),inframe insertion (416-422)	敏感性增加	PMID: 15618474	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Myeloid Leukemia	Pre-clinical	Imatinib	Approved
L01833	Cancer Genome Interpreter	D0AZ3C	KIT::consequence::inframe_deletion:V560.	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT inframe deletion (V560)	敏感性增加	PMID: 15201427	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Thymoma	Case report	Imatinib	Approved
L01622	Cancer Genome Interpreter	D0AZ3C	NF1:del	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	NF1	NF1 deletion	敏感性增加	PMID: 23099009	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Plexiform neurofibroma	Early trials	Imatinib	Approved
L01873	Cancer Genome Interpreter	D0AZ3C	NF2:del	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	NF2	NF2 deletion	敏感性增加	PMID: 19509233, 2290085	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Schwannoma	Pre-clinical	Imatinib	Approved
L01214	COSMIC	D0AZ3C	KIT#p.D579del	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.D579 del	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01970	search pubmed	D0AZ10C	KIT#p.577_579del	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.P577_D579 del	敏感性增加	PMID: 15201427	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Thymic Carcinoma	Case report	Imatinib	
L01969	search pubmed	D0AZ9C	KIT#p.V560del	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V560 del	敏感性增加	PMID: 15201427	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Thymic Carcinoma	Case report	Imatinib	
L01205	COSMIC	D0AZ3C	KIT#p.569_578del	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	p.V569_Y578 del	.	PMID: 25886408	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	.	Imatinib	Approved
L01661	Cancer Genome Interpreter	D0AZ3C	PDGFRA::consequence::inframe_deletion:I843.	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	PDGFRA inframe deletion (I843)	敏感性增加	NCCN guidelines	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	NCCN guidelines	Imatinib	Approved
L01684	Cancer Genome Interpreter	D0AZ3C	ABL1__BCR	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	ABL1-BCR fusion	敏感性增加	EMA	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukemia, Chronic myeloid leukemia	FDA guidelines	Imatinib	Approved
L01828	Cancer Genome Interpreter	D0AZ3C	KIT:627-664,664-714,449-514	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT (627-664,664-714,449-514)	耐药性增加	PMID: 18955458, 18955451, 16624552	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	Late trials	Imatinib	Approved
L01824	Cancer Genome Interpreter	D0AZ3C	KIT:D816.	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT (D816)	耐药性增加	FDA	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Acute Lymphoblastic Leukemia, Chronic myeloid leukemia, Eosinophilic chronic leukemia, Gastrointestinal Stromal Tumor, Hyper eosinophilic advanced snydrome, Myelodisplasic proliferative syndrome, Myelodisplasic syndrome, Systemic mastocytosis cancer	FDA guidelines	Imatinib	Approved
L01825	Cancer Genome Interpreter	D0AZ3C	KIT:amp	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT amplification	敏感性降低	PMID: 23775962	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Cutaneous carcinoma	Early trials	Imatinib	Approved
L01827	Cancer Genome Interpreter	D0AZ3C	KIT:788-828	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT mutation in exon 17	耐药性增加	PMID: 23840364	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	Pre-clinical	Imatinib	Approved
L01826	Cancer Genome Interpreter	D0AZ3C	KIT:788-828,829-860	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT mutation in exon 17 or 18	耐药性增加	PMID: 21690468, 21642685	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Cutaneous carcinoma	Early trials	Imatinib	Approved
L01829	Cancer Genome Interpreter	D0AZ3C	KIT:550-592,627-664	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT mutation in exon 9,11,13,14 or 17	敏感性增加	NCCN	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Cutaneous carcinoma	NCCN guidelines	Imatinib	Approved
L01830	Cancer Genome Interpreter	D0AZ3C	KIT:550-592,627-664	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT mutation in exon 9,11,13,14 or 17	敏感性增加	PMID: 18421059, 21642685, 21690468, 22261812	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Cutaneous carcinoma	Late trials	Imatinib	Approved
L01831	Cancer Genome Interpreter	D0AZ3C	KIT:449-514,550-592,627-664,664-714,788-828	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT mutation in exon 9,11,13,14 or 17	敏感性增加	FDA	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	FDA guidelines	Imatinib	Approved
L01832	Cancer Genome Interpreter	D0AZ3C	KIT::wildtype:.	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KIT	KIT wildtype	耐药性增加	PMID: 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	Late trials	Imatinib	Approved
L01558	Cancer Genome Interpreter	D0AZ3C	KRAS:G12.	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	KRAS	KRAS (G12)	耐药性增加	PMID: 24687822	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	Case report	Imatinib	Approved
L01623	Cancer Genome Interpreter	D0AZ3C	NF1:.	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	NF1	NF1 oncogenic mutation	敏感性增加	PMID: 23099009	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Plexiform neurofibroma	Early trials	Imatinib	Approved
L01874	Cancer Genome Interpreter	D0AZ3C	NF2:.	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	NF2	NF2 oncogenic mutation	敏感性增加	PMID: 19509233, 2290085	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤		NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Schwannoma	Pre-clinical	Imatinib	Approved
L01893	Cancer Genome Interpreter	D0AZ3C	PDGFB__COL1A1	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFB	PDGFB-COL1A1 fusion	敏感性增加	FDA	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤	有被报道发生严重肝脏毒性和严重的充血性心力衰竭；孕妇使用该药物可能发生胎儿毒性	NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Dermatofibrosarcoma	FDA guidelines	Imatinib	Approved
L01659	Cancer Genome Interpreter	D0AZ3C	PDGFRA:552-596,631-668,814-854	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	PDGFRA (552-596,631-668,814-854)	敏感性增加	NCCN guidelines	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤	有被报道发生严重肝脏毒性和严重的充血性心力衰竭；孕妇使用该药物可能发生胎儿毒性	NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	NCCN guidelines	Imatinib	Approved
L01658	Cancer Genome Interpreter	D0AZ3C	PDGFRA__.	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	PDGFRA fusion	敏感性增加	EMA	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤	有被报道发生严重肝脏毒性和严重的充血性心力衰竭；孕妇使用该药物可能发生胎儿毒性	NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Myelodisplasic proliferative syndrome, Myelodisplasic syndrome	FDA guidelines	Imatinib	Approved
L01660	Cancer Genome Interpreter	D0AZ3C	PDGFRA::wildtype:.	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	PDGFRA wildtype	耐药性增加	PMID: 14645423, 18955458	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤	有被报道发生严重肝脏毒性和严重的充血性心力衰竭；孕妇使用该药物可能发生胎儿毒性	NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Gastrointestinal Stromal Tumor	Late trials	Imatinib	Approved
L01657	Cancer Genome Interpreter	D0AZ3C	PDGFRA__FIP1L1	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PDGFRA	PDGFRA-FIP1L1 fusion	敏感性增加	EMA	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤	有被报道发生严重肝脏毒性和严重的充血性心力衰竭；孕妇使用该药物可能发生胎儿毒性	NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Eosinophilic chronic leukemia, Hyper eosinophilic advanced snydrome	FDA guidelines	Imatinib	Approved
L01683	Cancer Genome Interpreter	D0AZ3C	PRKCH:amp,ABL1__BCR	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	ABL1	PRKCH amplification + ABL1-BCR fusion	敏感性增加	PMID: 25186176	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤	有被报道发生严重肝脏毒性和严重的充血性心力衰竭；孕妇使用该药物可能发生胎儿毒性	NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic myeloid leukemia	Pre-clinical	Imatinib	Approved
L01901	Cancer Genome Interpreter	D0AZ3C	PRKCH:amp,ABL1__BCR	Imatinib	Imatinib (伊马替尼)	kinase inhibitor	PRKCH	PRKCH amplification + ABL1-BCR fusion	敏感性增加	PMID: 25186176	.		是	白血病, 皮肤纤维肉瘤, 胃肠道间质瘤	有被报道发生严重肝脏毒性和严重的充血性心力衰竭；孕妇使用该药物可能发生胎儿毒性	NCT00154375: 胶质瘤, NCT00427583: 恶性外周神经鞘瘤	Chronic myeloid leukemia	Pre-clinical	Imatinib	Approved
L01972	search pubmed	D07BVI	BRAF#p.V600E	Ipilimumab	Ipilimumab (易普利姆玛)	human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody	BRAF	p.V600E	敏感性增加	PMID: 22382362, 23709751	.		否	黑色素瘤	药物可引起严重和致死性的免疫调节副作用	NCT01285609: 非小细胞肺癌, NCT01450761: 小细胞肺癌, NCT02460068: 脑癌, NCT02477826: 非小细胞肺癌, NCT02741570: 头颈癌, NCT02785952: 鳞状细胞肺癌, NCT02864251: 非小细胞肺癌, NCT02872116: 胃癌，食管癌, NCT02899299: 间皮瘤, NCT02998528: 非小细胞肺癌, NCT03036098: 尿道癌, NCT03138512: 肾细胞癌, NCT03143153: 食管癌, NCT03215706: 非小细胞肺癌, NCT03302234: 非小细胞肺癌, NCT03391869: 非小细胞肺癌	BRAF Mutant Malignant Melanoma	FDA	Ipilimumab	Approved
L01973	search pubmed	D07BVI	BRAF#p.V600K	Ipilimumab	Ipilimumab (易普利姆玛)	human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody	BRAF	p.V600K	敏感性增加	PMID: 22382362, 23709751	.		否	黑色素瘤	药物可引起严重和致死性的免疫调节副作用	NCT01285609: 非小细胞肺癌, NCT01450761: 小细胞肺癌, NCT02460068: 脑癌, NCT02477826: 非小细胞肺癌, NCT02741570: 头颈癌, NCT02785952: 鳞状细胞肺癌, NCT02864251: 非小细胞肺癌, NCT02872116: 胃癌，食管癌, NCT02899299: 间皮瘤, NCT02998528: 非小细胞肺癌, NCT03036098: 尿道癌, NCT03138512: 肾细胞癌, NCT03143153: 食管癌, NCT03215706: 非小细胞肺癌, NCT03302234: 非小细胞肺癌, NCT03391869: 非小细胞肺癌	BRAF Mutant Malignant Melanoma	FDA	Ipilimumab	Approved
L01974	search pubmed	D07BVI	BRAF#p.V600R	Ipilimumab	Ipilimumab (易普利姆玛)	human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody	BRAF	p.V600R	敏感性增加	PMID: 22382362, 23709751	.		否	黑色素瘤	药物可引起严重和致死性的免疫调节副作用	NCT01285609: 非小细胞肺癌, NCT01450761: 小细胞肺癌, NCT02460068: 脑癌, NCT02477826: 非小细胞肺癌, NCT02741570: 头颈癌, NCT02785952: 鳞状细胞肺癌, NCT02864251: 非小细胞肺癌, NCT02872116: 胃癌，食管癌, NCT02899299: 间皮瘤, NCT02998528: 非小细胞肺癌, NCT03036098: 尿道癌, NCT03138512: 肾细胞癌, NCT03143153: 食管癌, NCT03215706: 非小细胞肺癌, NCT03302234: 非小细胞肺癌, NCT03391869: 非小细胞肺癌	BRAF Mutant Malignant Melanoma	FDA	Ipilimumab	Approved
L01704	Cancer Genome Interpreter	D07HOB	RAD50:L1237F,ATM:del	Irinotecan	Irinotecan		ATM	RAD50 (L1237F) + ATM deletion	敏感性增加	PMID: 24934408	.		.	.		.	Cancer	Case report	Irinotecan	Approved
L01914	Cancer Genome Interpreter	D07HOB	RAD50:L1237F,ATM:del	Irinotecan	Irinotecan		RAD50	RAD50 (L1237F) + ATM deletion	敏感性增加	PMID: 24934408	.		.	.		.	Cancer	Case report	Irinotecan	Approved
L01716	Cancer Genome Interpreter	D07HOB	BRAF:V600.	Irinotecan	Irinotecan		BRAF	BRAF (V600)	敏感性增加	PMID: 27729313	.		.	.		.	Colorectal adenocarcinoma	Early trials	Irinotecan	Approved
L01956	Cancer Genome Interpreter	D07HOB	UGT1A1:.	Irinotecan	Irinotecan		UGT1A1	UGT1A1 biallelic inactivation	毒性增加	FDA	.		.	.		.	Cancer	FDA guidelines	Irinotecan	Approved
L01368	search pubmed	D0E0GZ	ROS1#p.G2032R	Type I TKIs	I型酪氨酸激酶抑制剂		ROS1	p.G2032R	耐药性增加	PMID: 28625641	.		.	.		.	Cancer	.	Type I TKIs	Investigative
L01369	search pubmed	D0E0GZ	NTRK1#p.G595R	Type I TKIs	I型酪氨酸激酶抑制剂		NTRK1	p.G595R	耐药性增加	PMID: 28625641	.		.	.		.	Cancer	.	Type I TKIs	Investigative
L01370	search pubmed	D0E0GZ	NTRK3#p.G623R	Type I TKIs	I型酪氨酸激酶抑制剂		NTRK3	p.G623R	耐药性增加	PMID: 28625641	.		.	.		.	Cancer	.	Type I TKIs	Investigative
L00181	Cancer Genome Interpreter	D0G2VG	JAK3#p.A572V	JAK inhibitors	JAK 抑制剂		JAK3	p.A572V	敏感性增加	PMID: 22705984	.		.	.		.	Lymphoma	Pre-clinical	JAK inhibitors	.
L00182	Cancer Genome Interpreter	D0G2VG	JAK3#p.A573V	JAK inhibitors	JAK 抑制剂		JAK3	p.A573V	敏感性增加	PMID: 22705984	.		.	.		.	Lymphoma	Pre-clinical	JAK inhibitors	.
L00189	Cancer Genome Interpreter	D0G2VG	CBL#p.C384R	JAK inhibitors	JAK 抑制剂		CBL	p.C384R	敏感性增加	PMID: 23696637	.		.	.		.	Myelodysplastic Syndromes	Pre-clinical	JAK inhibitors	.
L00185	Cancer Genome Interpreter	D0G2VG	JAK3#p.I87T	JAK inhibitors	JAK 抑制剂		JAK3	p.I87T	敏感性增加	PMID: 18397343	.		.	.		.	Megakaryoblastic Leukemia	Pre-clinical	JAK inhibitors	.
L00186	Cancer Genome Interpreter	D0G2VG	JAK3#p.Q501H	JAK inhibitors	JAK 抑制剂		JAK3	p.Q501H	敏感性增加	PMID: 18397343	.		.	.		.	Megakaryoblastic Leukemia	Pre-clinical	JAK inhibitors	.
L00187	Cancer Genome Interpreter	D0G2VG	JAK3#p.R657Q	JAK inhibitors	JAK 抑制剂		JAK3	p.R657Q	敏感性增加	PMID: 18397343	.		.	.		.	Megakaryoblastic Leukemia	Pre-clinical	JAK inhibitors	.
L00191	Cancer Genome Interpreter	D0G2VG	MPL#p.W515F	JAK inhibitors	JAK 抑制剂		MPL	p.W515F	敏感性增加	PMID: 16834459	.		.	.		.	Myelodysplastic Syndromes	Pre-clinical	JAK inhibitors	.
L00190	Cancer Genome Interpreter	D0G2VG	CBL#p.Y371H	JAK inhibitors	JAK 抑制剂		CBL	p.Y371H	敏感性增加	PMID: 23696637	.		.	.		.	Myelodysplastic Syndromes	Pre-clinical	JAK inhibitors	.
L00184	Cancer Genome Interpreter	.	JAK2#p.V617F	JAK inhibitor (alone or in combination)s	JAK 抑制剂 		JAK2	p.V617F	敏感性增加	PMID: 22829971	.		.	.		.	Acute Myeloid Leukaemia	Pre-clinical	JAK inhibitor (alone or in combination)s	.
L01377	search pubmed	D00LNW	XPO1#p.C528S	Kpt-330	Kpt-330		XPO1	p.C528S	耐药性增加	PMID: 25579209	.		.	.		.	Solid tumours	.	Kpt-330	Phase 2
L00540	Cancer Genome Interpreter	D08CDI	ERBB2#p.D769H	Lapatinib	Lapatinib (拉帕替尼)		ERBB2	p.D769H	敏感性增加	PMID: 23220880	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast Cancer	Pre-clinical	Lapatinib	Approved
L00541	Cancer Genome Interpreter	D08CDI	ERBB2#p.D769Y	Lapatinib	Lapatinib (拉帕替尼)		ERBB2	p.D769Y	敏感性增加	PMID: 23220880	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast Cancer	Pre-clinical	Lapatinib	Approved
L00522	Cancer Genome Interpreter	D08CDI	ERBB4#p.E317K	Lapatinib	Lapatinib (拉帕替尼)		ERBB4	p.E317K	敏感性增加	PMID: 19718025	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Cutaneous Melanoma	Pre-clinical	Lapatinib	Approved
L00523	Cancer Genome Interpreter	D08CDI	ERBB4#p.E452K	Lapatinib	Lapatinib (拉帕替尼)		ERBB4	p.E452K	敏感性增加	PMID: 19718025	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Cutaneous Melanoma	Pre-clinical	Lapatinib	Approved
L00243	Cancer Genome Interpreter	D08CDI	EGFR#p.E690K	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.E690K	敏感性增加	PMID: 22885469	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Endometrium Cancer	Case report	Lapatinib	Approved
L00524	Cancer Genome Interpreter	D08CDI	ERBB4#p.E872K	Lapatinib	Lapatinib (拉帕替尼)		ERBB4	p.E872K	敏感性增加	PMID: 19718025	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Cutaneous Melanoma	Pre-clinical	Lapatinib	Approved
L00494	Cancer Genome Interpreter	D08CDI	ERBB3#p.G284R	Lapatinib	Lapatinib (拉帕替尼)		ERBB3	p.G284R	敏感性增加	PMID: 23680147	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Cancer	Pre-clinical	Lapatinib	Approved
L00542	Cancer Genome Interpreter	D08CDI	ERBB2#p.G309A	Lapatinib	Lapatinib (拉帕替尼)		ERBB2	p.G309A	敏感性增加	PMID: 23220880	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast Cancer	Pre-clinical	Lapatinib	Approved
L02084	hotspot3D	D08CDI	EGFR#p.G719A	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.G719A	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L02087	hotspot3D	D08CDI	EGFR#p.G719D	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.G719D	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L02090	hotspot3D	D08CDI	EGFR#p.G721V	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.G721V	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L00071	Cancer Genome Interpreter	D08CDI	ERBB4#p.H809G	Lapatinib	Lapatinib (拉帕替尼)		ERBB4	p.H809G	耐药性增加	PMID: 26530965	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast Cancer	Case report	Lapatinib	Approved
L02093	hotspot3D	D08CDI	EGFR#p.I789M	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.I789M	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L02096	hotspot3D	D08CDI	EGFR#p.K716R	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.K716R	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L00543	Cancer Genome Interpreter	D08CDI	ERBB2#p.K753E	Lapatinib	Lapatinib (拉帕替尼)		ERBB2	p.K753E	耐药性增加	PMID: 27697991	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast Cancer	Pre-clinical	Lapatinib	Approved
L02099	hotspot3D	D08CDI	EGFR#p.L858R	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.L858R	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L02102	hotspot3D	D08CDI	EGFR#p.N842H	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.N842H	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L00496	Cancer Genome Interpreter	D08CDI	ERBB3#p.P262H	Lapatinib	Lapatinib (拉帕替尼)		ERBB3	p.P262H	敏感性增加	PMID: 23680147	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Cancer	Pre-clinical	Lapatinib	Approved
L00495	Cancer Genome Interpreter	D08CDI	ERBB3#p.Q809R	Lapatinib	Lapatinib (拉帕替尼)		ERBB3	p.Q809R	敏感性增加	PMID: 23680147	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Cancer	Pre-clinical	Lapatinib	Approved
L00525	Cancer Genome Interpreter	D08CDI	ERBB4#p.R393W	Lapatinib	Lapatinib (拉帕替尼)		ERBB4	p.R393W	敏感性增加	PMID: 19718025	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Cutaneous Melanoma	Pre-clinical	Lapatinib	Approved
L00526	Cancer Genome Interpreter	D08CDI	ERBB4#p.R544W	Lapatinib	Lapatinib (拉帕替尼)		ERBB4	p.R544W	敏感性增加	PMID: 19718025	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Cutaneous Melanoma	Pre-clinical	Lapatinib	Approved
L00544	Cancer Genome Interpreter	D08CDI	ERBB2#p.R896C	Lapatinib	Lapatinib (拉帕替尼)		ERBB2	p.R896C	敏感性增加	PMID: 23220880	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast Cancer	Pre-clinical	Lapatinib	Approved
L02105	hotspot3D	D08CDI	EGFR#p.S720C	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.S720C	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L02108	hotspot3D	D08CDI	EGFR#p.T790M	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.T790M	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L00242	Cancer Genome Interpreter	D08CDI	ERBB2#p.V659E	Lapatinib	Lapatinib (拉帕替尼)		ERBB2	p.V659E	敏感性增加	PMID: 23950206	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast Cancer, Lung Adenocarcinoma	Case report	Lapatinib	Approved
L02111	hotspot3D	D08CDI	EGFR#p.V742I	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.V742I	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L02114	hotspot3D	D08CDI	EGFR#p.V769L	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.V769L	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L02117	hotspot3D	D08CDI	EGFR#p.V774M	Lapatinib	Lapatinib (拉帕替尼)		EGFR	p.V774M	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L00545	Cancer Genome Interpreter	D08CDI	ERBB2#p.V777L	Lapatinib	Lapatinib (拉帕替尼)		ERBB2	p.V777L	敏感性增加	PMID: 23220880	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast Cancer	Pre-clinical	Lapatinib	Approved
L00546	Cancer Genome Interpreter	D08CDI	ERBB2#p.V842I	Lapatinib	Lapatinib (拉帕替尼)		ERBB2	p.V842I	敏感性增加	PMID: 23220880	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast Cancer	Pre-clinical	Lapatinib	Approved
L01871	Cancer Genome Interpreter	D08CDI	NF2:del	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	NF2	NF2 deletion	敏感性增加	PMID: 22844108,NCT00973739	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡；患者发生了曲妥珠单抗治疗疾病进展，再使用该药物与卡培他滨治疗；	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Neurofibroma, Schwannoma	Early trials	Lapatinib	Approved
L02169	hotspot3D	D08CDI	EGFR#p.771in_frame_insSVD	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	EGFR	p.771in_frame_insSVD	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L02165	hotspot3D	D08CDI	EGFR#p.ELREA746in_frame_del	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	EGFR	p.ELREA746in_frame_ del	耐药性增加	.			是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	cancer	prediction	Lapatinib	
L01510	Cancer Genome Interpreter	D08CDI	ERBB2:amp	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB2	ERBB2 amplification	敏感性增加	FDA	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast invasive carcinoma	FDA guidelines	Lapatinib	Approved
L01511	Cancer Genome Interpreter	D08CDI	ERBB2:amp	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB2	ERBB2 amplification	敏感性增加	PMID: 26022204	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Billiary tract cancer	Early trials	Lapatinib	Approved
L01512	Cancer Genome Interpreter	D08CDI	ERBB2:amp	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB2	ERBB2 amplification	敏感性增加	PMID: 25694417,NCT02015169	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Stomach cancer	Early trials	Lapatinib	Approved
L01513	Cancer Genome Interpreter	D08CDI	ERBB2:amp	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB2	ERBB2 amplification	敏感性增加	ASCO 2015 (abstr 3508),NCT01104571,EBCC10	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Colorectal adenocarcinoma	Late trials	Lapatinib	Approved
L01514	Cancer Genome Interpreter	D08CDI	ERBB2:amp	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB2	ERBB2 amplification	敏感性增加	PMID: 25294905	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Endometrial cancer	Pre-clinical	Lapatinib	Approved
L01509	Cancer Genome Interpreter	D08CDI	ERBB2:over	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB2	ERBB2 overexpression	敏感性增加	FDA	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Breast invasive carcinoma	FDA guidelines	Lapatinib	Approved
L01515	Cancer Genome Interpreter	D08CDI	ERBB2::consequence::inframe_insertion:775-881	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB2	ERBB2 proximal exon 20	敏感性增加	PMID: 26598547	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Lung adenocarcinoma	Early trials	Lapatinib	Approved
L01516	Cancer Genome Interpreter	D08CDI	ERBB2::consequence::inframe_insertion:775-881	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB2	ERBB2 proximal exon 20	敏感性增加	PMID: 26598547,ASCO 2017 (abstr 9071)	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Lung adenocarcinoma	Early trials	Lapatinib	Approved
L01763	Cancer Genome Interpreter	D08CDI	ERBB4__.	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB4	ERBB4 fusion	敏感性增加	PMID: 24727320	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Lung adenocarcinoma	Pre-clinical	Lapatinib	Approved
L01556	Cancer Genome Interpreter	D08CDI	KRAS:.	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	KRAS	KRAS oncogenic mutation	耐药性增加	ASCO 2015 (abstr 3508),NCT01104571,EBCC10	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Colorectal adenocarcinoma	Late trials	Lapatinib	Approved
L01508	Cancer Genome Interpreter	D08CDI	MET:amp,ERBB2:amp	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	ERBB2	MET amplification + ERBB2 amplification	耐药性增加	PMID: 22238368	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Stomach cancer	Pre-clinical	Lapatinib	Approved
L01580	Cancer Genome Interpreter	D08CDI	MET:amp,ERBB2:amp	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	MET	MET amplification + ERBB2 amplification	耐药性增加	PMID: 22238368	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Stomach cancer	Pre-clinical	Lapatinib	Approved
L01872	Cancer Genome Interpreter	D08CDI	NF2:.	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	NF2	NF2 oncogenic mutation	敏感性增加	PMID: 22844108,NCT00973739	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Neurofibroma, Schwannoma	Early trials	Lapatinib	Approved
L01890	Cancer Genome Interpreter	D08CDI	NRG1__.	Lapatinib	Lapatinib (拉帕替尼)	kinase inhibitor	NRG1	NRG1 fusion	敏感性增加	PMID: 24727320	.		是	乳腺癌	少数案例中发生严重肝脏毒性和死亡	NCT00424255: 头颈癌, NCT00450203: 胃癌, NCT00486954: 胃肠道间质瘤, NCT00949455: 膀胱癌	Lung adenocarcinoma	Pre-clinical	Lapatinib	Approved
L01747	Cancer Genome Interpreter	D08MXP	CDK4:amp	LEE011	LEE011		CDK4	CDK4 amplification	敏感性增加	NCT02187783,NCT01237236, http: //meetinglibrary.asco.org/content/83791-102	.		.	.		.	Cancer, Liposarcoma	Early trials	LEE011	Clinical Trials
L01748	Cancer Genome Interpreter	D08MXP	CDK4:.	LEE011	LEE011		CDK4	CDK4 oncogenic mutation	敏感性增加	NCT02187783,NCT01237236, http: //meetinglibrary.asco.org/content/83791-102	.		.	.		.	Cancer, Liposarcoma	Early trials	LEE011	Clinical Trials
L01749	Cancer Genome Interpreter	D08MXP	CDK6:amp	LEE011	LEE011		CDK6	CDK6 amplification	敏感性增加	NCT02187783,NCT01237236,http: //meetinglibrary.asco.org/content/83791-102	.		.	.		.	Cancer, Liposarcoma	Early trials	LEE011	Clinical Trials
L01750	Cancer Genome Interpreter	D08MXP	CDK6:.	LEE011	LEE011		CDK6	CDK6 oncogenic mutation	敏感性增加	NCT02187783,NCT01237236	.		.	.		.	Cancer, Liposarcoma	Early trials	LEE011	Clinical Trials
L01755	Cancer Genome Interpreter	D0Q5NX	CRBN:under	Lenalidomide	Lenalidomide (来那度胺)		CRBN	CRBN undexpression	耐药性增加	PMID: 21860026	.		是	多发性骨髓瘤，骨髓增生异常综合征，套细胞淋巴瘤		.	Myeloma	Case report	Lenalidomide	Approved
L01756	Cancer Genome Interpreter	D0Q5NX	CRBN:.	Lenalidomide	Lenalidomide (来那度胺)		CRBN	CRBN oncogenic mutation	耐药性增加	PMID: 25108355	.		是	多发性骨髓瘤，骨髓增生异常综合征，套细胞淋巴瘤		.	Myeloma	Case report	Lenalidomide	Approved
L01981	search pubmed	.	SDHB#p.V140F	Lenvatinib	Lenvatinib (乐伐替尼)	kinase inhibitor	SDHB	p.V140F	敏感性增加	https: //doi.org/10.2217/ije-2016-0015	.		否	甲状腺癌, 肾癌	可能引起胚胎毒性、肝肾功影响以及心力衰竭等		Metastatic and rapidly progressive secretory paraganglioma	Case report	Lenvatinib	Approved
L01805	Cancer Genome Interpreter	D0V9WF	FLT3:D835.	Lestaurtinib	Lestaurtinib		FLT3	FLT3 (D835)	敏感性增加	PMID: 16857985	.		否	急性髓性白血病		.	Acute Myeloid Leukemia	Case report	Lestaurtinib	Approved (orphan drug)
L01517	Cancer Genome Interpreter	D0C1WH	ERBB2:norm,ESR1:over	Letrozole	Letrozole (来曲唑)		ERBB2	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		是	乳腺癌		.	Breast invasive carcinoma	FDA guidelines	Letrozole	Approved
L01777	Cancer Genome Interpreter	D0C1WH	ERBB2:norm,ESR1:over	Letrozole	Letrozole (来曲唑)		ESR1	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		是	乳腺癌		.	Breast invasive carcinoma	FDA guidelines	Letrozole	Approved
L01472	Cancer Genome Interpreter	.	ERBB2:norm,ESR1:over	LHRH analogues or antagonist	LHRH analogues or antagonist		ERBB2	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		.	.		.	Breast invasive carcinoma	FDA guidelines	LHRH analogues or antagonist	Approved
L01771	Cancer Genome Interpreter	.	ERBB2:norm,ESR1:over	LHRH analogues or antagonist	LHRH analogues or antagonist		ESR1	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		.	.		.	Breast invasive carcinoma	FDA guidelines	LHRH analogues or antagonist	Approved
L01409	Cancer Genome Interpreter	.	ALK__.	Lorlatinib	Lorlatinib		ALK	ALK fusion	敏感性增加	PMID: 26951079 	.		.	.		.	Non-small cell lung cancer	Early trials	Lorlatinib	.
L01403	search pubmed	D02WVT	FGFR1#p.V561M	Lucitanib	Lucitanib		FGFR1	p.V561M	耐药性增加	PMID: 25686244	.		.	.		.	Breast Cancer	.	Lucitanib	Phase 3
L01788	Cancer Genome Interpreter	D02WVT	FGF3:amp	Lucitanib	Lucitanib		FGF3	FGF3 amplification	敏感性增加	PMID: 25193991	.		.	.		.	Breast invasive carcinoma	Early trials	Lucitanib	Clinical Trials
L01790	Cancer Genome Interpreter	D02WVT	FGF4:amp	Lucitanib	Lucitanib		FGF4	FGF4 amplification	敏感性增加	PMID: 25193991	.		.	.		.	Breast invasive carcinoma	Early trials	Lucitanib	Clinical Trials
L01792	Cancer Genome Interpreter	D02WVT	FGFR1:amp	Lucitanib	Lucitanib		FGFR1	FGFR1 amplification	敏感性增加	PMID: 25193991	.		.	.		.	Breast invasive carcinoma	Early trials	Lucitanib	Clinical Trials
L00086	Cancer Genome Interpreter	.	MAP2K1#p.C121S	MEK inhibitors	MEK 抑制剂		MAP2K1	p.C121S	耐药性增加	PMID: 19915144, 23444215, 21383288	.		.	.		.	Cutaneous Melanoma	Case report	MEK inhibitors	.
L00165	Cancer Genome Interpreter	.	MAP2K2#p.C125S	MEK inhibitors	MEK 抑制剂		MAP2K2	p.C125S	耐药性增加	PMID: 24265153	.		.	.		.	Cutaneous Melanoma	Pre-clinical	MEK inhibitors	.
L00020	Cancer Genome Interpreter	.	MAP2K1#p.D67N	MEK inhibitors	MEK 抑制剂		MAP2K1	p.D67N	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00021	Cancer Genome Interpreter	.	MAP2K1#p.E120D	MEK inhibitors	MEK 抑制剂		MAP2K1	p.E120D	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00022	Cancer Genome Interpreter	.	MAP2K1#p.F129L	MEK inhibitors	MEK 抑制剂		MAP2K1	p.F129L	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00023	Cancer Genome Interpreter	.	MAP2K1#p.F133L	MEK inhibitors	MEK 抑制剂		MAP2K1	p.F133L	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00024	Cancer Genome Interpreter	.	MAP2K1#p.G128D	MEK inhibitors	MEK 抑制剂		MAP2K1	p.G128D	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00025	Cancer Genome Interpreter	.	MAP2K1#p.H119P	MEK inhibitors	MEK 抑制剂		MAP2K1	p.H119P	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00026	Cancer Genome Interpreter	.	MAP2K1#p.I103N	MEK inhibitors	MEK 抑制剂		MAP2K1	p.I103N	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00027	Cancer Genome Interpreter	.	MAP2K1#p.I111N	MEK inhibitors	MEK 抑制剂		MAP2K1	p.I111N	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00028	Cancer Genome Interpreter	.	MAP2K1#p.I99T	MEK inhibitors	MEK 抑制剂		MAP2K1	p.I99T	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00029	Cancer Genome Interpreter	.	MAP2K1#p.K104N	MEK inhibitors	MEK 抑制剂		MAP2K1	p.K104N	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00087	Cancer Genome Interpreter	.	MAP2K1#p.K57N	MEK inhibitors	MEK 抑制剂		MAP2K1	p.K57N	耐药性增加	PMID: 19915144, 23444215, 21383288	.		.	.		.	Cutaneous Melanoma	Case report	MEK inhibitors	.
L00030	Cancer Genome Interpreter	.	MAP2K1#p.L215P	MEK inhibitors	MEK 抑制剂		MAP2K1	p.L215P	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00167	Cancer Genome Interpreter	.	MAP2K2#p.L46F	MEK inhibitors	MEK 抑制剂		MAP2K2	p.L46F	耐药性增加	PMID: 24265153	.		.	.		.	Cutaneous Melanoma	Pre-clinical	MEK inhibitors	.
L00169	Cancer Genome Interpreter	.	MAP2K2#p.N126D	MEK inhibitors	MEK 抑制剂		MAP2K2	p.N126D	耐药性增加	PMID: 24265153	.		.	.		.	Cutaneous Melanoma	Pre-clinical	MEK inhibitors	.
L00091	Cancer Genome Interpreter	.	MAP2K1#p.P124L	MEK inhibitors	MEK 抑制剂		MAP2K1	p.P124L	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	Case report	MEK inhibitors	.
L00092	Cancer Genome Interpreter	.	MAP2K1#p.P124L	MEK inhibitors	MEK 抑制剂		MAP2K1	p.P124L	耐药性增加	PMID: 19915144, 23444215, 21383288	.		.	.		.	Cutaneous Melanoma	Case report	MEK inhibitors	.
L00093	Cancer Genome Interpreter	.	MAP2K1#p.P124S	MEK inhibitors	MEK 抑制剂		MAP2K1	p.P124S	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	Case report	MEK inhibitors	.
L00088	Cancer Genome Interpreter	.	MAP2K1#p.Q56P	MEK inhibitors	MEK 抑制剂		MAP2K1	p.Q56P	耐药性增加	PMID: 19915144	.		.	.		.	Cutaneous Melanoma	Case report	MEK inhibitors	.
L00090	Cancer Genome Interpreter	.	MAP2K2#p.Q60P	MEK inhibitors	MEK 抑制剂		MAP2K2	p.Q60P	耐药性增加	PMID: 24265154	.		.	.		.	Cutaneous Melanoma	Case report	MEK inhibitors	.
L00031	Cancer Genome Interpreter	.	MAP2K1#p.V211D	MEK inhibitors	MEK 抑制剂		MAP2K1	p.V211D	耐药性增加	PMID: 19915144	.		.	.		.	Cancer	Pre-clinical	MEK inhibitors	.
L00171	Cancer Genome Interpreter	.	MAP2K2#p.V35M	MEK inhibitors	MEK 抑制剂		MAP2K2	p.V35M	耐药性增加	PMID: 24265153	.		.	.		.	Cutaneous Melanoma	Pre-clinical	MEK inhibitors	.
L00099	Cancer Genome Interpreter	.	BRAF#p.V600E	MEK inhibitors	MEK 抑制剂		BRAF	p.V600E	敏感性增加	PMID: 22241789	.		.	.		.	Thyroid Cancer	Early trials	MEK inhibitors	.
L00130	Cancer Genome Interpreter	.	BRAF#p.V600E	MEK inhibitors	MEK 抑制剂		BRAF	p.V600E	敏感性增加	PMID: 19018267	.		.	.		.	Ovary Cancer	Pre-clinical	MEK inhibitors	.
L01547	Cancer Genome Interpreter	.	STK11:del,KRAS:.	MEK inhibitor	MEK 抑制剂		KRAS	STK11 deletion + KRAS oncogenic mutation	耐药性增加	PMID: 22425996	.		.	.		.	Lung adenocarcinoma	Pre-clinical	MEK inhibitor	.
L01934	Cancer Genome Interpreter	.	STK11:del,KRAS:.	MEK inhibitor	MEK 抑制剂		STK11	STK11 deletion + KRAS oncogenic mutation	耐药性增加	PMID: 22425996	.		.	.		.	Lung adenocarcinoma	Pre-clinical	MEK inhibitor	.
L01551	Cancer Genome Interpreter	.	KRAS:.	MEK inhibitor	MEK 抑制剂		KRAS	KRAS oncogenic mutation	敏感性增加	PMID: 23583440	.		.	.		.	Pancreatic cancer	Early trials	MEK inhibitor	.
L01552	Cancer Genome Interpreter	.	KRAS:.	MEK inhibitor	MEK 抑制剂		KRAS	KRAS oncogenic mutation	敏感性增加	PMID: 25294897	.		.	.		.	Hepatic carcinoma	Early Trials,Case Report	MEK inhibitor	.
L01884	Cancer Genome Interpreter	.	NRAS:.	MEK inhibitor	MEK 抑制剂		NRAS	NRAS oncogenic mutation	敏感性增加	PMID: 25294897	.		.	.		.	Hepatic carcinoma	Early Trials,Case Report	MEK inhibitor	.
L01548	Cancer Genome Interpreter	.	STK11:.,KRAS:.	MEK inhibitor	MEK 抑制剂		KRAS	STK11 oncogenic mutation + KRAS oncogenic mutation	耐药性增加	PMID: 22425996	.		.	.		.	Lung adenocarcinoma	Pre-clinical	MEK inhibitor	.
L01935	Cancer Genome Interpreter	.	STK11:.,KRAS:.	MEK inhibitor	MEK 抑制剂		STK11	STK11 oncogenic mutation + KRAS oncogenic mutation	耐药性增加	PMID: 22425996	.		.	.		.	Lung adenocarcinoma	Pre-clinical	MEK inhibitor	.
L00148	Cancer Genome Interpreter	.	EGFR#p.G719A	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.G719A	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00149	Cancer Genome Interpreter	.	EGFR#p.G719C	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.G719C	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00150	Cancer Genome Interpreter	.	EGFR#p.G719D	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.G719D	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00151	Cancer Genome Interpreter	.	EGFR#p.G719S	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.G719S	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00152	Cancer Genome Interpreter	.	EGFR#p.L747S	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.L747S	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00153	Cancer Genome Interpreter	.	EGFR#p.L858R	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.L858R	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00154	Cancer Genome Interpreter	.	EGFR#p.L861P	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.L861P	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00155	Cancer Genome Interpreter	.	EGFR#p.L861Q	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.L861Q	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00156	Cancer Genome Interpreter	.	EGFR#p.L861R	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.L861R	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00157	Cancer Genome Interpreter	.	EGFR#p.S768I	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.S768I	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L00158	Cancer Genome Interpreter	.	EGFR#p.T790M	MEK inhibitor (alone or in combination)s	MEK 抑制剂 		EGFR	p.T790M	敏感性增加	PMID: 23102728	.		.	.		.	Lung Cancer	Pre-clinical	MEK inhibitor (alone or in combination)s	.
L01943	Cancer Genome Interpreter	D09UZO	TPMT:.	Mercaptopurine	Mercaptopurine		TPMT	TPMT biallelic inactivation	毒性增加 (Myelosupression)	FDA	.		.	.		.	Cancer	FDA guidelines	Mercaptopurine	Approved
L01942	Cancer Genome Interpreter	D09UZO	TPMT::consequence::splice_acceptor_variant:.	Mercaptopurine	Mercaptopurine		TPMT	TPMT splice acceptor variant	毒性增加 (Myelosupression)	FDA	.		.	.		.	Cancer	FDA guidelines	Mercaptopurine	Approved
L00113	Cancer Genome Interpreter	.	MET#p.H1112R	MET inhibitors	MET 抑制剂		MET	p.H1112R	敏感性增加	PMID: 23213094	.		.	.		.	Renal Cancer	Early trials	MET inhibitors	.
L00096	Cancer Genome Interpreter	.	MET#p.M1268T	MET inhibitors	MET 抑制剂		MET	p.M1268T	敏感性增加	PMID: 23610116	.		.	.		.	Renal Cancer	Case report	MET inhibitors	.
L01803	Cancer Genome Interpreter	D07NVU	FLT3:D835.	Midostaurin	Midostaurin		FLT3	FLT3 (D835)	敏感性增加	PMID: 20733134	.		否	白血病			Acute Myeloid Leukemia	Case report	Midostaurin	Approved
L01802	Cancer Genome Interpreter	D07NVU	FLT3:N676.	Midostaurin	Midostaurin		FLT3	FLT3 (N676)	敏感性增加	PMID: 24619500	.		否	白血病			Acute Myeloid Leukemia	Pre-clinical	Midostaurin	Approved
L01654	Cancer Genome Interpreter	D07NVU	NTRK3__.	Midostaurin	Midostaurin		NTRK3	NTRK3 fusion	敏感性增加	PMID: 21148487, 23131561	.		否	白血病			Breast invasive carcinoma	Pre-clinical	Midostaurin	Approved
L01676	Cancer Genome Interpreter	D0NZ1U	TP53:.	Mitomycin C	Mitomycin C		TP53	TP53 oncogenic mutation	敏感性增加	PMID: 27397505	.		.	.		.	Bladder Urothelial Carcinoma	Pre-clinical	Mitomycin C	Approved
L01652	Cancer Genome Interpreter	D02HNG	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	Mk-0752	Mk-0752		NOTCH1	NOTCH1 activating mutation in Cterm-PEST domain	敏感性增加	NCT01703572,NCT01778439, NCT01098344, NCT01981551	.		.	.		.	Cancer	Early trials	Mk-0752	Clinical Trials
L01882	Cancer Genome Interpreter	D07NPS	NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420	Mk-0752	Mk-0752		NOTCH2	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	敏感性增加	PMID: 25564152	.		.	.		.	Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Breast invasive carcinoma	Early trials	Mk-0752	Clinical Trials
L01671	Cancer Genome Interpreter	D02KKA	TP53:.	MK-1775	MK-1775		TP53	TP53 oncogenic mutation	敏感性增加	NCT01357161,ASCO2015 (abstr 2507)	.		.	.		.	Ovarian cancer	Early trials	MK-1775	Clinical Trials
L01689	Cancer Genome Interpreter	.	AKT2:amp	MK2206	MK2206		AKT2	AKT2 amplification	敏感性增加	ENA 2014 (abstr 373)	.		.	.		.	Cancer	Pre-clinical	MK2206	Clinical Trials
L01471	Cancer Genome Interpreter	.	ERBB2:over	MK2206	MK2206		ERBB2	ERBB2 overexpression	敏感性增加	ASCO 2013 (abstr 2605), 26104654	.		.	.		.	Solid tumors	Early trials	MK2206	Clinical Trials
L02047	search pubmed	D0W3RW	HER2 amplification	MK-2206	MK-2206		HER2	HER2 amplification	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		.	.		.	Breast Cancer	In vitro	MK-2206	
L02035	search pubmed	D0W3RW	PI3KCA oncogenic mutation	MK-2206	MK-2206		PI3KCA	PI3KCA oncogenic mutation	敏感性增加	PMID: 22932669, 23714559	Both PIK3CA and PTEN mutations were associated with increased MK-2206 sensitivity		.	.		.	Breast Cancer	In vitro	MK-2206	
L02041	search pubmed	D0W3RW	PI3KCA oncogenic mutation	MK-2206	MK-2206		PIK3CA	PI3KCA oncogenic mutation	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		.	.		.	Breast Cancer	In vitro	MK-2206	
L02038	search pubmed	D0W3RW	PTEN loss (Loss of PTEN activity)	MK-2206	MK-2206		PTEN	PTEN loss (Loss of PTEN activity)	敏感性增加	PMID: 22932669, 23714559	Both PIK3CA and PTEN mutations were associated with increased MK-2206 sensitivity		.	.		.	Breast Cancer	In vitro	MK-2206	
L01388	search pubmed	D0ZD2M	UBA3#p.I310N	MLN4924	MLN4924		UBA3	p.I310N	耐药性增加	PMID: 24691136	.		.	.		.	Refractory hematologic malignancy	.	MLN4924	Phase 1
L01407	search pubmed	D0ZD2M	UBA3#p.Y352H	MLN4924	MLN4924		UBA3	p.Y352H	耐药性增加	PMID: 24691136	.		.	.		.	Refractory hematologic malignancy	.	MLN4924	Phase 1
L00139	Cancer Genome Interpreter	.	MTOR#p.F2108L	MTOR kinase inhibitors	MTOR kinase 抑制剂		MTOR	p.F2108L	敏感性增加	PMID: 25295501	.		.	.		.	Cancer	Pre-clinical	MTOR kinase inhibitors	.
L00177	Cancer Genome Interpreter	.	PIK3R2#p.A171V	MTOR inhibitors	MTOR 抑制剂		PIK3R2	p.A171V	敏感性增加	PMID: 21984976, 19962665	.		.	.		.	Endometrium Cancer	Pre-clinical	MTOR inhibitors	.
L00160	Cancer Genome Interpreter	.	EPHA2#p.G391R	MTOR inhibitors	MTOR 抑制剂		EPHA2	p.G391R	敏感性增加	PMID: 20360610	.		.	.		.	Lung Squamous Cell Carcinoma	Pre-clinical	MTOR inhibitors	.
L00178	Cancer Genome Interpreter	.	PIK3R2#p.N561D	MTOR inhibitors	MTOR 抑制剂		PIK3R2	p.N561D	敏感性增加	PMID: 21984976, 19962665	.		.	.		.	Endometrium Cancer	Pre-clinical	MTOR inhibitors	.
L00173	Cancer Genome Interpreter	.	PIK3CB#p.D1067Y	MTORC1/2 inhibitors	MTORC1/2 抑制剂		PIK3CB	p.D1067Y	敏感性增加	PMID: 26759240	.		.	.		.	Breast Cancer	Pre-clinical	MTORC1/2 inhibitors	.
L00547	Cancer Genome Interpreter	D0Q9CY	ERBB2#p.D769H	Neratinib	Neratinib (来那替尼)		ERBB2	p.D769H	敏感性增加	PMID: 23220880	.		否	乳腺癌			Breast Cancer	Pre-clinical	Neratinib	.
L00548	Cancer Genome Interpreter	D0Q9CY	ERBB2#p.D769Y	Neratinib	Neratinib (来那替尼)		ERBB2	p.D769Y	敏感性增加	PMID: 23220880	.		否	乳腺癌			Breast Cancer	Pre-clinical	Neratinib	.
L00549	Cancer Genome Interpreter	D0Q9CY	ERBB2#p.G309A	Neratinib	Neratinib (来那替尼)		ERBB2	p.G309A	敏感性增加	PMID: 23220880	.		否	乳腺癌			Breast Cancer	Pre-clinical	Neratinib	.
L00550	Cancer Genome Interpreter	D0Q9CY	ERBB2#p.K753E	Neratinib	Neratinib (来那替尼)		ERBB2	p.K753E	敏感性增加	PMID: 27697991	.		否	乳腺癌			Breast Cancer	Pre-clinical	Neratinib	.
L00551	Cancer Genome Interpreter	D0Q9CY	ERBB2#p.L755S	Neratinib	Neratinib (来那替尼)		ERBB2	p.L755S	敏感性增加	PMID: 23220880	.		否	乳腺癌			Breast Cancer	Pre-clinical	Neratinib	.
L00552	Cancer Genome Interpreter	D0Q9CY	ERBB2#p.R896C	Neratinib	Neratinib (来那替尼)		ERBB2	p.R896C	敏感性增加	PMID: 23220880	.		否	乳腺癌			Breast Cancer	Pre-clinical	Neratinib	.
L00553	Cancer Genome Interpreter	D0Q9CY	ERBB2#p.V777L	Neratinib	Neratinib (来那替尼)		ERBB2	p.V777L	敏感性增加	PMID: 23220880	.		否	乳腺癌			Breast Cancer	Pre-clinical	Neratinib	.
L00554	Cancer Genome Interpreter	D0Q9CY	ERBB2#p.V842I	Neratinib	Neratinib (来那替尼)		ERBB2	p.V842I	敏感性增加	PMID: 23220880	.		否	乳腺癌			Breast Cancer	Pre-clinical	Neratinib	.
L01535	Cancer Genome Interpreter	D0Q9CY	ERBB2::consequence::inframe_deletion:755-759,::inframe_insertion:.780GSP,::inframe_insertion:.781GSP	Neratinib	Neratinib (来那替尼)		ERBB2	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	敏感性增加	PMID: 23220880	.		否	乳腺癌			Breast invasive carcinoma	Pre-clinical	Neratinib	Phase 3
L01532	Cancer Genome Interpreter	D0Q9CY	ERBB2::consequence::inframe_insertion:P780GSP,::inframe_insertion:.781GSP,::inframe_insertion:A775YVMA,::inframe_insertion:G776YVMA	Neratinib	Neratinib (来那替尼)		ERBB2	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	敏感性增加	AACR 2017 (abstr CT001)	.		否	乳腺癌			Cancer	Early trials	Neratinib	Phase 3
L01530	Cancer Genome Interpreter	D0Q9CY	ERBB2:S310.,L755.,V777.	Neratinib	Neratinib (来那替尼)		ERBB2	ERBB2 (S310,L755,V777)	敏感性增加	AACR 2017 (abstr CT001)	.		否	乳腺癌			Cancer	Early trials	Neratinib	Phase 3
L01531	Cancer Genome Interpreter	D0Q9CY	ERBB2:amp	Neratinib	Neratinib (来那替尼)		ERBB2	ERBB2 amplification	敏感性增加	PMID: 20142587, 22418700, 23632474	.		否	乳腺癌			Breast invasive carcinoma	Late trials	Neratinib	Phase 3
L01536	Cancer Genome Interpreter	D0Q9CY	ERBB2:.	Neratinib	Neratinib (来那替尼)		ERBB2	ERBB2 oncogenic mutation	敏感性增加	ESMO 2014 (abstr LBA39_PR)	.		否	乳腺癌			Lung adenocarcinoma	Early trials	Neratinib	Phase 3
L01533	Cancer Genome Interpreter	D0Q9CY	ERBB2::consequence::inframe_insertion:775-881	Neratinib	Neratinib (来那替尼)		ERBB2	ERBB2 proximal exon 20	敏感性增加	PMID: 26598547	.		否	乳腺癌			Lung adenocarcinoma	Early trials	Neratinib	Phase 3
L01534	Cancer Genome Interpreter	D0Q9CY	ERBB2::consequence::inframe_insertion:775-881	Neratinib	Neratinib (来那替尼)		ERBB2	ERBB2 proximal exon 20	敏感性增加	PMID: 26598547,ASCO 2017 (abstr 9071)	.		否	乳腺癌			Lung adenocarcinoma	Early trials	Neratinib	Phase 3
L02144	hotspot3D	D00STL	ABL1#p.D400Y	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.D400Y	耐药性增加	.			是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	cancer	prediction	Nilotinib	
L00230	Cancer Genome Interpreter	D00STL	KIT#p.D820Y	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	p.D820Y	敏感性增加	PMID: 25695690	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Cutaneous Melanoma	Case report	Nilotinib	Approved
L00287	Cancer Genome Interpreter	D00STL	ABL1#p.E255K	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.E255K	耐药性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Nilotinib	Approved
L00641	COSMIC	D00STL	ABL1#p.E255K	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.E255K	.	PMID: 21156844	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Blast Phase Chronic Myeloid Leukaemia	.	Nilotinib	Approved
L00288	Cancer Genome Interpreter	D00STL	ABL1#p.E255V	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.E255V	耐药性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Nilotinib	Approved
L00642	COSMIC	D00STL	ABL1#p.E255V	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.E255V	.	PMID: 21156844	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Blast Phase Chronic Myeloid Leukaemia	.	Nilotinib	Approved
L02009	search pubmed	D00STL	KIT#p.E490K	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	p.E490K	敏感性增加	PMID: 21325067	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Thymic Carcinoma	Case report	Nilotinib	
L00440	Cancer Genome Interpreter	D00STL	ABL1#p.F317C	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.F317C	敏感性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	NCCN guidelines	Nilotinib	Approved
L00441	Cancer Genome Interpreter	D00STL	ABL1#p.F317I	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.F317I	敏感性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	NCCN guidelines	Nilotinib	Approved
L00442	Cancer Genome Interpreter	D00STL	ABL1#p.F317L	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.F317L	敏感性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	NCCN guidelines	Nilotinib	Approved
L00443	Cancer Genome Interpreter	D00STL	ABL1#p.F317V	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.F317V	敏感性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	NCCN guidelines	Nilotinib	Approved
L00289	Cancer Genome Interpreter	D00STL	ABL1#p.F359C	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.F359C	耐药性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Nilotinib	Approved
L00643	COSMIC	D00STL	ABL1#p.F359C	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 21156844	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Blast Phase Chronic Myeloid Leukaemia	.	Nilotinib	Approved
L00290	Cancer Genome Interpreter	D00STL	ABL1#p.F359I	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.F359I	耐药性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Nilotinib	Approved
L00291	Cancer Genome Interpreter	D00STL	ABL1#p.F359V	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.F359V	耐药性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Nilotinib	Approved
L02058	hotspot3D	D00STL	ABL1#p.F401L	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.F401L	耐药性增加	.			是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	cancer	prediction	Nilotinib	
L00636	COSMIC	D00STL	ABL1#p.G250E	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 21357704	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	.	Nilotinib	Approved
L00398	Cancer Genome Interpreter	D00STL	UGT1A1#p.G71R	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	UGT1A1	p.G71R	毒性增加	FDA	UGT1A1*6 G71R, a nonsynonymous variant also known to reduce UGT1A1 activity, Patients with the UGT1A1 (TA)6/(TA)6 genotype and chronic myeloid leukemia or acute lymphoblastic leukemia may have a decreased risk of hyperbilirubinemia when treated with nilotinib as compared to patients with the (TA)7/(TA)7 genotype.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Cancer	FDA guidelines	Nilotinib	Approved
L00637	COSMIC	D00STL	ABL1#p.H396R	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 22873741	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	.	Nilotinib	Approved
L02148	hotspot3D	D00STL	ABL1#p.K106N	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.K106N	耐药性增加	.			是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	cancer	prediction	Nilotinib	
L02004	search pubmed	D00STL	KIT#p.K642E	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	p.K642E	敏感性增加	http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032	In a phase II clinical trial, 5 of 26 patients with melanoma harboring KIT mutations responded to nilotinib		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Melanoma	Case report	Nilotinib	
L02133	hotspot3D	D00STL	MAPK11#p.L167M	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	MAPK11	p.L167M	耐药性增加	.			是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	cancer	prediction	Nilotinib	
L02000	search pubmed	D00STL	KIT#p.L576P	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	p.L576P	敏感性增加	http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032	In a phase II clinical trial, 5 of 26 patients with melanoma harboring KIT mutations responded to nilotinib		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Melanoma	Case report	Nilotinib	
L00638	COSMIC	D00STL	ABL1#p.M351T	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 19156415	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	.	Nilotinib	Approved
L00399	Cancer Genome Interpreter	D00STL	UGT1A1#p.P229Q	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	UGT1A1	p.P229Q	毒性增加	FDA	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Cancer	FDA guidelines	Nilotinib	Approved
L02134	hotspot3D	D00STL	MAPK11#p.R149W	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	MAPK11	p.R149W	耐药性增加	.			是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	cancer	prediction	Nilotinib	
L02152	hotspot3D	D00STL	ABL1#p.R783G	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.R783G	耐药性增加	.			是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	cancer	prediction	Nilotinib	
L00444	Cancer Genome Interpreter	D00STL	ABL1#p.T315A	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.T315A	敏感性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	NCCN guidelines	Nilotinib	Approved
L00073	Cancer Genome Interpreter	D00STL	ABL1#p.T315I	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.T315I	耐药性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Nilotinib	Approved
L00639	COSMIC	D00STL	ABL1#p.T315I	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 22489663	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	.	Nilotinib	Approved
L00644	COSMIC	D00STL	ABL1#p.T315V	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.T315V	.	PMID: 23044928	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Blast Phase Chronic Myeloid Leukaemia	.	Nilotinib	Approved
L00445	Cancer Genome Interpreter	D00STL	ABL1#p.V299L	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.V299L	敏感性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	NCCN guidelines	Nilotinib	Approved
L02156	hotspot3D	D00STL	ABL1#p.V390L	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.V390L	耐药性增加	.			是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	cancer	prediction	Nilotinib	
L02135	hotspot3D	D00STL	MAPK11#p.V52M	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	MAPK11	p.V52M	耐药性增加	.			是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	cancer	prediction	Nilotinib	
L01992	search pubmed	D00STL	KIT#p.V559A	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	p.V559A	敏感性增加	http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032	In a phase II clinical trial, 5 of 26 patients with melanoma harboring KIT mutations responded to nilotinib		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Melanoma	Case report	Nilotinib	
L01996	search pubmed	D00STL	KIT#p.V559D	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	p.V559D	敏感性增加	http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032	In a phase II clinical trial, 5 of 26 patients with melanoma harboring KIT mutations responded to nilotinib		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Melanoma	Case report	Nilotinib	
L01988	search pubmed	D00STL	KIT#p.W557R	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	p.W557R	敏感性增加	http: //hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9032	In a phase II clinical trial, 5 of 26 patients with melanoma harboring KIT mutations responded to nilotinib		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Melanoma	Case report	Nilotinib	
L02010	search pubmed	D00STL	KIT#p.W557R	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	p.W557R	敏感性增加	PMID: 12960119	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Thymic Carcinoma	Case report	Nilotinib	
L00292	Cancer Genome Interpreter	D00STL	ABL1#p.Y253H	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.Y253H	耐药性增加	PMID: 21562040	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	European LeukemiaNet guidelines	Nilotinib	Approved
L00640	COSMIC	D00STL	ABL1#p.Y253H	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	p.Y253H	.	PMID: 22873741	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic Myeloid Leukaemia	.	Nilotinib	Approved
L02008	search pubmed	D00STL	KIT#p.Y553N	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	p.Y553N	敏感性增加	PMID: 21969494	This mutation was described in a patient with a refractory metastatic thymic carcinoma tumor, exhibiting response to imatinib		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Thymic Carcinoma	Case report	Nilotinib	
L01591	Cancer Genome Interpreter	D00STL	NF1:del	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	NF1	NF1 deletion	敏感性增加	PMID: 24173684	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Malignant peripheral nerve sheat tumor, Plexiform neurofibroma	Pre-clinical	Nilotinib	Approved
L01592	Cancer Genome Interpreter	D00STL	NF1:del	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	NF1	NF1 deletion	敏感性增加	ASCO 2016 (abstr 10555)	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Glioma	Case report	Nilotinib	Approved
L01681	Cancer Genome Interpreter	D00STL	ABL1__BCR	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	ABL1	ABL1-BCR fusion	敏感性增加	FDA	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Chronic myeloid leukemia	FDA guidelines	Nilotinib	Approved
L01821	Cancer Genome Interpreter	D00STL	KIT:788-828	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	KIT mutation in exon 17	敏感性增加	PMID: 22119758, 21456006	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Gastrointestinal Stromal Tumor	Early trials	Nilotinib	Approved
L01822	Cancer Genome Interpreter	D00STL	KIT:550-592,627-664	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	KIT	KIT mutation in exon 9,11,13,14 or 17	敏感性增加	PMID: 22068222, 25695690	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Cutaneous carcinoma	Early trials	Nilotinib	Approved
L01593	Cancer Genome Interpreter	D00STL	NF1:.	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	NF1	NF1 oncogenic mutation	敏感性增加	PMID: 24173684	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Malignant peripheral nerve sheat tumor, Plexiform neurofibroma	Pre-clinical	Nilotinib	Approved
L01594	Cancer Genome Interpreter	D00STL	NF1:.	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	NF1	NF1 oncogenic mutation	敏感性增加	ASCO 2016 (abstr 10555)	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Glioma	Case report	Nilotinib	Approved
L01955	Cancer Genome Interpreter	D00STL	UGT1A1:.	Nilotinib	Nilotinib (尼洛替尼)	kinase inhibitor	UGT1A1	UGT1A1 biallelic inactivation	毒性增加 (Hyperbilirubinemia)	FDA	.		是	白血病	QT综合征、低钾血症、低镁血症患者不建议使用；且避免与延长QT间隔或者强CYP3A4药物一同使用，否则可能导致猝死；	NCT00471328: 胃肠道间质瘤, NCT00751036: 胃肠道间质瘤, NCT00785785: 胃肠道间质瘤, NCT01289028: 胃肠道间质瘤	Cancer	FDA guidelines	Nilotinib	Approved
L01926	Cancer Genome Interpreter	D0J1OJ	RET__.	Nintedanib	Nintedanib		RET	RET fusion	敏感性增加	PMID: 26787234	.		.	.		.	Lung adenocarcinoma	Case report	Nintedanib	Phase 3
L02175	search pubmed	.	BRCA1:.	Niraparib	Niraparib		BRCA1	mutation type	敏感性增加	.			否	腹膜癌, 卵巢癌, 输卵管癌				.	Niraparib	
L02176	search pubmed	.	BRCA2:.	Niraparib	Niraparib		BRCA2	mutation type	敏感性增加	.			否	腹膜癌, 卵巢癌, 输卵管癌				.	Niraparib	
L01742	Cancer Genome Interpreter	D00GOV	CD274:over	Nivolumab	Nivolumab (纳武单抗)	programmed death receptor-1 (PD-1) blocking antibody	CD274	CD274 overexpression	敏感性增加	PMID: 25452452	.		否	膀胱癌, 非小细胞肺癌, 黑色素瘤, 霍奇金淋巴瘤, 肾癌, 头颈癌	具有一定的胚胎毒性，可能引起肝肾功副作用	NCT02460068: 脑癌, NCT02617589: 脑癌, NCT02667587: 脑癌, NCT02743494: 食管或胃食管结癌, NCT02872116: 胃癌，食管癌, NCT02899299: 间皮瘤, NCT03092674: 急性髓性白血病, NCT03143153: 食道癌, NCT03383458: 肝癌	Renal cancer	Early trials	Nivolumab	Clinical Trials
L00014	Cancer Genome Interpreter	D0D5FF	AKT1#p.E17K	non-allosteric AKT inhibitors	non-allosteric AKT 抑制剂		AKT1	p.E17K	敏感性增加	ENA 2015 (abstract B109)	.		.	.		.	Cancer	Early trials	non-allosteric AKT inhibitors	.
L00159	Cancer Genome Interpreter	.	ALK#p.F1174L	novel ALK inhibitors	novel ALK 抑制剂		ALK	p.F1174L	敏感性增加	PMID: 24327273	.		.	.		.	Lung Adenocarcinoma	Pre-clinical	novel ALK inhibitors	.
L00100	Cancer Genome Interpreter	.	EGFR#p.S492R	novel EGFR mAb inhibitors	novel EGFR mAb 抑制剂		EGFR	p.S492R	敏感性增加	PMID: 25962717	.		.	.		.	Colorectal Adenocarcinoma	Early trials	novel EGFR mAb inhibitors	.
L00163	Cancer Genome Interpreter	.	MAP2K1#p.C121S	novel MEK inhibitors	novel MEK 抑制剂		MAP2K1	p.C121S	敏感性增加	PMID: 24448821	.		.	.		.	Cutaneous Melanoma	Pre-clinical	novel MEK inhibitors	.
L01404	search pubmed	D00MYW	JAK2#p.V617F	NS-018	NS-018		JAK2	p.V617F	耐药性增加	PMID: 24766055	.		.	.		.	Myelofibrosis	.	NS-018	Phase 1/2
L02173	search pubmed	.	TP53:.	Nutlin-3a	Nutlin-3a		TP53	mutation type	耐药性增加	PMID:  27813088	TP53 was subsequently sequenced from all immortalised clones. We found that all Nutlin-3a-resistant clones harboured TP53 mutations, which were diverse in position and functional impact, while all but one of the Nutlin-3a-sensitive clones were TP53-WT.		.	.		.	cancer	In vitro	Nutlin-3a	
L02174	search pubmed	.	TP53:wild type	Nutlin-3a	Nutlin-3a		TP53	wild type	敏感性增加	PMID:  27813088	TP53 was subsequently sequenced from all immortalised clones. We found that all Nutlin-3a-resistant clones harboured TP53 mutations, which were diverse in position and functional impact, while all but one of the Nutlin-3a-sensitive clones were TP53-WT.		.	.		.	cancer	In vitro	Nutlin-3a	
L01863	Cancer Genome Interpreter	D02XIY	NF2:del	Octreotide	Octreotide		NF2	NF2 deletion	敏感性增加	PMID: 26015296	.		.	.		.	Meningioma	Pre-clinical	Octreotide	Approved
L01864	Cancer Genome Interpreter	D02XIY	NF2:.	Octreotide	Octreotide		NF2	NF2 oncogenic mutation	敏感性增加	PMID: 26015296	.		.	.		.	Meningioma	Pre-clinical	Octreotide	Approved
L01426	Cancer Genome Interpreter	D0J9HW	ATR:del	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	ATR	ATR deletion	敏感性增加	PMID: 23548269	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Cancer, Ovarian cancer	Pre-clinical	Olaparib	Approved
L01431	Cancer Genome Interpreter	D0J9HW	BRCA2:del	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	BRCA2	BRCA2 deletion	敏感性增加	PMID: 22392482	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Ovarian cancer	Pre-clinical	Olaparib	Approved
L01751	Cancer Genome Interpreter	D0J9HW	CHEK2:del	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	CHEK2	CHEK2 deletion	敏感性增加	AACR 2015 (abstr CT322)	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Prostate adenocarcinoma	Early trials	Olaparib	Approved
L01783	Cancer Genome Interpreter	D0J9HW	FANCA:del	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	FANCA	FANCA deletion	敏感性增加	PMID: 26510020	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Prostate adenocarcinoma	Case report	Olaparib	Approved
L01707	Cancer Genome Interpreter	D0J9HW	ATM:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	ATM	ATM oncogenic mutation	敏感性增加	ENA 2014 (abstr 8LBA), 26510020	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Prostate adenocarcinoma, Stomach cancer	Early trials	Olaparib	Approved
L01427	Cancer Genome Interpreter	D0J9HW	ATR:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	ATR	ATR oncogenic mutation	敏感性增加	PMID: 23548269	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Cancer, Ovarian cancer	Pre-clinical	Olaparib	Approved
L01734	Cancer Genome Interpreter	D0J9HW	BRCA1:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	BRCA1	BRCA1 oncogenic mutation	敏感性增加	FDA	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Ovarian cancer	FDA guidelines	Olaparib	Approved
L01735	Cancer Genome Interpreter	D0J9HW	BRCA1:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	BRCA1	BRCA1 oncogenic mutation	敏感性增加	PMID: 20609467, 25366685	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Breast invasive carcinoma	Early trials	Olaparib	Approved
L01736	Cancer Genome Interpreter	D0J9HW	BRCA1:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	BRCA1	BRCA1 oncogenic mutation	敏感性增加	PMID: 26510020	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Prostate adenocarcinoma	Early trials	Olaparib	Approved
L01432	Cancer Genome Interpreter	D0J9HW	BRCA2:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	BRCA2	BRCA2 oncogenic mutation	敏感性增加	PMID: 20609467	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Breast invasive carcinoma	Early trials	Olaparib	Approved
L01433	Cancer Genome Interpreter	D0J9HW	BRCA2:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	BRCA2	BRCA2 oncogenic mutation	敏感性增加	PMID: 26510020,NCT01682772,http: //cancerres.aacrjournals.org/content/75/15_Supplement/CT322	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Prostate adenocarcinoma	Early trials	Olaparib	Approved
L01434	Cancer Genome Interpreter	D0J9HW	BRCA2:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	BRCA2	BRCA2 oncogenic mutation	敏感性增加	FDA	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Ovarian cancer	FDA guidelines	Olaparib	Approved
L01752	Cancer Genome Interpreter	D0J9HW	CHEK2:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	CHEK2	CHEK2 oncogenic mutation	敏感性增加	PMID: 26510020,AACR 2015 (abstr CT322)	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Prostate adenocarcinoma	Early trials	Olaparib	Approved
L01784	Cancer Genome Interpreter	D0J9HW	FANCA:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	FANCA	FANCA oncogenic mutation	敏感性增加	PMID: 26510020	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Prostate adenocarcinoma	Case report	Olaparib	Approved
L01811	Cancer Genome Interpreter	D0J9HW	HDAC2:.	Olaparib	Olaparib (奥拉帕尼)	poly (ADP-ribose) polymerase (PARP) inhibitor	HDAC2	HDAC2 biallelic inactivation	敏感性增加	PMID: 26510020	.		否	卵巢癌，乳腺癌	用于有害性的BRCA胚系突变卵巢癌患者；部分患者药物使用发生骨髓综合征/急性白血病的副作用	NCT02184195: 胰腺癌, NCT02987543: 前列腺癌	Prostate adenocarcinoma	Case report	Olaparib	Approved
L01653	Cancer Genome Interpreter	D0X3YY	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	OMP-52M51	OMP-52M51		NOTCH1	NOTCH1 activating mutation in Cterm-PEST domain	敏感性增加	NCT01703572,NCT01778439	.		.	.		.	Cancer	Early trials	OMP-52M51	Clinical Trials
L01881	Cancer Genome Interpreter	.	NOTCH2::consequence::splice_donor_variant:2381-2420,::splice_acceptor_variant:2381-2420,::stop_gained:2381-2420,::stop_lost:2381-2420,::frameshift_variant:2381-2420	OMP-59R5	OMP-59R5		NOTCH2	NOTCH2 activating mutation (missense in TAD or truncating in Cterm-PEST domain)	敏感性增加	NCT01859741,NCT01277146	.		.	.		.	Solid tumors	Early trials	OMP-59R5	Clinical Trials
L01712	Cancer Genome Interpreter	.	BCL6:over	Onalespib	Onalespib		BCL6	BCL6 overexpression	敏感性增加	NCT02572453	.		.	.		.	Liposarcoma	Early trials	Onalespib	.
L01700	Cancer Genome Interpreter	D0X3OI	AR:over	Orterone	Orterone		AR	AR overexpression	敏感性增加	ASCO 2015 (abstr 1003)	.		.	.		.	Breast invasive carcinoma	Early trials	Orterone	Clinical Trials
L00263	Cancer Genome Interpreter	D0O8GK	EGFR#p.L858R	Osimertinib	Osimertinib (奥希替尼)	用于治疗EGFR T790M突变NSCLC的激酶抑制剂	EGFR	p.L858R	敏感性增加	NCT02465060	.		是	肺癌			Lung Cancer	Early trials	Osimertinib	.
L00404	Cancer Genome Interpreter	D0O8GK	EGFR#p.T790M	Osimertinib	Osimertinib (奥希替尼)	用于治疗EGFR T790M突变NSCLC的激酶抑制剂	EGFR	p.T790M	敏感性增加	FDA	.		是	肺癌			Non-small Cell  Lung Cancer	FDA guidelines	Osimertinib	Approved
L01470	Cancer Genome Interpreter	D0O8GK	EGFR::consequence::inframe_deletion:729-761	Osimertinib	Osimertinib (奥希替尼)	用于治疗EGFR T790M突变NSCLC的激酶抑制剂	EGFR	EGFR exon 19 deletions	敏感性增加	NCT02465060	.		是	肺癌	少数案例中发生胚胎毒性和心肌病		Lung cancer	Early trials	Osimertinib	Approved
L01469	Cancer Genome Interpreter	D0O8GK	EGFR::consequence::inframe_insertion:762-823	Osimertinib	Osimertinib (奥希替尼)	用于治疗EGFR T790M突变NSCLC的激酶抑制剂	EGFR	EGFR exon 20 insertions	敏感性增加	PMID: 26515464	.		是	肺癌	少数案例中发生胚胎毒性和心肌病		Lung cancer	Pre-clinical	Osimertinib	Approved
L01468	Cancer Genome Interpreter	D0O8GK	EGFR:L718.	Osimertinib	Osimertinib (奥希替尼)	用于治疗EGFR T790M突变NSCLC的激酶抑制剂	EGFR	EGFR (L718)	耐药性增加	ASCO 2017 (abstr 2572)	.		是	肺癌	少数案例中发生胚胎毒性和心肌病		Lung cancer	Early trials	Osimertinib	Approved
L01467	Cancer Genome Interpreter	D0O8GK	EGFR:L792.	Osimertinib	Osimertinib (奥希替尼)	用于治疗EGFR T790M突变NSCLC的激酶抑制剂	EGFR	EGFR (L792)	耐药性增加	ASCO 2017 (abstr 2572)	.		是	肺癌	少数案例中发生胚胎毒性和心肌病		Lung cancer	Early trials	Osimertinib	Approved
L01529	Cancer Genome Interpreter	D0O8GK	ERBB2:amp	Osimertinib	Osimertinib (奥希替尼)	用于治疗EGFR T790M突变NSCLC的激酶抑制剂	ERBB2	ERBB2 amplification	耐药性增加	PMID: 27252416	.		是	肺癌	少数案例中发生胚胎毒性和心肌病		Lung adenocarcinoma	Case report	Osimertinib	Approved
L01585	Cancer Genome Interpreter	D0O8GK	MET:amp	Osimertinib	Osimertinib (奥希替尼)	用于治疗EGFR T790M突变NSCLC的激酶抑制剂	MET	MET amplification	耐药性增加	PMID: 27252416	.		是	肺癌	少数案例中发生胚胎毒性和心肌病		Lung adenocarcinoma	Case report	Osimertinib	Approved
L01739	Cancer Genome Interpreter	.	CCND1:amp	Palbociclib	Palbociclib (帕博西尼)	kinase inhibitor	CCND1	CCND1 amplification	敏感性降低	ASCO 2017 (abstr 9056)	.		否	乳腺癌	用于HR阳性、HER2阴性的进展性或转移性乳腺癌的激酶抑制剂		Lung cancer	Early trials	Palbociclib	Pre-clinical
L01740	Cancer Genome Interpreter	.	CCND2:amp	Palbociclib	Palbociclib (帕博西尼)	kinase inhibitor	CCND2	CCND2 amplification	敏感性增加	NCT02154490	.		否	乳腺癌	用于HR阳性、HER2阴性的进展性或转移性乳腺癌的激酶抑制剂		Lung cancer	Early trials	Palbociclib	Approved
L01746	Cancer Genome Interpreter	.	CDK4:amp	Palbociclib	Palbociclib (帕博西尼)	kinase inhibitor	CDK4	CDK4 amplification	敏感性降低	ASCO 2017 (abstr 9056)	.		否	乳腺癌	用于HR阳性、HER2阴性的进展性或转移性乳腺癌的激酶抑制剂		Lung cancer	Early trials	Palbociclib	Pre-clinical
L02271	Cancer Genome Interpreter	.	CDKN2A: inactivating mutation	Palbociclib	Palbociclib (帕博西尼)	kinase inhibitor	CDKN2A	CDKN2A: inactivating mutation	敏感性增加	PMID:  29487225	.		否	乳腺癌	用于HR阳性、HER2阴性的进展性或转移性乳腺癌的激酶抑制剂		Hepatocellular carcinoma	Case report	Palbociclib	Approved
L01473	Cancer Genome Interpreter	.	ERBB2:norm,ESR1:over	Palbociclib	Palbociclib (帕博西尼)	kinase inhibitor	ERBB2	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		否	乳腺癌	用于HR阳性、HER2阴性的进展性或转移性乳腺癌的激酶抑制剂		Breast invasive carcinoma	FDA guidelines	Palbociclib	Approved
L01772	Cancer Genome Interpreter	.	ERBB2:norm,ESR1:over	Palbociclib	Palbociclib (帕博西尼)	kinase inhibitor	ESR1	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		否	乳腺癌	用于HR阳性、HER2阴性的进展性或转移性乳腺癌的激酶抑制剂		Breast invasive carcinoma	FDA guidelines	Palbociclib	Approved
L01918	Cancer Genome Interpreter	.	RB1:over	Palbociclib	Palbociclib (帕博西尼)	kinase inhibitor	RB1	RB1 overexpression	敏感性增加	PMID: 23708653	.		否	乳腺癌	用于HR阳性、HER2阴性的进展性或转移性乳腺癌的激酶抑制剂		Prostate adenocarcinoma	Pre-clinical	Palbociclib	Pre-clinical
L00197	Cancer Genome Interpreter	D0HU9H	EGFR#p.G465R	Panitumumab	Panitumumab (帕尼单抗)		EGFR	p.G465R	耐药性增加	PMID: 26059438	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal Adenocarcinoma	Case report	Panitumumab	Approved
L00198	Cancer Genome Interpreter	D0HU9H	EGFR#p.S492R	Panitumumab	Panitumumab (帕尼单抗)		EGFR	p.S492R	敏感性增加	PMID: 22270724	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal Adenocarcinoma	Case report	Panitumumab	Approved
L00410	Cancer Genome Interpreter	D0HU9H	BRAF#p.V600E	Panitumumab	Panitumumab (帕尼单抗)		BRAF	p.V600E	耐药性增加	PMID: 20619739, 21163703, 23325582	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal Adenocarcinoma	Late trials	Panitumumab	Approved
L01718	Cancer Genome Interpreter	D0HU9H	BRAF:V600.	Panitumumab	Panitumumab (帕尼单抗)		BRAF	BRAF (V600)	敏感性增加	ENA 2014 (abstr 11LBA)	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal adenocarcinoma	Early trials	Panitumumab	Approved, Approved,Clinical Trials
L01462	Cancer Genome Interpreter	D0HU9H	EGFR:over	Panitumumab	Panitumumab (帕尼单抗)		EGFR	EGFR overexpression	耐药性增加	FDA guidelines	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal adenocarcinoma	FDA guidelines	Panitumumab	Approved
L01560	Cancer Genome Interpreter	D0HU9H	KRAS:.	Panitumumab	Panitumumab (帕尼单抗)		KRAS	KRAS oncogenic mutation	耐药性增加	FDA guidelines	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal adenocarcinoma	FDA guidelines	Panitumumab	Approved
L01583	Cancer Genome Interpreter	D0HU9H	MET:amp	Panitumumab	Panitumumab (帕尼单抗)		MET	MET amplification	敏感性增加	ENA 2015 (abstr A52)	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal adenocarcinoma	Case report	Panitumumab	Clinical Trials
L01582	Cancer Genome Interpreter	D0HU9H	MET:amp,BRAF:V600E	Panitumumab	Panitumumab (帕尼单抗)		MET	MET amplification + BRAF (V600E)	耐药性增加	PMID: 27325282	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal adenocarcinoma	Case report	Panitumumab	Clinical Trials
L01717	Cancer Genome Interpreter	D0HU9H	MET:amp,BRAF:V600E	Panitumumab	Panitumumab (帕尼单抗)		BRAF	MET amplification + BRAF (V600E)	耐药性增加	PMID: 27325282	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal adenocarcinoma	Case report	Panitumumab	Clinical Trials
L01885	Cancer Genome Interpreter	D0HU9H	NRAS:.	Panitumumab	Panitumumab (帕尼单抗)		NRAS	NRAS oncogenic mutation	耐药性增加	PMID: 24024839, 20619739, 23325582	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal adenocarcinoma	NCCN guidelines	Panitumumab	Approved
L01907	Cancer Genome Interpreter	D0HU9H	PTEN:.	Panitumumab	Panitumumab (帕尼单抗)		PTEN	PTEN biallelic inactivation	耐药性增加	Caris molecular intelligence	.		否	结直肠癌		NCT00460265: 头颈癌, NCT00820248: 头颈癌, NCT00824785: 胃癌, NCT01142414: 头颈癌	Colorectal adenocarcinoma	Case report	Panitumumab	Clinical Trials
L00256	Cancer Genome Interpreter	D0HU9H-D05ROI-D04XVN	BRAF#p.V600E	Panitumumab + Dabrafenib + Trametinib	Panitumumab + Dabrafenib + Trametinib		BRAF	p.V600E	敏感性增加	ASCO 2014 (abstr 3515),ASCO 2015 (abstr 103)	.		.	.		.	Colorectal Adenocarcinoma	Early trials	Panitumumab + Dabrafenib + Trametinib	.
L00203	Cancer Genome Interpreter	D0HU9H-D04XVN	MAP2K1#p.K57T	Panitumumab + Trametinib	Panitumumab + Trametinib		MAP2K1	p.K57T	敏感性增加	PMID: 26644315	.		.	.		.	Colorectal Adenocarcinoma	Case report	Panitumumab + Trametinib	.
L00015	Cancer Genome Interpreter	D03RYR	BRAF#p.V600E	Pan-RAF inhibitors	Pan-RAF 抑制剂		BRAF	p.V600E	敏感性增加	ESMO 2015 (abstract 300),AACR 2016 (abstr CT005)	.		.	.		.	Cutaneous Melanoma, Thyroid Cancer	Early trials	Pan-RAF inhibitors	.
L01589	Cancer Genome Interpreter	D0F0ZY	NF1:.	Pazopanib	Pazopanib (培唑帕尼)		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 24931142	.		是	软组织肉瘤, 肾癌		NCT00775307: 非小细胞肺癌, NCT00866697: 卵巢癌, NCT01208064: 肺癌, NCT02180867: 皮肤癌	Hepatic carcinoma	Case report	Pazopanib	Approved
L01954	Cancer Genome Interpreter	D0F0ZY	UGT1A1:.	Pazopanib	Pazopanib (培唑帕尼)		UGT1A1	UGT1A1 biallelic inactivation	毒性增加	FDA	.		是	软组织肉瘤, 肾癌		NCT00775307: 非小细胞肺癌, NCT00866697: 卵巢癌, NCT01208064: 肺癌, NCT02180867: 皮肤癌	Cancer	FDA guidelines	Pazopanib	Approved
L01402	search pubmed	D0VF6E	FGFR3#p.V555M	PD173074	PD173074		FGFR3	p.V555M	耐药性增加	PMID: 22869148	.		.	.		.	Myeloma	.	PD173074	Phase 2
L01743	Cancer Genome Interpreter	D08ANZ	CD274:over	Pembrolizumab	Pembrolizumab (派姆单抗)	"programmed death receptor-1 (PD-1)-blocking antibody"	CD274	CD274 overexpression	敏感性增加	NCT01848834	.		否	膀胱癌, 非小细胞肺癌, 黑色素瘤, 淋巴瘤, 头颈癌	用于治疗不可切除或转移黑色素瘤；高PD-L1表达且EGFR\ALK未检测到突变，未进行化疗的非小细胞肺癌或EGFR/ALK突变疾病进展的非小细胞肺癌；已经获批用于MSI-H或dMMR的实体瘤患者	NCT02564263: 胃癌，食管癌, NCT02576977: 多发性骨髓瘤, NCT02579863: 多发性骨髓瘤, NCT02811861: 肾细胞癌, NCT02819518: 乳腺癌, NCT02853305: 尿道癌, NCT02954874: 乳腺癌, NCT02991482: 间皮瘤, NCT03019588: 胃癌，食管癌, NCT03036488: 乳腺癌, NCT03062358: 肝癌, NCT03142334: 肾细胞癌, NCT03189719: 食管癌, NCT03221426: 胃癌，食管癌, NCT03244384: 膀胱尿路上皮癌, NCT03260894: 肾细胞癌, NCT03361865: 尿道癌, NCT03374488: 尿道癌	Bladder Urothelial Carcinoma	Early trials	Pembrolizumab	Clinical Trials
L00497	Cancer Genome Interpreter	D0CI4E	ERBB3#p.G284R	Pertuzumab	Pertuzumab (帕妥珠单抗)	Her2/neu受体拮抗剂	ERBB3	p.G284R	敏感性增加	PMID: 23680147	.		否	Her2阳性的乳腺癌	左心室功能障碍，胎儿致死	NCT01684878: 卵巢癌, NCT02581462: 胃癌，食管癌	Cancer	Pre-clinical	Pertuzumab	.
L00498	Cancer Genome Interpreter	D0CI4E	ERBB3#p.P262H	Pertuzumab	Pertuzumab (帕妥珠单抗)	Her2/neu受体拮抗剂	ERBB3	p.P262H	敏感性增加	PMID: 23680147	.		否	Her2阳性的乳腺癌	左心室功能障碍，胎儿致死	NCT01684878: 卵巢癌, NCT02581462: 胃癌，食管癌	Cancer	Pre-clinical	Pertuzumab	.
L01520	Cancer Genome Interpreter	D0CI4E	ERBB2:amp	Pertuzumab	Pertuzumab (帕妥珠单抗)	Her2/neu受体拮抗剂	ERBB2	ERBB2 amplification	敏感性增加	PMID: 24960402	.		否	Her2阳性的乳腺癌	左心室功能障碍，胎儿致死	NCT01684878: 卵巢癌, NCT02581462: 胃癌，食管癌	Stomach cancer	Early trials	Pertuzumab	Approved
L01521	Cancer Genome Interpreter	D0CI4E	ERBB2:amp	Pertuzumab	Pertuzumab (帕妥珠单抗)	Her2/neu受体拮抗剂	ERBB2	ERBB2 amplification	敏感性增加	FDA	.		否	Her2阳性的乳腺癌	左心室功能障碍，胎儿致死	NCT01684878: 卵巢癌, NCT02581462: 胃癌，食管癌	Breast invasive carcinoma	FDA guidelines	Pertuzumab	Approved
L01522	Cancer Genome Interpreter	D0CI4E	ERBB2:amp	Pertuzumab	Pertuzumab (帕妥珠单抗)	Her2/neu受体拮抗剂	ERBB2	ERBB2 amplification	敏感性增加	PMID: 26022204	.		否	Her2阳性的乳腺癌	左心室功能障碍，胎儿致死	NCT01684878: 卵巢癌, NCT02581462: 胃癌，食管癌	Billiary tract cancer	Early trials	Pertuzumab	Approved
L01519	Cancer Genome Interpreter	D0CI4E	ERBB2:over	Pertuzumab	Pertuzumab (帕妥珠单抗)	Her2/neu受体拮抗剂	ERBB2	ERBB2 overexpression	敏感性增加	FDA	.		否	Her2阳性的乳腺癌	左心室功能障碍，胎儿致死	NCT01684878: 卵巢癌, NCT02581462: 胃癌，食管癌	Breast invasive carcinoma	FDA guidelines	Pertuzumab	Approved
L01651	Cancer Genome Interpreter	D00GPQ	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	Pf-03084014	Pf-03084014		NOTCH1	NOTCH1 activating mutation in Cterm-PEST domain	敏感性增加	NCT01703572,NCT01778439, NCT01098344, NCT01981551	.		.	.		.	Cancer	Early trials	Pf-03084014	Clinical Trials
L01936	Cancer Genome Interpreter	D07XPE	STK11:del	Phenformin	Phenformin		STK11	STK11 deletion	敏感性增加	PMID: 23352126	.		.	.		.	Lung adenocarcinoma	Pre-clinical	Phenformin	Withdrawn from market
L01937	Cancer Genome Interpreter	D07XPE	STK11:.	Phenformin	Phenformin		STK11	STK11 oncogenic mutation	敏感性增加	PMID: 23352126	.		.	.		.	Lung adenocarcinoma	Pre-clinical	Phenformin	Withdrawn from market
L00095	Cancer Genome Interpreter	D08XEM	PIK3CB#p.D1067Y	PI3K pathway inhibitors	PI3K pathway 抑制剂		PIK3CB	p.D1067Y	耐药性增加	PMID: 26759240	.		.	.		.	Breast Cancer	Case report	PI3K pathway inhibitors	.
L00097	Cancer Genome Interpreter	D08XEM	AKT1#p.E17K	PI3K pathway inhibitors	PI3K pathway 抑制剂		AKT1	p.E17K	敏感性增加	PMID: 26763254	.		.	.		.	Head-neck Squamous Cell Carcinoma	Case report	PI3K pathway inhibitors	.
L00136	Cancer Genome Interpreter	.	ERBB3#p.G284R	PI3K pathway inhibitor + MEK inhibitors	PI3K pathway 抑制剂 + MEK 抑制剂		ERBB3	p.G284R	敏感性增加	PMID: 23680147	.		.	.		.	Cancer	Pre-clinical	PI3K pathway inhibitor + MEK inhibitors	.
L00144	Cancer Genome Interpreter	.	ERBB3#p.P262H	PI3K pathway inhibitor + MEK inhibitors	PI3K pathway 抑制剂 + MEK 抑制剂		ERBB3	p.P262H	敏感性增加	PMID: 23680147	.		.	.		.	Cancer	Pre-clinical	PI3K pathway inhibitor + MEK inhibitors	.
L00161	Cancer Genome Interpreter	.	GNA11#p.Q209L	PI3K pathway inhibitor + MEK inhibitors	PI3K pathway 抑制剂 + MEK 抑制剂		GNA11	p.Q209L	敏感性增加	PMID: 22733540, 22808163	.		.	.		.	Cutaneous Melanoma	Pre-clinical	PI3K pathway inhibitor + MEK inhibitors	.
L00162	Cancer Genome Interpreter	.	GNA11#p.Q209P	PI3K pathway inhibitor + MEK inhibitors	PI3K pathway 抑制剂 + MEK 抑制剂		GNA11	p.Q209P	敏感性增加	PMID: 22733540, 22808163	.		.	.		.	Cutaneous Melanoma	Pre-clinical	PI3K pathway inhibitor + MEK inhibitors	.
L00137	Cancer Genome Interpreter	.	ERBB3#p.Q809R	PI3K pathway inhibitor + MEK inhibitors	PI3K pathway 抑制剂 + MEK 抑制剂		ERBB3	p.Q809R	敏感性增加	PMID: 23680147	.		.	.		.	Cancer	Pre-clinical	PI3K pathway inhibitor + MEK inhibitors	.
L01588	Cancer Genome Interpreter	.	NF1:del	PLX3397	PLX3397		NF1	NF1 deletion	敏感性增加	PMID: 23099891	.		.	.		.	Plexiform neurofibroma	Pre-clinical	PLX3397	.
L01590	Cancer Genome Interpreter	.	NF1:.	PLX3397	PLX3397		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 23099891	.		.	.		.	Plexiform neurofibroma	Pre-clinical	PLX3397	.
L01359	search pubmed	D0F5JZ	MAP2K1#p.P124S	PLX4720	PLX4720		MAP2K1	p.P124S	耐药性增加	PMID: 19915144, PMID: 21383288	.		.	.		.	Cutaneous Melanoma	.	PLX4720	Phase 1
L01360	search pubmed	D0F5JZ	MAP2K1#p.Q56P	PLX4720	PLX4720		MAP2K1	p.Q56P	耐药性增加	PMID: 19915144, PMID: 21383288	.		.	.		.	Cutaneous Melanoma	.	PLX4720	Phase 1
L00471	Cancer Genome Interpreter	D0F5JZ	BRAF#p.V600E	PLX4720	PLX4720		BRAF	p.V600E	敏感性增加	PMC3638050	.		.	.		.	Malignant Astrocytoma	Pre-clinical	PLX4720	Phase 1
L01753	Cancer Genome Interpreter	D0A3ZU	CRBN:under	Pomalidomide	Pomalidomide (泊马度胺)		CRBN	CRBN undexpression	耐药性增加	PMID: 21860026	.		否	多发性骨髓瘤		.	Myeloma	Case report	Pomalidomide	Approved
L01754	Cancer Genome Interpreter	D0A3ZU	CRBN:.	Pomalidomide	Pomalidomide (泊马度胺)		CRBN	CRBN oncogenic mutation	耐药性增加	PMID: 25108355	.		否	多发性骨髓瘤		.	Myeloma	Case report	Pomalidomide	Approved
L02136	hotspot3D	D0H0EQ	RIPK2#p.A73D	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	RIPK2	p.A73D	耐药性增加	.			否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	cancer	prediction	Ponatinib	
L00574	Cancer Genome Interpreter	D0H0EQ	KIT#p.A829P	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	KIT	p.A829P	敏感性增加	PMID: 25239608	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Gastrointestinal Stromal Tumour	Pre-clinical	Ponatinib	Approved
L00634	COSMIC	D0H0EQ	ABL1#p.D276G	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.D276G	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Acute Lymphoblastic Leukaemia	.	Ponatinib	Approved
L01168	COSMIC	D0H0EQ	ABL1#p.E279K	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.E279K	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01180	COSMIC	D0H0EQ	ABL1#p.E453K	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.E453K	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Blast Phase Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L00052	Cancer Genome Interpreter	D0H0EQ	FGFR2#p.E566G	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	FGFR2	p.E566G	敏感性增加	PMID: 23908597	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Endometrium Cancer	Pre-clinical	Ponatinib	Approved
L01169	COSMIC	D0H0EQ	ABL1#p.F317L	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01181	COSMIC	D0H0EQ	ABL1#p.F317L	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.F317L	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Blast Phase Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01170	COSMIC	D0H0EQ	ABL1#p.F359C	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.F359C	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01171	COSMIC	D0H0EQ	ABL1#p.F359I	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.F359I	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01172	COSMIC	D0H0EQ	ABL1#p.F359V	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.F359V	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01173	COSMIC	D0H0EQ	ABL1#p.G250E	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.G250E	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01174	COSMIC	D0H0EQ	ABL1#p.H396R	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01182	COSMIC	D0H0EQ	ABL1#p.H396R	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.H396R	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Blast Phase Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L00050	Cancer Genome Interpreter	D0H0EQ	FGFR2#p.I548V	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	FGFR2	p.I548V	敏感性增加	PMID: 23908597	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Endometrium Cancer	Pre-clinical	Ponatinib	Approved
L02137	hotspot3D	D0H0EQ	RIPK2#p.I93T	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	RIPK2	p.I93T	耐药性增加	.			否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	cancer	prediction	Ponatinib	
L00053	Cancer Genome Interpreter	D0H0EQ	FGFR2#p.K660E	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	FGFR2	p.K660E	敏感性增加	PMID: 23908597	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Endometrium Cancer	Pre-clinical	Ponatinib	Approved
L01175	COSMIC	D0H0EQ	ABL1#p.L273M	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.L273M	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01176	COSMIC	D0H0EQ	ABL1#p.L387F	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.L387F	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L00054	Cancer Genome Interpreter	D0H0EQ	FGFR2#p.L618M	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	FGFR2	p.L618M	敏感性增加	PMID: 23908597	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Endometrium Cancer	Pre-clinical	Ponatinib	Approved
L01177	COSMIC	D0H0EQ	ABL1#p.M244V	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.M244V	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01178	COSMIC	D0H0EQ	ABL1#p.M351T	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.M351T	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L00055	Cancer Genome Interpreter	D0H0EQ	FGFR2#p.M536I	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	FGFR2	p.M536I	敏感性增加	PMID: 23908597	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Endometrium Cancer	Pre-clinical	Ponatinib	Approved
L00051	Cancer Genome Interpreter	D0H0EQ	FGFR2#p.M538I	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	FGFR2	p.M538I	敏感性增加	PMID: 23908597	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Endometrium Cancer	Pre-clinical	Ponatinib	Approved
L02138	hotspot3D	D0H0EQ	RIPK2#p.N151K	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	RIPK2	p.N151K	耐药性增加	.			否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	cancer	prediction	Ponatinib	
L01183	COSMIC	D0H0EQ	ABL1#p.Q252H	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.Q252H	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Blast Phase Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01184	COSMIC	D0H0EQ	ABL1#p.T212R	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.T212R	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Blast Phase Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L00408	Cancer Genome Interpreter	D0H0EQ	ABL1#p.T315I	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.T315I	敏感性增加	FDA	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Acute Lymphoblastic Leukemia, Chronic Myeloid Leukaemia	FDA guidelines	Ponatinib	Approved
L00452	Cancer Genome Interpreter	D0H0EQ	ABL1#p.T315I	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.T315I	敏感性增加	PMID: 21562040	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	NCCN guidelines	Ponatinib	Approved
L00635	COSMIC	D0H0EQ	ABL1#p.T315I	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Acute Lymphoblastic Leukaemia	.	Ponatinib	Approved
L01179	COSMIC	D0H0EQ	ABL1#p.T315I	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L01185	COSMIC	D0H0EQ	ABL1#p.T315I	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	p.T315I	.	PMID: 23190221	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Blast Phase Chronic Myeloid Leukaemia	.	Ponatinib	Approved
L00575	Cancer Genome Interpreter	D0H0EQ	KIT#p.T670I	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	KIT	p.T670I	敏感性增加	PMID: 25239608	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Gastrointestinal Stromal Tumour	Pre-clinical	Ponatinib	Approved
L00576	Cancer Genome Interpreter	D0H0EQ	KIT#p.V654A	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	KIT	p.V654A	敏感性增加	PMID: 25239608	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Gastrointestinal Stromal Tumour	Pre-clinical	Ponatinib	Approved
L01687	Cancer Genome Interpreter	D0H0EQ	ABL1__BCR	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	ABL1	ABL1-BCR fusion	敏感性增加	FDA	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Acute Lymphoblastic Leukemia, Chronic myeloid leukemia	FDA guidelines	Ponatinib	Approved
L01540	Cancer Genome Interpreter	D0H0EQ	FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	FGFR2	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	敏感性增加	PMID: 23908597	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Endometrial cancer	Pre-clinical	Ponatinib	Approved
L01804	Cancer Genome Interpreter	D0H0EQ	FLT3:D835.,Y842.	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	FLT3	FLT3 (D835,Y842)	耐药性增加	PMID: 23430109	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Acute Myeloid Leukemia	Pre-clinical	Ponatinib	Approved
L01837	Cancer Genome Interpreter	D0H0EQ	KIT:788-828,829-860,550-592	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	KIT	KIT (788-828,829-860,550-592)	敏感性增加	ASCO 2015 (abstr 10517), 25239608,ASCO 2015 (abstr 10535)	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Gastrointestinal Stromal Tumor	Early trials	Ponatinib	Approved
L01559	Cancer Genome Interpreter	D0H0EQ	KRAS:.	Ponatinib	Ponatinib (普纳替尼)	kinase inhibitor	KRAS	KRAS oncogenic mutation	敏感性增加	PMID: 27338794	.		否	白血病	部分患者存在血管闭塞、心力衰竭和肝毒性	NCT01761747: 非小细胞肺癌，头颈癌	Lung adenocarcinoma	Pre-clinical	Ponatinib	Approved
L02052	search pubmed	.	HER2 amplification	PP24237	PP24237		HER2	HER2 amplification	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		.	.		.	Breast Cancer	In vitro	PP24237	
L02046	search pubmed	.	PI3KCA oncogenic mutation	PP24237	PP24237		PIK3CA	PI3KCA oncogenic mutation	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		.	.		.	Breast Cancer	In vitro	PP24237	
L01374	search pubmed	D0DP0J	PSMB5#p.A49T	PR-924	PR-924		PSMB5	p.A49T	耐药性增加	PMID: 24552657	.		.	.		.	T lymphoblastic lymphoma/leukemia	.	PR-924	Phase 1
L01393	search pubmed	D0DP0J	PSMB5#p.M45I	PR-924	PR-924		PSMB5	p.M45I	耐药性增加	PMID: 24552657	.		.	.		.	T lymphoblastic lymphoma/leukemia	.	PR-924	Phase 1
L01394	search pubmed	D0DP0J	PSMB5#p.M45V	PR-924	PR-924		PSMB5	p.M45V	耐药性增加	PMID: 24552657	.		.	.		.	T lymphoblastic lymphoma/leukemia	.	PR-924	Phase 1
L01679	Cancer Genome Interpreter	D0C4AM	TP53:del	Pramlintide	Pramlintide		TP53	TP53 deletion	敏感性增加	PMID: 25409149	.		.	.		.	Thymoma	Pre-clinical	Pramlintide	Approved
L01674	Cancer Genome Interpreter	D0C4AM	TP53:.	Pramlintide	Pramlintide		TP53	TP53 oncogenic mutation	敏感性增加	PMID: 25409149	.		.	.		.	Thymoma	Pre-clinical	Pramlintide	Approved
L01406	search pubmed	D01FYA	HSP90AA1#p.Y142N	PU-H71	PU-H71		HSP90AA1	p.Y142N	耐药性增加	PMID: 28032595	.		.	.		.	Cancer	.	PU-H71	Phase 1
L01191	COSMIC	D07KYT	FLT3#p.D835F	Quizartinib	Quizartinib		FLT3	p.D835F	.	PMID: 22504184	.		.	.		.	Acute Myeloid Leukaemia	.	Quizartinib	Phase 3
L01192	COSMIC	D07KYT	FLT3#p.D835V	Quizartinib	Quizartinib		FLT3	p.D835V	.	PMID: 22504184	.		.	.		.	Acute Myeloid Leukaemia	.	Quizartinib	Phase 3
L01193	COSMIC	D07KYT	FLT3#p.D835Y	Quizartinib	Quizartinib		FLT3	p.D835Y	.	PMID: 22354205	.		.	.		.	Acute Myeloid Leukaemia	.	Quizartinib	Phase 3
L01194	COSMIC	D07KYT	FLT3#p.D835Y	Quizartinib	Quizartinib		FLT3	p.D835Y	.	PMID: 22504184	.		.	.		.	Acute Myeloid Leukaemia	.	Quizartinib	Phase 3
L01195	COSMIC	D07KYT	FLT3#p.F691L	Quizartinib	Quizartinib		FLT3	p.F691L	.	PMID: 22504184	.		.	.		.	Acute Myeloid Leukaemia	.	Quizartinib	Phase 3
L01196	COSMIC	D07KYT	FLT3#p.F691L	Quizartinib	Quizartinib		FLT3	p.F691L	.	PMID: 23392356	.		.	.		.	Acute Myeloid Leukaemia	.	Quizartinib	Phase 3
L01800	Cancer Genome Interpreter	D07KYT	FLT3:F691.,D835.,N676.,Y842.	Quizartinib	Quizartinib		FLT3	FLT3 (F691,D835,N676,Y842)	耐药性增加	PMID: 22504184, 23878140	.		.	.		.	Acute Myeloid Leukemia	Pre-clinical	Quizartinib	Phase 3
L01801	Cancer Genome Interpreter	D07KYT	FLT3::consequence::inframe_variant:572-603	Quizartinib	Quizartinib		FLT3	FLT3-ITD	敏感性增加	ASH 2012 (abstr 673),ASH 2012 (abstr 48)	.		.	.		.	Acute Myeloid Leukemia	Early trials	Quizartinib	Phase 3
L01823	Cancer Genome Interpreter	D09GDD	KIT:449-514,550-592,627-664,664-714,788-828	Regorafenib	Regorafenib (瑞戈非尼)	kinase inhibitor	KIT	KIT mutation in exon 9,11,13,14 or 17	敏感性增加	FDA	.		肝癌还没批，结直肠癌、胃肠道间质瘤中国获批	肝癌, 结直肠癌, 胃肠道间质瘤	部分存在严重的肝脏毒性，建议治疗前和用药期间进行肝功能监测		Gastrointestinal Stromal Tumor	FDA guidelines	Regorafenib	Approved
L01557	Cancer Genome Interpreter	D09GDD	KRAS:.	Regorafenib	Regorafenib (瑞戈非尼)	kinase inhibitor	KRAS	KRAS oncogenic mutation	敏感性增加	FDA guidelines	.		肝癌还没批，结直肠癌、胃肠道间质瘤中国获批	肝癌, 结直肠癌, 胃肠道间质瘤	部分存在严重的肝脏毒性，建议治疗前和用药期间进行肝功能监测		Colorectal adenocarcinoma	FDA guidelines	Regorafenib	Approved
L01656	Cancer Genome Interpreter	D09GDD	PDGFRA:552-596,631-668,814-854	Regorafenib	Regorafenib (瑞戈非尼)	kinase inhibitor	PDGFRA	PDGFRA (552-596,631-668,814-854)	敏感性增加	NCCN guidelines	.		肝癌还没批，结直肠癌、胃肠道间质瘤中国获批	肝癌, 结直肠癌, 胃肠道间质瘤	部分存在严重的肝脏毒性，建议治疗前和用药期间进行肝功能监测		Gastrointestinal Stromal Tumor	NCCN guidelines	Regorafenib	Approved
L00179	Cancer Genome Interpreter	.	RET#p.C634W	RET inhibitors	RET 抑制剂		RET	p.C634W	敏感性增加	PMID: 23056499	.		.	.		.	Thyroid Cancer	Pre-clinical	RET inhibitors	.
L00180	Cancer Genome Interpreter	.	RET#p.M918T	RET inhibitors	RET 抑制剂		RET	p.M918T	敏感性增加	PMID: 23056499	.		.	.		.	Thyroid Cancer	Pre-clinical	RET inhibitors	.
L01444	Cancer Genome Interpreter	D05FRP	EGFR::consequence::inframe_deletion:6-273	Rindopepimut	Rindopepimut		EGFR	EGFR inframe deletion (6-273)	敏感性增加	NCT01480479	.		.	.		.	Glioblastoma	Late trials	Rindopepimut	Clinical Trials
L01650	Cancer Genome Interpreter	.	NOTCH1::consequence::missense_variant:1529-1732,::splice_donor_variant:2245-2536,::splice_acceptor_variant:2245-2536,::stop_gained:2245-2536,::stop_lost:2245-2536,::frameshift_variant:2245-2536	Ro4929097	Ro4929097		NOTCH1	NOTCH1 activating mutation in Cterm-PEST domain	敏感性增加	NCT01703572,NCT01778439, NCT01098344, NCT01981551	.		.	.		.	Cancer	Early trials	Ro4929097	Clinical Trials
L00220	Cancer Genome Interpreter	D0C8JY	EGFR#p.L798I	Rociletinib	Rociletinib		EGFR	p.L798I	耐药性增加	PMID: 27283993	.		.	.		.	Lung Adenocarcinoma	Case report	Rociletinib	Phase 3
L00076	Cancer Genome Interpreter	D0C8JY	EGFR#p.T790M	Rociletinib	Rociletinib		EGFR	p.T790M	敏感性增加	NCT02322281	.		.	.		.	Non-small Cell  Lung Cancer	Late trials	Rociletinib	Phase 3
L01518	Cancer Genome Interpreter	D0C8JY	ERBB2:amp	Rociletinib	Rociletinib		ERBB2	ERBB2 amplification	耐药性增加	PMID: 27252416	.		.	.		.	Lung adenocarcinoma	Case report	Rociletinib	Phase 3
L01581	Cancer Genome Interpreter	D0C8JY	MET:amp	Rociletinib	Rociletinib		MET	MET amplification	耐药性增加	PMID: 27252416	.		.	.		.	Lung adenocarcinoma	Case report	Rociletinib	Phase 3
L01733	Cancer Genome Interpreter	D01SHZ	BRCA1:.	Rucaparib	Rucaparib (瑞卡帕布)		BRCA1	BRCA1 oncogenic mutation	敏感性增加	FDA	.		否	卵巢癌		NCT02975934: 前列腺癌	Ovarian cancer	FDA guidelines	Rucaparib	Approved
L01430	Cancer Genome Interpreter	D01SHZ	BRCA2:.	Rucaparib	Rucaparib (瑞卡帕布)		BRCA2	BRCA2 oncogenic mutation	敏感性增加	FDA	.		否	卵巢癌		NCT02975934: 前列腺癌	Ovarian cancer	FDA guidelines	Rucaparib	Approved
L00284	Cancer Genome Interpreter	D04LKS	JAK2#p.V617F	Ruxolitinib	Ruxolitinib	kinase inhibitor	JAK2	p.V617F	敏感性增加	PMID: 22422826	.		.	骨髓纤维变性	.	.	Acute Myeloid Leukaemia	Early trials	Ruxolitinib	Phase 4
L00409	Cancer Genome Interpreter	D04LKS	JAK2#p.V617F	Ruxolitinib	Ruxolitinib	kinase inhibitor	JAK2	p.V617F	敏感性增加	FDA	.		.	.	.	.	Myelofibrosis	FDA guidelines	Ruxolitinib	Phase 4
L01361	search pubmed	D04LKS	JAK2#p.V617F	Ruxolitinib	Ruxolitinib	kinase inhibitor	JAK2	p.V617F	耐药性增加	PMID: 21926964, PMID: 24766055	.		.	.	.	.	Myeloproliferative Neoplasms	.	Ruxolitinib	Phase 4
L01544	Cancer Genome Interpreter	D04LKS	IL7R:S185C,SH2B3:del	Ruxolitinib	Ruxolitinib	kinase inhibitor	IL7R	IL7R (S185C) + SH2B3 deletion	敏感性增加	PMID: 22897847, 22955920	.		.	.	.	.	Acute Lymphoblastic Leukemia	Pre-clinical	Ruxolitinib	Phase 4
L01667	Cancer Genome Interpreter	D04LKS	IL7R:S185C,SH2B3:del	Ruxolitinib	Ruxolitinib	kinase inhibitor	SH2B3	IL7R (S185C) + SH2B3 deletion	敏感性增加	PMID: 22897847, 22955920	.		.	.	.	.	Acute Lymphoblastic Leukemia	Pre-clinical	Ruxolitinib	Phase 4
L01545	Cancer Genome Interpreter	D04LKS	IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255,SH2B3:del	Ruxolitinib	Ruxolitinib	kinase inhibitor	IL7R	IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion	敏感性增加	PMID: 22897847, 22955920	.		.	.	.	.	Acute Lymphoblastic Leukemia	Pre-clinical	Ruxolitinib	Phase 4
L01668	Cancer Genome Interpreter	D04LKS	IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255,SH2B3:del	Ruxolitinib	Ruxolitinib	kinase inhibitor	SH2B3	IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion	敏感性增加	PMID: 22897847, 22955920	.		.	.	.	.	Acute Lymphoblastic Leukemia	Pre-clinical	Ruxolitinib	Phase 4
L01546	Cancer Genome Interpreter	D04LKS	JAK1:S646F,R683.	Ruxolitinib	Ruxolitinib	kinase inhibitor	JAK1	JAK1 (S646F,R683)	敏感性增加	PMID: 22955920, 18805579	.		.	.	.	.	Acute Lymphoblastic Leukemia	Pre-clinical	Ruxolitinib	Phase 4
L01820	Cancer Genome Interpreter	D04LKS	JAK2__BRAF	Ruxolitinib	Ruxolitinib	kinase inhibitor	JAK2	JAK2-BRAF fusion	敏感性增加	PMID: 22875628, 22899477	.		.	.	.	.	Acute Lymphoblastic Leukemia	Pre-clinical	Ruxolitinib	Phase 4
L01379	search pubmed	D03JAO	SMO#p.D473H	Saridegib	Saridegib		SMO	p.D473H	耐药性增加	PMID: 22550175	.		.	.		.	Cancer	.	Saridegib	Discontinued in Phase 2
L01568	Cancer Genome Interpreter	.	MET:1078-1345	Savolitinib	Savolitinib		MET	MET kinase domain mutation	敏感性增加	PMID: 28644771	.		.	.		.	Renal cancer	Early trials	Savolitinib	.
L01975	Cancer Genome Interpreter	D0TH0Z	HRAS#p.G12R	Selumetinib	Selumetinib		HRAS	p.G12R	敏感性增加	PMID: 23406027, 21526955	A clinical trial showed that the MEK inhibitor selumetinib increased responses to radioactive iodine in patients with radioactive iodine–refractory metastatic thyroid cancer, particularly in RAS-mutated tumors		.	.		.	Thyroid cancer	Early trials	Selumetinib	Clinical Trials
L01976	Cancer Genome Interpreter	D0TH0Z	HRAS#p.G12V	Selumetinib	Selumetinib		HRAS	p.G12V	敏感性增加	PMID: 23406027, 21526955	A clinical trial showed that the MEK inhibitor selumetinib increased responses to radioactive iodine in patients with radioactive iodine–refractory metastatic thyroid cancer, particularly in RAS-mutated tumors		.	.		.	Thyroid cancer	Early trials	Selumetinib	Clinical Trials
L01977	Cancer Genome Interpreter	D0TH0Z	HRAS#p.G13C	Selumetinib	Selumetinib		HRAS	p.G13C	敏感性增加	PMID: 23406027, 21526955	A clinical trial showed that the MEK inhibitor selumetinib increased responses to radioactive iodine in patients with radioactive iodine–refractory metastatic thyroid cancer, particularly in RAS-mutated tumors		.	.		.	Thyroid cancer	Early trials	Selumetinib	Clinical Trials
L01978	Cancer Genome Interpreter	D0TH0Z	HRAS#p.G13R	Selumetinib	Selumetinib		HRAS	p.G13R	敏感性增加	PMID: 23406027, 21526955	A clinical trial showed that the MEK inhibitor selumetinib increased responses to radioactive iodine in patients with radioactive iodine–refractory metastatic thyroid cancer, particularly in RAS-mutated tumors		.	.		.	Thyroid cancer	Early trials	Selumetinib	Clinical Trials
L00277	Cancer Genome Interpreter	D0TH0Z	GNA11#p.Q209L	Selumetinib	Selumetinib		GNA11	p.Q209L	敏感性增加	ASCO 2013 (abstr CRA9003)	.		.	.		.	Cutaneous Melanoma	Early trials	Selumetinib	Phase 3
L01810	Cancer Genome Interpreter	D0TH0Z	GNAQ#p.Q209L	Selumetinib	Selumetinib		GNAQ	p.Q209L	敏感性增加	ASCO 2013 (abstr CRA9003)	.		.	.		.	Cutaneous carcinoma	Early trials	Selumetinib	Clinical Trials
L00278	Cancer Genome Interpreter	D0TH0Z	GNA11#p.Q209P	Selumetinib	Selumetinib		GNA11	p.Q209P	敏感性增加	ASCO 2013 (abstr CRA9003)	.		.	.		.	Cutaneous Melanoma	Early trials	Selumetinib	Phase 3
L02019	search pubmed	D0TH0Z	NRAS#p.Q61K	Selumetinib	Selumetinib		NRAS	p.Q61K	敏感性增加	PMID: 22194965	In a preclinical study, melanoma cell lines with both BRAF V600E mutations and NRAS Q61K mutations were resistant to BRAF inhibitor vemurafenib but sensitive to MEK inhibitor selumetinib.		.	.		.	Melanoma	Case report	Selumetinib	
L01979	Cancer Genome Interpreter	D0TH0Z	HRAS#p.Q61R	Selumetinib	Selumetinib		HRAS	p.Q61R	敏感性增加	PMID: 23406027, 21526955	A clinical trial showed that the MEK inhibitor selumetinib increased responses to radioactive iodine in patients with radioactive iodine–refractory metastatic thyroid cancer, particularly in RAS-mutated tumors		.	.		.	Thyroid cancer	Early trials	Selumetinib	Clinical Trials
L00258	Cancer Genome Interpreter	D0TH0Z	BRAF#p.V600E	Selumetinib	Selumetinib		BRAF	p.V600E	敏感性增加	NCT01089101	.		.	.		.	Pediatric Glioma	Early trials	Selumetinib	Phase 3
L01849	Cancer Genome Interpreter	D0TH0Z	MAP2K1::consequence::inframe_deletion:56-60	Selumetinib	Selumetinib		MAP2K1	MAP2K1 inframe deletion (56-60)	敏感性增加	PMID: 26324360	.		.	.		.	Ovarian cancer	Case report	Selumetinib	Clinical Trials
L01637	Cancer Genome Interpreter	D0TH0Z	NF1:del	Selumetinib	Selumetinib		NF1	NF1 deletion	敏感性增加	ASCO 2014 (abstr 10018)	.		.	.		.	Plexiform neurofibroma	Early trials	Selumetinib	Clinical Trials
L01636	Cancer Genome Interpreter	D0TH0Z	NF1:del,BRAF:.	Selumetinib	Selumetinib		NF1	NF1 deletion + BRAF oncogenic mutation	耐药性增加	PMID: 23444215	.		.	.		.	Cutaneous carcinoma	Case report	Selumetinib	Clinical Trials
L01720	Cancer Genome Interpreter	D0TH0Z	NF1:del,BRAF:.	Selumetinib	Selumetinib		BRAF	NF1 deletion + BRAF oncogenic mutation	耐药性增加	PMID: 23444215	.		.	.		.	Cutaneous carcinoma	Case report	Selumetinib	Clinical Trials
L01722	Cancer Genome Interpreter	D0TH0Z	BRAF__.	Selumetinib	Selumetinib		BRAF	BRAF fusion	敏感性增加	PMID: 26324360	.		.	.		.	Ovarian cancer	Case report	Selumetinib	Clinical Trials
L01564	Cancer Genome Interpreter	D0TH0Z	KRAS:.	Selumetinib	Selumetinib		KRAS	KRAS oncogenic mutation	敏感性增加	NCT00890825	.		.	.		.	Non-small cell lung cancer	Early trials	Selumetinib	Clinical Trials
L01565	Cancer Genome Interpreter	D0TH0Z	KRAS:.	Selumetinib	Selumetinib		KRAS	KRAS oncogenic mutation	敏感性降低	PMID: 26802155	.		.	.		.	Lung cancer	Early trials	Selumetinib	Clinical Trials
L01639	Cancer Genome Interpreter	D0TH0Z	NF1:.	Selumetinib	Selumetinib		NF1	NF1 oncogenic mutation	敏感性增加	ASCO 2014 (abstr 10018)	.		.	.		.	Plexiform neurofibroma	Early trials	Selumetinib	Clinical Trials
L01638	Cancer Genome Interpreter	D0TH0Z	NF1:.,BRAF:.	Selumetinib	Selumetinib		NF1	NF1 oncogenic mutation + BRAF oncogenic mutation	耐药性增加	PMID: 23444215	.		.	.		.	Cutaneous carcinoma	Case report	Selumetinib	Clinical Trials
L01721	Cancer Genome Interpreter	D0TH0Z	NF1:.,BRAF:.	Selumetinib	Selumetinib		BRAF	NF1 oncogenic mutation + BRAF oncogenic mutation	耐药性增加	PMID: 23444215	.		.	.		.	Cutaneous carcinoma	Case report	Selumetinib	Clinical Trials
L00474	Cancer Genome Interpreter	D03LJR	MTOR#p.L1460P	Sirolimus	Sirolimus (西罗莫司)		MTOR	p.L1460P	敏感性增加	PMID: 24631838	.		是	器官移植		.	Cancer	Pre-clinical	Sirolimus	Approved
L00475	Cancer Genome Interpreter	D03LJR	MTOR#p.R2505P	Sirolimus	Sirolimus (西罗莫司)		MTOR	p.R2505P	敏感性增加	PMID: 24631838	.		是	器官移植		.	Cancer	Pre-clinical	Sirolimus	Approved
L00476	Cancer Genome Interpreter	D03LJR	MTOR#p.S2215Y	Sirolimus	Sirolimus (西罗莫司)		MTOR	p.S2215Y	敏感性增加	PMID: 24631838	.		是	器官移植		.	Cancer	Pre-clinical	Sirolimus	Approved
L01787	Cancer Genome Interpreter	D03LJR	FBXW7:del	Sirolimus	Sirolimus (西罗莫司)		FBXW7	FBXW7 deletion	敏感性增加	PMID: 23558291	.		是	器官移植		.	Colorectal adenocarcinoma	Pre-clinical	Sirolimus	Approved
L01595	Cancer Genome Interpreter	D03LJR	NF1:del	Sirolimus	Sirolimus (西罗莫司)		NF1	NF1 deletion	敏感性增加	PMID: 25314964	.		是	器官移植		.	Plexiform neurofibroma	Early trials	Sirolimus	Approved
L01596	Cancer Genome Interpreter	D03LJR	NF1:del	Sirolimus	Sirolimus (西罗莫司)		NF1	NF1 deletion	敏感性增加	PMID: 22434731	.		是	器官移植		.	Glioma	Case report	Sirolimus	Approved
L01597	Cancer Genome Interpreter	D03LJR	NF1:del	Sirolimus	Sirolimus (西罗莫司)		NF1	NF1 deletion	敏感性增加	PMID: 25810463	.		是	器官移植		.	Malignant peripheral nerve sheat tumor	Pre-clinical	Sirolimus	Approved
L01904	Cancer Genome Interpreter	D03LJR	PTEN:del	Sirolimus	Sirolimus (西罗莫司)		PTEN	PTEN deletion	敏感性增加	ASCO 2013 (abstr 2532)	.		是	器官移植		.	Cancer	Early trials	Sirolimus	Approved
L01598	Cancer Genome Interpreter	D03LJR	NF1:.	Sirolimus	Sirolimus (西罗莫司)		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 25314964	.		是	器官移植		.	Plexiform neurofibroma	Early trials	Sirolimus	Approved
L01599	Cancer Genome Interpreter	D03LJR	NF1:.	Sirolimus	Sirolimus (西罗莫司)		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 22434731	.		是	器官移植		.	Glioma	Case report	Sirolimus	Approved
L01600	Cancer Genome Interpreter	D03LJR	NF1:.	Sirolimus	Sirolimus (西罗莫司)		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 25810463	.		是	器官移植		.	Malignant peripheral nerve sheat tumor	Pre-clinical	Sirolimus	Approved
L01905	Cancer Genome Interpreter	D03LJR	PTEN:.	Sirolimus	Sirolimus (西罗莫司)		PTEN	PTEN oncogenic mutation	敏感性增加	ASCO 2013 (abstr 2532)	.		是	器官移植		.	Cancer	Early trials	Sirolimus	Approved
L00065	Cancer Genome Interpreter	.	SMO#p.D473H	SMO inhibitors	SMO 抑制剂		SMO	p.D473H	耐药性增加	PMID: 24951114	.		.	.		.	Medulloblastoma	Pre-clinical	SMO inhibitors	.
L01318	search pubmed	D0L5LG	ABCG2#p.R482T	SN-38	SN-38		ABCG2	p.R482T	耐药性增加	PMID: 11559526	.		.	.		.	Cancer	.	SN-38	Phase 2
L01986	search pubmed	.	SMO#p.D473G	Sonidegib	Sonidegib (索尼德吉)	hedgehog pathway inhibitor	SMO	p.D473G	耐药性增加	PMID: 26546616	Mutations Q477 and D473 are within the drug-binding pocket of sonidegib		否	基底细胞癌	药物可能导致胚胎毒性或严重出生缺陷，治疗前需要确认女性的妊娠状况。建议治疗期间做好有效的避孕措施，并且至少距离最后一次服药20月。男性建议在药物治疗期间避免与怀孕配偶或生殖潜力的女性伴侣的精液暴露潜在风险，且至少维持距离最后一剂8个月。		Advanced Basal Cell Carcinoma	Case report	Sonidegib	Approved
L01984	search pubmed	.	SMO#p.D473H	Sonidegib	Sonidegib (索尼德吉)	hedgehog pathway inhibitor	SMO	p.D473H	耐药性增加	PMID: 26546616	Mutations Q477 and D473 are within the drug-binding pocket of sonidegib		否	基底细胞癌	药物可能导致胚胎毒性或严重出生缺陷，治疗前需要确认女性的妊娠状况。建议治疗期间做好有效的避孕措施，并且至少距离最后一次服药20月。男性建议在药物治疗期间避免与怀孕配偶或生殖潜力的女性伴侣的精液暴露潜在风险，且至少维持距离最后一剂8个月。		Advanced Basal Cell Carcinoma	Case report	Sonidegib	Approved
L01983	search pubmed	.	SMO#p.Q477E	Sonidegib	Sonidegib (索尼德吉)	hedgehog pathway inhibitor	SMO	p.Q477E	耐药性增加	PMID: 26546616	Mutations Q477 and D473 are within the drug-binding pocket of sonidegib		否	基底细胞癌	药物可能导致胚胎毒性或严重出生缺陷，治疗前需要确认女性的妊娠状况。建议治疗期间做好有效的避孕措施，并且至少距离最后一次服药20月。男性建议在药物治疗期间避免与怀孕配偶或生殖潜力的女性伴侣的精液暴露潜在风险，且至少维持距离最后一剂8个月。		Advanced Basal Cell Carcinoma	Case report	Sonidegib	Approved
L01985	search pubmed	.	SMO#p.S533N	Sonidegib	Sonidegib (索尼德吉)	hedgehog pathway inhibitor	SMO	p.S533N	耐药性增加	PMID: 26546616	Mutations S533 and W535 likely cause conformational change in SMO rendering the drug-binding pocket inaccessible to the sonidegib		否	基底细胞癌	药物可能导致胚胎毒性或严重出生缺陷，治疗前需要确认女性的妊娠状况。建议治疗期间做好有效的避孕措施，并且至少距离最后一次服药20月。男性建议在药物治疗期间避免与怀孕配偶或生殖潜力的女性伴侣的精液暴露潜在风险，且至少维持距离最后一剂8个月。		Advanced Basal Cell Carcinoma	Case report	Sonidegib	Approved
L01982	search pubmed	.	SMO#p.W535L	Sonidegib	Sonidegib (索尼德吉)	hedgehog pathway inhibitor	SMO	p.W535L	耐药性增加	PMID: 26546616	Mutations S533 and W535 likely cause conformational change in SMO rendering the drug-binding pocket inaccessible to the sonidegib		否	基底细胞癌	药物可能导致胚胎毒性或严重出生缺陷，治疗前需要确认女性的妊娠状况。建议治疗期间做好有效的避孕措施，并且至少距离最后一次服药20月。男性建议在药物治疗期间避免与怀孕配偶或生殖潜力的女性伴侣的精液暴露潜在风险，且至少维持距离最后一剂8个月。		Advanced Basal Cell Carcinoma	Case report	Sonidegib	Approved
L02072	hotspot3D	D0W5HK	CDK8#p.A155V	Sorafenib	Sorafenib (索拉非尼)		CDK8	p.A155V	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02073	hotspot3D	D0W5HK	CDK8#p.D103N	Sorafenib	Sorafenib (索拉非尼)		CDK8	p.D103N	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L00531	Cancer Genome Interpreter	D0W5HK	BRAF#p.D594G	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.D594G	敏感性增加	PMID: 18794803	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Cutaneous Melanoma	Pre-clinical	Sorafenib	Approved
L02060	hotspot3D	D0W5HK	BRAF#p.D594G	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.D594G	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02061	hotspot3D	D0W5HK	BRAF#p.D594H	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.D594H	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02062	hotspot3D	D0W5HK	BRAF#p.D594N	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.D594N	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L00229	Cancer Genome Interpreter	D0W5HK	KIT#p.D820E	Sorafenib	Sorafenib (索拉非尼)		KIT	p.D820E	敏感性增加	PMID: 19461405	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Thymic Carcinoma	Case report	Sorafenib	Approved
L01199	COSMIC	D0W5HK	FLT3#p.D835?	Sorafenib	Sorafenib (索拉非尼)		FLT3	p.D835?	.	PMID: 22368270	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Acute Myeloid Leukaemia	.	Sorafenib	Approved
L01198	COSMIC	D0W5HK	FLT3#p.D835H	Sorafenib	Sorafenib (索拉非尼)		FLT3	p.D835H	.	PMID: 23969938	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Acute Myeloid Leukaemia Associated With Mds	.	Sorafenib	Approved
L01200	COSMIC	D0W5HK	FLT3#p.D835H	Sorafenib	Sorafenib (索拉非尼)		FLT3	p.D835H	.	PMID: 22368270	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Acute Myeloid Leukaemia	.	Sorafenib	Approved
L01201	COSMIC	D0W5HK	FLT3#p.D835H	Sorafenib	Sorafenib (索拉非尼)		FLT3	p.D835H	.	PMID: 23969938	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Acute Myeloid Leukaemia	.	Sorafenib	Approved
L01202	COSMIC	D0W5HK	FLT3#p.D835Y	Sorafenib	Sorafenib (索拉非尼)		FLT3	p.D835Y	.	PMID: 22368270	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Acute Myeloid Leukaemia	.	Sorafenib	Approved
L02074	hotspot3D	D0W5HK	CDK8#p.E165Q	Sorafenib	Sorafenib (索拉非尼)		CDK8	p.E165Q	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02021	search pubmed	D0W5HK	KIT#p.E490K	Sorafenib	Sorafenib (索拉非尼)		KIT	p.E490K	敏感性增加	PMID: 21325067	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Thymic Carcinoma	Case report	Sorafenib	
L02075	hotspot3D	D0W5HK	CDK8#p.E66Q	Sorafenib	Sorafenib (索拉非尼)		CDK8	p.E66Q	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L01203	COSMIC	D0W5HK	FLT3#p.F691L	Sorafenib	Sorafenib (索拉非尼)		FLT3	p.F691L	.	PMID: 23969938	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Acute Myeloid Leukaemia	.	Sorafenib	Approved
L02063	hotspot3D	D0W5HK	BRAF#p.G469A	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.G469A	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L00532	Cancer Genome Interpreter	D0W5HK	BRAF#p.G469E	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.G469E	敏感性增加	PMID: 18794803	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Cutaneous Melanoma	Pre-clinical	Sorafenib	Approved
L02064	hotspot3D	D0W5HK	BRAF#p.G469R	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.G469R	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02065	hotspot3D	D0W5HK	BRAF#p.G596D	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.G596D	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02066	hotspot3D	D0W5HK	BRAF#p.K601E	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.K601E	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02007	search pubmed	D0W5HK	KIT#p.K642E	Sorafenib	Sorafenib (索拉非尼)		KIT	p.K642E	敏感性增加	PMID: 18936790	A case has been reported of clinical response of a KIT V560D-mutated melanoma to sorafenib		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Melanoma	Case report	Sorafenib	
L02076	hotspot3D	D0W5HK	CDK8#p.L142M	Sorafenib	Sorafenib (索拉非尼)		CDK8	p.L142M	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02003	search pubmed	D0W5HK	KIT#p.L576P	Sorafenib	Sorafenib (索拉非尼)		KIT	p.L576P	敏感性增加	PMID: 18936790	A case has been reported of clinical response of a KIT V560D-mutated melanoma to sorafenib		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Melanoma	Case report	Sorafenib	
L02077	hotspot3D	D0W5HK	CDK8#p.R150T	Sorafenib	Sorafenib (索拉非尼)		CDK8	p.R150T	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02067	hotspot3D	D0W5HK	BRAF#p.R462K	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.R462K	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02078	hotspot3D	D0W5HK	CDK8#p.R65K	Sorafenib	Sorafenib (索拉非尼)		CDK8	p.R65K	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L00224	Cancer Genome Interpreter	D0W5HK	ARAF#p.S214C	Sorafenib	Sorafenib (索拉非尼)		ARAF	p.S214C	敏感性增加	http: //www.jci.org/articles/view/72763, 24569458	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Lung Adenocarcinoma	Case report	Sorafenib	Approved
L01995	search pubmed	D0W5HK	KIT#p.V559A	Sorafenib	Sorafenib (索拉非尼)		KIT	p.V559A	敏感性增加	PMID: 18936790	A case has been reported of clinical response of a KIT V560D-mutated melanoma to sorafenib		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Melanoma	Case report	Sorafenib	
L01999	search pubmed	D0W5HK	KIT#p.V559D	Sorafenib	Sorafenib (索拉非尼)		KIT	p.V559D	敏感性增加	PMID: 18936790	A case has been reported of clinical response of a KIT V560D-mutated melanoma to sorafenib		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Melanoma	Case report	Sorafenib	
L01991	search pubmed	D0W5HK	KIT#p.V560D	Sorafenib	Sorafenib (索拉非尼)		KIT	p.V560D	敏感性增加	PMID: 18936790	A case has been reported of clinical response of a KIT V560D-mutated melanoma to sorafenib		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Melanoma	Case report	Sorafenib	
L02068	hotspot3D	D0W5HK	BRAF#p.V600E	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.V600E	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02069	hotspot3D	D0W5HK	BRAF#p.V600K	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.V600K	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02070	hotspot3D	D0W5HK	BRAF#p.V600R	Sorafenib	Sorafenib (索拉非尼)		BRAF	p.V600R	耐药性增加	.			是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	cancer	prediction	Sorafenib	
L02022	search pubmed	D0W5HK	KIT#p.W557R	Sorafenib	Sorafenib (索拉非尼)		KIT	p.W557R	敏感性增加	PMID: 12960119	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Thymic Carcinoma	Case report	Sorafenib	
L02020	search pubmed	D0W5HK	KIT#p.Y553N	Sorafenib	Sorafenib (索拉非尼)		KIT	p.Y553N	敏感性增加	PMID: 21969494	This mutation was described in a patient with a refractory metastatic thymic carcinoma tumor, exhibiting response to imatinib		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Thymic Carcinoma	Case report	Sorafenib	
L01848	Cancer Genome Interpreter	D0W5HK	KIT::consequence::inframe_deletion:577-579	Sorafenib	Sorafenib (索拉非尼)		KIT	KIT inframe deletion (577-579)	敏感性增加	PMID: 20970876	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Thymoma	Case report	Sorafenib	Approved
L01640	Cancer Genome Interpreter	D0W5HK	NF1:del	Sorafenib	Sorafenib (索拉非尼)		NF1	NF1 deletion	敏感性增加	PMID: 25810463	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Malignant peripheral nerve sheat tumor	Pre-clinical	Sorafenib	Approved
L01723	Cancer Genome Interpreter	D0W5HK	BRAF__.	Sorafenib	Sorafenib (索拉非尼)		BRAF	BRAF fusion	敏感性增加	PMID: 238900088, 20526349, 24727320	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Cutaneous carcinoma, Lung adenocarcinoma, Prostate adenocarcinoma	Pre-clinical	Sorafenib	Approved
L01806	Cancer Genome Interpreter	D0W5HK	FLT3::consequence::inframe_variant:572-603	Sorafenib	Sorafenib (索拉非尼)		FLT3	FLT3-ITD	敏感性增加	PMID: 19389879, 22368270	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Acute Myeloid Leukemia	Early trials	Sorafenib	Approved
L01807	Cancer Genome Interpreter	D0W5HK	FLT3::consequence::inframe_variant:572-603	Sorafenib	Sorafenib (索拉非尼)		FLT3	FLT3-ITD	敏感性增加	PMID: 23613521	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Acute Myeloid Leukemia	Early trials	Sorafenib	Approved
L01845	Cancer Genome Interpreter	D0W5HK	KIT:550-592,627-664,788-828,829-860	Sorafenib	Sorafenib (索拉非尼)		KIT	KIT (550-592,627-664,788-828,829-860)	敏感性增加	PMID: 18936790, 20372153	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Cutaneous carcinoma	Case report	Sorafenib	Approved
L01844	Cancer Genome Interpreter	D0W5HK	KIT:788-828	Sorafenib	Sorafenib (索拉非尼)		KIT	KIT mutation in exon 17	敏感性增加	PMID: 23840364	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Gastrointestinal Stromal Tumor	Pre-clinical	Sorafenib	Approved
L01846	Cancer Genome Interpreter	D0W5HK	KIT:550-592,449-514	Sorafenib	Sorafenib (索拉非尼)		KIT	KIT mutation in exon 9 or 11	敏感性增加	PMID: 22270258	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Gastrointestinal Stromal Tumor	Early trials	Sorafenib	Approved
L01847	Cancer Genome Interpreter	D0W5HK	KIT::wildtype:.	Sorafenib	Sorafenib (索拉非尼)		KIT	KIT wildtype	敏感性增加	ASCO 2011 (abstr 10009)	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Gastrointestinal Stromal Tumor	Early trials	Sorafenib	Approved
L01566	Cancer Genome Interpreter	D0W5HK	KRAS:.	Sorafenib	Sorafenib (索拉非尼)		KRAS	KRAS oncogenic mutation	敏感性增加	PMID: 25294897	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Hepatic carcinoma	Early Trials,Case Report	Sorafenib	Approved
L01641	Cancer Genome Interpreter	D0W5HK	NF1:.	Sorafenib	Sorafenib (索拉非尼)		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 25810463	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Malignant peripheral nerve sheat tumor	Pre-clinical	Sorafenib	Approved
L01887	Cancer Genome Interpreter	D0W5HK	NRAS:.	Sorafenib	Sorafenib (索拉非尼)		NRAS	NRAS oncogenic mutation	敏感性增加	PMID: 25294897	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Hepatic carcinoma	Early Trials,Case Report	Sorafenib	Approved
L01666	Cancer Genome Interpreter	D0W5HK	PDGFRA::wildtype:.	Sorafenib	Sorafenib (索拉非尼)		PDGFRA	PDGFRA wildtype	敏感性增加	ASCO 2011 (abstr 10009)	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Gastrointestinal Stromal Tumor	Early trials	Sorafenib	Approved
L01916	Cancer Genome Interpreter	D0W5HK	RAF1__.	Sorafenib	Sorafenib (索拉非尼)		RAF1	RAF1 fusion	敏感性增加	PMID: 20526349	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Prostate adenocarcinoma	Pre-clinical	Sorafenib	Approved
L01917	Cancer Genome Interpreter	D0W5HK	RAF1:over	Sorafenib	Sorafenib (索拉非尼)		RAF1	RAF1 overexpression	敏感性增加	PMID: 24375110	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Osteosarcoma	Pre-clinical	Sorafenib	Approved
L01957	Cancer Genome Interpreter	D0W5HK	VEGFA:amp	Sorafenib	Sorafenib (索拉非尼)		VEGFA	VEGFA amplification	敏感性增加	PMID: 24687604	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Hepatic carcinoma	Early trials	Sorafenib	Approved
L01961	Cancer Genome Interpreter	D0W5HK	VHL:.	Sorafenib	Sorafenib (索拉非尼)		VHL	VHL oncogenic mutation	敏感性增加	PMID: 18635227	.		是	肝癌, 甲状腺癌, 肾癌		NCT00110019: 黑色素瘤, NCT00300885: 非小细胞肺癌, NCT00449033: 非小细胞肺癌, NCT00541021: 胰腺癌, NCT00558636: 非小细胞肺癌, NCT00863746: 非小细胞肺癌, NCT01234337: 乳腺癌, NCT02474290: 急性髓性白血病	Renal cancer	Pre-clinical	Sorafenib	Approved
L00132	Cancer Genome Interpreter	D0N0VC	SF3B1#p.K666N	Spliceosome inhibitors	Spliceosome 抑制剂		SF3B1	p.K666N	敏感性增加	ENA 2014 (abstr 456),ENA 2014 (abstr 575), 25424858	.		.	.		.	Cancer	Pre-clinical	Spliceosome inhibitors	.
L00133	Cancer Genome Interpreter	D0N0VC	SF3B1#p.K700E	Spliceosome inhibitors	Spliceosome 抑制剂		SF3B1	p.K700E	敏感性增加	ENA 2014 (abstr 456),ENA 2014 (abstr 575), 25424858	.		.	.		.	Cancer	Pre-clinical	Spliceosome inhibitors	.
L00567	Cancer Genome Interpreter	D0R0MW	RET#p.C634W	Sunitinib	Sunitinib (舒尼替尼)		RET	p.C634W	敏感性增加	PMID: 21470995	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thyroid Cancer	Pre-clinical	Sunitinib	Approved
L01197	COSMIC	D0R0MW	FLT3#p.D835Y	Sunitinib	Sunitinib (舒尼替尼)		FLT3	p.D835Y	.	PMID: 23969938	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Acute Myeloid Leukaemia	.	Sunitinib	Approved
L00414	Cancer Genome Interpreter	D0R0MW	PDGFRA#p.D842V	Sunitinib	Sunitinib (舒尼替尼)		PDGFRA	p.D842V	耐药性增加	PMID: 22718859, 16638875	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumour	Late trials,Pre-clinical	Sunitinib	Approved
L01311	COSMIC	D0R0MW	PDGFRA#p.D842V	Sunitinib	Sunitinib (舒尼替尼)		PDGFRA	p.D842V	.	PMID: 25735500	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	.	Sunitinib	Approved
L02015	search pubmed	D0R0MW	KIT#p.E490K	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.E490K	敏感性增加	PMID: 21325067	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thymic Carcinoma	Case report	Sunitinib	
L02128	hotspot3D	D0R0MW	KIT#p.G812V	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.G812V	耐药性增加	.			是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	cancer	prediction	Sunitinib	
L00516	Cancer Genome Interpreter	D0R0MW	KIT#p.H697Y	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.H697Y	敏感性增加	PMID: 19861435	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thymic Carcinoma	Pre-clinical	Sunitinib	Approved
L02018	search pubmed	D0R0MW	KIT#p.H697Y	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.H697Y	敏感性增加	PMID: 19861435	The KIT H697Y mutation confers gain-of-function to the KIT kinase. The growth in vitro of Ba/F3 cells harboring the KIT H697Y mutation was more potently inhibited by sunitinib than by imatinib.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thymic Carcinoma	Case report	Sunitinib	
L02130	hotspot3D	D0R0MW	KIT#p.I571K	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.I571K	耐药性增加	.			是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	cancer	prediction	Sunitinib	
L02006	search pubmed	D0R0MW	KIT#p.K642E	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.K642E	敏感性增加	PMID: 22261812	three out of four evaluable patients with KIT mutations (two with L576P and one with W557G) responded to sunitinib in a recent study		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Melanoma	Case report	Sunitinib	
L02002	search pubmed	D0R0MW	KIT#p.L576P	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.L576P	敏感性增加	PMID: 22261812	three out of four evaluable patients with KIT mutations (two with L576P and one with W557G) responded to sunitinib in a recent study		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Melanoma	Case report	Sunitinib	
L02017	search pubmed	D0R0MW	KIT#p.L576P	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.L576P	敏感性增加	PMID: 17372901, 18448188	A KIT-mutated case of thymic carcinoma reported in the literature harbored an L576P mutation in exon 11. No follow-up of the patient was reported regarding therapeutics with specific inhibitors. However, this mutation has also previously been described in GIST and melanoma. It has been biologically characterized as being sensitive to imatinib but even more sensitive to sunitinib and dasatinib.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thymic Carcinoma	Case report	Sunitinib	
L02160	hotspot3D	D0R0MW	PHKG2#p.M260I	Sunitinib	Sunitinib (舒尼替尼)		PHKG2	p.M260I	耐药性增加	.			是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	cancer	prediction	Sunitinib	
L00568	Cancer Genome Interpreter	D0R0MW	RET#p.M918T	Sunitinib	Sunitinib (舒尼替尼)		RET	p.M918T	敏感性增加	PMID: 21470995	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thyroid Cancer	Pre-clinical	Sunitinib	Approved
L01312	COSMIC	D0R0MW	KIT#p.N822K	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.N822K	.	PMID: 21394667	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	.	Sunitinib	Approved
L01313	COSMIC	D0R0MW	KIT#p.N822K	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.N822K	.	PMID: 21394667	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	.	Sunitinib	Approved
L02158	hotspot3D	D0R0MW	PHKG2#p.V50M	Sunitinib	Sunitinib (舒尼替尼)		PHKG2	p.V50M	耐药性增加	.			是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	cancer	prediction	Sunitinib	
L01994	search pubmed	D0R0MW	KIT#p.V559A	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.V559A	敏感性增加	PMID: 22261812	three out of four evaluable patients with KIT mutations (two with L576P and one with W557G) responded to sunitinib in a recent study		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Melanoma	Case report	Sunitinib	
L01998	search pubmed	D0R0MW	KIT#p.V559D	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.V559D	敏感性增加	PMID: 22261812	three out of four evaluable patients with KIT mutations (two with L576P and one with W557G) responded to sunitinib in a recent study		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Melanoma	Case report	Sunitinib	
L00581	COSMIC	D0R0MW	BRAF#p.V600E	Sunitinib	Sunitinib (舒尼替尼)		BRAF	p.V600E	耐药性增加	PMID: 25182956	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	.	Sunitinib	Approved
L02132	hotspot3D	D0R0MW	KIT#p.V603D	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.V603D	耐药性增加	.			是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	cancer	prediction	Sunitinib	
L01990	search pubmed	D0R0MW	KIT#p.W557R	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.W557R	敏感性增加	PMID: 22261812	three out of four evaluable patients with KIT mutations (two with L576P and one with W557G) responded to sunitinib in a recent study		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Melanoma	Case report	Sunitinib	
L02016	search pubmed	D0R0MW	KIT#p.W557R	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.W557R	敏感性增加	PMID: 12960119	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thymic Carcinoma	Case report	Sunitinib	
L00228	Cancer Genome Interpreter	D0R0MW	KIT#p.Y553N	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.Y553N	敏感性增加	PMID: 23375402	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thymic Carcinoma	Case report	Sunitinib	Approved
L02014	search pubmed	D0R0MW	KIT#p.Y553N	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.Y553N	敏感性增加	PMID: 21969494	This mutation was described in a patient with a refractory metastatic thymic carcinoma tumor, exhibiting response to imatinib		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thymic Carcinoma	Case report	Sunitinib	
L01362	search pubmed	D0R0MW	KIT#p.Y823D	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.Y823D	耐药性增加	PMID: 24205792	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	.	Sunitinib	Approved
L01968	search pubmed	D0R0MW	KIT#p.577_579del	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.P577_D579 del	敏感性增加	PMID: 15201427	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thymic Carcinoma	Case report	Sunitinib	
L01967	search pubmed	D0R0MW	KIT#p.V560del	Sunitinib	Sunitinib (舒尼替尼)		KIT	p.V560 del	敏感性增加	PMID: 15201427	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thymic Carcinoma	Case report	Sunitinib	
L01436	Cancer Genome Interpreter	D0R0MW	CA9:over	Sunitinib	Sunitinib (舒尼替尼)		CA9	CA9 overexpression	敏感性增加	PMID: 24086736	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Renal cancer	Pre-clinical	Sunitinib	Approved
L01796	Cancer Genome Interpreter	D0R0MW	VEGFR2:over	Sunitinib	Sunitinib (舒尼替尼)		FLT1	FLT1 overexpression	敏感性增加	PMID: 24086736, 21478036	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Renal cancer	Pre-clinical	Sunitinib	Approved
L01797	Cancer Genome Interpreter	D0R0MW	VEGFR1:over	Sunitinib	Sunitinib (舒尼替尼)		FLT1	FLT1 overexpression	敏感性增加	PMID: 24086736, 21478036	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Renal cancer	Pre-clinical	Sunitinib	Approved
L01814	Cancer Genome Interpreter	D0R0MW	HIF1A:over	Sunitinib	Sunitinib (舒尼替尼)		HIF1A	HIF1A overexpression	敏感性增加	PMID: 24086736	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Renal cancer	Pre-clinical	Sunitinib	Approved
L01838	Cancer Genome Interpreter	D0R0MW	KIT:amp	Sunitinib	Sunitinib (舒尼替尼)		KIT	KIT amplification	敏感性降低	PMID: 22261812	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Cutaneous carcinoma	Early trials	Sunitinib	Approved
L01841	Cancer Genome Interpreter	D0R0MW	KIT:550-592	Sunitinib	Sunitinib (舒尼替尼)		KIT	KIT mutation in exon 11	耐药性增加	PMID: 18955458	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	Late trials	Sunitinib	Approved
L01839	Cancer Genome Interpreter	D0R0MW	KIT:788-828	Sunitinib	Sunitinib (舒尼替尼)		KIT	KIT mutation in exon 17	耐药性增加	PMID: 23840364	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	Pre-clinical	Sunitinib	Approved
L01840	Cancer Genome Interpreter	D0R0MW	KIT:550-592,627-664	Sunitinib	Sunitinib (舒尼替尼)		KIT	KIT mutation in exon 9,11,13,14 or 17	敏感性增加	PMID: 18421059, 21642685, 21690468, 22261812	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Cutaneous carcinoma	Late trials	Sunitinib	Approved
L01842	Cancer Genome Interpreter	D0R0MW	KIT:449-514,550-592,627-664,664-714,788-828	Sunitinib	Sunitinib (舒尼替尼)		KIT	KIT mutation in exon 9,11,13,14 or 17	敏感性增加	FDA	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	FDA guidelines	Sunitinib	Approved
L01843	Cancer Genome Interpreter	D0R0MW	KIT::wildtype:.	Sunitinib	Sunitinib (舒尼替尼)		KIT	KIT wildtype	敏感性增加	PMID: 18955458	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	Late trials	Sunitinib	Approved
L01851	Cancer Genome Interpreter	D0R0MW	MKI67:over	Sunitinib	Sunitinib (舒尼替尼)		MKI67	MKI67 overexpression	敏感性增加	PMID: 24086736	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Renal cancer	Pre-clinical	Sunitinib	Approved
L01664	Cancer Genome Interpreter	D0R0MW	PDGFRA:552-596,631-668,814-854	Sunitinib	Sunitinib (舒尼替尼)		PDGFRA	PDGFRA (552-596,631-668,814-854)	敏感性增加	NCCN guidelines	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	NCCN guidelines	Sunitinib	Approved
L01663	Cancer Genome Interpreter	D0R0MW	PDGFRA:over	Sunitinib	Sunitinib (舒尼替尼)		PDGFRA	PDGFRA overexpression	敏感性增加	PMID: 24086736	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Renal cancer	Pre-clinical	Sunitinib	Approved
L01665	Cancer Genome Interpreter	D0R0MW	PDGFRA::wildtype:.	Sunitinib	Sunitinib (舒尼替尼)		PDGFRA	PDGFRA wildtype	敏感性增加	PMID: 18955458	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Gastrointestinal Stromal Tumor	Late trials	Sunitinib	Approved
L01928	Cancer Genome Interpreter	D0R0MW	RET__.	Sunitinib	Sunitinib (舒尼替尼)		RET	RET fusion	敏感性增加	PMID: 28447912	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Lung adenocarcinoma	Early trials	Sunitinib	Approved
L01927	Cancer Genome Interpreter	D0R0MW	RET__TPCN1	Sunitinib	Sunitinib (舒尼替尼)		RET	RET-TPCN1 fusion	敏感性增加	PMID: 21470995	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Thyroid carcinoma	Pre-clinical	Sunitinib	Approved
L01960	Cancer Genome Interpreter	D0R0MW	VHL:.	Sunitinib	Sunitinib (舒尼替尼)		VHL	VHL oncogenic mutation	敏感性增加	PMID: 18635227	.		是	肾癌, 胃肠道间质瘤, 胰腺癌		NCT00373113: 乳腺癌, NCT00393939: 乳腺癌, NCT00435409: 乳腺癌, NCT00457691: 结直肠癌, NCT00676650: 前列腺癌, NCT00693992: 非小细胞肺癌, NCT00699374: 肝癌	Renal cancer	Pre-clinical	Sunitinib	Approved
L02120	hotspot3D	D06OMK	FKBP5#p.G59R	Tacrolimus	Tacrolimus (他克莫司)		FKBP5	p.G59R	耐药性增加	.			是	器官移植		.	cancer	prediction	Tacrolimus	
L02121	hotspot3D	D06OMK	FKBP5#p.I122M	Tacrolimus	Tacrolimus (他克莫司)		FKBP5	p.I122M	耐药性增加	.			是	器官移植		.	cancer	prediction	Tacrolimus	
L02122	hotspot3D	D06OMK	FKBP5#p.I87M	Tacrolimus	Tacrolimus (他克莫司)		FKBP5	p.I87M	耐药性增加	.			是	器官移植		.	cancer	prediction	Tacrolimus	
L02140	hotspot3D	D06OMK	FKBP5#p.P199L	Tacrolimus	Tacrolimus (他克莫司)		FKBP5	p.P199L	耐药性增加	.			是	器官移植		.	cancer	prediction	Tacrolimus	
L02123	hotspot3D	D06OMK	FKBP5#p.S309L	Tacrolimus	Tacrolimus (他克莫司)		FKBP5	p.S309L	耐药性增加	.			是	器官移植		.	cancer	prediction	Tacrolimus	
L01400	search pubmed	D02UFQ	ERBB2#p.T798M	Tak-285	Tak-285		ERBB2	p.T798M	耐药性增加	PMID: 26439378	.		.	.		.	Breast Cancer	.	Tak-285	Phase 1
L00063	Cancer Genome Interpreter	D07KSG	ESR1#p.E380Q	Tamoxifen	Tamoxifen		ESR1	p.E380Q	耐药性增加	PMID: 24185512, 24185510, 24398047	.		.	.		.	Breast Cancer	Early trials	Tamoxifen	Approved
L00064	Cancer Genome Interpreter	D07KSG	ESR1#p.P535H	Tamoxifen	Tamoxifen		ESR1	p.P535H	耐药性增加	PMID: 24185512, 24185510, 24398047	.		.	.		.	Breast Cancer	Early trials	Tamoxifen	Approved
L01611	Cancer Genome Interpreter	D07KSG	NF1:del	Tamoxifen	Tamoxifen		NF1	NF1 deletion	敏感性增加	PMID: 21075781	.		.	.		.	Malignant peripheral nerve sheat tumor	Pre-clinical	Tamoxifen	Approved
L01507	Cancer Genome Interpreter	D07KSG	ERBB2:norm,ESR1:over	Tamoxifen	Tamoxifen		ERBB2	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		.	.		.	Breast invasive carcinoma	FDA guidelines	Tamoxifen	Approved
L01776	Cancer Genome Interpreter	D07KSG	ERBB2:norm,ESR1:over	Tamoxifen	Tamoxifen		ESR1	ERBB2 expression + ESR1 overexpression	敏感性增加	FDA	.		.	.		.	Breast invasive carcinoma	FDA guidelines	Tamoxifen	Approved
L01775	Cancer Genome Interpreter	D07KSG	ESR1:E380Q,.537.,.538.,L536.,P535H	Tamoxifen	Tamoxifen		ESR1	ESR1 (E380Q,537,538,L536,P535H)	耐药性增加	PMID: 24185512, 24185510, 24398047	.		.	.		.	Breast invasive carcinoma	Early trials	Tamoxifen	Approved
L01612	Cancer Genome Interpreter	D07KSG	NF1:.	Tamoxifen	Tamoxifen		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 21075781	.		.	.		.	Malignant peripheral nerve sheat tumor	Pre-clinical	Tamoxifen	Approved
L01321	search pubmed	D04RLX	HSP90AA1#p.Y142N	Tariquidar	Tariquidar		HSP90AA1	p.Y142N	耐药性增加	PMID: 28032595	.		.	.		.	Breast Cancer	.	Tariquidar	Discontinued in Phase 2
L01405	search pubmed	D00EQL	EZH2#p.Y111D	Tazemetostat	Tazemetostat		EZH2	p.Y111D	耐药性增加	PMID: 26360609	.		.	.		.	Solid tumours	.	Tazemetostat	Phase 1/2
L01441	Cancer Genome Interpreter	D0F3SY	DPYD:.	Tegafur	Tegafur		DPYD	DPYD biallelic inactivation	毒性增加	PMID: 23988873	.		.	.		.	Cancer	CPIC guidelines	Tegafur	Approved
L01440	Cancer Genome Interpreter	D0F3SY	DPYD::consequence::splice_donor_variant:.	Tegafur	Tegafur		DPYD	DPYD splice donor variant	毒性增加	PMID: 23988873	.		.	.		.	Cancer	CPIC guidelines	Tegafur	Approved
L01705	Cancer Genome Interpreter	D0C8EU	ATM:.	Temozolomide	Temozolomide		ATM	ATM oncogenic mutation	敏感性增加	PMID: 23960094	.		.	.		.	Glioma	Pre-clinical	Temozolomide	Approved
L01425	Cancer Genome Interpreter	D0C8EU	ATR:.	Temozolomide	Temozolomide		ATR	ATR oncogenic mutation	敏感性增加	PMID: 23960094	.		.	.		.	Glioma	Pre-clinical	Temozolomide	Approved
L01856	Cancer Genome Interpreter	D0C8EU	MYC:amp	Temozolomide	Temozolomide		MYC	MYC amplification	敏感性增加	PMID: 27397505	.		.	.		.	Colorectal adenocarcinoma	Pre-clinical	Temozolomide	Approved
L02049	search pubmed	D0ES1Q	HER2 amplification	Temsirolimus	Temsirolimus		HER2	HER2 amplification	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		否	肾癌			Breast Cancer	In vitro	Temsirolimus	
L02037	search pubmed	D0ES1Q	PI3KCA oncogenic mutation	Temsirolimus	Temsirolimus		PI3KCA	PI3KCA oncogenic mutation	敏感性增加	PMID: 22932669, 23714559	Both PIK3CA and PTEN mutations were associated with increased MK-2206 sensitivity		否	肾癌			Breast Cancer	In vitro	Temsirolimus	
L02043	search pubmed	D0ES1Q	PI3KCA oncogenic mutation	Temsirolimus	Temsirolimus		PIK3CA	PI3KCA oncogenic mutation	敏感性增加	PMID: 20453058, 23714559	We found that cell lines harboring oncogenic mutations in PIK3CA, or HER2 amplification, were significantly more sensitive than cell lines without these alterations (P = 0.005 PIK3CA versus WT, P = 0.048 HER2 versus WT, Fig. 1C)		否	肾癌			Breast Cancer	In vitro	Temsirolimus	
L02040	search pubmed	D0ES1Q	PTEN loss (Loss of PTEN activity)	Temsirolimus	Temsirolimus		PTEN	PTEN loss (Loss of PTEN activity)	敏感性增加	PMID: 22932669, 23714559	Both PIK3CA and PTEN mutations were associated with increased MK-2206 sensitivity		否	肾癌			Breast Cancer	In vitro	Temsirolimus	
L01971	search pubmed	D0ES1Q	TSC1#p.E636fs	Temsirolimus	Temsirolimus (替西罗莫司)		TSC1	p.E636fs	敏感性增加	PMID: 22923433	.		否	肾癌			Bladder Cancer	Case report	Temsirolimus	
L01861	Cancer Genome Interpreter	D00GBP	NF2:del	Tensirolimus	Tensirolimus		NF2	NF2 deletion	敏感性增加	PMID: 25878190	.		.	.		.	Breast invasive carcinoma	Case report	Tensirolimus	.
L01476	Cancer Genome Interpreter	D00GBP	ERBB2:.	Tensirolimus	Tensirolimus		ERBB2	ERBB2 oncogenic mutation	敏感性增加	ESMO 2014 (abstr LBA39_PR)	.		.	.		.	Lung adenocarcinoma	Early trials	Tensirolimus	.
L01862	Cancer Genome Interpreter	D00GBP	NF2:.	Tensirolimus	Tensirolimus		NF2	NF2 oncogenic mutation	敏感性增加	PMID: 25878190	.		.	.		.	Breast invasive carcinoma	Case report	Tensirolimus	.
L01941	Cancer Genome Interpreter	D02ZXM	TPMT:.	Thioguanine	Thioguanine		TPMT	TPMT biallelic inactivation	毒性增加 (Myelosupression)	FDA	.		.	.		.	Cancer	FDA guidelines	Thioguanine	Approved
L01940	Cancer Genome Interpreter	D02ZXM	TPMT::consequence::splice_acceptor_variant:.	Thioguanine	Thioguanine		TPMT	TPMT splice acceptor variant	毒性增加 (Myelosupression)	FDA	.		.	.		.	Cancer	FDA guidelines	Thioguanine	Approved
L01649	Cancer Genome Interpreter	D10NPS	NF1:del	Tipifarnib	Tipifarnib		NF1	NF1 deletion	敏感性降低	PMID: 24500418	.		.	.		.	Plexiform neurofibroma	Early trials	Tipifarnib	Clinical Trials
L01619	Cancer Genome Interpreter	D09NPS	NF1:.	Tipifarnib	Tipifarnib		NF1	NF1 oncogenic mutation	敏感性降低	PMID: 24500418	.		.	.		.	Plexiform neurofibroma	Early trials	Tipifarnib	Clinical Trials
L01363	search pubmed	D04XVN	MAP2K2#p.C125S	Trametinib	Trametinib (曲美替尼)		MAP2K2	p.C125S	耐药性增加	PMID: 24265153	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous Melanoma	.	Trametinib	Approved
L00068	Cancer Genome Interpreter	D04XVN	BRAF#p.K601R	Trametinib	Trametinib (曲美替尼)		BRAF	p.K601R	敏感性增加	PMID: 23248257, 22805292, 23248257	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous Melanoma	Case report	Trametinib	Approved
L01364	search pubmed	D04XVN	MAP2K2#p.L46F	Trametinib	Trametinib (曲美替尼)		MAP2K2	p.L46F	耐药性增加	PMID: 24265153	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous Melanoma	.	Trametinib	Approved
L00069	Cancer Genome Interpreter	D04XVN	BRAF#p.L597R	Trametinib	Trametinib (曲美替尼)		BRAF	p.L597R	敏感性增加	PMID: 23248257, 22805292, 23248257	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous Melanoma	Case report	Trametinib	Approved
L01365	search pubmed	D04XVN	MAP2K2#p.N126D	Trametinib	Trametinib (曲美替尼)		MAP2K2	p.N126D	耐药性增加	PMID: 24265153	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous Melanoma	.	Trametinib	Approved
L00493	Cancer Genome Interpreter	D04XVN	MAP2K1#p.Q56P	Trametinib	Trametinib (曲美替尼)		MAP2K1	p.Q56P	敏感性增加	PMID: 26582713	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cancer	Pre-clinical	Trametinib	Approved
L01366	search pubmed	D04XVN	MAP2K2#p.V35M	Trametinib	Trametinib (曲美替尼)		MAP2K2	p.V35M	耐药性增加	PMID: 24265153	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous Melanoma	.	Trametinib	Approved
L00393	Cancer Genome Interpreter	D04XVN	BRAF#p.V600E	Trametinib	Trametinib (曲美替尼)		BRAF	p.V600E	敏感性增加	FDA	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous Melanoma	FDA guidelines	Trametinib	Approved
L00405	Cancer Genome Interpreter	D04XVN	BRAF#p.V600K	Trametinib	Trametinib (曲美替尼)		BRAF	p.V600K	敏感性增加	FDA	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous Melanoma	FDA guidelines	Trametinib	Approved
L00070	Cancer Genome Interpreter	D04XVN	BRAF#p.V600R	Trametinib	Trametinib (曲美替尼)		BRAF	p.V600R	敏感性增加	PMID: 23248257, 22805292, 23248257	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous Melanoma	Case report	Trametinib	Approved
L01605	Cancer Genome Interpreter	D04XVN	NF1:del	Trametinib	Trametinib (曲美替尼)		NF1	NF1 deletion	敏感性增加	PMID: 26936308	.		否	黑色素瘤		NCT02101788: 卵巢癌	Glioma	Case report	Trametinib	Approved
L01606	Cancer Genome Interpreter	D04XVN	NF1:del	Trametinib	Trametinib (曲美替尼)		NF1	NF1 deletion	敏感性增加	PMID: 24576830, 2524381	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous carcinoma	Pre-clinical	Trametinib	Approved
L01607	Cancer Genome Interpreter	D04XVN	NF1:del	Trametinib	Trametinib (曲美替尼)		NF1	NF1 deletion	敏感性降低	PMID: 26325560	.		否	黑色素瘤		NCT02101788: 卵巢癌	Osteosarcoma	Case report	Trametinib	Approved
L01714	Cancer Genome Interpreter	D04XVN	BRAF__.	Trametinib	Trametinib (曲美替尼)		BRAF	BRAF fusion	敏感性增加	PMID: 24727320, 24345920, 20526349	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous carcinoma, Lung adenocarcinoma, Prostate adenocarcinoma	Pre-clinical	Trametinib	Approved
L01555	Cancer Genome Interpreter	D04XVN	KRAS:.	Trametinib	Trametinib (曲美替尼)		KRAS	KRAS oncogenic mutation	敏感性增加	PMID: 27338794	.		否	黑色素瘤		NCT02101788: 卵巢癌	Lung adenocarcinoma	Pre-clinical	Trametinib	Approved
L01608	Cancer Genome Interpreter	D04XVN	NF1:.	Trametinib	Trametinib (曲美替尼)		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 26936308	.		否	黑色素瘤		NCT02101788: 卵巢癌	Glioma	Case report	Trametinib	Approved
L01609	Cancer Genome Interpreter	D04XVN	NF1:.	Trametinib	Trametinib (曲美替尼)		NF1	NF1 oncogenic mutation	敏感性增加	PMID: 24576830, 2524381	.		否	黑色素瘤		NCT02101788: 卵巢癌	Cutaneous carcinoma	Pre-clinical	Trametinib	Approved
L01610	Cancer Genome Interpreter	D04XVN	NF1:.	Trametinib	Trametinib (曲美替尼)		NF1	NF1 oncogenic mutation	敏感性降低	PMID: 26325560	.		否	黑色素瘤		NCT02101788: 卵巢癌	Osteosarcoma	Case report	Trametinib	Approved
L01682	Cancer Genome Interpreter	D04XVN	PRKCH:amp,ABL1__BCR	Trametinib	Trametinib (曲美替尼)		ABL1	PRKCH amplification + ABL1-BCR fusion	敏感性增加	PMID: 25186176	.		否	黑色素瘤		NCT02101788: 卵巢癌	Chronic myeloid leukemia	Pre-clinical	Trametinib	Approved
L01900	Cancer Genome Interpreter	D04XVN	PRKCH:amp,ABL1__BCR	Trametinib	Trametinib (曲美替尼)		PRKCH	PRKCH amplification + ABL1-BCR fusion	敏感性增加	PMID: 25186176	.		否	黑色素瘤		NCT02101788: 卵巢癌	Chronic myeloid leukemia	Pre-clinical	Trametinib	Approved
L00484	Cancer Genome Interpreter	D04WFL	ERBB2#p.C311R	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.C311R	敏感性增加	PMID: 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Cancer	Pre-clinical	Trastuzumab	Approved
L00533	Cancer Genome Interpreter	D04WFL	ERBB2#p.C311R	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.C311R	敏感性增加	PMID: 23220880, 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast Cancer	Pre-clinical	Trastuzumab	Approved
L00485	Cancer Genome Interpreter	D04WFL	ERBB2#p.C334S	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.C334S	敏感性增加	PMID: 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Cancer	Pre-clinical	Trastuzumab	Approved
L00534	Cancer Genome Interpreter	D04WFL	ERBB2#p.D769H	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.D769H	敏感性增加	PMID: 23220880, 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast Cancer	Pre-clinical	Trastuzumab	Approved
L00535	Cancer Genome Interpreter	D04WFL	ERBB2#p.D769Y	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.D769Y	敏感性增加	PMID: 23220880, 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast Cancer	Pre-clinical	Trastuzumab	Approved
L00486	Cancer Genome Interpreter	D04WFL	ERBB2#p.E321G	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.E321G	敏感性增加	PMID: 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Cancer	Pre-clinical	Trastuzumab	Approved
L00490	Cancer Genome Interpreter	D04WFL	ERBB3#p.G284R	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB3	p.G284R	敏感性增加	PMID: 23680147	.		是	乳腺癌, 胃癌或食管胃结合部癌			Cancer	Pre-clinical	Trastuzumab	Approved
L00487	Cancer Genome Interpreter	D04WFL	ERBB2#p.G309E	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.G309E	敏感性增加	PMID: 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Cancer	Pre-clinical	Trastuzumab	Approved
L00536	Cancer Genome Interpreter	D04WFL	ERBB2#p.G309E	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.G309E	敏感性增加	PMID: 23220880, 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast Cancer	Pre-clinical	Trastuzumab	Approved
L00216	Cancer Genome Interpreter	D04WFL	ERBB2#p.G776L	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.G776L	敏感性增加	PMID: 16775247	.		是	乳腺癌, 胃癌或食管胃结合部癌			Lung Adenocarcinoma	Case report	Trastuzumab	Approved
L00492	Cancer Genome Interpreter	D04WFL	ERBB3#p.P262H	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB3	p.P262H	敏感性增加	PMID: 23680147	.		是	乳腺癌, 胃癌或食管胃结合部癌			Cancer	Pre-clinical	Trastuzumab	Approved
L00491	Cancer Genome Interpreter	D04WFL	ERBB3#p.Q809R	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB3	p.Q809R	敏感性增加	PMID: 23680147	.		是	乳腺癌, 胃癌或食管胃结合部癌			Cancer	Pre-clinical	Trastuzumab	Approved
L01367	search pubmed	D04WFL	AKT3#p.R247C	Trastuzumab	Trastuzumab (曲妥珠单抗)		AKT3	p.R247C	耐药性增加	PMID: 26645663	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast Cancer	.	Trastuzumab	Approved
L00537	Cancer Genome Interpreter	D04WFL	ERBB2#p.R896C	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.R896C	敏感性增加	PMID: 23220880, 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast Cancer	Pre-clinical	Trastuzumab	Approved
L00488	Cancer Genome Interpreter	D04WFL	ERBB2#p.S310F	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.S310F	敏感性增加	PMID: 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Cancer	Pre-clinical	Trastuzumab	Approved
L00538	Cancer Genome Interpreter	D04WFL	ERBB2#p.S310F	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.S310F	敏感性增加	PMID: 23220880, 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast Cancer	Pre-clinical	Trastuzumab	Approved
L00489	Cancer Genome Interpreter	D04WFL	ERBB2#p.S310Y	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.S310Y	敏感性增加	PMID: 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Cancer	Pre-clinical	Trastuzumab	Approved
L00539	Cancer Genome Interpreter	D04WFL	ERBB2#p.S310Y	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	p.S310Y	敏感性增加	PMID: 23220880, 22908275	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast Cancer	Pre-clinical	Trastuzumab	Approved
L01498	Cancer Genome Interpreter	D04WFL	ERBB2::consequence::inframe_insertion:A775YVMA,::inframe_insertion:G776VC	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	敏感性增加	ASCO 2017 (abstr 8510)	.		是	乳腺癌, 胃癌或食管胃结合部癌			Lung cancer	Early trials	Trastuzumab	FDA approved
L01692	Cancer Genome Interpreter	D04WFL	ARID1A:amp,ANXA1:over	Trastuzumab	Trastuzumab (曲妥珠单抗)		ANXA1	ARID1A amplification + ANXA1 overexpression	耐药性增加	PMID: 27172896	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01701	Cancer Genome Interpreter	D04WFL	ARID1A:amp,ANXA1:over	Trastuzumab	Trastuzumab (曲妥珠单抗)		ARID1A	ARID1A amplification + ANXA1 overexpression	耐药性增加	PMID: 27172896	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01693	Cancer Genome Interpreter	D04WFL	ARID1A:.,ANXA1:over	Trastuzumab	Trastuzumab (曲妥珠单抗)		ANXA1	ARID1A oncogenic mutation + ANXA1 overexpression	耐药性增加	PMID: 27172896	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01702	Cancer Genome Interpreter	D04WFL	ARID1A:.,ANXA1:over	Trastuzumab	Trastuzumab (曲妥珠单抗)		ARID1A	ARID1A oncogenic mutation + ANXA1 overexpression	耐药性增加	PMID: 27172896	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01487	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	FDA	.		是	乳腺癌, 胃癌或食管胃结合部癌			Gastroesophageal junction adenocarcinoma, Stomach cancer	FDA guidelines	Trastuzumab	FDA approved
L01488	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	FDA	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	FDA guidelines	Trastuzumab	FDA approved
L01489	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	PMID: 26022204	.		是	乳腺癌, 胃癌或食管胃结合部癌			Billiary tract cancer	Early trials	Trastuzumab	FDA approved
L01490	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性降低	PMID: 26099744, 19840887	.		是	乳腺癌, 胃癌或食管胃结合部癌			Endometrial cancer	Early trials	Trastuzumab	FDA approved
L01491	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	PMID: 21380780	.		是	乳腺癌, 胃癌或食管胃结合部癌			Head and neck cancer	Case report	Trastuzumab	FDA approved
L01492	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	PMID: 20003286, 12525520	.		是	乳腺癌, 胃癌或食管胃结合部癌			Ovarian cancer	Early trials	Trastuzumab	FDA approved
L01493	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	PMID: 21107682, 20975068	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01494	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	PMID: 21558407	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01495	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	ASCO 2015 (abstr 3508),NCT01104571,EBCC10	.		是	乳腺癌, 胃癌或食管胃结合部癌			Colorectal adenocarcinoma	Late trials	Trastuzumab	FDA approved
L01496	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	PMID: 25294905	.		是	乳腺癌, 胃癌或食管胃结合部癌			Endometrial cancer	Pre-clinical	Trastuzumab	FDA approved
L01497	Cancer Genome Interpreter	D04WFL	ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 amplification	敏感性增加	http: //ascopubs.org/doi/full/10.1200/PO.16.00055	.		是	乳腺癌, 胃癌或食管胃结合部癌			Colorectal adenocarcinoma	Case report	Trastuzumab	FDA approved
L01484	Cancer Genome Interpreter	D04WFL	ERBB2:over	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 overexpression	敏感性增加	ASCO 2013 (abstr 2605), 26104654	.		是	乳腺癌, 胃癌或食管胃结合部癌			Solid tumors	Early trials	Trastuzumab	FDA approved
L01485	Cancer Genome Interpreter	D04WFL	ERBB2:over	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 overexpression	敏感性增加	FDA	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	FDA guidelines	Trastuzumab	Approved
L01486	Cancer Genome Interpreter	D04WFL	ERBB2:over	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 overexpression	敏感性增加	FDA	.		是	乳腺癌, 胃癌或食管胃结合部癌			Gastroesophageal junction adenocarcinoma, Stomach cancer	FDA guidelines	Trastuzumab	Approved
L01499	Cancer Genome Interpreter	D04WFL	ERBB2::consequence::inframe_insertion:775-881	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 proximal exon 20	敏感性增加	PMID: 26598547	.		是	乳腺癌, 胃癌或食管胃结合部癌			Lung adenocarcinoma	Early trials	Trastuzumab	FDA approved
L01500	Cancer Genome Interpreter	D04WFL	ERBB2::consequence::inframe_insertion:775-881	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	ERBB2 proximal exon 20	敏感性增加	PMID: 26598547,ASCO 2017 (abstr 9071)	.		是	乳腺癌, 胃癌或食管胃结合部癌			Lung adenocarcinoma	Early trials	Trastuzumab	FDA approved
L01483	Cancer Genome Interpreter	D04WFL	HGF:amp,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	HGF amplification + ERBB2 amplification	耐药性增加	PMID: 22850551	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01812	Cancer Genome Interpreter	D04WFL	HGF:amp,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		HGF	HGF amplification + ERBB2 amplification	耐药性增加	PMID: 22850551	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01554	Cancer Genome Interpreter	D04WFL	KRAS:.	Trastuzumab	Trastuzumab (曲妥珠单抗)		KRAS	KRAS oncogenic mutation	耐药性增加	ASCO 2015 (abstr 3508),NCT01104571,EBCC10	.		是	乳腺癌, 胃癌或食管胃结合部癌			Colorectal adenocarcinoma	Late trials	Trastuzumab	FDA approved
L01480	Cancer Genome Interpreter	D04WFL	MET:amp,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	MET amplification + ERBB2 amplification	敏感性增加	PMID: 26432108	.		是	乳腺癌, 胃癌或食管胃结合部癌			Stomach cancer	Case report	Trastuzumab	FDA approved
L01481	Cancer Genome Interpreter	D04WFL	MET:amp,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	MET amplification + ERBB2 amplification	耐药性增加	PMID: 22850551	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01482	Cancer Genome Interpreter	D04WFL	MET:amp,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	MET amplification + ERBB2 amplification	耐药性增加	PMID: 22850551, PMID: 26432108	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma, Stomach cancer	Early trials	Trastuzumab	FDA approved
L01577	Cancer Genome Interpreter	D04WFL	MET:amp,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		MET	MET amplification + ERBB2 amplification	敏感性增加	PMID: 26432108	.		是	乳腺癌, 胃癌或食管胃结合部癌			Stomach cancer	Case report	Trastuzumab	FDA approved
L01578	Cancer Genome Interpreter	D04WFL	MET:amp,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		MET	MET amplification + ERBB2 amplification	耐药性增加	PMID: 22850551	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Early trials	Trastuzumab	FDA approved
L01579	Cancer Genome Interpreter	D04WFL	MET:amp,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		MET	MET amplification + ERBB2 amplification	耐药性增加	PMID: 22850551, PMID: 26432108	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma, Stomach cancer	Early trials	Trastuzumab	FDA approved
L01479	Cancer Genome Interpreter	D04WFL	PIK3CA:.,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	PIK3CA oncogenic mutation + ERBB2 amplification	敏感性增加	PMID: 27091708	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Late trials	Trastuzumab	FDA approved
L01894	Cancer Genome Interpreter	D04WFL	PIK3CA:.,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		PIK3CA	PIK3CA oncogenic mutation + ERBB2 amplification	敏感性增加	PMID: 27091708	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Late trials	Trastuzumab	FDA approved
L01478	Cancer Genome Interpreter	D04WFL	PTEN:.,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		ERBB2	PTEN oncogenic mutation + ERBB2 amplification	敏感性增加	PMID: 27091708	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Late trials	Trastuzumab	FDA approved
L01906	Cancer Genome Interpreter	D04WFL	PTEN:.,ERBB2:amp	Trastuzumab	Trastuzumab (曲妥珠单抗)		PTEN	PTEN oncogenic mutation + ERBB2 amplification	敏感性增加	PMID: 27091708	.		是	乳腺癌, 胃癌或食管胃结合部癌			Breast invasive carcinoma	Late trials	Trastuzumab	FDA approved
L01399	search pubmed	D0N7XI	MAP2K2#p.Q60P	Tremetinib	Tremetinib		MAP2K2	p.Q60P	耐药性增加	PMID: 24265154	.		否	黑色素瘤		.	Cutaneous Melanoma	.	Tremetinib	Approved
L01898	Cancer Genome Interpreter	D02DGU	PML__RARA	Tretinoin	Tretinoin		PML	PML-RARA fusion	敏感性增加	FDA	.		.	.		.	Acute promyelocytic leukaemia	FDA guidelines	Tretinoin	Approved
L01899	Cancer Genome Interpreter	D02DGU	PML__RARA	Tretinoin	Tretinoin		PML	PML-RARA fusion	敏感性增加	FDA	.		.	.		.	Acute Myeloid Leukemia	FDA guidelines	Tretinoin	Approved
L01153	COSMIC	D0E0GZ	ABL1#p.?	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.?	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01084	COSMIC	D0E0GZ	ABL1#p.A399T	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.A399T	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01099	COSMIC	D0E0GZ	ABL1#p.D276G	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.D276G	.	PMID: 21895409	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01126	COSMIC	D0E0GZ	ABL1#p.D325G	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.D325G	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01114	COSMIC	D0E0GZ	ABL1#p.D444Y	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.D444Y	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01115	COSMIC	D0E0GZ	ABL1#p.E255K	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.E255K	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01127	COSMIC	D0E0GZ	ABL1#p.E255K	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.E255K	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01085	COSMIC	D0E0GZ	ABL1#p.E255V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.E255V	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01128	COSMIC	D0E0GZ	ABL1#p.E255V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.E255V	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01086	COSMIC	D0E0GZ	ABL1#p.E282K	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.E282K	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01108	COSMIC	D0E0GZ	ABL1#p.E355G	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.E355G	.	PMID: 19260121	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01116	COSMIC	D0E0GZ	ABL1#p.E355G	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.E355G	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01129	COSMIC	D0E0GZ	ABL1#p.E355G	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.E355G	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01130	COSMIC	D0E0GZ	ABL1#p.E459K	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.E459K	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01087	COSMIC	D0E0GZ	ABL1#p.F311L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F311L	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01131	COSMIC	D0E0GZ	ABL1#p.F311L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F311L	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01132	COSMIC	D0E0GZ	ABL1#p.F317C	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F317C	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01133	COSMIC	D0E0GZ	ABL1#p.F317I	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F317I	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01080	COSMIC	D0E0GZ	ABL1#p.F317L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F317L	.	PMID: 22870928	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01088	COSMIC	D0E0GZ	ABL1#p.F317L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F317L	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01100	COSMIC	D0E0GZ	ABL1#p.F317L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F317L	.	PMID: 21895409	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01109	COSMIC	D0E0GZ	ABL1#p.F317L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F317L	.	PMID: 19260121	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01117	COSMIC	D0E0GZ	ABL1#p.F317L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F317L	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01134	COSMIC	D0E0GZ	ABL1#p.F317L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F317L	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01135	COSMIC	D0E0GZ	ABL1#p.F317V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F317V	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01136	COSMIC	D0E0GZ	ABL1#p.F359C	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F359C	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01089	COSMIC	D0E0GZ	ABL1#p.F359I	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F359I	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01110	COSMIC	D0E0GZ	ABL1#p.F359I	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F359I	.	PMID: 19260121	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01101	COSMIC	D0E0GZ	ABL1#p.F359V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F359V	.	PMID: 21895409	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01137	COSMIC	D0E0GZ	ABL1#p.F359V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.F359V	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01081	COSMIC	D0E0GZ	ABL1#p.G250E	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.G250E	.	PMID: 22870928	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01090	COSMIC	D0E0GZ	ABL1#p.G250E	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.G250E	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01102	COSMIC	D0E0GZ	ABL1#p.G250E	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.G250E	.	PMID: 21895409	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01111	COSMIC	D0E0GZ	ABL1#p.G250E	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.G250E	.	PMID: 19260121	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01118	COSMIC	D0E0GZ	ABL1#p.G250E	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.G250E	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01138	COSMIC	D0E0GZ	ABL1#p.G250E	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.G250E	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01091	COSMIC	D0E0GZ	ABL1#p.H396R	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.H396R	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01139	COSMIC	D0E0GZ	ABL1#p.H396R	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.H396R	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01140	COSMIC	D0E0GZ	ABL1#p.L248V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.L248V	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01119	COSMIC	D0E0GZ	ABL1#p.L273M	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.L273M	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01141	COSMIC	D0E0GZ	ABL1#p.L298V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.L298V	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01092	COSMIC	D0E0GZ	ABL1#p.L384M	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.L384M	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01142	COSMIC	D0E0GZ	ABL1#p.L384M	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.L384M	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01103	COSMIC	D0E0GZ	ABL1#p.L387M	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.L387M	.	PMID: 21895409	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01143	COSMIC	D0E0GZ	ABL1#p.L387M	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.L387M	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01093	COSMIC	D0E0GZ	ABL1#p.M244V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.M244V	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01104	COSMIC	D0E0GZ	ABL1#p.M244V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.M244V	.	PMID: 21895409	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01144	COSMIC	D0E0GZ	ABL1#p.M244V	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.M244V	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01145	COSMIC	D0E0GZ	ABL1#p.M351T	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.M351T	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01105	COSMIC	D0E0GZ	ABL1#p.M388L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.M388L	.	PMID: 21895409	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01094	COSMIC	D0E0GZ	ABL1#p.Q252H	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.Q252H	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01146	COSMIC	D0E0GZ	ABL1#p.Q252H	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.Q252H	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01095	COSMIC	D0E0GZ	ABL1#p.R220H	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.R220H	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01147	COSMIC	D0E0GZ	ABL1#p.T315A	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.T315A	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01082	COSMIC	D0E0GZ	ABL1#p.T315I	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.T315I	.	PMID: 22870928	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01096	COSMIC	D0E0GZ	ABL1#p.T315I	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.T315I	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01106	COSMIC	D0E0GZ	ABL1#p.T315I	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.T315I	.	PMID: 21895409	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01120	COSMIC	D0E0GZ	ABL1#p.T315I	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.T315I	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01148	COSMIC	D0E0GZ	ABL1#p.T315I	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.T315I	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01112	COSMIC	D0E0GZ	ABL1#p.T495R	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.T495R	.	PMID: 19260121	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L00600	COSMIC	D0E0GZ	EGFR#p.T790M	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		EGFR	p.T790M	.	PMID: 22773810	.		.	.		.	Non-small Cell Lung Cancer	.	Tyrosine kinase inhibitor - NS	Investigative
L00601	COSMIC	D0E0GZ	EGFR#p.T790M	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		EGFR	p.T790M	.	PMID: 25939061	.		.	.		.	Non-small Cell Lung Cancer	.	Tyrosine kinase inhibitor - NS	Investigative
L00602	COSMIC	D0E0GZ	EGFR#p.T790M	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		EGFR	p.T790M	.	PMID: 23542356	.		.	.		.	Non-small Cell Lung Cancer	.	Tyrosine kinase inhibitor - NS	Investigative
L00603	COSMIC	D0E0GZ	EGFR#p.T790M	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		EGFR	p.T790M	.	PMID: 24035188	.		.	.		.	Non-small Cell Lung Cancer	.	Tyrosine kinase inhibitor - NS	Investigative
L01149	COSMIC	D0E0GZ	ABL1#p.V268A	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.V268A	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01097	COSMIC	D0E0GZ	ABL1#p.V289A	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.V289A	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01083	COSMIC	D0E0GZ	ABL1#p.V299L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.V299L	.	PMID: 22870928	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01098	COSMIC	D0E0GZ	ABL1#p.V299L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.V299L	.	PMID: 21961412	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01113	COSMIC	D0E0GZ	ABL1#p.V299L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.V299L	.	PMID: 19260121	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01121	COSMIC	D0E0GZ	ABL1#p.V299L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.V299L	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01150	COSMIC	D0E0GZ	ABL1#p.V299L	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.V299L	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01151	COSMIC	D0E0GZ	ABL1#p.V338F	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.V338F	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01122	COSMIC	D0E0GZ	ABL1#p.V379I	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.V379I	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01123	COSMIC	D0E0GZ	ABL1#p.Y253F	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.Y253F	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01107	COSMIC	D0E0GZ	ABL1#p.Y253H	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.Y253H	.	PMID: 21895409	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01124	COSMIC	D0E0GZ	ABL1#p.Y253H	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.Y253H	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01152	COSMIC	D0E0GZ	ABL1#p.Y253H	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.Y253H	.	PMID: 23223358	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01125	COSMIC	D0E0GZ	ABL1#p.Y353H	Tyrosine kinase inhibitor - NS	Tyrosine kinase inhibitor - NS (酪氨酸激酶抑制剂)		ABL1	p.Y353H	.	PMID: 20673586	.		.	.		.	Chronic Myeloid Leukaemia	.	Tyrosine kinase inhibitor - NS	Investigative
L01915	Cancer Genome Interpreter	D0GD8Y	RAF1__.	U0126	U0126		RAF1	RAF1 fusion	敏感性增加	PMID: 20526349	.		.	.		.	Prostate adenocarcinoma	Pre-clinical	U0126	Approved
L00035	Cancer Genome Interpreter	D0G6QF	RET#p.C634W	Vandetanib	Vandetanib (凡德他尼)		RET	p.C634W	敏感性增加	PMID: 20065189, 22025146	.		否	甲状腺癌			Thyroid Cancer	FDA guidelines	Vandetanib	Approved
L00036	Cancer Genome Interpreter	D0G6QF	RET#p.M918T	Vandetanib	Vandetanib (凡德他尼)		RET	p.M918T	敏感性增加	PMID: 20065189, 22025146	.		否	甲状腺癌			Thyroid Cancer	FDA guidelines	Vandetanib	Approved
L02012	search pubmed	D0G6QF	RET#p.M918T	Vandetanib	Vandetanib (凡德他尼)		RET	p.M918T	敏感性增加	PMID: 20368568	Improved Progression-free survival		否	甲状腺癌			Thyroid Cancer	Case report	Vandetanib	
L00502	Cancer Genome Interpreter	D0G6QF	ABL1#p.V299L	Vandetanib	Vandetanib (凡德他尼)		ABL1	p.V299L	敏感性增加	PMID: 26924578	.		否	甲状腺癌			Cancer	Pre-clinical	Vandetanib	Approved
L00034	Cancer Genome Interpreter	D0G6QF	BRAF#p.V600E	Vandetanib	Vandetanib (凡德他尼)		BRAF	p.V600E	敏感性增加	PMID: 20065189, 22025146	.		否	甲状腺癌			Thyroid Cancer	FDA guidelines	Vandetanib	Approved
L01371	search pubmed	D0G6QF	RET#p.V804M	Vandetanib	Vandetanib (凡德他尼)		RET	p.V804M	耐药性增加	PMID: 24336963	.		否	甲状腺癌			Cancer	.	Vandetanib	Approved
L01923	Cancer Genome Interpreter	D0G6QF	RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	Vandetanib	Vandetanib (凡德他尼)		RET	RET (618,620,634,768,791,891,918,C634W,M918T)	敏感性增加	PMID: 20065189, 22025146	.		否	甲状腺癌			Thyroid carcinoma	FDA guidelines	Vandetanib	Approved
L01922	Cancer Genome Interpreter	D0G6QF	RET__.	Vandetanib	Vandetanib (凡德他尼)		RET	RET fusion	敏感性增加	PMID: 28447912	.		否	甲状腺癌			Lung adenocarcinoma	Early trials	Vandetanib	Approved
L01921	Cancer Genome Interpreter	D0G6QF	RET__TPCN1	Vandetanib	Vandetanib (凡德他尼)		RET	RET-TPCN1 fusion	敏感性增加	PMID: 21470995	.		否	甲状腺癌			Thyroid carcinoma	Pre-clinical	Vandetanib	Approved
L00138	Cancer Genome Interpreter	.	KDR#p.A1065T	VEGFR inhibitors	VEGFR 抑制剂		KDR	p.A1065T	敏感性增加	PMID: 24569783	.		.	.		.	Cancer	Pre-clinical	VEGFR inhibitors	.
L01732	Cancer Genome Interpreter	.	BRCA1:.	Veliparib	Veliparib		BRCA1	BRCA1 oncogenic mutation	敏感性增加	PMID: 26801247	.		.	.		.	Breast invasive carcinoma	Early trials	Veliparib	.
L01429	Cancer Genome Interpreter	.	BRCA2:.	Veliparib	Veliparib		BRCA2	BRCA2 oncogenic mutation	敏感性增加	PMID: 26801247	.		.	.		.	Breast invasive carcinoma	Early trials	Veliparib	.
L00232	Cancer Genome Interpreter	D0Y9EW	MAP2K1#p.E203K	Vemurafenib	Vemurafenib (维莫非尼)		MAP2K1	p.E203K	耐药性增加	PMID: 23569304	.		是	黑色素瘤			Cutaneous Melanoma	Case report	Vemurafenib	Approved
L01372	search pubmed	D0Y9EW	PIK3CA#p.E545*	Vemurafenib	Vemurafenib (维莫非尼)		PIK3CA	p.E545*	耐药性增加	PMID: 24265155	.		是	黑色素瘤			Melanoma	.	Vemurafenib	Approved
L00233	Cancer Genome Interpreter	D0Y9EW	MAP2K1#p.K57E	Vemurafenib	Vemurafenib (维莫非尼)		MAP2K1	p.K57E	耐药性增加	PMID: 23569304	.		是	黑色素瘤			Cutaneous Melanoma	Case report	Vemurafenib	Approved
L00234	Cancer Genome Interpreter	D0Y9EW	MAP2K1#p.Q56P	Vemurafenib	Vemurafenib (维莫非尼)		MAP2K1	p.Q56P	耐药性增加	PMID: 23569304	.		是	黑色素瘤			Cutaneous Melanoma	Case report	Vemurafenib	Approved
L01373	search pubmed	D0Y9EW	MAP2K2#p.Q60P	Vemurafenib	Vemurafenib (维莫非尼)		MAP2K2	p.Q60P	耐药性增加	PMID: 24265154	.		是	黑色素瘤			Melanoma	.	Vemurafenib	Approved
L02023	search pubmed	D0Y9EW	NRAS#p.Q61K	Vemurafenib	Vemurafenib (维莫非尼)		NRAS	p.Q61K	耐药性增加	PMID: 22194965	In a preclinical study, melanoma cell lines with both BRAF V600E mutations and NRAS Q61K mutations were resistant to BRAF inhibitor vemurafenib but sensitive to MEK inhibitor selumetinib.		是	黑色素瘤			Melanoma	Case report	Vemurafenib	
L00435	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600D	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600D	敏感性增加	NCCN	.		是	黑色素瘤			Cutaneous Melanoma	NCCN guidelines	Vemurafenib	Approved
L00464	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600D	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600D	敏感性增加	PMID: 26287849	.		是	黑色素瘤			Erdheim-chester Histiocytosis, Lagerhans Cell Histiocytosis, Non-small Cell  Lung Cancer	NCCN guidelines	Vemurafenib	Approved
L00193	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600E	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600E	敏感性增加	PMID: 22743296, 22621641, 23612012	The BRAF inhibitor, vemurafenib, has shown up to 78% objective response rates in melanoma patients harboring the BRAF-V600E mutation but not in patients lacking the mutation.		是	黑色素瘤			Hairy Cell Leukaemia, Lung Adenocarcinoma, Myeloma	Case report	Vemurafenib	Approved
L00259	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600E	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600E	敏感性增加	PMID: 22586120	The BRAF inhibitor, vemurafenib, has shown up to 78% objective response rates in melanoma patients harboring the BRAF-V600E mutation but not in patients lacking the mutation.		是	黑色素瘤			Malignant Astrocytoma	Early trials	Vemurafenib	Approved
L00260	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600E	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600E	敏感性增加	PMID: 22608338, 20818844, 23489023	The BRAF inhibitor, vemurafenib, has shown up to 78% objective response rates in melanoma patients harboring the BRAF-V600E mutation but not in patients lacking the mutation.		是	黑色素瘤			Thyroid Cancer	Early trials	Vemurafenib	Approved
L00396	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600E	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600E	敏感性增加	FDA	The BRAF inhibitor, vemurafenib, has shown up to 78% objective response rates in melanoma patients harboring the BRAF-V600E mutation but not in patients lacking the mutation.		是	黑色素瘤			Cutaneous Melanoma	FDA guidelines	Vemurafenib	Approved
L00416	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600E	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600E	敏感性增加	PMID: 26287849	The BRAF inhibitor, vemurafenib, has shown up to 78% objective response rates in melanoma patients harboring the BRAF-V600E mutation but not in patients lacking the mutation.		是	黑色素瘤			Erdheim-chester Histiocytosis, Lagerhans Cell Histiocytosis, Non-small Cell  Lung Cancer	NCCN guidelines	Vemurafenib	Approved
L00436	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600G	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600G	敏感性增加	NCCN	.		是	黑色素瘤			Cutaneous Melanoma	NCCN guidelines	Vemurafenib	Approved
L00465	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600G	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600G	敏感性增加	PMID: 26287849	.		是	黑色素瘤			Erdheim-chester Histiocytosis, Lagerhans Cell Histiocytosis, Non-small Cell  Lung Cancer	NCCN guidelines	Vemurafenib	Approved
L00437	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600K	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600K	敏感性增加	NCCN	.		是	黑色素瘤			Cutaneous Melanoma	NCCN guidelines	Vemurafenib	Approved
L00466	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600K	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600K	敏感性增加	PMID: 26287849	.		是	黑色素瘤			Erdheim-chester Histiocytosis, Lagerhans Cell Histiocytosis, Non-small Cell  Lung Cancer	NCCN guidelines	Vemurafenib	Approved
L00438	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600M	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600M	敏感性增加	NCCN	.		是	黑色素瘤			Cutaneous Melanoma	NCCN guidelines	Vemurafenib	Approved
L00467	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600M	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600M	敏感性增加	PMID: 26287849	.		是	黑色素瘤			Erdheim-chester Histiocytosis, Lagerhans Cell Histiocytosis, Non-small Cell  Lung Cancer	NCCN guidelines	Vemurafenib	Approved
L00439	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600R	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600R	敏感性增加	NCCN	.		是	黑色素瘤			Cutaneous Melanoma	NCCN guidelines	Vemurafenib	Approved
L00468	Cancer Genome Interpreter	D0Y9EW	BRAF#p.V600R	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	p.V600R	敏感性增加	PMID: 26287849	.		是	黑色素瘤			Erdheim-chester Histiocytosis, Lagerhans Cell Histiocytosis, Non-small Cell  Lung Cancer	NCCN guidelines	Vemurafenib	Approved
L01731	Cancer Genome Interpreter	D0Y9EW	BRAF::consequence::inframe_deletion:L485.,::inframe_deletion:P490.	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	BRAF inframe deletion (L485),inframe deletion (P490)	耐药性增加	PMID: 26732095	.		是	黑色素瘤			Cancer	Pre-clinical	Vemurafenib	Approved
L01646	Cancer Genome Interpreter	D0Y9EW	NF1:del,BRAF:.	Vemurafenib	Vemurafenib (维莫非尼)		NF1	NF1 deletion + BRAF oncogenic mutation	耐药性增加	PMID: 23288408, 231718	.		是	黑色素瘤			Cutaneous carcinoma	Case report	Vemurafenib	Approved
L01725	Cancer Genome Interpreter	D0Y9EW	NF1:del,BRAF:.	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	NF1 deletion + BRAF oncogenic mutation	耐药性增加	PMID: 23288408, 231718	.		是	黑色素瘤			Cutaneous carcinoma	Case report	Vemurafenib	Approved
L01729	Cancer Genome Interpreter	D0Y9EW	BRAF:V600.	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	BRAF (V600)	敏感性降低	PMID: 26287849	.		是	黑色素瘤			Colorectal adenocarcinoma	Early trials	Vemurafenib	Approved
L01730	Cancer Genome Interpreter	D0Y9EW	BRAF:V600.	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	BRAF (V600)	敏感性增加	PMID: 27729313	.		是	黑色素瘤			Colorectal adenocarcinoma	Early trials	Vemurafenib	Approved
L01586	Cancer Genome Interpreter	D0Y9EW	MET:amp,BRAF:V600E	Vemurafenib	Vemurafenib (维莫非尼)		MET	MET amplification + BRAF (V600E)	敏感性增加	PMID: 27325282	.		是	黑色素瘤			Colorectal adenocarcinoma	Case report	Vemurafenib	Approved
L01587	Cancer Genome Interpreter	D0Y9EW	MET:amp,BRAF:V600E	Vemurafenib	Vemurafenib (维莫非尼)		MET	MET amplification + BRAF (V600E)	耐药性增加	PMID: 27325282	.		是	黑色素瘤			Colorectal adenocarcinoma	Case report	Vemurafenib	Approved
L01727	Cancer Genome Interpreter	D0Y9EW	MET:amp,BRAF:V600E	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	MET amplification + BRAF (V600E)	敏感性增加	PMID: 27325282	.		是	黑色素瘤			Colorectal adenocarcinoma	Case report	Vemurafenib	Approved
L01728	Cancer Genome Interpreter	D0Y9EW	MET:amp,BRAF:V600E	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	MET amplification + BRAF (V600E)	耐药性增加	PMID: 27325282	.		是	黑色素瘤			Colorectal adenocarcinoma	Case report	Vemurafenib	Approved
L01648	Cancer Genome Interpreter	D0Y9EW	NF1:.	Vemurafenib	Vemurafenib (维莫非尼)		NF1	NF1 biallelic inactivation	耐药性增加	PMID: 23171796	.		是	黑色素瘤			Cutaneous carcinoma	Pre-clinical	Vemurafenib	Approved
L01647	Cancer Genome Interpreter	D0Y9EW	NF1:.,BRAF:.	Vemurafenib	Vemurafenib (维莫非尼)		NF1	NF1 oncogenic mutation + BRAF oncogenic mutation	耐药性增加	PMID: 23288408, 231718	.		是	黑色素瘤			Cutaneous carcinoma	Case report	Vemurafenib	Approved
L01726	Cancer Genome Interpreter	D0Y9EW	NF1:.,BRAF:.	Vemurafenib	Vemurafenib (维莫非尼)		BRAF	NF1 oncogenic mutation + BRAF oncogenic mutation	耐药性增加	PMID: 23288408, 231718	.		是	黑色素瘤			Cutaneous carcinoma	Case report	Vemurafenib	Approved
L01888	Cancer Genome Interpreter	D0Y9EW	NRAS:.	Vemurafenib	Vemurafenib (维莫非尼)		NRAS	NRAS oncogenic mutation	耐药性增加	PMID: 20179705	.		是	黑色素瘤			Cutaneous carcinoma	Pre-clinical	Vemurafenib	Approved
L00395	Cancer Genome Interpreter	D0I5EU	BRAF#p.V600E	Vemurafenib + Cobimetinib	Vemurafenib + Cobimetinib		BRAF	p.V600E	敏感性增加	FDA	.		.	.		.	Cutaneous Melanoma	FDA guidelines	Vemurafenib + Cobimetinib	Approved
L00406	Cancer Genome Interpreter	D0I5EU	BRAF#p.V600K	Vemurafenib + Cobimetinib	Vemurafenib + Cobimetinib		BRAF	p.V600K	敏感性增加	FDA	.		.	.		.	Cutaneous Melanoma	FDA guidelines	Vemurafenib + Cobimetinib	.
L01710	Cancer Genome Interpreter	.	BCL2:over	Venetoclax	Venetoclax		BCL2	BCL2 overexpression	敏感性增加	ASH 2015 (Blood 2015 126: 2975)	.		否	慢性淋巴细胞白血病		.	Multiple myeloma	Early trials	Venetoclax	.
L01798	Cancer Genome Interpreter	.	FLT3::consequence::inframe_variant:572-603	Venetoclax	Venetoclax		FLT3	FLT3-ITD	耐药性增加	PMID: 27520294	.		否	慢性淋巴细胞白血病		.	Acute Myeloid Leukemia	Early trials	Venetoclax	.
L01815	Cancer Genome Interpreter	.	IDH1:.	Venetoclax	Venetoclax		IDH1	IDH1 oncogenic mutation	敏感性增加	PMID: 27520294	.		否	慢性淋巴细胞白血病		.	Acute Myeloid Leukemia	Early trials	Venetoclax	.
L01541	Cancer Genome Interpreter	.	IDH2:.	Venetoclax	Venetoclax		IDH2	IDH2 oncogenic mutation	敏感性增加	PMID: 27520294	.		否	慢性淋巴细胞白血病		.	Acute Myeloid Leukemia	Early trials	Venetoclax	.
L00473	Cancer Genome Interpreter	D0R0FE	KCNJ5#p.L168R	Verapamil	Verapamil		KCNJ5	p.L168R	敏感性增加	PMID: 24506072	.		.	.		.	Adrenal Adenoma	Pre-clinical	Verapamil	.
L01642	Cancer Genome Interpreter	D0W9MM	NF1:del	Vinblastine	Vinblastine		NF1	NF1 deletion	敏感性增加	ASCO 2016 (abstr 2019)	.		.	.		.	Glioma	Early trials	Vinblastine	Approved
L01643	Cancer Genome Interpreter	D0W9MM	NF1:del	Vinblastine	Vinblastine		NF1	NF1 deletion	敏感性增加	ASCO 2016 (abstr 10555)	.		.	.		.	Glioma	Case report	Vinblastine	Approved
L01644	Cancer Genome Interpreter	D0W9MM	NF1:.	Vinblastine	Vinblastine		NF1	NF1 oncogenic mutation	敏感性增加	ASCO 2016 (abstr 2019)	.		.	.		.	Glioma	Early trials	Vinblastine	Approved
L01645	Cancer Genome Interpreter	D0W9MM	NF1:.	Vinblastine	Vinblastine		NF1	NF1 oncogenic mutation	敏感性增加	ASCO 2016 (abstr 10555)	.		.	.		.	Glioma	Case report	Vinblastine	Approved
L00235	Cancer Genome Interpreter	D03EDQ	SMO#p.D473G	Vismodegib	Vismodegib (维莫德吉)		SMO	p.D473G	耐药性增加	PMID: 25759020, 25306392	.		否	基底细胞癌			Basal-cell Carcinoma	Case report	Vismodegib	Approved
L00236	Cancer Genome Interpreter	D03EDQ	SMO#p.D473H	Vismodegib	Vismodegib (维莫德吉)		SMO	p.D473H	耐药性增加	PMID: 25759020, 25306392	.		否	基底细胞癌			Basal-cell Carcinoma	Case report	Vismodegib	Approved
L00244	Cancer Genome Interpreter	D03EDQ	SMO#p.D473H	Vismodegib	Vismodegib (维莫德吉)		SMO	p.D473H	耐药性增加	PMID: 19726788, 25759019	.		否	基底细胞癌			Medulloblastoma	Case report	Vismodegib	Approved
L00237	Cancer Genome Interpreter	D03EDQ	SMO#p.G497W	Vismodegib	Vismodegib (维莫德吉)		SMO	p.G497W	耐药性增加	PMID: 25759020, 25306392	.		否	基底细胞癌			Basal-cell Carcinoma	Case report	Vismodegib	Approved
L00238	Cancer Genome Interpreter	D03EDQ	SMO#p.L412F	Vismodegib	Vismodegib (维莫德吉)		SMO	p.L412F	耐药性增加	PMID: 25759020, 25306392	.		否	基底细胞癌			Basal-cell Carcinoma	Case report	Vismodegib	Approved
L00239	Cancer Genome Interpreter	D03EDQ	SMO#p.Q477E	Vismodegib	Vismodegib (维莫德吉)		SMO	p.Q477E	耐药性增加	PMID: 25759020, 25306392	.		否	基底细胞癌			Basal-cell Carcinoma	Case report	Vismodegib	Approved
L00240	Cancer Genome Interpreter	D03EDQ	SMO#p.W281C	Vismodegib	Vismodegib (维莫德吉)		SMO	p.W281C	耐药性增加	PMID: 25759020, 25306392	.		否	基底细胞癌			Basal-cell Carcinoma	Case report	Vismodegib	Approved
L00241	Cancer Genome Interpreter	D03EDQ	SMO#p.W535L	Vismodegib	Vismodegib (维莫德吉)		SMO	p.W535L	耐药性增加	PMID: 25759020, 25306392	.		否	基底细胞癌			Basal-cell Carcinoma	Case report	Vismodegib	Approved
L01902	Cancer Genome Interpreter	D03EDQ	PTCH1:.	Vismodegib	Vismodegib (维莫德吉)		PTCH1	PTCH1 oncogenic mutation	敏感性增加	PMID: 19726763, 19726761	.		否	基底细胞癌			Basal Cell Carcinoma, Medulloblastoma	FDA guidelines	Vismodegib	Approved
L01897	Cancer Genome Interpreter	D00BYM	PML__RARA	Volasertib	Volasertib		PML	PML-RARA fusion	敏感性增加	NCT02198482,NCT01662505	.		.	.		.	Acute Myeloid Leukemia	Early trials	Volasertib	Clinical Trials
L01375	search pubmed	D08XNW	PTPN6#p.A550V	WHIP-154	WHIP-154		PTPN6	p.A550V	耐药性增加	PMID: 26565811	.		.	.		.	Diffuse large B-cell lymphoma	.	WHIP-154	Investigative
L01395	search pubmed	D08XNW	PTPN6#p.N225K	WHIP-154	WHIP-154		PTPN6	p.N225K	耐药性增加	PMID: 26565811	.		.	.		.	Diffuse large B-cell lymphoma	.	WHIP-154	Investigative
